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Abstract 
Leprosy is a chronic granulomatous infectious disease, affecting the skin and nerves. 
Neuropathic pain (NP), which is defined as pain caused by a lesion or disease of the 
somatosensory nervous system, is now being recognized as an important complication 
of leprosy. It occurs in 10-20% of patients as a result of persisting nerve damage. Patient 
with NP is associated with significant suffering, morbidity and limitation of quality of 
life. Thus, the accurate identification of NP in patients with pain is required. The clinical 
aspects of NP in leprosy patients in India were investigated using highly specialised 
assessment tool; quantitative sensory testing (QST). A case control study was conducted 
in 90 patients with and without pain. Two validation studies were conducted among 
healthy volunteers in London (18 participants) and Mumbai (52 participants).  
Somatosensory profiles were compared in leprosy patients to healthy control subjects. 
The pattern revealed a novel profile of loss of cool and warm detection thresholds and 
also mechanical detection but with preservation of vibration detection. This is different 
to profiles seen in other NP conditions. The QST parameters were effective in detecting 
neuropathy, but were not able to distinguish between patients with and without NP. 
Patients with leprosy NP had a high rate of abnormal findings in almost all QST 
parameters in the maximum pain area over the ulnar nerve. Their sensory profiles were 
categorised into two subgroups. The majority of patients have spontaneous pain with 
evidence of sensory loss, but no signs of sensory gain. The second subgroup had 
profoundly impaired pain and temperature sensation, but light mechanical stimuli often 
produce pain. Patients with NP had a poor quality of life and psychological well-being 
compared to pain-free neuropathy. 
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Chapter 1 Introduction 
1.1 PhD approach  
This PhD work was a collaborative study between the leprosy group at the London 
School of Hygiene and Tropical Medicine (LSHTM) and the pain group at Imperial 
College London (ICL). Our international collaborators are from the London Pain 
Consortium (LPC) and the German Research Network on Neuropathic Pain (DFNS), 
and our local collaborators from India are: the Foundation for Medical Research (FMR) 
and Bombay Leprosy Project (BLP). 
I came to LSHTM to study for an MSc in Tropical Medicine and International Health 
(TMIH) in 2007. I was supervised by Professor Lockwood and Professor Rice for my 
dissertation, which was on leprosy and neuropathic pain (NP). Since that time I have 
been interested in leprosy and research. 
After I completed my MSc, and throughout my work as researcher at ALERT (The 
Leprosy Centre in Ethiopia), and at the Neglected Tropical Diseases at Federal Ministry 
of Health, Sudan, I noticed that although neglected tropical diseases are essentially 
preventable, little is done to control important endemic diseases such as Leishmaniasis, 
HIV/AIDS and Leprosy. The morbidity and mortality from infectious diseases are 
alarming. Since that time I have felt one of my responsibilities is to work for 
improvements in this situation. 
Leprosy is still an endemic disease in developing countries. Management of leprosy 
(diagnosis and treatment) is still challenging. Antimicrobial therapy kills M. leprae, but 
immune mediated peripheral nerve damage can continue long after effective drug 
treatment. Consequently, as a result of persistent damage, patients who have been 
successfully treated with multi-drug therapy (MDT), suffer from NP and associated co-
morbidity long after the infection has been cured. NP is now being recognized as an 
important long-term complication in a proportion of people previously treated for 
leprosy. Considering the high prevalence and morbidity of NP in treated leprosy 
patients, there is a pressing need for clinical trial evidence to assess the efficacy of pain 
therapies in the management of leprosy-associated NP. 
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This PhD work was conducted in Mumbai, India. The rationale for the study emerged 
in recognition of the growing challenges of NP, as well as a gap in the knowledge 
regarding identification and treatment of leprosy patients with NP, particularly in 
resource-limited settings. Preliminary discussion with leprosy and pain experts revealed 
that no single drug for the treatment approach stood out as a potential intervention 
study on NP in leprosy. Instead, key experts highlighted the need to accurately 
characterise the somatosensory profiles of leprosy patients with NP, in order to develop 
appropriate tools for the investigation and design of suitable treatment interventions. 
Preliminary work was then carried out to define the scope and design of the main PhD 
study of profiling leprosy NP patients. This information helped formulate the objective 
of the PhD work as conducting a case-control study using highly specialised tools to 
investigate the clinical characteristics of leprosy patients with NP and to inform 
development tools in the furure. As part of this PhD study, two validation studies were 
conducted in London and Mumbai. Validating the Mumbai site for study protocols in 
Hindi and Marathi, and establishing leprosy profiles in resource-limited setting were 
important preliminary steps to develop an optimal trial design to use for future studies. 
1.2 PhD thesis timeline  
I started my PhD work in October 2010. Recruitment for the validation study in 
London began in April 2011 and was completed in July 2011. During this time I trained 
and qualified in the use of the German Research Network on Neuropathic Pain DFNS-
QST protocol (Appendix 40). I successfully upgraded from MPhil to PhD in November 
2011. Recruitment for the local healthy volunteers study and the PhD main study took 
place between October 2012 and June 2013. Data recording, management, and writing 
up began in July 2013 and the thesis was submitted for examination in August 2014. 
The detailed timeline of my PhD thesis is shown in (Appendix 54).  
1.3 Overview of my role in this PhD research 
My roles in this study included writing the grant proposal, and designing the studies. I 
was responsible for the design and writing of study forms including consent forms and 
information sheets for both healthy volunteers and patients. I developed the study 
protocols with advice from Professor Lockwood, Professor Rice, Dr Nichols, Professor 
Maier, Professor Treede R-D, Dr Bennett, Dr Pfau, Dr Pai, Dr Shetty, Dr Walker and 
Dr Tudor. I was responsible for obtaining various ethical approvals. In addition, all 
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study work including patient recruitment, screening and enrolment procedures, clinical 
examination, administration of testing protocols, data recording and management 
presented in this thesis were performed by me, unless otherwise indicated. In particular, 
I conducted interviews in the local language through an interpreter. The study on the 
use of Semmes-Weinstein monofilaments to simplify the DFNS-QST protocol was 
conducted in collaboration with the DFNS group; I conducted the study and Dr Pfau 
completed the analysis and wrote up the findings. For the PhD main study, I conducted 
the data analysis with advice from Dr Nichols and Dr Tudor.  
1.4 Structure of the PhD thesis 
This thesis is organised into ten chapters: 
Chapter one presents introductory and background information regarding NP in 
leprosy. It describes how the thesis is set-up, and introduces the reader to the burden of 
NP in leprosy patients. It then outlines the reasons for carrying out this research as well 
as the objectives of this study. Chapter two, the literature review, presents the current 
literature on leprosy, its complications and management; and looking particular at the 
central role of nerve damage in leprosy. Chapter three, the identification of neuropathic 
pain, gives a general introduction on the NP theme and, in particular, NP in leprosy. In 
chapter four the instruments for assessing sensory abnormalities, pain disorders and 
techniques for assessing the psychological impact of NP are assessed. Chapter five 
describes the clinical difficulties in identifying NP in diseases such as leprosy, with some 
current thoughts on NP pain assessment and the need to develop tools for the 
assessment of NP in leprosy. The background information from the above mentioned 
chapters aims to place the rationale of the PhD work in the context of current 
knowledge and identify a gap in existing research, thus providing a framework for this 
study.  
Chapter six describes the study designed methods and chapter seven describes the 
validation studies. These include the validation of the investigator, the centre and study 
protocol. The aim of the first validation study was to validate the investigator in the 
London centre and the aim of the second was to validate the DFNS-QST protocol in 
the local Indian population and the site centre. The third validation study explored the 
utility of Brazilian Semmes-Weinstein monofilaments and aimed to simplify the DFNS-
QST protocol. For these studies only healthy controls were recruited. This information 
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provided the basis of validating the investigator and the centre site in Mumbai for the 
use of DFNS-QST protocol. 
Chapters eight and nine describe and discuss various aspects of the results. These 
include the baseline findings on the leprosy patients; the difference between healthy 
controls and the patient group; the assessment using pain questionnaires, clinical 
examination, quantitative sensory testing and psychological assessment techniques; and 
the role of somatosensory profiling in the assessment of leprosy-related NP.  
Finally, based on the findings from this PhD work, the main summary of the findings 
and recommendations for future studies are presented in the last chapter, chapter ten.  
1.5 Rationale of the PhD thesis 
NP is a severe form of chronic pain caused by a lesion or disease of the somatosensory 
system and is associated with many diseases (Jensen et al., 2011). Leprosy, the most 
common cause of treatable neuropathy worldwide (Scollard et al., 2006), is now being 
recognised as one such disease. The Lancet Neurology highlighted the importance of 
leprosy as a neurological disease in an editorial in 2009 (Lancet, 2009), and we have 
recently shown in India and Ethiopia that 17-20% of treated leprosy patients cured of 
their infection but left with peripheral nerve damage, have significant NP, which is 
associated with reduced quality of life (Lasry-Levy et al., 2011, Haroun et al., 2012). 
Previous work has shown that patients with NP have significant levels of depression 
(Jensen et al., 2007, Doth et al., 2010). This makes NP one of the most prevalent 
disabilities among leprosy patients and thus a significant health problem worldwide. 
Thus, the accurate identification of NP in patients with chronic pain is crucial for 
targeting appropriate treatment as NP conditions require a different therapeutic 
approach from other pain types. 
The German Research Network on Neuropathic Pain (DFNS) has developed a 
standardised QST battery that consists of 7 tests measuring 13 parameters (Rolke et al., 
2006a, Rolke et al., 2006b), which may identify changes in sensory parameters related to 
chronic NP. This protocol has been used successfully to establish the somatosensory 
profile of patients with HIV-associated sensory neuropathy (Phillips et al., 2014). It has 
been also used in patients with different NP conditions such as post-herpetic neuralgia 
and diabetic mellitus, where a subgroup of patients with different somatosensory 
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profiles have been identified (Maier et al., 2010). Although NP occurs in approximately 
one-fifth of leprosy affected patients, little attention has been paid to assessing patients 
and treatment regimens have not been defined. No study to date has established the 
complete QST somatosensory profile of leprosy patients with NP. To better 
characterise this somatosensory profile, comparison was made to local Indian healthy 
control subjects, DFNS reference data, and to patients with and without neuropathy and 
pain. The ability to accurately identify sensory, psychological, and metabolic dysfunction 
profiles in leprosy patients with NP is essential for better understanding of the patho-
physiological mechanisms as well as informing mechanism-based prescribing and thus 
has the ability to dramatically improve clinical trial design and NP treatment defined by 
drug response. 
1.6 Aims of the PhD thesis 
The overall aim of the study was to characterise the somatosensory profiles of leprosy 
patients with NP. 
1.7 Objectives of the PhD thesis 
1. To measure the somatosensory responses of leprosy patients including thermal 
detection and pain thresholds, paradoxical heat sensations, mechanical detection 
thresholds to von Frey filaments, vibration detection threshold, mechanical pain 
thresholds to pinprick stimuli and blunt pressure, stimulus/response-functions 
for pinprick and dynamic mechanical allodynia, and pain summation (wind-up 
ratio)  and to compare these measures between leprosy patients with painful 
neuropathy; non-painful neuropathy, leprosy patients without pain and age and 
sex matched healthy controls. 
2. To elucidate the impact of leprosy NP on quality of life and psychological well-
being in patients with painful neuropathy compared with patients with non-
painful neuropathy. 
3. To stratify leprosy patients by symptoms, sensory profile and psychological state  
1.8 Hypotheses of the PhD thesis 
NP in leprosy patients could be caused by immune neuronal interaction which can be 
due to destruction or impaired functions of cells as a result of chronic inflammatory 
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processes, or it could be caused by sensitisation and spontaneous activity in sensory 
neurons which can be due to the effect of M. leprae. As a functional compensation pain 
thresholds are lower, leading to increased pain sensation even though the stimulus is 
minor. I hypothesise that:  
 The thermal and mechanical detection threshold, pain threshold (CPT and 
WPT), pressure pain threshold (PPT), and vibration detection threshold (VDT) 
are lower in leprosy patients with painful neuropathy than patients with non-
painful neuropathy 
 There is significant impact of neuropathic pain on quality of life and 
psychological well-being in leprosy patients with painful neuropathy compared 
to patients with non-painful neuropathy. 
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Chapter 2 Review of Literature  
2.1 Literature review of leprosy 
2.1.1 Definition of leprosy  
Leprosy is a chronic granulomatous infectious disease, affecting the skin and peripheral 
nerves (Britton and Lockwood, 2004). It is one of the most common causes of 
peripheral neuropathies worldwide. The disease is caused by Mycobacterium leprae (M. 
leprae) (Job, 1989), which is a unique intracellular organism discovered by Armauer 
Hansen in 1873. The organism is the only bacterium that invades and multiplies inside 
Schwann cells, which this is the hallmark of the disease (Job, 1989). M. leprae cannot be 
cultured in routine laboratory media, but will multiply slowly in certain animal species, 
such as the nine-banded armadillo, which is a natural reservoir of the organism (Truman 
et al., 2011).  
2.1.2 Leprosy transmission 
Leprosy is thought to be spread through aerosol transmission of nasal secretions of 
untreated lepromatous leprosy patients, but the precise mechanism, the route of entry, 
and the role of skin contact are still debated (Pfaltzgraff R. E and G, 1994). It is widely 
believed that M. leprae probably enters the body via the nasal mucosa with subsequent 
haematogenous spread to the skin and peripheral nerves (Scollard et al., 1999). 
2.1.3 Epidemiology of leprosy 
2.1.3.1 Global Leprosy Prevalence 
Globally the prevalence of leprosy has declined over the last 25 years (WHO, 2013b). At 
the beginning of 2013, the WHO reported a global prevalence of leprosy of less than 
one per 10 000 population, with 189 018 registered cases compared to 1.2 million cases 
in 1995 (WHO, 2013b) (Figure 2.1). The global case-detection rate remains high, with 
about 230 000 new cases being detected worldwide and reported to the WHO during 
the year 2012. The global rate of new cases with grade two disabilities per 100 000 
population was 0.25, with 14 409 registered cases during the year 2012 (WHO, 2013b). 
However, due to recent major operational changes relating to the diagnosis and 
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registration of cases in many countries, these leprosy statistics are probably under-
estimates (Fine, 2008). 
 
Figure 2.1. Global leprosy prevalence 2012 
2.1.3.2 Regional Leprosy Prevalence 
Leprosy patients are found mainly in the tropical and warm temperate regions of the 
world, but cases have been also reported elsewhere, as patients may present with the 
disease long after leaving an endemic region. Currently 95% of new leprosy cases are 
concentrated in three geographical regions, namely, South Asia (India: 91 743, Nepal: 3 
118 and Bangladesh: 3 848); Latin America (mainly Brazil: 34 894); and sub-Saharan 
Africa (Angola: 1 076, the Democratic Republic of Congo: 5 049, Mozambique: 1 207, 
and the United Republic of Tanzania: 2 349). South Asia, Latin America, and sub-
Saharan Africa still have a prevalence of more than 1 case per 10 000, with 60% of all 
leprosy cases worldwide being concentrated in Brazil and India (WHO, 2013b).  
Leprosy in India  
India is the largest country in South Asia with a population of more than one billion 
(WHO, 2013a). It is the biggest contributor to the global burden of leprosy with 134 
752 new cases were detected during the year 2012 (WHO, 2013b). 
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The prevalence of leprosy has declined over the last decade in India according to 
government records. The total number of leprosy cases in India fell strikingly from 265 
781 in 2004 to 91 743 in 2013 (WHO, 2013b). This changing picture is attributed to 
introduction of multi-drug therapy (MDT) and the duration of treatment being reduced 
from 24 months to 12 months. Another contributing factor to the decreased prevalence 
observed in India is operational activities, such as level of case finding activity and 
integration of leprosy services into primary health care services. 
In recent years, heavy migration into cities such as Mumbai from under developed or 
poorly surrounded region such as Uttar Pradesh and Bihar may have contributed to an 
increase in leprosy cases in urban areas. In the Bombay Leprosy Project clinic, 80% of 
the newly diagnosed leprosy patients from January to November 2013 were reported 
from urban slums and outside Mumbai.  
 
Figure 2.2. Prevalence and incidence of leprosy in India 
Data for leprosy prevalence and number of new cases in India are shown in Figure 2.2. 
These data clarify the importance of using the number of new cases as a marker of 
transmission of leprosy. High numbers of new cases continue to be reported. For 
instance, 91 743 new cases were reported in 2012 compared to 83 187 cases in 2011. A 
cross-sectional study from Maharashtra, showed rates of three-to-nine cases per 10 000 
population, of which 30% of these newly diagnosed patients were children. 
Furthermore, the WHO global leprosy update reported that 9.9% of new leprosy cases 
in India in 2012 were among children. Multibacillary (MB) cases were the most frequent 
type of leprosy among the total number of new leprosy cases detected during the 
reporting year in India (Kumar, 2010). In 2012, 30% of the newly diagnosed MB cases 
had neuropathy and nerve damage. These data indicate ongoing transmission of leprosy 
in India. 
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2.1.4  Leprosy Classification 
The clinical features of leprosy are determined by the host’s immune response. 
Therefore, there are two main systems used to classify leprosy patients. In 1966, 
Doctors Ridley and Jopling proposed a system of leprosy classification known as Ridley-
Jopling classification. They described a spectrum of leprosy from tuberculoid (TT) to 
lepromatous leprosy (LL) based on their clinical, bacteriological, immunological and 
histopathological features (Figure 2.3). Between these two poles there are three 
borderlines: borderline tuberculoid (BT), mid-borderline (BB), and borderline 
lepromatous (BL). Borderline patients can remain in positions or more towards either 
end of spectrum. This classification is mainly used in referral centres. It helps to predict 
patients at risk of reaction and their prognosis, in addition to their appropriate treatment 
(Ridley and Jopling, 1966). The other classification scheme was recommended by WHO, 
which suggests that for the purpose of treatment it is adequate to classify patients on the 
basis of clinical features. Patients are classified as paucibacillary (PB) and multibacillary 
(MB) by the number of skin lesions they have: PB (one-to-five skin patches); and MB 
(more than five skin lesions). This operational classification was introduced to simplify 
disease recognition and to ensure that patients were appropriately treated with MDT.  
 
Figure 2.3. R-J scale and the relation with bacterial and immune response 
The five forms of leprosy based on the Ridley-Jopling Scale are tuberculoid 
(TT), borderline tuberculoid (BT), midborderline (BB), borderline lepromatous 
(BL), and lepromatous (LL). CMI = cell-mediated immunity; AFB = acid-fast 
bacilli. Picture modified from (Walker and Lockwood, 2006)  
 
Chapter 2 – Review of Literature 
 
29 
 
2.1.5 Clinical Features of Leprosy  
Patients with leprosy can present with prodromal symptoms and skin and nerve-related 
symptoms or complications of the disease. The prodromal symptoms, which is rare now 
and may occur only in LL such as nasal stuffiness, precede the typical skin and nerve 
features. The main presenting features are related to skin, nerve or reactions (Britton 
and Lockwood, 2004). A patient may present with a range of skin lesions such as 
macular hypo-pigmintation. Patients with affected nerves may present with new 
evidence of neuropathy such as, weakness and loss of function, or secondary to 
neuropathy e.g. ulcer. Patients with leprosy reaction can present with skin changes or 
neuritis. These features are diagnostic. The common presenting complications of 
leprosy are reactions. Patients may present with skin lesions that are erythematous, 
tender, and swollen due to type 1 leprosy reactions. Others may present with systemic 
manifestations, such as fever and malaise due to erythema nodusoum leprosum. Five-to-
ten percent of leprosy patients may present with acute neuritic features, spontaneous 
nerve pain, new sensory or motor impairment of recent onset, or mixed-sign neuritis 
(Mahajan et al., 1996, Van Brakel et al., 1992).  
Cardinal signs 
There are three cardinal signs (WHO, 2012):  
1. Definite loss of sensation in a pale (hypo-pigmented) or reddish skin lesion 
2. Thickened or enlarged peripheral nerve, with loss of sensation and/or weakness 
of the muscles supplied by that nerve  
3. Presence of acid fast-bacilli in a slit-skin smear. 
The clinical diagnosis is confirmed when a patient has at least one of the cardinal signs 
(Britton and Lockwood, 2004).  
2.1.6 Diagnosis of Leprosy  
The diagnosis of leprosy is important for the individual and the community. For the 
individual with leprosy, accurate diagnosis is essential for providing appropriate 
management and to reduce stigma associated with the disease. Early identification of 
suspected cases, will reduce the incidence of impairments and their effects. Also, it 
reduces the spread of leprosy to other individuals in the community. 
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The diagnosis of leprosy is made clinically based on clinical history and a full clinical 
examination of the skin and peripheral nerves (WHO, 2012). Bacteriological and 
histological investigations also aid in the diagnosis. 
In the presence of clinical symptoms, the first step towards diagnosing leprosy is to 
think of the possibility of leprosy among those who are at risk of exposure to infection 
which includes residence in an endemic country and being a household contact. 
2.1.6.1 History and clinical examination 
For every potential leprosy patient seen, a detailed clinical history must include: any 
changes in skin colour and texture; area of sensory loss; weakness of the hands, feet, and 
eyes; and any signs of reactions. The clinical history is followed by examination of the 
skin and peripheral nerves. When looking for signs of leprosy the procedure should be 
carried out in good light and the patients should be examined while maintaining and 
respecting privacy. M. leprae multiplies at relatively low temperature; therefore, areas 
such as the ears, face, lateral aspects of the limbs, the back, and the buttocks are to be 
examined. These areas of skin have relatively low temperatures compared to other less 
affected regions such as the axillae, groin, perineum, and hairy scalp. The body map is 
used to record the results of the examinations of skin lesions, nerve thickening, and any 
tissue damage. For each patient, the following information is required; number and type 
of skin lesions; loss of sensory and motor functions; bacterial index if skin smear is 
taken; eye assessment; and treatment regimen.  
2.1.6.2 Bacteriological examination   
M. leprae can be demonstrated in slit skin smear and/or tissue biopsies. In suspected 
case, slit skin smears are taken to look for acid-fast bacilli. This test is one of the 
essential component of definitive leprosy diagnosis by demonstrating acid-fast bacilli on 
microscopy. Patients with pure neuritic leprosy, in which no visible skin lesions are 
found, may require a nerve biopsy for accurate diagnosis of leprosy.  
Histopathological evaluation is essential for accurate classification of skin lesions across 
the spectrum. The diagnosis is made by the presence of granulomata and lymphocytic 
infiltration of dermal nerves in anaesthetic skin lesions. These criteria help to confirm 
and exclude the diagnosis of leprosy. 
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2.1.6.3 Diagnostic immunology in leprosy 
There is currently no established role for an immunodiagnostic test (serology, skin test, 
or polymerase chain reaction) of leprosy. There is no good serological test with adequate 
sensitivity and specificity for leprosy. For instance, the serological tests for phenolic 
glycolipid have a good but insufficient specificity for the diagnosis of leprosy patients 
and their sensitivity is generally high for the MB patients (>90%), but low for the PB 
patients (50-60%). It has also been detected positive (15-20%) in household contacts 
(Chanteau et al., 1992). Polymerase chain reaction methods for detection of M. leprae 
DNA have been developed and are potentially highly specific and sensitive, detecting M. 
leprae DNA in  >95% of MB and 55% of PB cases, but they cannot be used routinely 
due to reliance on skilled technicians and expensive equipment (Oskam et al., 2003, 
Parkash, 2011).  
The diagnosis of leprosy is typically clinical but sometimes slit skin smears are needed to 
confirm the M. leprae. In each patient, the definite diagnosis of leprosy includes: the 
spectrum of disease, type of reactions, and nerve function impairments. 
2.1.7 Treatment of Leprosy 
A comprehensive approach to treating leprosy patients may be used, including 
chemotherapy, treating reactions and complications of nerve damage, prevention of 
neuropathic damage, education, psychological support, and stigma reduction.  
Curing the active mycobacterium infection through chemotherapy is essential in the 
treatment of leprosy patients. In 1982, WHO introduced and recommends MDT 
regimens for all leprosy patients. The regimens are combinations of rifampicine, 
clofazimine and dapsone. There are two types of WHO-MDT regimens used: the PB-
MDT (given for six months: 600mg rifampicin once a month, 100mg dapsone daily), 
and MB-MDT (given for 12 months: 600mg rifampicin once a month, 100mg 
dapsonedaily, and 300mg clofazimine once a month and 50mg daily) (Table 2.1). A 
regimen for children is also available in reduced doses of the drug format. Within this 
combination, rifampicin has the highest bactericidal activity compared to other two 
drugs. There are several second line of treatments to MDT. These antibiotics such as 
minocycline, ofloxacin, clarithromycin and moxifloxacin required a shorter duration of 
therapy (Britton and Lockwood, 2004). A single dose of monthly for six months MDT 
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known as ROM (rifampicin, ofloxacin and minocycline) in combination is now available 
for PB disease (Setia et al., 2011). 
The WHO-MDT regimen is highly effective and has been used successfully in treating 
leprosy patients with a high cure rate, few side effects, and low relapse rates; globally, 
more than 14.5 million patients have been treated with good clinical response 
(Lockwood, 2002). Moreover, it is safe in pregnancy and in breastfeeding mothers. 
WHO technical advisory group in leprosy chemotherapy noted low relapse rates (0.79% 
for MB patients compared to 1.09% for PB patients). These relapse rates were obtained 
from 20 141 MB patients and 51 553 PB patients, where 67 and 306 patients 
respectively were reported to have relapsed over a nine year period of follow up in 1994 
(WHO, 1994). Relapse in MB patients, which is defined as the multiplication of M. 
leprae, is associated with clinical deterioration in skin and nerve function impairments 
and marked increase in bacteriological index. In contrast, relapse in PB patients is 
difficult to recognise as it is hard to distinguish from type 1 leprosy reaction. The 
committee also noted no evidence of M. leprae having resistance to the WHO-MDT 
regimen (WHO, 2012).  
Additional benefits of WHO-MDT regimens include the prevention of drug resistance 
and better patient compliance due to a fixed duration of treatment. Another advantage 
is that supervised drug administration and health education provided by field workers 
review patients in each visit where leprosy complications such as reactions and nerve 
function impairments can be early detected and treated. 
There are some reports on the adverse effects of WHO-MDT regimens. For instance, 
clofazamine is documented to cause troublesome skin pigmentations in many leprosy 
patients in particular among females (Maia et al., 2013). Other adverse effects associated 
with individual MDT drugs are listed below. After giving WHO-MDT treatment few 
patients develop an immune upgrading response and get reactions, and some of them 
may develop pain (Haroun et al., 2012). This indicates that neuritis may be worsened by 
WHO-MDT treatment and then cause pain. However, there is no association of 
neuropathic pain with starting WHO-MDT treatment. Although minocycline is effective 
in preventing neuropathic pain in animal models, it has not yet been demonstrated to be 
effective in clinical trials (Rojewska et al., 2014, Martinez et al., 2013). It has not been 
shown to have a role in leprosy neuropathic pain. Minocycline is only used as second 
line drug in the treatment of leprosy.  
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2.1.7.1 Rifampicin 
Rifampicin is a potent bactericide for M. leprae. Previous studies in untreated MB 
patients have shown that rifampicin administered in single doses of 600mg killed more 
than 99% of viable M. leprae within three or four days (Levy et al., 1976). Its mode of 
action is via inhibition of DNA-dependent RNA polymerase, and it needs to be 
combined with other anti-leprosy drugs to minimize the risk of developing drug 
resistance. In untreated MB patients, a single monthly dose of rifampicin (1200mg) plus 
daily dapsone was as effective as daily rifampicin (450mg) plus dapsone (Yawalkar et al., 
1982). A single monthly dose has been the current dose used in WHO-MDT regimen 
with few serious side effects. This drug dose produce red-brown discoloration of bodily 
secretions such as urine and faeces, so patients should be warned. 
2.1.7.2 Clofazimine 
Clofazimine is a drug with dual activity in leprosy: anti-bacterial and anti-inflammatory. 
It has weak bactericidal action for M. leprae, the mechanism of which is unknown. After 
a few weeks of commencing 300mg of clofazimine once a month and 50mg daily, active 
skin lesions start to improve. The most common adverse effects of clofazimine are in 
the skin (lesions and normal skin), and include troublesome pigmentation and dryness. 
These pigmentations occur in almost all patients in the first few days to weeks as the 
drug becomes clinically effective, but are not severe enough to warrant discontinuation, 
since most symptoms resolve spontaneously (Maia et al., 2013). Discoloration may also 
occur in hair, the eyes, and in body excretions, such as urine and faeces. Other reported 
side effects of clofazimine are gastrointestinal-related, such as nausea, vomiting, and 
diarrhoea. 
2.1.7.3 Dapsone  
Dapsone is both bacteriostatic and weakly bactericidal against M. leprae. Its mode of 
action is predominantly via inhibition of the synthesis of dihydrofolic acid. Dapsone can 
cause a few side effects, including haemolytic anaemia and skin reactions. These effects 
are rare, occurring within the first few months of treatment. 
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Table 2.1. WHO-recommended MDT doses and regimes for adult with 
leprosy 
Type of 
leprosy 
Drug treatment Duration 
of 
treatment Monthly, supervised Daily, self-administered 
PB Rifampicin 600mg; Dapsone 100mg Dapsone 100mg 6 months 
MB Rifampicin 600mg; Clofazimine 
300mg; Dapsone 100mg 
Clofazimine 50mg; Dapsone 
100mg 
12 months 
 
2.1.8 Immunological complications of leprosy 
The role of immune system as causing leprosy complications is well documented 
(Walker and Lockwood, 2006). M. leprae invades and multiplies in Schwann cells and 
cutaneous macrophages (Britton and Lockwood, 2004). Such neuronal attack not only 
resulted in impairments of the sensory functions, but is also associated with a robust 
inflammatory immune response. As the damaged axons undergo Wallerian 
degeneration, non-myelinated Schwan cells proliferate and release chemokines, which 
recruit immune cells such as macrophages. Other resident cells such as mast cells and 
neutrophils provide the majority of the early immune cell attack, i.e. innate immune 
response. This process is followed by the accumulation of inflammatory mediators, 
which enhance the recruitment of immune cells such as CD4 and CD8, i.e. adaptive 
immune response. As a result, the transduction and transmission of signals are changed 
and cause ectopic activity and pain in affected nerve. The percentage of leprosy patients 
with nerve inflammation and pain is around 9% and 5% of patients with MB and PB 
respectively (van Brakel et al., 2005b, Richardus et al., 2004).     
In neuropathic pain inflammatory models, activation of the Schwann cells, leukocytes, 
Toll-like receptors, inflammatory mediators and cytokines contributes to generation of 
pain and the severity of this responses is related to the degree of neuropathic pain 
(Gaudet et al., 2011, Lindenlaub and Sommer, 2003, Calvo et al., 2012). These mediators 
are important for the recruitment of immune cells such as neutrophils, macrophages, 
dendritic cells, and B and T lymphocytes to the site of nerve injury. The recruitment of 
inflammatory cells and cytokine expression such as TNF and IL-6 is also increased in 
nerve biopsies with inflammation in leprosy patients with neuropathic pain (Haanpaa et 
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al., 2004). This suggests that the immune cells is the main player in the generation of 
leprosy nerve damage and thus neuropathic pain. The nerve, M. leprae and host 
immune response interactions are discussed in detail under the central role of nerve 
damage in leprosy. 
2.1.9 Leprosy Reactions 
Leprosy reactions are an immunological complication of the disease, which are 
associated with inflammation and acute peripheral nerve damage. Forty percent of MB 
leprosy patients experience significant appearance of symptoms and signs of acute 
inflammation in skin lesions and nerves at some stage in their disease course (Pocaterra 
et al., 2006, Walker et al., 2008). These reactions could occur before, during, and after 
successful completion of leprosy MDT and are serious because they cause an acute 
inflammatory immune response. Such acute onset of inflammation may rapidly and 
extensively damage a peripheral nerve already affected by the disease.  
The two main types of reactions are Type 1 (reversal reaction) and Type 2 reactions, 
also known as Erythema nodosum leprosum (ENL). Neuritis, which is known as nerve 
inflammation without a Type 1 or 2 reaction, is the third form of leprosy reaction. 
2.1.9.1 Type 1 Reactions 
Background 
Type 1 (reversal) reactions are acute inflammatory episodes, which may occur as a result 
of increased cell mediated immunity towards M. leprae antigen (Lockwood et al., 2002). 
Up to 30% of individuals with leprosy will be affected, but the prevalence shows large 
variations in a retrospective study with 386 leprosy patients in Nepal, one third of 
patients had a type 1 reactions at recruitment (Van Brakel et al., 1994a). In similar study 
in Ethiopia, type 1 reactions was reported in 16.5% of 594 patients followed for 10 
years (Saunderson et al., 2000b). Patients with the borderline leprosy (BT, BB, and BL), 
whose immunological status is unstable, are at greater risk (Walker et al., 2008, Ranque 
et al., 2007). Another group of patients who are also at high risk for type 1 reactions is 
women after child birth (Lockwood & Sinha 1999). The onset of T1R is in the first six 
months of anti-leprosy treatment, but may occur rarely many years after completion of 
MDT (Croft 2000).  
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Immune responses occurring in type 1 reactions 
Type 1 reactions are the result of delayed type hypersensitivity reactions to M. leprae 
antigens (Lockwood et al., 2002). They are characterised by T cell activation resulting in 
inflammation in the affected skin and nerve (Lockwood et al., 2002, Schenk et al., 2012). 
The increase in cell mediated immunity could lead to immunological upgrading of the 
patients towards the tuberculoid pole of the clinical spectrum of leprosy. In the affected 
sites, the CD4+ T cells increase in number and secrete Th1- type pro-inflammatory 
cytokines, such as IL-1, IL-2, IL-12, and IFN-γ1, which may shift the immune response 
towards Th1 immunity. Th1-type cytokines could be responsible for the local tissue 
damage occurring in T1Rs, including: the swelling and painful inflammation in skin 
lesions and nerves. In addition, the increase in TNF-α is responsible for these local and 
systemic inflammatory symptoms that may occur in type 1 reactions (Khanolkar-Young 
et al., 1995, Little et al., 2001). 
Clinical features of type 1 reactions 
Patients with type 1 reactions presented with features localised to the skin lesions and 
peripheral nerves. Skin lesions develop swelling, redness and tenderness, with some 
emergence of new lesions. Erythema is often followed by desquamation and ulceration. 
Affected nerves will become rapidly swollen, extremely painful and tender. This is 
commonly followed by paraesthesia or pain in nerves distribution, accompanied very 
often by loss of sensory function.  Loss of motor nerve functions also develops rapidly. 
If not treated, patients with type 1 reactions may end up with irreversible nerve damage.  
Treatment of type 1 reactions 
Type 1 reactions are usually treated with oral corticosteroids (40 mg/day of 
prednisolone reducing to 5 mg/day every month over six months) with monitoring of 
skin lesions and nerve function. However, a recent Cochrane systematic review, which 
looked at the frequency and features of nerve function impairment (NFI), noted that 
oral corticosteroids are accepted as treatment, but there is no consensus about the dose 
or duration of treatment, hence further randomised controlled trials (RCTs) are needed 
to identify the best treatment regimens (Walker and Lockwood, 2008). 
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2.1.9.2 Type 2 Reactions  
Background  
Type 2 reactions or (ENL) occurs as a result of antigen-antibody reactions with the 
formation of immune complexes that leads to systematic inflammation (Pfaltzgraff R. E 
and G, 1994). Type 2 reaction occurs in up to 50% of LL patients, and in 5-15% of 
patients with BL disease. The main risk factor for ENL is a high bacteriological index 
(Voorend and Post, 2013). The prevalence of ENL has decreased after the introduction 
of MDT, but there is still wide geographical variation. In an Indian retrospective study 
with 481 leprosy patients the prevalence of ENL was 49.4% in those with LL and 9% in 
BL cases (Pocaterra et al., 2006). In contrast, the prevalence in Ethiopia is low, where 
the AMFES study of MB patients found that 5.3% of individuals experienced ENL 
(Saunderson et al., 2000a). The onset of ENL often starts during the first year of MDT 
and can relapse intermittently over several years (Balagon et al., 2010).  
Immune response occurring in type 2 reactions  
Patients with type 2 reactions have high quantities of antibodies and M. leprae antigens. 
The relative increase in the antigen concentrations and precipitating antibodies could 
lead to formation of immune complexes, which are then precipitated out of the blood 
and can deposit in the tissues. This deposition can lead to vasculitis with 
immunoglobulin and complement activations in the vessel wall. During the ENL 
episodes, the immune complexes may lead to activation of neutrophils seen in vasculitis. 
Further, the episodes are associated with antigen-specific T cell activation. The 
mononuclear cell increase in number and release cytokines such as TNF-α (Oliveira et 
al., 1999). The over-production of TNF-α could be responsible for the tissue damage 
and systemic toxicity occurring during ENL reactions.    
Clinical features of type 2 reactions 
Clinical features of ENL reactions are usually systematic. Patients may present with 
painful, tender, erythematous skin nodules appearing in crops. Subsequently, they 
develop a generalized illness with high fever; malaise; and oedema of the hands, feet, 
and face. Other systemic involvement includes iritis, conjunctivitis, arthritis, arthralgia, 
dactylitis, lymphadenopathy, orchaitis, and renal disease. Peripheral nerves are also 
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affected in ENL, as the recurrent episodes can repeatedly affect them, and may result in 
damage. 
Treatment of type 2 reactions 
The aim of type 2 reaction management is to control pain and inflammation, acute 
neuritis, and eye damage. For mild cases, aspirin may be used, but many cases require 
treatment with steroids and an increased dose of clofazimine (up to 300mg) (Britton and 
Lockwood, 2004) or thalidomide. The anti-inflammatory effect of clofazimine has 
reduced the incidence of ENL reactions (Lockwood, 1996). Thalidomide is the 
treatment of choice for severe ENL but its availability and teratogenicity limits its use 
(Walker et al., 2007). It is given in a dose of 400 mg daily until the reaction is controlled, 
and then reduced gradually to 50mg daily. Thalidomide treatment has been shown in 
other conditions to cause peripheral neuropathy, but not seen clinically in leprosy. 
2.1.9.3 Neuritis 
Neuritis is an important aspect of leprosy reactions, because it is difficult to classify, 
difficult to treat and is associated with disability. Patients with leprosy may experience 
neuritis at different times during the disease. Two types of patients can be distinguished: 
those with neuritis associated with both type of reactions (reversal and ENL) and those 
with pure neuritis pain. The latter may be defined as inflammation of the peripheral 
nerve trunk without features of the above mentioned reactions (Mahajan et al., 1996). 5-
10% of leprosy patients may present with pure neuritis. Those patients may present with 
spontaneous nerve pain, new sensory or motor impairment of recent onset, or mixed 
signs neuritis (Mahajan et al., 1996, Van Brakel et al., 1992). The absence of skin lesions 
and negative skin smear in those patients contribute to the delay of diagnosis (Mishra et 
al., 1995). Acute loss of function is a hallmark of neuritis in leprosy, which, if not treated 
rapidly and adequately becomes permanent. Neuritis may occur in the absence of pain 
and may go unnoticed by the patient ‘silent neuropathy’. Patient with neuritis is treated 
with standard dose of prednisolone starting at 40–60 mg daily, decreasing by 5 mg every 
2–4 weeks after evidence of nerve functions recovery (Britton, 1998, Kamath et al., 
2014). Neuritis is reviewed under the nerve in leprosy too. 
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2.2 The central role of nerve damage in leprosy 
2.2.1 Introduction and definitions  
Nerve damage is a central aspect of leprosy, affecting autonomic, sensory, and motor 
functions. It is the major cause of morbidity in leprosy. A landmark pioneering 
publication in early 1950s by Fite stated that there is no leprosy without nerve damage 
(Fite, 1951). Since then the disease is best described as a neurological condition rather 
than a simple skin problem. M. leprae has a predilection for nerve tissue and the 
associated perineural inflammation is a characteristic and hallmark of early leprosy. 
Further complications arise from the host’s immune-mediated events that occur during 
disease progression. Pain due to peripheral nerve damage and/or treated skin lesions is 
now being recognised as a late complication of leprosy among treated patients. The 
consequences of nerve damage, such as hands and feet deformities are also responsible 
for the associated social stigma and disability. 
For the purpose of the current study, the term “nerve” refers to the small dermal nerves 
and peripheral nerve trunk. The general term “neuropathy” is a clinical term used here 
to mean any detectable abnormality in a particular peripheral nerve. It includes: 
peripheral nerve damage; nerve function impairment (NFI), such as a motor or sensory 
deficit; and pain and tenderness. 
2.2.1.1 Epidemiology 
The epidemiology of nerve damage, in particular, its incidence and natural history of 
neuropathy in patients with leprosy is well documented. There have been major studies 
in large groups of patients in geographically diverse settings that have been very useful. 
Longitudinal data from the Bangladesh Acute Nerve Damage (BAND) cohort support 
the contention that most patients with leprosy have some demonstrable nerve damage 
(Richardus et al., 2004). The authors found that the level of nerve damage in 2664 newly 
diagnosed leprosy patients was high, with up to 60% of MB patients having clinically 
apparent nerve damage at the time of diagnosis. Presentation of nerve damage at 
diagnosis is also described in the ILEP Nerve Function Impairment and Reaction 
(‘INFIR’) study. Van Brakel et al. studied a cohort of 303 newly diagnosed MB leprosy 
patients for two years in India and found that 38% of patients had nerve damage at the 
time of intake into the study (van Brakel et al., 2005b). This high level of nerve damage 
at diagnosis reflects the delay of leprosy diagnosis, which often takes years and allows 
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the development of neuropathy (Van Veen et al., 2006). Damage during treatment is 
noted by Schreuder et al., who investigated 640 newly diagnosed leprosy patients from 
Thailand. The authors found that the presence of nerve impairment at time of leprosy 
diagnosis is a key risk factor for new nerve functional impairment (Schreuder, 1998). 
The study showed that the incidence of NFI among patients without any abnormalities 
at first examination while on treatment was 1.7 and 12 per 100 person-years at risk 
(PYAR) for the PB and MB patients, respectively. In addition, 2% of the PB and 11% 
of the MB patients who already had impairments at first examination developed new 
NFI while on treatment. Damage after treatment is illustrated by Saunderson et al. who 
examined 594 new leprosy cases in study known as ALERT MDT Field Evaluation 
Study (AMFES) in Ethiopia and found that 12% developed new NFI after starting 
MDT (Saunderson et al., 2000c). Nerve damage in leprosy is common; 60% of MB 
patients have nerve damage at the time of diagnosis, 30% of patients may develop 
further nerve damage during MDT treatment and 10% may develop new nerve damage 
after drug treatment. 
2.2.1.2 Risk factors 
The major risk factors for nerve damage, especially clinical rather than genetic or 
immunological, can be grouped into personal factors, visible signs, advanced stage of 
nerve involvement, and others. The personal factors are: age; sex; pregnancy; and 
lactation. The criteria for advanced stage of nerve involvement are the WHO disability 
grades and other factors are the clinical and physical state of the patient. In the INFIR 
study (van Brakel et al., 2005b), which was designed to assess measures that may predict 
NFI in a cohort of 303 previously untreated newly diagnosed MB patients, found that 
age, pre-existing sensory loss, count of enlarged nerves, and WHO grade two were the 
main predictors of NFI. A further independent risk factor for neuropathy in leprosy is 
the presence of skin lesions overlying nerve trunks (van Brakel et al., 2005b). Croft and 
colleagues (Croft et al., 2000) described a simple method, based on disease classification 
and the presence of loss of nerve function at registration, to identify patients at risk of 
developing NFI in Bangladesh. Patients who had PB leprosy with no clinical evidence 
of NFI had a low risk (about 1%) of developing further NFI with treatment. Patients 
with PB leprosy and clinically detectable nerve function loss who received standard 
treatment over two two-year observation periods had a risk of around 15% for 
developing further impairment. The highest risk (around 65%) of further NFI was seen 
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in patient with MB leprosy and clinical NFI. Additional risk factors identified in the 
INFIR cohort study were deterioration in: ulnar above-elbow motor nerve conduction 
amplitude or latency; ulnar, median, radial or sural sensory nerve conduction amplitude 
or latency; and posterior tibial or sural cold or warm sensation (Smith et al., 2009). 
2.2.1.3 Previous studies on leprosy neuropathy 
While data from previous studies on leprosy neuropathy have contributed to the 
understanding of many aspects of neuropathy, research relying on leprosy neuropathy 
has important limitations: 
 Limited opportunities to study persons early in process of neuropathy. Patients 
at diagnosis of leprosy may have already had neuropathy for some time. 
 Limited generalisability to all leprosy patients with neuropathy, because patients 
in leprosy clinics often have severe or complicated cases of neuropathy; only few 
studies are based on patients in the field. Thus, by studying clinic-based patients, 
one cannot postulate the variability in and natural course of neuropathy. 
 Limited opportunities to make a definitive diagnosis of neuropathy; various 
methods of nerve function assessment are used. The same case definition of 
leprosy neuropathy is not being applied by the different protocols. Thus, by 
using different protocols, one cannot identify the case definition of leprosy 
neuropathy.  
 Limited generalisability to all leprosy patients with neuropathy, because the 
treatment may vary (steroids, thalidomide and MDT). 
These limitations within leprosy neuropathy research suggest that the development of 
new tools may yield new insight into the course of neuropathy and its associated pain 
dysfunction. 
2.2.2 The nerve in Leprosy 
2.2.2.1 The nerve, M. leprae and host immune response interactions 
The nerve damage in leprosy is characterised by the unique interaction of the M. leprae, 
the Schwann cell, and the host immune response; the mechanism underlying this 
process is still very poorly understood (Scollard, 2008).  
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Following entry into the human, M. leprae grows preferentially in the coolest and most 
superficial nerve branches, affecting the Schwann cells of the unmyelinated small 
sensory fibres. It has been suggested that in the skin, M. leprae first binds to exposed 
Schwann cells and then moves proximally within the nerve (Khanolkar, 1964). 
However, a more recent study from animal models indicated that M. leprae infects nerves 
via lymphatics and blood vessels. The authors postulated that M. leprae first aggregates in 
epineurial lymphatics and blood vessels and then enters the endoneurial compartment 
through its blood supply (Scollard, 2000, Scollard et al., 1999). At this stage, M. leprae 
targets the Schwann cell where several potential mechanisms of binding have been 
suggested (Ng et al., 2000, Rambukkana et al., 1997, Suneetha et al., 2001). The phenolic 
glycolipid-1 (PGL-1) of M. leprae binds specifically to the native laminin-2 in the basal 
lamina of Schwann cell axon units (Ng et al., 2000). Rambukkana has demonstrated that 
M. leprae specifically binds to α-dystroglycan in the presence of the G domain of the α2 
chain on laminin-2 (Rambukkana et al., 1997). Other studies have also demonstrated the 
ability of myelin P0 to bind M. leprae (Suneetha et al., 2001). Once invaded, the Schwann 
cell provides a suitable environment for M. leprae. The blood-nerve barrier in the 
peripheral nervous system protects M. leprae from host immune attack (Job, 1989). At 
this stage, M. leprae appears to persist and grows slowly within Schwann cells.  
There are arguments about the M. leprae Schwann cell interactions. Proponents of 
interactions between M. leprae and Schwann cells claim that the benign characteristic of 
M. leprae may contribute to this favourable environment. For instance, M. leprae is non-
toxic and therefore, it does not harm the Schwann cell. They also maintain that the 
presence of M. leprae in the nerve may enhance Schwann cell survival in order to 
maintain the affected cell in an active stage (Lahiri et al., 2010, Tapinos et al., 2006, 
Hagge et al., 2002, Rambukkana et al., 2002). However, such an argument discounts the 
fact that M. leprae constantly interacts with host cells in the nerves and skin. It should be 
evident that the argument against the M. leprae Schwann cell interaction is not valid. On 
the contrary, studies have shown that human Schwann cells express toll-like receptor 2 
(TLR2), and that the activation of TLR2 by M. leprae can lead to apoptosis (Oliveira et 
al., 2003). Furthermore, it has been shown that even in the absence of immune cells, M. 
leprae induced ErbB2 activation mediates demyelination (Rambukkana et al., 2002, 
Rambukkana, 2004). More recently, Masaki et al. (Masaki et al., 2013), investigated the 
interactions between M. leprae and Schwann cells and suggested a novel model to explain 
the spread of the infection. This study suggested that M. leprae bacillus not only interact 
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with Schwann cells, but also change its fate to become progenitor/stem cells with 
mesenchymal characteristics that promote bacterial dissemination (Masaki et al., 2013). 
However, these models have not been supported by human studies or even armadillo 
studies. In summary, the interaction between Schwann cells, M. leprae, and host immune 
responses yields nerve damage in leprosy. 
2.2.2.2 Nerve damage mechanisms across the leprosy spectrum 
The process of nerve damage in leprosy occurs gradually through the course of the 
disease and its presentation differs at different stages of the disease. Following entry into 
the human, M. leprae affects the Schwann cells of the unmyelinated small sensory fibres. 
In addition, the immune response to M. leprae may aggravate nerve damage, either by 
inflammatory and immune-mediated processes, or oedema induced mechanical 
processes (Haanpaa et al., 2004). 
Several factors contribute to the development of nerve damage in leprosy. The direct 
presence of M. leprae within Schwann cells results in immunological stimulation. This 
interaction is mediated by toll-like receptors (TLRs), which kills Schwann cells and 
causes nerve damage (Krutzik et al., 2003, Oliveira et al., 2003). The presence of M. 
leprae enhances HLA-II expression on Schwann cells; mycobacterial peptides are 
presented to HLA-II-restricted CD4+ T cells, which can attack and damage Schwann 
cells. Additionally, activated natural killer cells may participate in these Schwann cell 
damaging processes. Another possible contributing factor for nerve damage is the ability 
of T cells to recognise the presence of mycobacterial antigens within the nerve, which 
contributes to chronic ongoing neural inflammation. Swelling within the perineurium 
leads to ischaemia, fibrosis, axonal death, and nerve damage. Furthermore, the presence 
of pro-inflammatory cytokines such as TNF-α in the affected nerve may also contribute 
to nerve damage. The direct effect of M. leprae on the nerve’s protein also promote 
nerve damage (Save et al., 2004).   
The unique pathology of nerve damage in leprosy is probably determined by the host’s 
immune response, which differs across the leprosy spectrum. Additionally, the different 
clinical outcomes within leprosy sub-types may also contribute to the process of the 
nerve damage.  
The two main processes of nerve damage are wallerian degeneration and demyelination. 
In tuberculoid disease (TT), the predominant process is wallerian degeneration. Patients 
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in this group have vigorous cell-mediated immune responses to M. leprae that lead to 
granuloma formation with gross destruction of the nerve fibres. The epithelioid cell 
response to bacilli within the nerve is a characteristic of this type of leprosy. It forms 
cuffs of epithelioid cells that enclose the nerve as a whole (Fite, 1951). Histologically, 
the bacilli are found in fair numbers within the nerve itself, but rarely in the granuloma. 
Clinically, the nerve damage occurs early, and may be severe, but is not widespread in 
the body (Britton and Lockwood, 2004).  
In contrast, the predominant process in the other group, lepromatous leprosy (LL), is 
demyelination. Patients with a lepromatous-type disease show very poor cell-mediated 
immune responses, but vigorous humoral responses. The bacilli are seen in every part of 
the nerve fibre, intensifying around Schwann cells. There is therefore demyelination and 
damage of the nerve fibres. The nerve fibres are less severely damaged compared to 
tuberculoid leprosy (Britton and Lockwood, 2004).  
In the borderline (BB, BT and BL) groups, the nerve damage is obvious. It is explained 
by the instabilities between the cell-mediated and humoral immune responses. The 
nerve damage process may be cell-mediated and/or humoral to varying degrees. Patients 
in this group may have a mix of direct effects of the M. leprae and inflammatory 
immune-mediated pathology (Haanpaa et al., 2004). 
2.2.3 Clinical presentations 
The clinical presentation of leprosy patients with nerve damage depends on two 
features: damage of small dermal nerves and/or the peripheral nerve trunks. Although 
symptoms related to cutaneous loss of sensation occurs early in leprosy, the majority of 
patients present with symptoms of skin lesions or reactions (enlarged, painful and 
tender nerve). Besides this, a considerable proportion of patients present with a 
weakness in their hands, feet or face caused by motor involvement. The high number of 
patients presenting with clinically apparent nerve damage reflects the delay between the 
appearance of early leprosy skin lesions and diagnosis.  
Loss of sensation (cutaneous anaesthesia) 
The loss of sensation and autonomic nerve fibre functions in affected skin lesions is an 
early manifestation of the disease. Patients may have impaired thermal perception (to 
temperature), nociception and touch sensation. The skin may be dry due to autonomic 
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fibre damage. Damage to the peripheral nerve trunks leads to regional sensory loss. 
These sensory abnormalities may be confined to the innervated territory of the affected 
peripheral nerves or it may show a glove and stocking distribution when it is severe and 
widespread. 
Nerve thickness, tenderness and pain:  
Patients with affected peripheral nerve trunks have thickened peripheral nerves, with or 
without tenderness and standard regional patterns of sensory and motor loss 
corresponding to the nerve affected. A thickened or enlarged peripheral nerve, with loss 
of sensation and/or weakness of the muscles supplied by that nerve is one of the 
cardinal signs for a leprosy diagnosis (WHO, 2012). The nerve can be enlarged palpably 
in 40-55% of patients and it may be noticed by the patient, especially if it is painful or 
tender. In leprosy, certain nerves at certain sites are often more involved than others. 
This difference may be explained by the characteristics of M. leprae, which multiplies at 
relatively low temperatures and has an affinity for Schwan cells. The nerves most likely 
to be involved are therefore the peripheral nerve trunks in the upper and lower 
extremity, including: the ulnar nerve at the ulnar grove; the median nerve at the wrist; 
the cutaneous branch of the radial nerve at the lateral border of the radius; and the 
lateral popliteal nerve around the neck of the fibula. Figure 2.4 shows the most 
commonly enlarged nerves and the sites of enlargement in leprosy-affected patients. 
Studies have shown that the ulnar nerve is the nerve most commonly affected by 
leprosy. Haroun et al. (2012) found that in a cohort of 80 leprosy patients who had 
completed MDT within 18 months, the ulnar nerve was the nerve most frequently 
affected (78%) (Haroun et al., 2012). Nerve enlargement can be identified by clinical 
examinations although this is not always reproducible. However, the degree of 
enlargement has little bearing on the severity of neuropathy. Nerve pain and tenderness 
is known as neuritis, which may be defined as inflammation of the peripheral nerve 
trunk without features of reactions (Mahajan et al., 1996). Patients with neuritis may 
present with spontaneous nerve pain or recent onset of new sensory or motor 
impairment (Mahajan et al., 1996). The nerve pain/tenderness may be so severe that 
even gentle palpation produces an electric shock-like sensation. A detailed description of 
the peripheral sensory fibres and function is discussed in Chapter 4. 
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Weakness:  
Depending on the sites of the enlargement of the peripheral nerve trunk, the number of 
affected nerves and disease sub-type, the standard regional pattern of motor loss may 
include: claw hand; foot drop; and/or facial muscle weakness. The ulnar innervated 
muscles of the hand and forearm, the median innervated muscles in the hand, the tibial 
innervated muscles in the foot, the peroneal innervated muscles in the foot and the leg, 
and the facial innervated muscles are most commonly affected by the disease.  
2.2.3.1 Clinical presentation of nerve damage across the leprosy spectrum 
As described above, the involvement of peripheral nerves in patients with leprosy is 
clinically different across the disease spectrum as follows: 
Neuropathy in tuberculoid leprosy:  
The clinical neuropathy of tuberculoid leprosy is characterised by asymmetrical 
enlargement of a single nerve. Damage to the small dermal sensory and autonomic 
nerves produces hypoesthesia and anhidrosis (Bryceson and Pfaltzgraff, 1990). Marked 
nerve damage can occur in nerves underlying or surrounding skin lesions, which may 
result in wrist drop, clawing of the hand, and/or foot drop. 
Neuropathy in lepromatous leprosy:  
Nerve damage in lepromatous leprosy is slow and progressive. It characterised by 
bilateral symmetrical distal polyneuropathy. The damage to the small dermal sensory and 
autonomic nerves produces glove and stocking sensory loss. Damage to the nerve trunk 
produces bilateral and symmetrical thickening and tenderness, which may result in distal 
weakness of the intrinsic muscles of hands and feet.  
Neuropathy in borderline leprosy:  
In contrast to that seen in tuberculoid and lepromatous leprosy, nerve damage in 
borderline leprosy has a relatively rapid onset and acute progress. It is characterised by 
irregular and asymmetrical neuropathy. Damage to the small dermal sensory and 
autonomic nerves produces hypoesthesia and anhidrosis (Bryceson and Pfaltzgraff, 
1990). Multiple affected nerves produces deformities in the hands and feet. 
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Figure 2.4. Commonly affected peripheral nerve in leprosy 
Picture modified from Khambati and colleagues (Khambati et al., 2009) 
2.2.4 Nerve function assessment  
It is important to carry out a full/routine clinical assessment of nerve function in 
leprosy, as early detection of neuropathy will reduce the incidence of impairment and its 
effects. A comprehensive overview of the detailed methods for the assessment and 
detection of neuropathy will be explored further in Chapter 4, including the instruments 
for assessing of sensory abnormalities and pain-related phenomena. 
2.2.4.1 Assessment of neuropathy:  
History and clinical examination 
The clinical history (described in section 2.1.6.1) is followed by palpation of the 
involved nerves to assess for nerve size, and tenderness.  
Nerve assessment includes motor, sensory and autonomic functions. Table 2.2 shows 
different modalities of nerve fibre functions. A detailed description of the peripheral 
sensory fibres and function is discussed in Chapter 4. Aα/β fibres are large in diameter, 
myelinated and have fast conduction velocity (Barrett et al., 2010). They are normally 
activated by non-noxious mechanical stimuli such as touch. In contrast, Aδ fibres are 
medium in diameter, myelinated and have intermediate conduction velocity (Barrett et 
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al., 2010). They are normally activated by noxious stimuli and transmit sharp pain. C 
fibres are small in diameter, unmyelinated and have slow conduction velocity (Barrett et 
al., 2010). They are normally activated by noxious stimuli responsible for secondary 
pain, like burning and aching pain. These modalities can be assessed using 
electrophysiological methods such as nerve conduction study, cold and warm 
temperature sensation assessment or monofilaments. 
Table 2.2. Physiological function of the motor, sensory and autonomic 
nerve fibres 
Motor Sensory Autonomic  
Myelinated Thinly myelinated Un-myelinated 
Muscle 
control 
Touch, vibration, 
position perception 
Cold perception, 
pain 
Warm 
perception, pain 
Sweating  
 
The choice of the test for the nerve function assessment depends on the availability of 
the tool and availability of qualified trained staff. For leprosy, nerve functions have been 
assessed using different methods such as cotton-wool, monofilaments, voluntary muscle 
testing, nerve conduction study and biopsies.  
Assessment of autonomic nerve fibre function: The assessment of autonomic 
components of the nerve includes testing for sweating of the hands and feet.  
Assessment of sensory function: Ideally testing should be for light touch, light 
pressure, pain and temperature, but it is rarely done in the field. The performance of the 
test depends on the availability of the tools and qualified trained staff. Light touch is the 
most frequent sensory modality assessed using different methods such as cotton wool, a 
ball point pen, and Semmes-Weinstein Monofilaments (MFs) in resource-limited 
settings (Brandsma et al., 2014). 
Assessment of motor function: The assessment of motor components of the nerve is 
done by voluntary muscle testing in the face, hands and feet. Voluntary muscle testing 
assesses innervated facial muscles, ulnar and median nerves of the hand and common 
peroneal nerves of the feet using a modified Medical Research Council (MRC) scale 
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(Brandsma, 2000). MRC is a modified grading system to assess muscle weakness due to 
peripheral nerve involvement. It asses voluntary movement against resistance. 
Voluntary muscle assessment is suitable for measuring NFI in a resource- limited 
setting. In a cohort study of 303 untreated MB patients from India, assessing the 
sensitivity and specificity of MFs and VMT using nerve conduction study as the gold 
standard for detecting NFI (Van Brakel et al., 2005a). The authors found that the 
concordance between VMT results and motor nerve conduction was good for the ulnar 
nerve, but very few median and peroneal nerves with abnormal conduction had an 
abnormal VMT. The authors also noted that both methods have good inter-tester 
reliability and reproducibility and good specificity of more than 80% for most nerves. A 
similar study on different tests of nerve function by Khambati and colleagues supports 
the conclusion that MFs and VMT have good specificity, but moderate-to-low 
sensitivity of less than 40% in detecting nerve involvement using NCS as a gold 
standard (Khambati et al., 2009). 
2.2.4.2 Disability grading  
The physical impairment associated with nerve damage in leprosy occurs mainly in the 
hands, feet and eyes. It can be assessed using WHO disability criteria, which defines 
grade zero as no loss of sensation or visible deformity, grade one as a loss of sensation 
without visible deformity, and grade two as the presence of visible deformity (WHO, 
1988). 
Physical disability from nerve damage in leprosy can occur before, during and after 
MDT. A recent survey of 1358 leprosy patients who had been released from MDT up 
to 5 years earlier in Indonesia found that 77% of the patients had a physical impairment 
(van Brakel et al., 2012). In the INFIR Cohort Study in India, 40.9% of the newly 
diagnosed Indian patients had a WHO disability grade of one and 9.6% had a disability 
grade of two at enrolment (van Brakel et al. 2005). The BANDS cohort had a 
prevalence of disability grades one and two of 9.6% and 6.0%, respectively (PB and MB 
patients) at enrolment. Among MB patients, the prevalence of disability grades one and 
two was 28.5% 18.2% respectively (Croft et al. 1999).  
WHO’s current ‘Enhanced global strategy to further reduce the disease burden due to 
leprosy’ aims to reduce the rate of new cases diagnosed with disability grade two (WHO, 
2009a). The reduction of grade two disability is one of the new indices for successful 
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leprosy burden reduction as well as a marker for early detection of nerve damage. In 
2011, a WHO report showed the proportion of grade two disability in newly diagnosed 
leprosy cases varied between India at 3% and China at 27% (WHO 2012a).  
2.2.5 The differential diagnosis of neurological lesions of leprosy 
The neurological disorders that share the similar features to leprosy are many, but most 
do not have sensory loss. In a patient from an endemic area and with enlarged nerves, 
Amyloidosis, Neurofibromatosis, Sarcoidosis, and Vasculitis may need exclusion. For 
peripheral neuropathy with generalized neuropathy rather than attributed to a specific 
nerve innervation, conditions such as Guillain-Barré syndrome, Vitamin B12 deficiency, 
HIV/AIDS, Alcoholism, Hypothyroidism, Hereditary disorders, and heavy metal 
poisoning will require consideration and appropriate investigation. If motor 
involvement is prominent, the possibility of trauma, Dupuytren's contraction, Cervical 
rib, and Scleroderma will arise. Leprosy ulcer has to be distinguish from tropical ulcer 
and other trophic ulcers. Tropical ulcer is the commonest cause of ulceration in the 
poorer leprosy-endemic countries. Ulceration in the presence of sensory loss can be 
seen also in Diabetic Mellitus, the most common cause of sensory neuropathy.  
2.2.6 Nerve damage consequences in leprosy 
Nerve damage is incapacitating for many people in countries where leprosy is endemic. 
Patients may develop dryness of the skin, impairment of various sensory modalities, and 
motor impairment causing muscle weakness. But with time and without appropriate 
care, these impairments may lead to skin cracks, wounds, clawing of digits, contractures 
and shortening of limbs, and blindness (Bryceson and Pfaltzgraff, 1990). Impairments 
may interfere with quality of life and activities of daily living. Therefore, patients 
continue to be stigmatised and suffer from associated co-morbidities. 
Paradoxically, although leprosy is classically associated with sensory loss affecting the 
hands and feet, pain due to peripheral nerve damage and/or skin lesion may become a 
problem for some patients. Those patients who do experience pain may develop an 
additional quality of life burden over that of leprosy itself or leprosy with painless nerve 
damage. It is not known why some leprosy patients develop painful neuropathy while 
others are pain-free throughout the course of the disease. 
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Chapter 3 Identification of neuropathic pain 
3.1 Literature review of pain 
3.1.1 Definition of pain 
Pain is defined by the International Association for the Study of Pain (IASP) as “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage” (Merskey and Bogduk, 1994). The 
unpleasant is perceived in the brain in the response of afferent activity in nociceptive 
sensory neurons. However, pain is more than a sensation, or the physical awareness of 
pain; it also involves affective aspects. This gives further information on the pain’s 
nature, intensity and location. Other factors such as social, psychological and 
behavioural aspects of pain are also not considered in this definition. These factors need 
to be taken into consideration in any interaction with the patient (McMahon SB et al., 
2013). The inclusion of the various cultural and behavioural aspects to pain would add 
further definition to the overall concept of pain. 
3.1.2 Classification of pain 
Pain can be classified into “nociceptive” or “neuropathic” types, Table 3.1. 
3.1.2.1 Nociceptive pain 
Nociceptive pain occurs as a result of tissue damage in response to a noxious stimulus, 
such as impending tissue injury, ongoing tissue destruction, or inflammation, in the 
presence of intact sensory nerve system e.g. osteoarthritis.  
3.1.2.2 Neuropathic Pain 
Neuropathic Pain is defined by the IASP as “pain caused by a lesion or disease of the 
somatosensory system” (Jensen et al., 2011).  
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Table 3.1. Nociceptive pain vs. Neuropathic pain 
 Nociceptive Pain Neuropathic Pin 
Definition Pain caused by physiological 
activation of pain receptors 
Pain arising as a direct consequence 
of a lesion or disease affecting the 
somatosensory system 
Symptoms Local +/- referred pain At the neuro-anatomical lesion 
Quality of 
symptoms 
Easy to describe by patients 
(Good clinical descriptors) 
Difficult to describe by patients 
(Poor verbal descriptors) 
Treatment Good response Poor to moderate response 
 
3.2 Literature review of Neuropathic pain  
3.2.1 The concept of neuropathic pain 
Neuropathy is defined as the disturbance of function or pathological change in a nerve 
(Merskey and Bogduk, 1994); therefore, NP is pain arises from this process. NP can 
occur as a result of a lesion or disease of the somatosensory system at the brain and 
spinal cord (central pain); or posterior roots and peripheral nerves (peripheral 
neuropathic pain). The definition of NP has been changed over the time due to a 
change in the use of terms referring to pain caused by sensory abnormalities, and 
uncertainties about the pathophysiology of chronic pain states. Originally NP term 
referred to pain due to peripheral neuropathies, but this brought out some difficulties 
such as the ability to distinguish neuropathic dysfunction from psychological 
interference. For instance, in patients with leprosy, chronic ulcer, arthralgia, skeletal 
deformities and depression may all significantly contribute to symptomatology of pain. 
Later in 1994, this definition was broadened to include the term “dysfunction”, where 
the IASP defined NP, as “a pain initiated or caused by a primary lesion or dysfunction 
in the peripheral or central nervous system” (IASP, 1994). Recently, this has been also 
revised by a group of pain experts on the basis of how it could be distinguished from 
nociceptive pain (Treede et al., 2008) . In the new definition the word “dysfunction” has 
been removed and the phrase “a lesion or disease affecting the nervous system” has 
been specified to be “a lesion or disease of the somatosensory system”.   
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3.2.2 Epidemiology  
The prevalence of NP among the general population is variable and influenced by the 
rates of aetiology of the underlying disease and the method of assessment (Smith and 
Torrance, 2012). Torrance et al. (2006), who surveyed 3 002 people from the general 
population in the UK through a postal survey using the Leeds Assessment of 
Neuropathic Symptoms and Signs score (S-LANSS), noted that 8.2% had pain of 
predominately neuropathic origin (Torrance et al., 2006). Bouhassira et al. (2008), who 
investigated the epidemiology of NP among 23 712 participants using “Douleur 
Neuropathique en 4 questions” (DN4) sent to 30 155 randomly selected adults in the 
“Acess Sante” data base, found that 6.9% of them had chronic pain with neuropathic 
characteristics (Bouhassira et al., 2008). NP affects as much as 8% of general population 
and in 5% of these cases, it may be severe (Torrance et al., 2006, Bouhassira et al., 
2008). These prevalences are related to wealthy western societies and may not 
necessarily reflect the occurrence of NP in developing countries. Table 3.2 shows the 
prevalence of peripheral NP in different conditions estimated from single studies. 
Table 3.2. The prevalence of NP in different conditions 
Condition   Neuropathic pain prevalence  
Diabetic Mellitus   Prevalence 8% (Wu et al., 2007) and 20% (Davies et al., 2006) 
Post herpetic neuralgia 
(PHN) 
Prevalence ranging from 2.6 to 7.2% (Choo et al., 1997, Helgason 
et al., 2000, Scott et al., 2003) 
HIV sensory neuropathy  42% (Smyth et al., 2007) 
 
3.2.3 Neuropathic pain classification and aetiology  
Neuropathic pain may result from disorders of both the peripheral and central nervous 
system. This classification is based on the anatomical site of the lesion, even though 
traditionally NP has been classified according to the aetiological diagnosis. The 
underling nerve damage may occur due to metabolic, ischemic, hereditary, traumatic, 
toxic, infectious or immune-related cause. Of those, the major causes of NP include: 
peripheral nerve trauma, spinal cord injuries, diabetes mellitus, multiple sclerosis, herpes 
zoster, and HIV infection (Merskey and Bogduk, 1994, Attal et al., 2008).  
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3.2.4 Development of neuropathic pain 
The development of NP arises from pathological responses in somatosensory systems 
in response to nerve damage. NP and associated sensory aberrances probably represent 
disordered repair process in response to damage. It is important to note that NP is not 
an inevitable consequence of nerve damage; the minority of patients develop NP after 
somatosensory insult. Pathophysiological underlying mechanisms, either in the 
peripheral or the central nervous system, may lead to symptoms such as spontaneous 
pain or stimulus-evoked pain, as well as other associated sensory disturbances such as 
sensory loss (anaesthesia dolorosa), hyperalgesia, allodynia and hyperpathia. These 
collections of symptoms and signs are known as NP syndrome. The exact constellation 
of NP characteristic, and associated sensory aberrations, which are manifested in an 
individual patient are variable and complex and often only fully revealed by the use of 
sophisticated investigation techniques (Jensen and Baron, 2003, Baron et al., 2009). 
These patterns do not necessarily reflect the condition from which the nerve damage 
arose, but importantly may well reflect pain generating mechanisms and therefore give a 
clue to mechanisms and thus likely drug responses on an individual patient level. Thus, 
it is vital to accurately phenotype the sensory abnormalities in each patients. 
3.2.5 Neuropathic pain underling mechanisms  
Animal research and the use of human investigative techniques such as 
microneurography, functional brain imaging, quantitative sensory testing, skin punch 
biopsies and experimental human pain models have furthered human pain research. The 
rationale for the mechanism-based approached is to stratify patients according to 
mechanism and therefore have mechanism-based prescribing of appropriate drugs at the 
individual patient level. However, the mechanisms of NP have not yet been fully 
established and research has yielded an array of potential pain generating mechanisms 
any of which may be operating in an individual patient. This further emphasises the 
necessity of properly phenotyping patients as discussed in the preceding section. The 
broad domains of possible underlying patho-physiological pain related phenomena 
which might contribute to NP development (Baron, 2006, Bridges et al., 2001, Baron, 
2009, Baron et al., 2010a, Costigan et al., 2009), are described in Table 3.3. However 
none of them are unifying hypotheses for the NP mechanism (Bridges et al., 2001).  
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Table 3.3. Possible neuropathic pain mechanisms 
Neuropathic pain underling mechanisms * 
Peripheral mechanisms Central mechanisms  
Sensitisation and spontaneous activity in 
sensory neurons    
Sensitisation in the spinal cord 
Inflammation induced ectopic activities Central sensitisation (changes in the brain) 
Loss of trophic support for neurons  Loss of inhibitory controls and increased 
facilitation of pain signalling  
Alteration in ion channel  
Immune-neuronal interaction Neuronal immune and glial cell interactions 
* Cited in Ralf Baron (Baron, 2006),  Wallace VCJ and Rice ASC (Wallace and Rice, 
2008), Costigan and colleagues (Costigan et al., 2009), and Scholz J, Woolf CJ (Scholz 
and Woolf, 2007) 
3.2.6 Clinical features of neuropathic pain 
3.2.6.1 Symptoms 
Patients with NP commonly present features of spontaneous pain and/or stimulus 
evoked pain. The onset of these symptoms usually occurs soon after nerve damage. The 
overall intensity of pain rated symptoms in patients with NP is higher compared to 
nociceptive pain, possibly due to paroxysmal episodes (Wilkie et al., 2001). A brief 
description of these different types of pain is given below. 
Spontaneous pain 
Spontaneous pain, which is described as pain arise without stimulus, can be continuous 
or paroxysmal (McMahon SB et al., 2013). Continuous pain is described in terms of 
dysaesthesia: burning, pricking, tingling, cutting, and stabbing; or deep pain which 
described as aching, cramping, throbbing, and crushing. A recent definition of 
spontaneous pain as pain due to neuropathic spontaneous discharge in somatosensory 
neurons that is caused by changes that are intrinsic to the neuron was introduced 
(Bennett 2012). This definition was introduced by Bennett due to uncertainty about the 
concept of spontaneous pain making no sense when the pain is the result of an ongoing 
inflammatory reaction. Although spontaneous pain can be hardly distinguished from 
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ongoing pain, which is defined as pain due to inflammatory ongoing discharge caused 
by the ongoing presence of the products of inflammation, it might lead to ongoing pain. 
Spontaneous pain commonly occurs in neuropathic pain patients. For example, 100% of 
1 236 patients with NP reported spontaneous pain, usually shooting, burning, or 
electric-shock like sensation (Maier et al., 2010).  
Stimulus-evoked pain 
Stimulus-evoked pain, which is described as abnormal responses to stimuli, is often 
referred to hyperalgesic and allodynic. It is characterised by hypersensitivity of the 
nervous system. 
Hyperalgesia (increased sensation of pain in response to normally painful stimuli), 
allodynia (pain in response to normally non-painful stimuli) and hyperpathia (explosive 
pain response when stimulus intensity exceeds sensory threshold)  are features of 
sensory gain (Baumgartner et al., 2002) (Cavenagh et al., 2006).      
3.2.6.2 Signs 
The demonstration of nerve damage dysfunction is essential evidence in the diagnosis of 
neuropathic pain. Damage can be due to motor, sensory or autonomic dysfunction 
attributable to a lesion of the afferent transmission system. A loss of sensation/ 
“negative” signs may result due to complete or partial loss of input to the nervous 
system and a corresponding sensory loss. A reduction of afferent input caused by a 
nerve lesion may contribute to regeneration and loss of inhibitory output with 
development of hypersensitivity resulting in gain of sensation/ “positive” signs (Jensen 
and Baron, 2003). These loss and gain signs can be demonstrated by clinical 
examinations and laboratory testing such as quantitative sensory testing. 
Negative signs:  
Negative signs refer to loss of sensory and/or motor function due to nerve damage. 
Loss of sensory function is usually to thermal and noxious stimuli, indicating damage to 
small-diameter afferent fibres or to the spino-thalamic tract. Sensory loss manifestations 
can result in loss of thermal sensations, light touch, pinprick, and vibration.  
Loss of motor functions result in muscle wasting with motor weakness.  
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Positive signs:  
Positive signs in patients with NP usually result from stimulus evoked pain. It can be 
exaggerated responses to stimuli with either reduced pain threshold (allodynia), normal 
pain threshold (hyperalgesia) or increased pain threshold (hyperpathia). Allodynia is 
defined as pain due to a stimulus that does not normally provoke pain (Merskey and 
Bogduk, 1994). Different types of allodynia are associated with different stimuli: 
mechanical, thermal and dynamic. Hyperalgesia is defined as increased pain from a 
stimulus that normally provokes pain (Merskey and Bogduk, 1994). Hyperpathia is a 
painful syndrome characterized by an abnormally painful reaction to a stimulus, 
especially a repetitive stimulus, as well as an increased threshold (Merskey and Bogduk, 
1994). 
3.2.7 Diagnosis and assessment of neuropathic pain 
Clinical evaluation is the common method for diagnosing neuropathic pain. It involves a 
series of systematic steps which include past and present history, a detailed description 
of pain distribution, quality and intensity of pain and a neurological examination with 
the emphasis on sensory testing (Jensen et al., 2001, Hansson, 2002). There are two 
definitive steps in the process: firstly to confirm that some form of damage to the 
somatosensory system has occurred, without this the diagnosis is impossible. Secondly, 
to determine that any pain is indeed neuropathic, this because the occurrence of nerve 
damage does not necessarily follow that any pain is neuropathic in origin, therefore 
screening tools such as DN4 may help in identifying symptoms and signs suggestive of 
NP. The sensory findings should be neuroanatomically logical and compatible with a 
definitive lesion site (Treede et al., 2008).  
Patients may be classified as having NP according to the grading system for NP 
diagnosis, Table 3.4. The grading system considers pain to be definitive NP if all criteria 
are present, probable NP if criteria “1” and “2” are present, plus either “3” or “4,” and 
possible NP if criteria “1” and “2” are present, without confirmatory evidence from “3” 
or “4” (Treede et al., 2008).  
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Table 3.4. Grading system for neuropathic pain 
Criteria to be evaluated for each patient 
1. Pain with a distinct neuroanatomically plausible distribution 
2. A history suggestive of a relevant lesion or disease affecting the PNS or CNS 
3. Demonstration of the distinct neuroanatomically plausible distribution by at least one 
confirmatory test 
4. Demonstration of the relevant lesion or disease by at least one confirmatory test 
 
Recently, a comprehensive guideline on neuropathic pain assessment has been 
developed by the assessment committee of the Neuropathic Pain Special Interest Group 
(NeuPSIG) of the International Association for the Study of Pain (IASP) (Haanpaa et 
al., 2011a). The guideline identifies five areas for the assessment as follows: investigation 
of underlying disease, evidence of somatosensory system dysfunction, confirmation pain 
is neuropathic pain, severity of pain, and the impact of the pain. 
The diagnosis and assessment of neuropathic pain is discussed in detail in Chapter 4.  
3.2.8 Psychological co-morbidity, quality of life and neuropathic pain 
Neuropathic pain is associated with psychological problems which impact upon quality 
of life. It interferes with physical and psychological functioning and causes disability 
(Fishbain et al., 1997). The International Classification of Functioning, Disability and 
Health describes functioning as “the complex interplay of body functions, body 
structures, activities and participation, environmental and personal factors” (WHO, 
2009b). Disability is defined as “a physical or mental condition that limits a person’s 
movements, sense or activities” (Oxford, 2009).  
There is good evidence that depression is a consequence of chronic pain in other 
conditions (Fishbain et al., 1997). Williams et al. found a high prevalence of depression 
(33%) in 483 patients with neurological problems followed for 12 months; pain was 
more likely to persist in those with depression and depression was more likely to persist 
in those with coexistent pain (Williams et al., 2004). This was supported by independent 
effect of antidepressant drugs on pain and depression.  A study carried out by Meyer-
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Rosberg et al. in 2001 assessed 126 patients suffering from NP due to a peripheral nerve 
lesion, recruited from two multidisciplinary pain clinics in Sweden (Meyer-Rosberg et al., 
2001). The study identified depression, anxiety, altered sleep patterns, social isolation 
and reduced employment status as important co-morbidities (Meyer-Rosberg et al., 
2001). Figure 3.1 shows co-morbidity associated with NP.  
 
Figure 3.1. Co-morbidity associated with neuropathic pain 
Patients with moderate to severe discomfort due to neuropathic pain symptoms 
(n=126), taken from study by Meyer-Rosberg (Meyer-Rosberg et al., 2001) 
 
Daniel et al., 2008, who compared NP condition in 46 patients with post-herpetic 
neuralgia with a persistent pain of nociceptive origin in 55 patients with low back pain 
from pain management clinics in Scotland and England to determine the differences in 
physical and psychological function; factors that increase difficulties; responses to pain; 
beliefs about pain and problems experienced (Daniel et al., 2008). The authors noted 
that the differences between the two groups were not on the major variables of pain, 
mood, cognition and physical function. The main differences were in factors that 
increase pain, people’s responses to pain, their beliefs about diagnosis and the cause of 
pain and the problems they reported as a result of experiencing pain.  
3.2.9 Treatment of neuropathic pain 
The management of patients with chronic NP is multifactorial. It may involve primary 
therapy for underlying neuropathy and disease, drug therapy for alleviation of pain and 
treatment of co-morbidity associated with pain. 
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3.2.9.1 Primary therapy for underlying neuropathy and disease  
Early detection and treatment of the underlying cause may reduce the risk of nerve 
function impairment; controlling hyperglycaemia may attenuate diabetic neuropathy. 
However, permanent nerve damage that leads to chronic pain does not respond 
consistently to such treatment and other therapeutic agents may be needed. 
3.2.9.2 Drug therapy for alleviation of chronic neuropathic pain 
Both oral and topical drug therapies are used to treat NP. The main classes of oral 
therapy are tricyclic antidepressants, anticonvulsants, tramadol, and opioids. Topical 
therapies include capsaicin and local anaesthetic.  
According to the European Federation of Neurological Societies (EFNS) guidelines on 
pharmacological treatment of NP, the first two classes of medication (tricyclic 
antidepressants and anticonvulsant) are recommended (Finnerup et al., 2010, Dworkin 
et al., 2007).  
Other therapies such as opioids, topical local anaesthetics, topical capsaicin (0.075% and 
8%) may be used, but the first two drugs still represent the main options for treating the 
condition and both of them are appropriate for use in developing countries (Finnerup et 
al., 2010). 
Antidepressants 
Tricyclic antidepressants have analgesic properties in addition to their antidepressant 
effect. This effectiveness has been shown in different clinical trials (Finnerup et al., 
2005). Therefore, they are commonly used for pain relief in patients with NP 
(McCleane, 2003, Sindrup et al., 2005). The analgesic effects of antidepressants are not 
fully understood and their mode of action could be predominantly via inhibition of 
reuptake of serotonin and/or norepinephrine; blocking of sodium channels; or 
anticholinergic. The most common antidepressants used are imipramine, clomipramine, 
amitriptyline, desipramine, nortriptyline, venlafaxine, and duloxetine. A combination of 
drugs is often used. For instance, duloxetine and venlafaxine which are selective 
serotonin norepinephrine reuptake inhibitors were effective in patients with painful 
diabetic neuropathy (Baron, 2011).  
Anticonvulsants 
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Anticonvulsants drugs such as oxcarbazepine, topiramate, lamotrigine, gabapentin, and 
pregabalin have an analgesic effect in chronic NP (McCleane, 2003). Anticonvulsants 
with Na+ channel actions such as carbamazepine are effective in trigeminal neuralgia 
(Baron et al., 2010a). Those acting on alpha2-delta-1 subunit of neuronal Ca++  
channels, such as gabapentin and pregabalin, show efficacy in postherpetic neuralgia, 
diabetic painful neuropathy, central pain states and other NP conditions (Finnerup et al., 
2005, Field et al., 2006).  
Opioids 
Opioid analgesics, such as morphine, codeine, methadone, and oxycodone, are used for 
the treatment of NP. Their mode of action could be predominantly via agonists at 
presynaptic and postsynaptic opioids receptors. Tramadol, which acts via inhibition of 
norepinephrine and serotonin reuptake, also has a role in the treatment of NP. Opioids 
have an analgesic efficacy the same as antidepressants; however, their use is limited, due 
to long term side effects and a lack of data supporting long term efficacy (Raja et al., 
2002). 
Capsaicin 
Capsaicin is the active component of chilli pepper, produces burning and heat sensation 
in contact to skin. Interestingly, topical application of capsaicin was found to be useful 
in relieving chronic pain caused by nerve damage. Its mode of action was thought to 
occur at C-nociceptive fibres resulted in depletion of substance P and the nociceptor 
fibres (Attal, 2000). It is available in two forms: capsaicin cream (0.025-0.075%), and 
patch (8%). The former has had varying results in patients with painful diabetic 
neuropathy, and postherpetic neuralgia, whereas the topical high-dose capsaicin patch 
was found to be effective in patients with postherpetic neuralgia and HIV neuropathy 
(Backonja et al., 2008, Simpson et al., 2008). Use of capsaicin is limited due to its short-
lived effect and burning sensation. It is predominately used as adjuvant therapy.   
3.2.9.3 Treatment of co-morbidity  
Depending on pain intensity and psychological assessment, patients with chronic NP 
may need further clinical, psychological and psychiatric treatment. 
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3.3 Pain in leprosy 
3.3.1 Types of pain in leprosy 
Patients with leprosy may experience skin and nerve pain at different times during the 
disease. Two types of patients can be distinguished: those with pain associated with 
tissue inflammation occurring during episodes of immune mediated reactions and those 
with leprosy affecting the somatosensory system.  
3.3.1.1 Nociceptive pain 
Leprosy nociceptive pain may occur due to activation of the nociceptive system either 
by tissue injury; ongoing tissue destruction such as pain around infected ulcer or swollen 
joint; or inflammation. Inflammatory pain is caused primarily by immune-mediated 
responses and can continue after completion of leprosy MDT.  
3.3.1.2 Neuropathic pain 
Leprosy neuropathic pain occurs due to damage to the somatosensory system. It may 
occurs in the skin lesions and/or nerves, even years after successful completion of the 
MDT.  
3.3.1.3 Mixed pain  
Leprosy mixed pain can occurs as a combination of both neuropathic and nociceptive 
pain; i.e., both components were present in different parts of the body. 
3.3.2 Literature review of neuropathic pain in leprosy 
3.3.2.1 Epidemiology 
Recent studies show that NP is not uncommon among leprosy patients (Haanpaa et al., 
2004). Table 3.5 shows NP studies that have been done in leprosy endemic settings over 
the last decade (Hietaharju et al., 2000, Haanpaa et al., 2004, Croft, 2004, Stump et al., 
2004, Malaviya, 2005, Lund et al., 2007, Saunderson et al., 2008). The prevalence of NP 
range from 17.5% to 56.1%, however, these studies have been cross-sectional and 
hospital-based, which might over-estimate the prevalence of pain. In a cross-sectional 
study from Ethiopia with 96 patients who had been treated for leprosy more than 10 
years prior to assessment, NP was found in 28 (29%) (Saunderson et al., 2008). Another 
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cross-sectional study on 358 leprosy patients from a referral centre in Brazil in 2004, 
reported 201 (56.1 %) of the patients had past or current moderate to severe NP that 
interfered with daily life activities (Stump et al., 2004). 
Table 3.5. Overview of studies carried out on neuropathic pain in leprosy 
Authors, year Country Type of 
study 
Number 
enrolled 
outcome 
Hietaharju 
(Hietaharju et al., 
2000) 
Bangladesh Cross-
sectional 
16 Majority of patients had a 
sensory changes suggestive 
of NP 
Stump (Stump et al., 
2004) 
Brazil Cross-
sectional 
358 56.1% of patients with 
treated leprosy had NP that 
interfered with daily life 
activities 
Lund (Lund et al., 
2007) 
India Cross-
sectional 
17 81.3% had neuropathy. All 
nerve biopsies showed 
intraneural inflammation 
Saunderson 
(Saunderson et al., 
2008) 
Ethiopia Cross-
sectional 
96 29% of patients treated for 
MB leprosy more than ten 
years previously had NP 
Lasry-Levy (Lasry-
Levy et al., 2011)  
India Cross-
sectional 
101 21% of patients had NP 
Haroun (Haroun et 
al., 2012) 
Ethiopia  Cross-
sectional 
80 17.5% of patients had NP 
Reis (Reis et al., 
2013)  
Brazil Cross-
sectional 
33 66.3% of patients had NP 
Ramos (Ramos et al., 
2014) 
Ethiopia Cross-
sectional 
74 70.3% of patients had NP 
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3.3.2.2 Psychological co-morbidity, quality of life and leprosy neuropathic pain 
Patients with leprosy have a higher prevalence of psychiatric problems, probably 
because of the chronicity of the disease, disability caused by neuropathy and stigma. 
Although several studies have confirmed that depression was the most common 
psychiatric problem, affecting between 10% and 52.4% of patients, there is little 
published literature exploring the interactions between pain, psychological status and 
quality of life among leprosy patients (Fishbain et al., 1997, Williams et al., 2004, Meyer-
Rosberg et al., 2001). A study from India in 2009, evaluated the association of chronic 
NP with psychological morbidity in 101 leprosy patients, the DN4 and GHQ-12 were 
used to identify NP and psychological morbidity, showed that 21.8% of the leprosy 
patients in the study had NP and that psychological morbidity was detected in 41% of 
patients with NP (Lasry-Levy et al., 2011). Another study, which included 80 patients 
from a leprosy centre in Ethiopia, noted that 68 (85%) of the patients had depression 
(Leekassa et al., 2004). 
3.3.2.3 Mechanisms of NP in leprosy patients 
In leprosy, there is increasing evidence that the development of neuropathic pain is 
probably immunologically mediated (Lund et al., 2007). Reactions, neuritis and 
inflammation, which are common among leprosy patients who develop NP, are a risk 
factor. The immune response in the peripheral nerves may recur and if they repeatedly 
affect the peripheral nerves, chronic-post inflammatory pain may result. Lockwood et al. 
(2002) have shown that M. leprae protein and lipid antigens are present in skin and 
nerves at the time of acute reversal reactions (Lockwood et al., 2002). A recent study, 
which examined 27 ulnar nerves of leprosy patients using nerve conduction studies in 
Brazil, showed the association between NP patients with reactions (Garbino et al., 
2011). In addition, small fibre neuropathy (SFN), which is the most common 
neurological complication of leprosy, may have a significant contribution to the 
occurrence of NP in leprosy (Hietaharju et al., 2000). Table 3.6 shows the most typical 
symptoms of NP and possible related mechanisms that may occur due to nerve damage 
in leprosy. 
 
Chapter 3 – Identification of Neuroapthic Pain 
 
65 
 
Table 3.6. NP symptoms and related mechanisms in leprosy patients* 
Symptoms  Possible related mechanism 
Dysaesthesia Ectopic discharges in Aβ fibres 
Spontaneous paroxysmal 
shooting or lancinating 
pain 
Ectopic discharges in C fibres, Inflammation induced ectopic 
activities or Immune-neuronal interaction 
Continuous spontaneous 
evoked  pain 
Peripheral nociceptor sensitisation, loss of inhibitory control or 
ectopic discharges in C fibres 
* Table adapted from Woolf and Mannion. Lancet 1999; 353: 1959-1964 
3.3.2.4 Clinical presentation of leprosy patients with pain  
Patients with leprosy NP commonly present with continuous burning pain, dysesthesia, 
paraesthesia and/or paroxysmal pain attacks (Hietaharju et al., 2000). Dysaesthesia and 
paraesthesia may occur as a result of increased expression of Na+ channels in injured 
nerve fibre which may leads to ectopic discharges in Aβ fibres (Woolf and Mannion, 
1999). Ectopic discharges in C fibres may contribute to the occurrence of paroxysmal 
shooting or lancinating pain. Continuous burning pain may occur due to peripheral 
nociceptor sensitisation, loss of inhibitory control or ectopic discharges in C fibres in 
affected nerves (Woolf and Mannion, 1999).  
A frequent finding in leprosy patients with NP is loss of pin-prick and temperature 
sensation (cold and warm). Other stimulus-dependent signs such as allodynia and 
hyperalgesia may not usually occur in leprosy patients (Hietaharju et al., 2000), but may 
occur in leprosy patients with chronic neuritis (Hietaharju et al., 2000). Allodynia, which 
is defined as pain due to a stimulus that does not normally provoke pain, and 
hyperalgesia, which is defined as an increased response to a stimulus that is normally 
painful, are typical in states with well preserved and irritated peripheral sensory fibre 
which are overactive and cause central sensitisation (Bridges et al., 2001, Baumgartner et 
al., 2002), but in leprosy there is silent inflammation and slow but complete destruction 
of the nerve (Job, 1989). Inflammatory pain is usually considered to be of nociceptive 
character, because it partly results from hyperexcitability of intact nociceptive dorsal 
root ganglion neurons innervating inflamed tissue. However, chronic inflammatory pain 
is often characterized by positive signs such as hyperalgesia and allodynia, suggesting 
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possible neuropathic component. Recent studies have shown that inflammation-induced 
nociceptor hyperexcitability is sustained by C-nociceptors, which may contribute to 
inflammatory hyperalgesia.  This may also explain why in some inflammatory conditions 
both nociceptive and NP may overlap. 
Hietaharju et al. reported detailed characteristics of chronic NP in 16 patients with 
treated multibacillary leprosy in Bangladesh (Hietaharju et al., 2000). 10 patients (62.5%) 
the pain had a glove and stocking like distribution, which suggests a distal symmetrical 
polyneuropathy, rather than mononeuropathy, in these cases. The quality of pain was 
burning in 9 (56.3%), and the occurrence of pain was continuous in 8 (50%) patients. A 
study from Brazil with 358 leprosy patients, showed that a glove (22.4%), and stocking 
(24.9%) like distribution of pain was common (Stump et al., 2004). In an Indian study 
with 17 leprosy patients with chronic NP who had completed MDT, the pain was 
burning in all patients (Lund et al., 2007). In leprosy, the presentation of painful 
neuropathy is heterogeneous, some patients have symptoms of polyneuropathy others 
may have mononeuropathy. Both neuropathies potentially may present in the same 
patients. 
3.3.2.5 Diagnosis and assessment 
Clinical evaluation is the common method for diagnosing NP in leprosy patients. It 
involves a series of systematic steps which include past and present history, a detailed 
description of pain distribution, quality and intensity of pain and a neurological 
examination with the emphasis on sensory testing (Jensen et al., 2001, Hansson, 2002). 
The diagnosis and assessment of NP in leprosy is discussed in detail in Chapter 5. 
3.3.2.6 Treatment of neuropathic pain in leprosy 
Amitriptyline for the treatment of neuropathic pain in leprosy 
Overview of amitriptyline 
Amitriptyline HCl is a tricyclic antidepressant drug, which possesses marked 
neurotrophic activity (Association, 2011). It was approved for depression by the Food 
and Drug Administration (FDA) in May 1983. Since then the drug has been widely and 
successfully used as a treatment for several conditions such as depression, nocturnal 
enuresis, migraine prophylaxis, and NP (Jang et al., 2009). 
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Amitriptyline has a well-documented efficacy on different types of NP. The drug dose is 
started at 10-25mg in the evening, and the dose is increased to adequate level of pain 
relief, with a maximum tolerated dose up to 150 mg per day. In addition, it is a known 
antidepressant drug and its effect on mood can be attained at lower doses. The 
amitriptyline dose for depression is started initially at 75mg daily in divided doses or as a 
single dose at bedtime escalated gradually as necessary to 200mg. The improvement in 
NP outcomes is independent of the effect of amitriptyline on mood (Max et al., 1987). 
The anti-cholinergic adverse effects of amitriptyline include dry mouth, constipation, 
nausea, difficulty with micturition, sweating and cardiovascular effects (Association, 
2011). These side effects are common in all tricyclic antidepressants drugs and can be 
reduced by starting with low dosages administered at bedtime. 
Amitriptyline studies for the treatment of neuropathic pain 
Previous studies on amitriptyline for the treatment of chronic NP have shown that a 
dose of 50-150mg is beneficial when used for treatment of painful neuropathy in a 
chronic disease (Max, 1987, Graff-Radford et al., 2000). These conditions include 
diabetic mellitus and post herpetic neuralgia. However, two studies found this drug to 
have no effect on HIV neuropathy compared with a placebo (Kieburtz et al., 1998, 
Shlay et al., 1998). Also, a similar study failed to find any effect of amitriptyline on 
chemotherapy induced neuropathic symptoms (Kautio et al., 2008). Appendix 53 shows 
various amitriptyline studies for the treatment of NP.   
The results of the above studies were encouraging as it has been shown that 
amitriptyline was efficacious, and superior to placebo treatment, in treating NP caused 
by diabetes and post herpes infection.  The median effective dose of amitriptyline in 
these studies was 75mg. Amitriptyline was not more effective than placebo in relieving 
pain in malignancy or chemotherapy induced neuropathy probably explained by low 
dose of 50 mg. In HIV neuropathy the results of amitriptyline have shown no 
significant pain relief. It is unknown whether this is explained by the underlying 
mechanism, because it also showed no effect in animal models (Phillips et al., 2010).  
Although there are reports on the use of amitriptyline for the treatment of chronic pain 
in leprosy and clinicians often prescribe this drug and other antidepressants in treating 
NP, there are no data from controlled studies in well-defined groups of leprosy patients 
Chapter 3 – Identification of Neuroapthic Pain 
 
68 
 
that demonstrate efficacy and guide their use. A single unpublished abstract work 
evaluating the treatment of 49 patients with leprosy and paraesthesia in a randomised 
non-blinded comparative 8-week trial at an Indian hospital was conducted in 2006. The 
author found that both amitriptyline and gabapentin produce modest improvements of 
the condition (Bhat and Khanna, 2006). 
3.3.3 Summary  
 Neuropathic pain is being increasingly recognised among leprosy patients 
 No standard methods for assessing chronic neuropathic pain in leprosy 
 Patients with leprosy may have a higher prevalence of psychiatric problems, 
probably because of the chronicity of the disease, disability and stigma caused by 
neuropathy 
 High prevalence and morbidity of neuropathic pain in treated leprosy patients 
warrant clinical trials to assess the efficacy of pain therapies for leprosy-
associated neuropathic pain. 
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Chapter 4 Instruments for assessing sensory abnormalities, 
pain disorders and techniques for assessing the 
psychological impact of neuropathic pain 
4.1 Introduction 
This chapter provides an overview of the somatosensory system and the main 
instruments for assessing sensory abnormalities used in the study, namely; instruments 
for symptoms: pain questionnaires (DN4 and PainDETECT), and quality of life and 
psychological factors (BPI and GHQ-12 questionnaires); and instruments for clinical 
signs: quantitative sensory testing (QST).  
4.2 Overview of the structure and function of the somatosensory system 
4.2.1 Introduction 
The nervous system is divided into the central nervous system (CNS) and the peripheral 
nervous system (PNS) (Figure 4.1). It integrates sensory information and controls motor 
and cognitive function. This section will focus on the somatosensory components, 
which are responsible for the sensations of light touch, vibration, temperature and pain.  
Nerve fibres in the skin are initiated in the spinal cord and traverse through the dorsal 
root ganglia which host the cell bodies, into peripheral nerves (Figure 4.1). After 
entering the skin, the nerve fibres pass in nerve bundles to the superficial dermis. These 
are small sensory fibres that provide protective sensibility. It includes small myelinated 
fibres (Aδ) and unmyleinated axons. The latter, arranged in Remak bundles, is defined 
as a non-myelin forming Schwann cell and the unmyelinated C-fibre axons that it 
ensheathes. At the dermal-epidermal junction the smaller unmyelinated fibres penetrate 
into the epidermis, where individual epidermal nerve fibres emerge from the bundles 
and shed their collagen collar and Schwann cell sheath as they pierce the dermal-
epidermal basement membrane. They penetrate through the epidermis to the stratum 
corneum, usually vertically, establishing free nerve endings (Griffin et al., 2001). In 
contrast the myelinated fibres tend to penetrate only into the dermis. Changes to these 
intra-epidermal nerve fibre densities (IENFD) are valuable in quantifying small fibre 
neuropathy. 
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Figure 4.1. The somatosensory system 
Picture modified from Backonja and colleagues (Backonja et al., 2013) 
 
4.2.2 Types and functions of the peripheral nerve fibre 
Two different methods are used to classify types of peripheral nerve fibres: letter and 
numerical classification (McMahon SB et al., 2013). The ABC classification is based on 
function, size and myelination of the fibres. Using size classification, the largest diameter 
fibres are classified as A. This group is further sub-divided into four groups; α, β, δ and 
γ. The number classification is based on conduction velocity I-IV in descending order of 
velocity. Table 4.1 shows the different types of peripheral nerve fibre and their 
classification. The table also shows the different modalities of somatosensory nerve 
fibre functions. The primary afferent fibres Aδ, Aβ and C, which transmit the initial 
stimulus from the periphery, are located in the skin. Aδ and C fibres are the main pain-
mediating nerve fibre systems. Aα/β fibres are large diameter, myelinated and have fast 
conduction velocity (Barrett et al., 2010). They are normally activated by non-noxious 
mechanical stimuli such as touch, vibration and pressure. Following injury they have 
been shown to respond to mechanical stimuli and contribute to mechanical allodynia 
(Treede and Cole, 1993). Aδ fibres are medium diameter, myelinated fibres of 
intermediate conduction velocity (Barrett et al., 2010). They are normally activated by 
noxious stimuli and transmit the rapid phase of pain, which is sharp in nature. In 
contrast, C fibres are of small diameter, unmyelinated and have slow conduction 
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velocity (Barrett et al., 2010). They are normally activated by noxious stimuli responsible 
for secondary pain; burning, dull and aching pain (Craig, 2003). Different receptors 
related to C fibres have been described, including thermoreceptors which respond to 
warming and cooling, chemo specific nociceptors and low threshold mechanoreceptors 
which respond to pressure (Meyer et al., 2006). In addition to thermorreceptors, some C 
fibres respond to mechanical, heat, irritant chemical stimuli and itch also have been 
described (Meyer et al., 2006, Lynn et al., 1996). Some groups of Aδ and C fibres, 
known as ‘silent nociceptors’ may be insensitive to chemical or mechanical stimuli, but 
some sensitised following inflammation and then can be activated by mechanical stimuli. 
This may be the underlying mechanism for hyperalgesia (Xu et al., 2000). These fibres 
are thought to be important in inflammatory pain conditions and central sensitisation 
(Weidner et al., 1999). Damage to these fibres may also leads an ongoing pain and if this 
associated with sensory abnormalities the pain is defined as neuropathic pain (Jensen et 
al., 2011).   
4.2.3 Somatosensory receptors 
All the peripheral terminal branches of a primary axon form only one type of 
somatosensory receptor. Based on function, these sensory receptors can be divided into 
three groups: mechanoreceptors, thermoreceptors and nociceptors. The former contains 
ion channels that respond to stretching or changing in tension of the surrounding 
membrane. They mediate the sensations of light touch, pressure, vibration, flutter, limb 
position and movement. The second group has receptors for warm or cold stimuli. The 
third one is selective for different types of noxious stimuli such as thermal, mechanical, 
and chemical. These stimuli are those that can cause tissue damage.  
Signals from these receptors are transmitted to the central nervous system (Table 4.1). 
Each sensory neurone in the peripheral has a cell body in the dorsal root ganglia of the 
spinal cord. These bipolar neurones have a long peripheral axon branch and a central 
axonal projection.  
Following damage to somatosensory system, there may be a partial or complete loss of 
sensory functions, and the development of symptoms such as pain. This indicates that 
pain is a protective response preventing further damage to an affected area. For 
instance, injury to the sole of the foot leading to pain would cause the bearer to avoid 
putting further weight on the affected area until it was healed. Damage to this system 
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may also leads an ongoing pain and if this associated with sensory abnormalities the pain 
is defined as neuropathic pain (Jensen et al., 2011).  This type of pain does not require 
any receptor stimulation and can be severe, chronic and intractable. 
Table 4.1. Peripheral nerve fibre types and classification 
Type 
of 
fibre 
Diameter 
(micro-
metres) 
Conduction 
speed (m/s) 
I-IV 
Class 
Modality Method of 
Assessment 
A-α 8 – 13  44 -78  n/a Efferent, 
motorneurone to 
muscle 
n/a 
A-δ 3 – 8  18 – 48  n/a Efferent, 
motorneurone to 
muscle spindle 
n/a 
A-α 12 – 20  75 – 120  I Afferent, limb, 
position and 
motion 
- 
A-β 6 – 12  30 – 75  II Afferent, touch, 
pressure, vibration 
proprioception  
MFs, JPS, brush, 
allodynia 
A-δ 1 – 6  5 – 30  III Afferent, fast pain, 
cold, crude touch 
 
B 1 – 3  3 – 15  n/a Autonomic pre-
ganglionic 
neurones 
- 
C <1.5  0.5 – 2  IV Afferent, slow 
pain, warm 
Pinprick, hyperalgesia 
warm sensation, heat 
and cold pain 
4.3 Instruments for assessing sensory and pain-related phenomena 
A number of assessments tools are available for the identification of symptoms and 
clinical signs of pain-related sensory abnormalities. Symptoms including pain and 
psychological factors are assessed with a validated questionnaire. This is a list of 
purposely designed questions that captures the quality and intensity of pain-related 
sensory symptoms perceived by patients, i.e. patient-reported outcomes. Clinical 
examination, supplemented by additional diagnostic methods, is commonly used to 
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ascertain the clinical signs of the various sensory perturbations associated with nerve 
damage. These include quantitative sensory tests (QST), neurophysiological methods, 
microneurography and skin biopsy (Haanpaa et al., 2011b). QST is a psychophysical 
method that provides a comprehensive measure of the somatosensory functions. The 
perception thresholds to various thermal and mechanical sensory stimuli are accurately 
measured using the QST battery, but the outcome relies on the patient’s subjective 
response. Neurophysiological methods, which include nerve conduction studies, 
somatosensory evoked potentials and laser-evoked potentials, are objective tests that 
assess function of large and small afferent fibres (Cruccu and Truini, 2009). Skin biopsy 
enables quantification of the number of intra-epidermal nerve fibres, which provides a 
measure of small fibre density (Griffin et al., 2001). Composite tools of symptoms 
screening questionnaires and diagnostic procedures are often used. 
Neuropathic pain, which is defined as pain caused by a lesion or a disease of the 
somatosensory system, may be manifest in a variety of ways, depending on the location, 
severity and the underlying cause (Jensen et al., 2011).  
The symptoms manifest in association with heterogeneous sensory disturbance range 
from sensory gain to sensory loss. For example, many patients with NP due to HIV 
neuropathy have loss of mechanical and vibration detection thresholds. Other “sensory 
gain” symptoms such as allodynia and hyperalgesia may have a variety of causes such as 
complex regional pain syndrome (CRPS), Trigeminal Neuralgia (TN) and Postherptic 
Neuralgia (PHN)(Maier et al., 2010). Analysis of somatosensory profile graphs may help 
in identifying the presence of sensory gain or sensory loss. However, this profiling and 
grouping of patients with sensory disturbance cannot be determined by clinical 
examination alone.  
The ability to stratify patients by symptom, clinical signs and psychological state has 
greatly influenced the identification of NP. A mechanism based approach to NP 
treatment, guided by symptoms and sensory profiles, has been significantly enhanced by 
the use of different methods of assessing the pain-related sensory abnormalities. In the 
following sections, an overview is given of the standard tools that are currently available 
in existing NP clinical practice to determine whether these are valid for the purpose. 
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4.3.1 Pain scales and questionnaires for symptoms  
Clinical investigators have long recognised the variety of pain experienced by patients, 
such as shooting, fearful descriptors of neurologic pain to the burning pain after 
peripheral nerve damage.  
These symptoms, along with clinical examination, provide the key to diagnosis and may 
even suggest the course of treatment. In assessing such patients, it is important that the 
measure is: valid, reliable, reproducible and useful. I will now describe some instruments 
that have been validated and are reliable in assessing pain symptom. 
4.3.1.1 Pain scores and scales 
Pain intensity can be measured on Likert scales, Visual analogue scales (VAS), Verbal 
rating scales (VRS), or a combination of verbal and numerical rating (Gracely Pain 
Scale) (Haanpaa et al., 2011a). Verbal rating scales typically consist of a series of verbal 
pain descriptors ordered from least to most intense (no pain, mild, moderate, severe). 
The patient reads the list and chooses the one word that best describes the intensity of 
pain at that moment.  A score of zero is assigned to the descriptor with the lowest rank; 
a score of 1 is assigned to the next lowest rank (McMahon SB et al., 2013).   
The Likert numerical rating scale is the most frequently used scale for pain intensity 
(Farrar et al., 2001). It is recommended by the IASP for assessing pain intensity 
(Haanpaa et al., 2011a). Likert is an 11- point numerical scale ranging from “0” (no pain) 
to “10” (worst possible pain) (Farrar et al., 2001). The scale is validated and may be 
easier to use than the VAS (Dworkin et al., 2005). It is commonly used to assess 
treatment effect in chronic pain (Dworkin et al., 2005). Using this scale, patients are 
asked to describe the average intensity of pain by choosing the appropriate number 
between 0 and 10 in response to the question “tell me what number best represents the 
greatest pain you have had in the last week”. 
The other options for recording pain - the NRS and the VAS - are represented by a 
10cm line, with one end representing no pain and the other representing worst pain; the 
patient is asked to mark a point on this line that represents their pain level, and this line 
is then measured to arrive at a numerical measurement (McMahon SB et al., 2013). 
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4.3.1.2 Pain questionnaires 
To identify patients with sensory abnormalities and possible NP, no single symptom is 
found, but a combination of symptoms and signs. Several available screening tools are 
used, such as the PainDETECT Questionnaire (PD-Q), the Leeds assessment of 
neuropathic symptoms and signs (LANSS), the neuropathic pain questionnaire (NPQ), 
the McGill Pain Questionnaire (MPQ) and the Douleur Neuropathique en 4 Questions 
(DN4). These questionnaires are particularly recommended for non-specialists (Haanpaa 
et al., 2011a).   
Pain Detect Questionnaire (PD-Q) 
The PD-Q questionnaire is one of the most widely used questionnaires for recording 
somatosensory systems of NP. It was designed by Thomas R. Tolle in 2006 based on 
the German Research Network on Neuropathic Pain data base, and takes into account a 
large number of descriptors of pain (Freynhagen et al., 2006a). The PD-Q comprises 
nine questions regarding the severity, course, quality and nature of the patient’s pain and 
the specific NP symptoms. Please see the Methods section for an illustration of the PD-
Q score described here. 
Leeds assessment of neuropathic symptoms and signs (LANSS) 
The Leeds assessment of neuropathic symptoms and signs questionnaire was designed 
as a scale measure for identifying patients whose pain is dominated by neuropathic 
mechanisms. It was developed and validated in two different populations of chronic 
pain patients by Michael Bennett in 1999 (Bennett, 2001). The scale consists of seven 
items measuring five symptoms and two aspects of sensory dysfunction. Each item 
requires yes or no responses and the scores is compared with the cut-off values; a score 
of 12 or more suggests pain of predominately neuropathic origin (Bennett et al., 2005). 
Neuropathic Symptom Inventory (NPSI) 
Neuropathic Symptom Inventory (NPSI) is a validated questionnaire designed to 
evaluate the different symptoms of NP (Bouhassira et al., 2004, Crawford et al., 2008). 
It was validated in 176 consecutive patients with NP in France and Belgium (Bouhassira 
et al., 2004). It includes 10 items (plus two temporal items), quantified on a (0–10) 
numerical scale, that allow discrimination and quantification of five distinct clinical 
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relevant dimensions of NP syndromes and that are sensitive to treatment (Bouhassira et 
al., 2004, Crawford et al., 2008). 
McGill Pain Questionnaire (MPQ) 
The McGill pain questionnaire consists of three major classes of word descriptors 
(sensory, affective and evaluative) that are used by patients to specify subjective pain 
experience. It was designed by Roland Melzak in 1975, but later he recognised that the 
instrument was too long for use in clinical trials and introduced a short-form McGill 
pain questionnaire (SF-MPQ) (Melzack, 1975, Melzack, 1987). The SF-MPQ consists of 
15 descriptors (11 sensory and 4 affective), along with a visual analogue scale for pain 
intensity. The sensory and affective descriptors are rated on an intensity scale as 0 = 
none, 1 = mild, 2 = moderate or 3 = severe. A maximum score of 55 indicate severe 
symptoms (Melzack, 1987).   
Douleur Neuropathique en 4 Questionnaire (DN4) 
The DN4 questionnaire is a widely used questionnaire in NP clinical practice. It was 
developed in France in 160 patients with either NP or nociceptive pain. It has been 
translated into several languages (Bouhassira et al., 2005). Please see the use of DN4 and 
the Methods section for an illustration of the score described here. 
4.3.2 Clinical signs assessment 
The assessment of clinical signs in patients with sensory abnormalities and pain is 
essential, because it helps the diagnosis and classification of patients. A range of 
methods from simple bedside examination to more sophisticated neurological 
techniques such as nerve conduction study and QST, are used to assess sensory 
abnormalities (Haanpaa et al., 2011a).  
There are two definitive steps the clinician can use when examining patients for the 
diagnosis of the pain-related sensory abnormalities. Firstly to confirm that some form of 
damage to the somatosensory system has occurred, without this the diagnosis is 
impossible. The sensory findings should be neuroanatomically logical and compatible 
with a definitive lesion site (Treede et al., 2008). Secondly, to determine that any pain is 
indeed neuropathic, this because the occurrence of nerve damage does not necessarily 
follow that any pain is neuropathic in origin.  
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For the purposes of this study, an ideal test for an individual patient should:   
i. provide specific information about pathophysiological nature of the mechanisms 
of disease when disease processes are taking place 
ii. have sensitivity and specificity and positive predictive accuracy  
iii. be interpretable within the context of clinical practice 
iv. provide information about where the pathophysiology of pain takes place, i.e., 
the location of a lesion for neuropathic pain. 
4.3.2.1 Clinical examination 
Clinical examination is of paramount importance in assessing neurological disorder. It 
involves sensory, motor and autonomic signs (Hansson et al., 2001). The examination 
involves a series of systematic steps, including past and present history, a detailed 
description of pain distribution, quality and intensity of pain and a neurological 
examination with the emphasis on sensory testing (Jensen et al., 2001, Hansson, 2002). 
Standard bedside neurological sensory testing 
Neurological examination involves assessment of muscle tone and power, tendon 
reflexes and sensory examination. Sensory examination is critical in providing evidence 
necessary for the diagnosis of NP (Haanpaa et al., 2011b). Sensory abnormalities are 
mapped out using cotton wool for tactile sensation (Aβ fibres), pin-prick sensation with 
a small pin or cocktail-stick (Aδ fibres), gross temperature sensation with warm or cool 
objects (warm – C-fibres, cool – Aδ fibres) and vibration sense with a tuning fork 
(128Hz) (Aβ fibres) (Cruccu et al., 2004). This examination is performed to determine 
the presence of suspected sensory loss or gain of function that are associated with NP 
and at the same time to document the presence of allodynia, hyperalgesia and 
hyperpathia as hallmarks of NP.  
However, clinical examination of a patient with pain which aims to assess the 
somatosensory system and may provide supporting evidence for altered function of the 
nervous system, can never prove any pain to be of neuropathic origin. In patients with a 
possible NP condition, the sensory dysfunction is coordinated by somatosensory 
abnormalities (Treede et al., 2008), and cannot be determined by clinical examination 
alone. For instance, if afferent fibres from the skin are affected, sensory abnormalities 
can be detected using simple bedside tools for supra threshold stimulation (Haanpaa et 
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al., 2011a). The light touch of cotton wool and the vibration stimulus of the tuning fork, 
which activate large A-beta fibres, as well as the dorsal columns and their thalamo-
cortical extension, are used to assess the sensitivity to touch and vibration, respectively. 
Other test stimuli, such as cold and warm metallic rollers and pins could be used to 
assess thermal and pain sensation and hence activate different types of A-delta and C-
fibres and spino-thalamo-cortical system. But, despite its clinical significance and 
identification of the neuroanatomical distribution of symptoms, pain in an area with 
sensory dysfunction is not to be associated with NP since other types of pain may be 
expressed in such an area (Hansson, P. and Lindblom 1993). A study by Freynhagen et 
al, reported that 5 out of 12 patients classified with painful radiculopathy had normal  
sensory function on bedside examination (Freynhagen et al., 2008). The diagnostic 
prerequisite in NP conditions, i.e. sensory abnormalities in the distribution of the 
affected nervous structure, is not identified by bedside examination. Given that sensory 
abnormalities are not confined only to NP states, the outcome of sensibility 
examinations, especially by clinicians lacking experience in detailed sensory examination, 
could be a source of confusion and possible diagnostic errors. Another drawback of 
these tests is that they are often not sensitive enough to show longitudinal change. 
Therefore, the characteristics of the pain need further assessment to allow for its 
classification. Quantitative Sensory Testing of perception thresholds in the above 
mentioned somatosensory channels could be used to complement the assessment of 
somatosensory abnormalities at bedside examination (Leffler and Hansson, 2008a). 
4.3.2.2 Conventional electrophysiological studies 
Nerve conduction studies 
Nerve conduction study is considered as an extension of the patient history and clinical 
examination. It comprises an electophysiological test that assesses the motor and 
sensory function of the nerve. These are obtained by stimulating the nerve and a 
response is recorded directly from the nerve or from a muscle innervated by the tested 
nerve. In this way, NCS are able to detect and differentiate general from focal nerve 
abnormalities, type of neuropathy (demyelinating, axonal and conduction block), type of 
involved axons (motor, sensory and autonomic) and localisation (distal, proximal and 
entrapment site).  
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While NCS is a relatively non-invasive method, its main limitation is that it cannot be 
used to assess small fibre neuropathy or the function of nociceptive pathways (Cruccu 
et al., 2004). In such conditions, special methods are used such as testing thermal 
thresholds and quantitative mechanical testing. Quantitative sensory testing, in general, 
quantifies the functional status of the peripheral nervous system by nerve fibres of 
various sizes and by central pathways. The QST is most useful in the diagnosis of small 
fibre neuropathy.  
4.3.2.3 Quantitative measurements  
“Quantitative measurement” describes tests where the intensity and characteristics of 
the test stimulus are well controlled and reproducible, and the detection threshold is 
determined in parametric units that can be compared to established normal values. 
Stimuli are usually delivered in accordance with specific testing algorithms, and the 
subject’s response is predefined according to standardised instructions. A number of 
instruments and validated tools for quantitative assessment of neuropathy have been 
established, ranging from simple instruments such as monofilaments to more 
sophisticated computer-aided systems such as quantitative sensory testing (Valk et al., 
1997, Rolke et al., 2006a). 
Semmes-Weinstein Monofilaments (MFs)  
Monofilaments, which were originally made from horsehair, have been developed over 
time from simple, natural materials to synthetic devices. In the late 19th century, the 
horsehair was used as a method to quantify pain induced by punctate stimulation 
(Weinstein, 1968). Von Frey used various thicknesses of horsehair to determine the 
thresholds of touch recognition. Later this technique was refined and amended by 
others, such as Semmes and Weinstein in the 1960s. They developed a standard set of 
nylon monofilaments that exert predefined forces onto the skin (Semmes et al., 1960). 
Now, however, a more field friendly method has been introduced; Von Frey hairs made 
from optical glass. A testing kit comprises a standard set of glass filaments which are 
widely used in clinical practice by neurologists for assessing sensory abnormalities. 
Semmes-Weinstein Monofilaments are a standard set of six coloured monofilaments 
ranging from 5mg, 200mg, 2g, 4g, 10g and 300g (Bell-Krotoski, 1990). When used for 
the hand specifically the stimulus was found to have a cut off 200mg, but for the foot 
the cut off was found to be 2g. Semmes-Weinstein Monofilaments were developed to 
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detect sensory loss in leprosy programmes but have been widely used by other 
programmes as a diagnostic technique for routine clinical and research purposes 
(Jamison, 1969). Their use has led to a significant improvement in screening diabetic 
patients; for example inability to feel a 10gm monofilament is recognised as a risk factor 
for ulcer (Birke and Sims, 1986). 
Both MFs and VMT using a modified MRC scale are suitable and reliable tools for 
measuring nerve function impairment in a resource-limited setting (Brandsma et al., 
2014). In a cohort study of 357 untreated multibacillary patients from India between 
2001 and 2005, which assessed the sensitivity and specificity of MFs and VMT using 
nerve conduction study as gold standard for detecting nerve function impairment, the 
authors noted that both methods have good inter-tester reliability and reducibility and 
good specificity of more than 80%. The sensitivity of both tests in detecting nerve 
involvement was low, less than 40% (Khambati et al., 2009). 
Quantitative Sensory Testing (QST) 
Quantitative sensory testing is defined by the Peripheral Neuropathy Association as the 
technique(s) used to measure the intensity of stimuli needed to produce specific sensory 
perceptions (PNA., 1993). For more details on QST please, see section 4.6. 
4.3.3 Skin biopsy 
Intra Epidermal Nerve Fibre Density (IENFD)  
Intra-epidermal nerve fibre density is a technique for measuring the endings of small 
peripheral nerve fibres in the epidermis (Lauria et al., 2005). It has been used for 
identifying the presence of nerve damage (Lauria et al., 2005). Both myelinated (Aβ and 
Aδ) and unmyelinated (C) nerve fibres can be assessed (Devigili et al., 2008). These 
nerve fibres along with sweat glands, blood vessel, epidermis cells and superficial dermis 
are investigated using skin biopsy. Skin biopsy is a safe and reliable technique used to 
investigate IENF (Lauria et al., 2005). Nerve fibres are immunostained by antibodies 
against PGP 9.5 using either immunohistochemistry or immunofluorescence, and fixed 
by 2% paraformaldehyde-lysine-periodate (2% PLP) or Zamboni’s solution. Fibres 
crossing the dermal epidermal junction are counted and quantified to confirm the 
clinical diagnosis of neuropathy (Lauria et al., 2005). The density is calculated in at least 
three sections as the number of IENF per length of the section (IENF/mm) (Lauria et 
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al., 2005). Devigili et al. who screened 486 Italian patients and collected 124 patients 
with neuropathy found 67 patients had small fibre neuropathy using skin biopsy 
(Devigili et al., 2008). The author noted that quantification of IENF density in skin 
biopsy for diagnosis of neuropathy showed a diagnostic efficiency of 88.4% (Devigili et 
al., 2008).   
European Federation of Neurological Societies (EFNS) has recommended the use of 
skin biopsy with linear quantification of IENF density as a reliable and efficient 
technique to confirm the clinical diagnosis of small fibre neuropathy (Lauria et al., 
2010). 
Previous studies on IENF, pain and QST parameters 
As peripheral neuropathic pain abnormal sensations may be related to dysfunction of 
Aβ, Aδ or C- fibres, IENFD may be correlated with pain. Studies have identified 
IENFD, pain and QST parameters correlation in post herpetic neuralgia, Diabetics and 
HIV pain neuropathy (Zhou et al., 2007, Sorensen et al., 2006, Devigili et al., 2008, 
Loseth et al., 2008, Vlckova-Moravcova et al., 2008a). 
In patients with post herpetic neuralgia, the number of intra-epidermal fibres is lower in 
the biopsies taken from pain area compared to the control site. (Oaklander, 2001)  
Sorensen et al. 2006, who studied the correlation between IENF density and pain in 38 
patients with diabetes using skin punch biopsy, noted that IENF density was 
significantly lower in the biopsies taken from those with pain compared with those 
without pain (Sorensen et al., 2006). A similar conclusion, greater fibre loss correlated 
with more severe pain, was obtained also by Zhou et al. 2007, who studied the 
relationship between IENF density and pain in 101 patients with HIV neuropathy 
(Zhou et al., 2007). 
Other studies have shown the correlation between IENFD and QST parameters. 
Studies carried by Devigili et al. 2008, Loseth et al. 2008 and Moravcova et al. 2008, who 
assessed patients with sensory neuropathy to demonstrate the relationship between the 
IENF density and QST, have shown an inverse correlation between IENFD and 
thermal threshold, a significant correlation between IENFD and QST parameters and 
IENFD correlated with warm detection threshold on QST, respectively (Devigili et al., 
2008, Loseth et al., 2008, Vlckova-Moravcova et al., 2008a). 
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4.4 Techniques for assessing psychological impact of neuropathic pain 
4.4.1 Introduction: 
Measurement of subjective experience, such as pain, inevitably relies heavily on self-
report, which is valuable but its impact is difficult to determine. The complexity of pain 
phenomena in an area of sensory loss, also known as NP, is a factor that hinders its 
management and control. For instance, pain intensity and interference with function can 
have a marked impact upon daily routine, affective and motivational states, social 
relationships, sleep and economic factors. This indicates the importance of evaluating 
the relationship between the intensity of pain, disability and depression with the quality 
of life of individuals with chronic pain. Instruments, such as quality of life 
questionnaires are used to deepen knowledge of the perceived pain and thus enable an 
evaluation of effectiveness of the treatment used. I will now describe the instruments 
that have been validated and are reliable in assessing psychological impact of NP. 
4.4.2 Quality of life and psychological state questionnaires literature review 
Health is defined by the World Health Organization (WHO) as a state of complete 
physical, mental and social well-being and not merely the absence of diseases and 
infirmity (WHO, 1946).  
4.4.2.1 General Health Questionnaires (GHQs) 
The GHQs is the most widely used standardised self-completion measure of 
psychological well-being globally. It was developed by Godberg in the 1970s for use in 
primary practice settings (Goldberg, 1972). Its main focus is to assess psychological 
components of ill health, in particular screening for common psychiatric disorders such 
as anxiety and depression. 
Content: the initial version of the GHQ contains 60-items which measure common 
mental health problems/domains of depression, anxiety, somatic symptoms and social 
withdrawal dimensions. Shorter versions of 30, 28, 20 and 12-items have also been 
developed. The 12-items version, is in fact, as efficient as the 30-items version as a case 
detector (Bowling, 2005). The questions assess psychological well-being state over the 
past few weeks, including:  
Have you recently: 
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 Been able to concentrate on whatever you are doing 
 Lost much sleep over worry 
 Felt that you are playing a useful part in things 
 Felt capable of making decisions about things 
 Felt constantly under strain 
 Felt you couldn’t overcome your difficulties 
 Been able to enjoy your normal day to day activities 
 Been able to face up to your problems 
 Been feeling unhappy and depressed 
 Been losing confidence in yourself 
 Been thinking of yourself as a worthless person 
 Been feeling reasonably happy, all things considered 
Scoring: Detailed instructions on the rating, coding and scoring procedures are 
described in Chapter 6. 
The GHQ-12 is one of the most commonly used screening tool for mental health 
assessment in community settings (Furukawa and Goldberg, 1999), and has been 
validated in other mental disorders around the world (Goldberg and Williams, 1988, 
Goldberg et al., 1997). Particularly relevant to this study is its validation both in India 
and leprosy (Gautam et al., 1987, Verma and Gautam, 1994, Senturk et al., 2007, Jindal 
et al., 2013, Bandyopadhyay et al., 1988, Sriram et al., 1989). Further, The GHQ-12 has 
been demonstrated to be a valid screening in patients with leprosy NP (Lasry-Levy et al., 
2011, Haroun et al., 2012) 
4.4.2.2 Brief Pain Inventory (BPI) 
The short form of the BPI is constructed of nine self-report items and measures two 
main domains: the intensity of pain (sensory dimension) and interference of pain in the 
patient's life (reactive dimension). It is probably the most widely used measurement 
scale for clinical pain (Cleeland and Ryan, 1994), and its validity comes from several 
studies of cancer pain and pain of other diseases. It also demonstrates good test-retest 
item correlations over short time intervals (Daut et al., 1983). Patients rate their pain on 
a 11 – point numerical scale for the average, worst and current pain in the preceding 24 
hours. The second part of the questionnaire ask patients to indicate the extent to which 
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pain interferes, on a scale of 0 (‘pain has not interfered’) to 10 (‘pain completely 
interfered’), with the daily activities addressed by the subscales (e.g. general activity, 
mood, mobility, normal work, relations with others, sleep, enjoyment of life, self-care, 
recreational activities and social activities).  
4.5 The use of DN4 and PD-Q questionnaires for assessing NP 
This section describes the items and structure of the main questionnaires, namely; DN4 
and PD-Q, used for the screening and measurement of NP in this study, as well as their 
potential value and limitations. 
4.5.1 Overview: 
DN4 consists of 10 items: seven interview items and three clinical signs. The interview 
items are related to the quality of pain (burning, painful cold, electric shocks) and its 
association to abnormal sensation (tingling, pins and needles, numbness, itching). The 
clinical signs are related to sensory examination in the most affected area (touch 
hypoesthesia, pinprick hypoesthesia, tactile allodynia) (Bouhassira et al., 2005). Items are 
grouped in four sections; each one requires yes or no responses to questions on the 
quality of pain or clinical signs. The DN4 rating and scoring is simple; a score of 1 is 
given to each positive item and a score of 0 to each negative item. The total score is 
calculated as the sum of the 10 items and the cut-off value for the diagnosis neuropathic 
pain is a total score of 4 out of 10 (Bouhassira et al., 2005).     
DN4 is often compared to other screening tools for neuropathic pain (LANSS, NPQ, 
PD-Q); however some differences should be recognised. In particular, these tools 
require no clinical examination. In contrast, the full versions of DN4 and LANSS are 
clinician-administered questionnaires. In these screening tools the clinical signs are 
tested by the examiner. Short versions of DN4 (DN4-Interview) and LANSS (S-
LANSS), which omit the items related to sensory examination, have been developed for 
use as self-administered questionnaires (Bouhassira et al., 2008, Bennett et al., 2005). 
Another relevant difference from screening tools is the method of validation. The DN4 
validation study included patients with either peripheral or central NP, whereas other 
studies included only patients with peripheral NP. In addition, the DN4 validation study 
included only patients with pure NP, while other studies included patients with mixed 
pain (PD-Q) or complex regional syndrome type 1 (LANSS). The number of items, 
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their phrasing and the scoring methods also differ between DN4 and the other 
screening tools.  
Despite the methodological differences between DN4 and other questionnaires 
mentioned above, it appears that most of the DN4 items are also present in the final 
versions of these questionnaires. For instance, the DN4 pain descriptors “hot or 
burning,” “shooting or electric shock,” “numbness,” “tingling,” pins and needles” and 
items related to abnormal clinical signs “allodynia” are used in all the other 
questionnaires. This may suggest that DN4 has the main common symptoms of NP 
conditions. 
4.5.2 Limitations of the DN4 and PD-Q questionnaires 
As will be discussed in Chapter 5, DN4 has become one of the most common screening 
questionnaires for NP; in particular for the identification of possible NP among leprosy 
patients. As discussed earlier, no single symptom is diagnostic of NP, but combinations 
of certain symptoms, pain descriptors and clinical findings increase the possibility of a 
NP condition. Both DN4 and PD-Q attempt to provide an accurate selection of 
patients with symptoms and signs suggestive of NP. However, as in other 
questionnaires, the following issues have been identified as drawbacks:  
First, DN4 has limited diagnostic value in patients with widespread pain. It has been 
validated in patients with pain at a single body location. Their ability to distinguish 
between pain and pain-free neuropathy is reliable only when applied to a limited painful 
area. A study carried by Attal and colleagues, which investigated the neuropathic 
components of chronic low back pain in 132 patients with and without lower limb pain 
using the DN4 questionnaire, showed that DN4 can be used to assess patients with up 
to three pain locations (Attal et al., 2011b). Hence, DN4 is less practical in patients with 
multiple pain locations, i.e. more than three. Secondly, DN4 is increasingly used for NP 
epidemiological studies in different settings, but validation studies for this purpose are 
necessary. Furthermore, NP screening questionnaires fail to identify 10 to 20% of 
patients with clinician diagnosed NP (Haanpaa et al., 2011a). This implies that screening 
questionnaires cannot replace clinical judgment, but may play role in guidance for 
further diagnostic evaluation and pain management. Another limitation of the DN4 
questionnaire is that it provides no information about the relationship between 
symptoms and lesions or disease mechanism. This is illustrated by Rasmussen et.al, in a 
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study that compared verbal pain description and detailed sensory testing using the short 
form of McGill pain questionnaire (Rasmussen et al., 2004).  The authors examined 214 
patients with suspected chronic NP of moderate to severe intensity. They proposed 
clinical criteria for NP based on pain aetiology and presence of pain sensory loss, and 
labelled patients as having “unlikely”, “possible” and “definite” NP. The authors found 
no differences in verbal descriptions across the groups. The identification of NP 
conditions may require a further clinical examination, together with imaging, laboratory, 
or electrophysiological tests in some cases (Baron et al., 2010a, Haanpaa et al., 2011a, 
Haanpaa et al., 2009). Finally, PD-Q has limited applicability for assessment of the 
effects of treatment. 
4.6 The use of QST methods for assessing sensory abnormalities and NP 
4.6.1 Introduction 
This section explores the background information behind quantitative sensory testing 
measurement of sensory function, the basic principles of QST, the type of information 
obtained and their potential clinical utility as an aid to the diagnosis of NP. There are 
several protocols for QST and this will be discussed further in section 5.2.2 under 
available protocols for QST. A comprehensive overview of the detailed parameters and 
methods of DFNS-QST protocol will be provided in Chapter 6.  
4.6.2 History and background 
Quantitative sensory testing (QST) in medicine has roots in quantification and non-
invasive testing and the first descriptions of the potential of QST as a standard 
evaluation procedures took place in the 1970s. A landmark pioneering publication by 
Fruhstorfer (Fruhstorfer et al., 1976) described the use of QST for thermal thresholds 
that may detect preclinical diabetic neuropathy. Fruhstorfer’s group went on to develop 
a quantitative technique for the examination of thermal sensibility and, in parallel with 
other researchers across the world, developed a method for quantitative thermal 
thresholds in the late 1970s. At this early stage, the main advantage of the quantification 
technique was that its ease of use enabled it to be employed routinely and repeatedly in 
patients with symptoms of, or the potential, for neurologic damage or disease. Since 
then, there has been increasing interest in using QST to give insights into the underlying 
pathophysiological mechanisms of pain. The next break through was the development 
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of various quantitative methods for assessing sensory abnormalities, such as Von Frey 
hairs for touch, which enable the clinician to assess other modalities of sensory 
abnormalities, rather than just using a selected thermal test. A major improvement in 
quantitative sensory testing quality arrived with the development of electronic devices in 
the late 1980s and early 1990s. Table 4.2 shows the devices cleared by the Food and 
Drug Administration (FDA) in the 1980s and 2000s. Despite the advantages of being 
non-invasive, non-interventional techniques to complement standard neurological 
bedside examination, in order to help detect and quantify positive and negative sensory 
phenomena, there was no standardised QST testing procedure. For instance, there was 
no consensus regarding which specific QST device or algorithm should be used 
preferentially. This showed the growing need to develop standardised QST protocols. In 
recent years, the German Research Network on Neuropathic Pain-DFNS has developed 
a standardised and comprehensive QST protocol (Rolke et al., 2006a).  
The emergence of DFNS-QST as a new and comprehensive protocol for quantifying 
somatosensory changes in human skin and even pain-related phenomena has made it 
the technique of choice for assessing diseases of the central and peripheral nervous 
system. The DFNS-QST battery consists of seven tests measuring 13 parameters, 
including various types of mechanical and thermal detection and pain thresholds for the 
hand, foot and face. The QST protocol was implemented in 180 healthy volunteers, 
thus providing a complete profile of sensory function (gender, age and location 
matched) and normative data that can be used as reference values for statistical analysis 
in studies on patients with NP (Rolke et al., 2006a). By affording such accurate 
measurement of sensory loss and gain, as well as psychophysical responses, DFNS-QST 
offers a high degree of detailed and precise information in the clinical diagnosis domain. 
Table 4.2. Devices cleared for marketing by the FDA (1980-2003) 
Year  Product Comments 
1987 Thermal Threshold Tester (TTT) Teca, Inc. 
1992 CASE IV Computer Aided Sensory Evaluator Vibration & thermal threshold testing 
1993 Thermal Sensory Analyzer (TSA) Medoc Corporation  
1994 Nk Pressure-Specified Sensory Device NK Biotechnical Corporation 
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1994 Neurometer Current Perception Threshold 
1994 Pressure-Specified Sensory Device Sensory Management Services LLC 
1997 Medi-Dx 7000 Neuro Diagnostic Associates 
2003 Vibration Perception Threshold (VPT) meter Xilas Medical 
 
4.6.3 Literature review of QST 
In this section, I describe the basic principles and information behind QST. I review the 
different methods of stimulation that are currently available and provide an overview of 
the methods used by the DFNS. For the purpose of the current study, the DFNS-QST 
protocol will be the main protocol for QST. 
4.6.4 Overview of the QST principle 
QST is a non-invasive, sophisticated clinical examination of the sensory nervous system, 
whereby the perception thresholds to various thermal and mechanical sensory stimuli 
are accurately measured using the QST battery. The thermal testing modality assesses 
small myelinated (A-δ fibre) and unmyelinated (C-fibre) sensory nerve function, whereas 
the mechanical testing (light touch and vibration) evaluates the large myelinated A-α and 
A-β sensory fibres (Vinik et al., 1995). The pain modality, heat-pain and cold-pain 
threshold tests have been found to document increased pain sensitivity (hyperalgesia, 
allodynia and hyperpathia) (Verdugo and Ochoa, 1992). Others, such as mechanical pain 
and pressure pain have been used to document hyperalgesia (dynamic and static) and 
pain sensitivity (cutaneous and deep), respectively (Ochoa and Yarnitsky, 1993, Treede 
et al., 2002). Therefore, QST and in particular DFNS-QST, can study large myelinated, 
small myelinated and unmyelinated fibres in addition to documenting sensory gain and 
loss (hyperalgesia and hypoesthesia). 
4.6.5 QST algorithms  
A number of algorithms of testing and finding thresholds are used to quantify the 
sensory thresholds and pain-related phenomena in clinical practice. The test should 
yeilded accurate and reproducible results within a reasonable amount of time. Tests for 
pain sensation have the additional requirement of minimizing the number of stimuli that 
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are unpleasant to the patient. In QST, the method of limits and the method of levels are 
the most common algorithms used. This makes QST reasonably reproducible over the 
course of several days to a week (Heldestad et al., 2010). However, describing an 
algorithm in these terms does not in itself ensure that a particular standard or adequate 
algorithm is being used. A number of issues should be taken into consideration for any 
QST algorithm.  
Factors influencing QST algorithm: 
 Type of instrument 
 Room temperature and humidity 
 Site of stimulus 
 Patient related factors: age, gender, cooperation and motivation 
 Availability of standardised protocol. 
The method of limits and the method of levels – the two common algorithms for pain 
threshold - are described in more detail. Others, such as tolerance, magnitude estimation 
of supra-threshold pain intensity and summation are excluded from the present review. 
Method of limits: is one of the most commonly used algorithms for quantitative 
sensory testing (Figure 4.2). The threshold is determined with ramped stimuli that are 
stopped immediately when the subject presses a button. Two types of ramp stimuli are 
used: the ascending ramp and the descending ramp. In the former, the intensity of the 
stimulus is gradually increased until the subject perceives the stimulus as painful; the so-
called appearance threshold. Another, less common, approach is the determination of a 
disappearance threshold, by decreasing the stimulus intensity until it is no longer 
detected. Thermal and vibratory thresholds are frequently assessed with this method 
(Verdugo and Ochoa, 1992, Chong and Cros, 2004). The advantage of this algorithm is 
that pain threshold can be determined very quickly (Dotson, 1997). Thus the chance 
that fatigue, loss of motivation, inattention and malingering will occur is minimal.  
The feedback mechanism, however, is the main disadvantage of the method of limits. 
The subject’s reaction time is the period between processing the information and the 
subject’s indication of a response. For example, a subject needs to perceive the stimulus, 
process the information and generate an action to indicate a response. This may lead to 
an overestimation of the pain threshold. The extent of overestimation of the threshold 
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depends on the rate of stimulus change, i.e., the slope of the ramp (Dyck et al., 1990, 
Shy et al., 2003, Chong and Cros, 2004, Hansson et al., 2007).  
Method of levels: is an algorithm method that obtains results by applying a series of 
predefined stimuli to the skin in ascending or descending order (Figure 4.2). The 
stimulus has a defined intensity and duration and the subject has to choose whether or 
not the stimulus is felt after each trial. Hence, it is also referred to as “forced choice” 
algorithm (Shy et al., 2003).  
While the method of levels does not depend on reaction time, its main limitation is that 
it cannot be used frequently. The method of levels is generally more time-consuming 
and may subsequently lead to boredom and inattention (Hansson et al., 2007). 
 
Figure 4.2. Summary of the methods used for QST 
 
4.6.6 QST instruments 
Detailed descriptions of the thermal and mechanical instruments are described in 
Chapter 6. 
4.6.7 QST and standard bedside neurologic sensory testing compared 
While the focus of this study is the profiling and stratification of leprosy patients, it is 
useful to make a comparison, in this preliminary chapter, of the known advantages and 
disadvantages of the validated techniques. I have summarised the practicalities of the 
QST compared to other methods in Table 4.3 and Table 4.4. 
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Table 4.3. QST and standard bedside neurologic sensory testing 
 Quantitative Sensory Testing  Standard bedside sensory testing 
Advantages 
o Stimuli delivered in 
accordance with specific 
testing algorithms 
o Greater precision 
o Potential possibility of 
diagnosis of sensory 
neuropathy (Shy et al., 
2003, Chong and Cros, 
2004) 
o Possible to follow up 
o Highly reproducible (Bouhassira 
et al., 2005) 
o Generates and ranks other types 
of pain as matter of differential 
diagnosis 
o Answers the question where on 
the somatosensory system is the 
pathology that generates 
neuropathic pain 
o Can distinguish between pain 
and pain-free condition 
(Rasmussen et al., 2004) 
o More sensitive than QST 
Disadvantages  
o Time-consuming  
o Lack standardization 
o Subjective  
o Stimuli are not calibrated  
o Not able to prove any pain to be 
neuropathic origin 
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Table 4.4. QST and conventional electrophysiological techniques 
 Quantitative Sensory Testing 
(QST) (Cruccu et al., 2004) 
Conventional electrophysiological 
techniques (NCS) 
Advantages 
o Psycho-physical o Does not require responses 
from the  subject 
o No active cooperation 
required 
o Useful to localise the nerve 
lesion, its severity and to 
suggest prognosis 
o Training required for 
investigators but not for 
subjects 
o Published normative data 
and available data from most 
electro-physiological 
laboratories 
o Objective 
Disadvantages 
o Requires a response from 
the subject, so is subjective 
and not objective 
o Standardisation  
o Time-consuming  
o High cost  
o Lacks reproducibility (Bird 
et al., 2006) 
o Tests only large fibres 
*cited in (Backonja et al., 2013) 
4.7 Previous studies on painful and painless neuropathy using QST 
Several studies have considered neuropathy and pain using QST, (Table 4.5). The main 
findings of these studies were encouraging as it appeared that QST parameters may 
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show distinct changes in patients with painful neuropathy compared to patients with 
pain-free neuropathy.  
Vrethem et al. measured the different responses to the panel of stimuli used in the QST 
in 55 diabetic patients, with neuropathy, in Sweden. The study showed that touch was 
more affected in patients with painful neuropathy compared with patients with painless  
neuropathy; otherwise, there were no differences between the patient groups (Vrethem 
et al., 2002). In HIV-related neuropathy, Martin et al. 2003 examined 36 HIV infected 
patients with painful (20 patients) and non-painful (16 patients) sensory neuropathy 
assessed by clinical, quantitative thermal testing and nerve conduction examination. 
Control reference data were obtained from 49 healthy participants with a corresponding 
age and sex match. The authors showed that patients with painful neuropathy had a 
significantly lower cold pain threshold than healthy controls which demonstrates 
impairment of C-fibres function (Martin et al., 2003). A similar conclusion, low cold 
detection threshold associated with HIV neuropathy compared to healthy controls, was 
also obtained by Simpson et al. 2002, who studied a cohort of 270 HIV patients from 
the United States (Simpson et al., 2002). In contrast, Ulf et al. 2002, who assessed the 
patterns of sensory changes caused by different conditions using the QST parameters in 
30 patients with dysaesthesia and 15 controls in Germany, noted no association of any 
parameter obtained by QST with a particular disease (Baumgartner et al., 2002). In a 
QST profile study of 66 HIV infected participants, Phillips and colleagues (Phillips et 
al., 2014), reported no differences in regard to thermal and mechanical perception 
thresholds between painful and non-painful sides of denervated skin.  
Despite the differences in assessing sensory changes caused by different conditions in 
these studies, QST may help to identify the sensory modalities mediated by different 
nerve fibres. In diseases such as PHN and traumatic lesions QST parameters were 
found to differentiate between patients with and without pain, whereas in DM and HIV 
neuropathy the finding were not generalised. Overall, the findings emphasise the 
importance of sensory profiles of patients who presented with neuropathy and pain, 
which might help in grouping patients according to the changes of the sensory patterns 
identified by QST.  
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Table 4.5. QST studies on painful neuropathy and painless neuropathy 
Authors, 
year, 
country 
Purpose of 
the study  
Study 
population, 
N 
 
Controls  
Interventio
n / test 
Main findings 
Vrethem et 
al. 
(Vrethem et 
al., 2002) 
Sweden  
To study 
pain 
characteristic
s in diabetic 
patients  
55 patients: 
painful 
neuropathy 
37,  painless 
neuropathy 
18 
Healthy 
controls: 14 
and non-
DM 
neuropathy: 
18 
Clinical, 
neurophysio
logy and 
QST 
there were no 
differences 
between the 
patient groups, 
except for touch (p 
= 0.02) 
Martin et 
al. (Martin 
et al., 2003) 
Sweden 
To 
investigate 
sensory 
profile in 
HIV patients 
36 AIDS 
patients: 20 
painful, 16 
non painful 
Healthy 
controls: 49 
participants 
Clinical, 
QST and 
NCS 
Warm 
Hypothaethesia (p 
=0.06) and CPT (p 
=0.03) gain greater 
in painful group  
Simpson et 
al. 
(Simpson et 
al., 2002) 
United 
States 
To 
investigate 
HIV 
associated 
neuropathy 
236 patients 
with HIV 
neuropathy 
nested from 
a cohort of 
270 
No controls QST CDT associated 
with pain in HIV 
neuropathy 
Fitzek et al. 
(Fitzek et 
al., 2001) 
Germany 
To identify 
clinical 
predictors in 
patients with 
pain 
12 patients 
with dorso 
lateral 
medullary 
infarction 
No controls Thermal 
testing and 
MRI 
Facial pain 
predicted by loss 
of pinprick 
heat/cold pain, 
TSL 
Finnerup et 
al. 
(Finnerup 
et al., 2003) 
Denmark 
To 
investigate 
NP 
mechanism 
40 patients 
with SCI: 
painful 20, 
pain free 20 
Healthy 
controls: 20 
participants 
Clinical, 
QST and 
somatosens
ory evoke 
potentials 
At lesion level 
hyperalgesia differs 
(p =0.03) 
Ulf et al. 
(Baumgart
ner et al., 
2002) 
Germany 
To assess 
underlying 
mechanism 
of NP 
Patients 
with 
dysaesthesia: 
30 
Healthy 
controls: 15 
participants 
MDT, S/R 
(stimulus/re
sponse) 
functions 
No association of 
QST parameters in 
a particular disease  
Phillip 
(Phillips et 
al., 2014), 
UK 
To assess 
sensory 
profile in 
HIV patients 
HIV-SN: 38 
HIV-no SN 
28 patients 
Healthy 
controls: 66 
participants 
Clinical, 
QST, NCS, 
IENFD 
No single QST 
parameters were 
different between 
the groups 
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4.8 Chapter summary  
This chapter summarised neuropathic pain and the methods, particularly profiling 
methods, used to aid in its diagnosis and impact. Only two of the profiling methods 
discussed have the capacity of adding somatosensory profiling measurements: QST and 
skin biopsy. While QST techniques are well established in term of quantification of 
sensory profile, they are often limited by its applicability in limited resource setting. QST 
techniques have the advantage of being able to test the entire sensory axis from 
receptors to brain. However, as will be outlined in Chapter 5, the use of QST techniques 
to quantify the peripheral sensory system has not yet been fully investigated in leprosy. 
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Chapter 5 The clinical problem and aims of the thesis  
5.1 The clinical difficulties in NP in diseases such as leprosy 
5.1.1 Problems of defining neuropathic pain in leprosy 
5.1.1.1 Case study: a problem of identifying a case of NP in leprosy 
Case history 1: 
A 49 year old female from Worli village, Mumbai sub-urban district. She is a service 
worker and the family’s only earning member. She has received full treatment for multi-
bacillary (MB) leprosy, completed in September 2002. She has no other medical 
comorbidities and notably has no clinical evidence of hypertension or diabetes mellitus 
on laboratory investigations.  
Presenting complaint 
Severe pain, tingling, numbness and burning sensations in both hands and feet 
bilaterally for the last 5 years      
Origin, duration and progress of leprosy 
In 2001, when the patient was 37 years of age and in the third trimester of her first (and 
last) pregnancy, she presented with painful nodules on her leg arms and back with 
associated fever and joint pain. She was admitted to hospital, diagnosed as having MB 
leprosy with erythema nodosum leprosum reaction (ENL), and commenced one year 
multi-drug treatment (MDT). She had a normal vaginal delivery, and gave birth to 
healthy baby with no medical problems. 
Post-delivery she had repeated episodes of ENL reactions. During the first episode, in 
2001, she received a six months course of prednisone. The second episode in June 2003 
was managed with a further six months of prednisone. After the third recurrent episode 
of ENL reaction in 2004, she was diagnosed as chronic ENL and commenced and 
completed another 6 months treatment with prednisone. 
After anti reaction treatment, she showed steady improvement. Her pain and skin 
lesions subsided, and she felt better. However, seven years later in 2008; she developed 
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burning sensations, tingling and numbness in both hands and feet. By late 2011, she was 
admitted to hospital with bilateral weakness, sensory loss and severe burning sensations 
in her hands and feet. Two weeks later, she complained of insomnia due to her pain. 
The pain in her hands and feet was described as sharp, stabbing, burning and “electric 
shock” like and the patient described it as “putting her hands and feet into a fire”. No 
formal assessment of her pain symptoms was made by the attending physician. 
Neurological examination of her limbs was normal. She completed steroid treatment 
after consultation with a dermatologist to relieve pain, but her description of the pain 
remained as before. Treatment with MDT for the second time had been recommended 
by her doctor in a private clinic along with analgesics, but this did not improve her pain.  
Radiological imaging (MRI of cervical spines) on 26/11/2012 was normal and included 
the basal ganglia. Nerve conduction studies (NCS) revealed predominately a severe 
sensory peripheral neuropathy in all four limbs, so a neuropathic mechanism was 
suspected as the dominant cause of her pain. The second course of MB-MDT was 
stopped after three months and her steroid dose was reduced. She commenced analgesic 
treatment with Amitriptyline 10 mg initially, increased to 75 mg which was effective in 
relieving her pain and then shifted to combination of Gabapentine 30 mg TDS and 
Duloxetine 20 mg BD. This produced substantially better pain relief without any 
disability for several weeks.       
Assessment 
Initially, her pain was considered to be nociceptive in type, i.e., pain caused by normal 
activation of peripheral nociceptors following tissue damage. It was managed by 
combination of MDT and increasing oral prednisolone up to 60 mg per 24 hours 
(median daily dose between 40 mg and 60 mg tapering over 6 months). Despite this she 
described only 50 % pain relief and showed symptoms and signs suggestive of 
psychological disturbance (GHQ score = 7). Over the last five years she had missed her 
work several times because of her pain.  
Throughout her illness, this patient always described the pain as tingling, numbness, 
burning and “electric shock” like. Several pathological processes were suspected as 
aetiological factors such as, an immune mediated inflammatory process, leprosy relapse 
or reinfection. However, her clinicians were unable to elucidate the neuropathic 
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component of her pain until a late stage and therefore the period of ineffective pain 
management could lead to psychological disability. 
Case history 2: 
An 18-year-old boy from Dharavi, Mumbai’ largest slum (Figure 5.1). He is a right 
handed student. He was newly diagnosed with PB leprosy on 30.03.2013 and he is on 
pain medication for the last week. He has no other medical comorbidities and notably 
has no clinical evidence of hypertension or diabetes mellitus on laboratory 
investigations.   
Presenting complaint 
Severe pain, burning, and tingling sensations in the right medial aspect of the forearm, 
and associated with right hand weakness for the last three days. 
Origin, duration and progress of the condition 
The condition started in early March 2013 (four weeks prior to the current visit), when 
the patient developed an acute onset of pain sensations in the medial aspect of the right 
hand. The pain was described as “insects crawling” in his hand and associated with 
burning and shooting pain along the medial side of his right forearm. The patient sought 
medical advice at a private clinic and received combiflam pain-killers (a combination of 
Paracetamol and Ibuprofen), one tablet four times a day. After pain killer treatment, he 
showed improvement. His pain subsided and he felt better. However, one week later; he 
developed sever pain around his right ulnar nerve associated with reduced function of 
the right hand. By late March 2013, he was referred to the BLP clinic by a leprosy 
affected member of the Dharavi slum community. At the BLP clinic he was diagnosed 
as having PB leprosy with neuritis, based on clinical examination: the presence of single 
skin lesions located on the face, and painful right ulnar nerve with reduced function. 
Further investigation such as skin smear was requested. The treatment plans was a high 
dose of prednisolone (60 mg), PB-MDT treatment for the next six months, and hand 
physiotherapy.  
Assessment 
This patients with leprosy presented with symptoms of acute pain while seeking 
treatment. Initially, the nature of the pain was nociceptive inflammatory pain, which is 
Chapter 5 – The Clinical Problem and Aims of the Thesis 
 
99 
 
usually amenable to treatment such as steroids, other anti-inflammatory medications, or 
immobilisation, but the nerve function impairment may continue even after starting 
MDT, which may serve as a source for the development of NP (Haanpaa et al., 2004, 
Haroun et al., 2012). This patients had right ulnar neuritis with sensory loss in the right 
ulnar nerve territories, hence the possibility of having acute NP cannot be ruled out.  
 
Figure 5.1. Dharavi, Mumbai’ largest slum 
Source: this picture was taken in March 2013 in Mumbai 
5.1.1.2 Summary of the case studies  
From the above two different scenarios, leprosy patients with neuropathy and pain 
could benefit from a much clearer distinction between mono-neuropathies–the usual 
presentation of NP in leprosy–and distal symmetrical poly-neuropathies which are much 
more unusual. 
5.1.2 Challenges in defining NP in leprosy patients 
5.1.2.1 Introduction 
NP, recognised to occur in approximately one-fifth of treated leprosy patients, is a 
major issue for patients and the health system care. Previous work has shown that 
patients with NP have significant levels of depression (Lasry-Levy et al., 2011, Haroun 
et al., 2012). For individuals, life with neuropathic pain can be disabling even after their 
disease has been “cured” adding a burden to the patient’s suffering and health service 
cost. As diagnosis is challenging for clinicians, misdiagnosis often leads to further health 
and social consequences. Because of the resource poor setting we need better diagnostic 
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tests purely for identification as this the main barrier to effective treatment. This is 
caused by a number of obstacles which still exist in clinical practice.  
The first difficulty is the variety of symptoms and signs of pain-related sensory 
abnormalities. The exact constellation of neuropathic pain characteristics, and associated 
sensory aberrations, which are manifested in an individual patient are variable and 
complex and often only fully revealed by the use of sophisticated investigation 
techniques (Jensen and Baron, 2003, Baron et al., 2009). This can result in common 
clinical features such as spontaneous pain or stimulus-evoked pain, as well as other 
associated sensory disturbances such as sensory loss (anaesthesia dolorosa).  
It has been argued that rather than categorising neuropathic patients according to their 
aetiological diagnosis, the stratification of patients on the basis of individual symptom 
sensory profiles should be done to understand better the underlying processes (Baron et 
al., 2012). In a study from Germany, Baron and colleagues (Baron et al., 2009) examined 
symptom profiles in more than 2000 patients with diabetic neuropathy and post herpetic 
neuralgia using standard clinical examination and the PD symptom questionnaire. The 
authors found that patients with NP could be sub-grouped based on specific symptom 
profiles. The authors identified 5 subgroups where the symptom profiles were found to 
be different on the basis of the prominent features. For instance, subgroup 1 report 
spontaneous burning pain. Whereas, subgroup 2 demonstrates only severe pain attacks. 
In subgroup 3 the values of the sensory profile are mainly concentrated around the 
zero-line for all parameters. In contrast, subgroup 4 demonstrates considerable evoked 
pain symptoms and less burning sensations and paresthesia. Others such as subgroup 5 
demonstrate considerable spontaneous symptoms without cutaneous allodynia or 
hyperalgesia. This indicates that the information obtained from pain questionnaires and 
clinical examination can be used to distinguish symptom profiles in patients with NP 
across different conditions. A similar grouping of NP patients based on sensory 
symptom profiles and co-morbidity, obtained in study of more than 2000 patients with 
painful radiculopathy (Mahn et al., 2011). These patterns do not necessarily reflect the 
condition from which the nerve damage arose, but importantly may well reflect pain 
generating mechanisms and therefore give a clue to mechanisms and thus likely drug 
responses on an individual patient level. Thus it is vital to accurately phenotype the 
sensory abnormalities in each patient with leprosy and NP. 
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Another major difficulty is the distinction between the different types of pain which are 
associated with leprosy. These are difficult to distinguish clinically, yet require different 
management strategies. Patients with leprosy may experience skin and nerve pain at 
different times during the disease. Skin lesions may affect sensory processing, but the 
pain mechanism differs from patients with nerve damage (i.e. not peripheral 
mechanism). Two main groups of leprosy patients experiencing pain can be 
distinguished: those with pain associated with reactions, and those with NP. However 
the two categories overlap (Haroun et al., 2012).  
In addition to the difficulties of assessing the heterogeneous features following nerve 
damage and the distinction between the different types of pain, relationships between 
underlying pain and sensory deficit cannot be accurately determined. The process is 
based primarily on patients’ descriptions supported by examination and investigation. 
Whilst any leprosy patients with neuropathy and pain is highly categorised as NP, the 
evidence of associations are required. This may not be a proven causation; neuropathy 
can be identified objectively, but it cannot be assumed that a causal relationship exists 
with the patient’s pain. This scenario is further complicated, as illustrated in the 
preceding section, when mixed types of pain exist in the presence of a progressive 
immunological and pathological process or in the occurrence of pain in subclinical 
neuropathy. There are several advantages of accurately phenotyped abnormalities, if 
uncertainties regarding the relationships between different sources of underlying pain 
are to be avoided. 
Finally, assessing an experience of pain itself is difficult. According to the IASP, 
irrespective of the underlying mechanism, pain is always subjective (IASP, 2009). Each 
individual feels and reports their pain experience differently, and the sensation of pain 
itself cannot be objectively measured. Even though certain behaviours have been 
identified as associated with pain, these are only corroborative. Also, although numerous 
psychophysical methods exist for the measurement of pain, these are entirely subjective 
(Chong and Cros, 2004).  
The variability of nerve damage in leprosy, the existence of different types of pain, the 
uncertainty in the relationships between underlying pain mechanisms and the subjective 
experience of pain makes the identification of pain-related sensory abnormalities a 
continuing challenge. Therefore, a new classification of leprosy patients with NP could 
take into account subgroups of patients with different sensory profiles. This provides 
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information about the pathophysiological process that helps improve understanding of 
the various NP mechanisms operating in leprosy. 
5.1.2.2 How to define neuropathic pain in leprosy 
For this current study, a two-step case definition was used to define NP in leprosy:  
1) Is there evidence of nerve damage?  
In accordance with the above definition the demonstration of nerve damage is an 
essential pre-requisite to diagnosing the presence of neuropathic pain.    
2) Is the pain neuropathic?  
Although demonstration of nerve damage is an essential first step in this diagnostic 
triage, the mere presence of nerve damage does not necessarily indicate that any pain is 
neuropathic in origin. Therefore, an essential second step is to classify any pain as being 
likely neuropathic origin. For this two criteria are required:  
i. Is the pain distributed in a “neuroanatomically plausible” location (e.g. a single 
peripheral nerve innervation)? A body chart where the pain location is drawn is 
used.  
ii. Is the symptom profile/ pain descriptors characteristic of neuropathic pain? For 
example by a score of ≥ 4/10 using the DN4 questionnaire. 
There are two definitive steps in the process: firstly to confirm that some form of 
damage to the somatosensory system has occurred, should be neuroanatomically logical 
and compatible with a definitive lesion site, without this the diagnosis is impossible 
(Treede et al., 2008). In leprosy, somatosensory system damage is a recognised 
complication. Body charts, which are routinely used in leprosy clinics to map skin 
lesions, can be used to identify distribution of pain by drawing pain location; in addition 
to patient’s pain description (i.e. is the pain for example burning, stabbing or aching). 
The demonstration of pain distribution may determine whether pain lies within 
dermatomes or peripheral nerve distribution. Also, pain patterns such as glove and 
stocking distribution can be mapped on the body template. This may help in 
understanding the relationship between the location and quality of pain. Likert scales, 
Visual analog scales (VAS), Verbal rating scales (VRS), or a combination of verbal and 
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numerical rating (Gracely Pain Scale) can be used to determine the severity of pain. BPI 
can be used for assessing fluctuation of pain over time (Haanpaa et al., 2011a). 
Secondly, to determine that any pain is indeed neuropathic, because nerve damage does 
not necessarily mean that pain is neuropathic in origin. To identify patients with 
possible NP, several screening tools are available such as the DN4, LANSS, NPQ and 
PD-Q. These screening tools are recommended particularly for non-specialists to 
consider the diagnosis of NP (Haanpaa et al., 2011a). It helps to determine the 
prevalence of NP in epidemiological studies, and it may also help to distinguish between 
inflammatory pain that is due to ongoing acute leprosy reactions and NP that is due to 
the effects of leprosy on sensory fibres. Nevertheless, these screening tools cannot 
replace clinical judgment in diagnosing NP in leprosy patients.  
5.1.2.3 How to apply a case definition of NP in leprosy 
Variation of defining NP in diseases such as leprosy 
Different types of leprosy-related pain may occur during the course of the disease; 
inflammatory and NP (Haroun et al., 2012). Pain associated with neuritis reaction, 
which is defined by the development of inflammation of a nerve sheath without 
abnormal findings in sensory testing, is clinically defined as nociceptive pain (Bove and 
Light, 1997). Importantly this term has been noted not to be used unless inflammation 
is thought to be present (IASP, 2012). However, if an inflammatory neuritis causes 
nerve damage then the pain is by definition neuropathic. Another subtype of NP is 
neuralgia, which is defined as pain arising in the distribution of a nerve or nerves (IASP, 
1994). Although neuralgia is the preferred term used generically to describe chronic pain 
following herpes zoster reactivation, it is used to describe NP arising from a lesion of 
specific nerves. NP in leprosy may occur even years after completion of the MDT. It 
usually occurs in distribution that is anatomically appropriate to the affected nerve(s) 
and in skin lesions. 
5.1.3 The impact of diagnosis on treatment 
Although there are no data from controlled studies in well-defined groups of leprosy 
patients that demonstrate the efficacy of the NP drugs, the treatment of the condition is 
less satisfactory. There are three principle reasons for this, the first being the difficulty in 
identifying and defining NP cases in leprosy. The second is the failure to identify the 
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presence of NP mechanisms. The third is the use of treatment that is based on one 
specific mechanism when each patient with NP is likely to have more underlying causes 
leading to pain. For instance, clinicians often prescribe a tricyclic antidepressant when 
treating chronic pain in leprosy based on reports on the use of these drugs with no 
clinical evidence. Thus for some patients, even optimal use of current treatments by 
experienced clinicians will not relieve their pain. 
5.1.4 The need of profiling and stratification of leprosy patients group 
Despite the problems outlined above regarding the identification, defining and 
treatment of neuropathic pain in leprosy, a majority of leprosy patients will benefit from 
the new profiling and stratification of neuropathic pain in order to: 
i. improve clinical trial design 
ii. identify neuropathic pain mechanisms 
iii. shape the development of new drugs     
iv. individualise treatment leading to improved pain control 
Given that the neuropathic pain mechanism-based approach is guided by targeted 
treatment according to pain mechanisms, it seems unlikely that there is a way to measure 
the mechanisms routinely. Therefore, identification of neuropathic pain mechanisms 
from symptoms and sensory profiles stratification would appear to be a sensible 
approach to inferring mechanisms operating at the individual patient level. In fact, 
Baron described an ideal situation in which subgrouping of patients with different 
sensory profiles guides the clinician in matching a particular treatment to a particular 
patient with predictable responses especially in clinical trial setting (Baron et al., 2012).  
The identification of sensory profiles can be best achieved with validated questionnaires 
such as the DN4 or BPI as regards symptoms, and with an extension of the clinical 
examination such as QST for sensory signs (Haanpaa et al., 2011a, Backonja et al., 
2013). For the purpose of this study the different approaches related to mechanisms and 
patients subgrouping are explained as follows: the mechanism-based is approach 
adopted by NP expert to target treatment with mechanisms; Patient profile (phenotype) 
is grouping of patients according to their symptoms and signs. Any profiling approach 
should stratify patients by symptom, sensory and psychological state. This has the 
potential to improve clinical trial design and might be adopted into routine practice. 
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5.2 The role of instruments for assessing sensory abnormality and 
psychological impact of NP in leprosy 
This section describes the role of different instruments for assessing pain-related 
sensory abnormalities, their availability and justification for use in leprosy. 
5.2.1 The role of pain questionnaires 
5.2.1.1 Background 
Pain questionnaires are tools that can accurately identify patients with symptoms and 
signs suggestive of neuropathic pain (Haanpaa et al., 2011a).  
5.2.1.2 Available instruments 
There are several validated questionnaires designed to identify neuropathic pain 
characteristic. These instruments can be classified into two groups: diagnostic screening 
and symptom profiling questionnaires. The former include LANSS, NPQ, DN4, PD-Q, 
StEP and ID-pain questionnaires, which have sensitivities ranging from 66% to 94% 
and specificities in the range 69% to 97% (Üçeyler and Sommer, 2011). Whereas, the 
symptom profiling questionnaires include NPS, NPSI, PQAS and SF-MPQ. For leprosy 
work the linguistic and cultural (context) validation are required in local languages and 
the DN4, LANSS and the NPSI have been used (Saunderson et al., 2008, Lasry-Levy et 
al., 2011, Haroun et al., 2012). I will present here the screening tools used in leprosy 
neuropathic pain, others are explained in detail in Chapter 3. 
Pain screening questionnaires and leprosy 
In recent years, more attention has been given to screening tools in identifying 
neuropathic pain among leprosy patients. The preference is given to a tool validated in 
the language in which it will be applied. Stump (Stump et al., 2004) described the use of 
McGill pain questionnaire which identified 53 (15%) patients with pain in sample of 358 
Brazilian leprosy patients, but there was no information regarding the validation. In 
contrast, DN4 has been used for studies in India and Ethiopia (Lasry-Levy et al., 2011, 
Haroun et al., 2012). The different screening tools are summarised in Table 5.1. I elected 
to use the DN4 questionnaire.  
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Table 5.1. Overview of screening tools in studies carried out on leprosy 
NP 
Authors, year Country Study population Tools 
Hietaharju (Hietaharju 
et al., 2000) 
Bangladesh 16 leprosy patients with chronic 
pain 
Clinical 
assessment 
Stump (Stump et al., 
2004) 
Brazil 358 leprosy patients from a referral 
centre    
McGill Pain 
Questionnaires 
Lund (Lund et al., 
2007) 
India 17 leprosy patients who had 
completed MDT 
Clinical 
assessment 
Saunderson 
(Saunderson et al., 
2008) 
Ethiopia 96 leprosy patients who had 
completed MDT more than 10 
years 
NPSI 
Lasry-Levy (Lasry-
Levy et al., 2011) 
India 101 leprosy patients who had 
completed MDT 
DN4 and 
LANSS 
Haroun (Haroun et al., 
2012) 
Ethiopia 80 leprosy patients who had 
completed MDT within 18 months  
DN4 and 
LANSS 
Chen (Chen et al., 
2012) 
China 275 leprosy patients NPSI 
Felipe Reis (Reis et al., 
2013) 
Brazil 33 leprosy patients with pain DN4 
Raicher (Raicher et al., 
2013) 
Brazil 90 leprosy patients with pain DN4 and NPSI 
Gosling (Gosling et al., 
2013) 
Brazil 114 leprosy patients with pain  DN4 and 
McGill Pain 
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5.2.1.3 Justification for using DN4 in identifying NP among leprosy patients 
In the current study, leprosy patients have been assessed for NP using highly specialised 
assessments tools. Of these validated tools, the DN4 was selected, which may help in 
identifying NP characteristics. 
First, DN4 is a simple, short and validated questionnaire to identify patients with NP. It 
uses both interview questions and brief bedside examinations, so it helps in assessing 
symptoms as well as clinical signs of NP. Whereas, other questionnaires are more 
complex, lengthy and have limited clinical examinations. 
Secondly, DN4 has a good diagnostic yield. Previous studies evaluating diagnostic 
characteristics of DN4 for neuropathic pain of different aetiology have found values of 
sensitivity and specificity for neuropathic pain from 82% to 95% and from 78% to 97%, 
respectively (Bouhassira et al., 2005, Perez et al., 2007, Unal-Cevik et al., 2010).   
Furthermore, in leprosy, DN4 is commonly used to identify patients with NP. It has a 
higher sensitivity as screening tool for NP in leprosy. In the 18th International Leprosy 
Congress, Raicher (Raicher et al., 2013), who investigated the prevalence of NP among 
90 leprosy patients with pain using DN4 in Brazil, reported sensitivity and specificity of 
96% and 58%, respectively. Similarly, in the 14th World Congress on Pain, Stump 
(Stump et al., 2012) reported high sensitivity of DN4 as a screening tool for NP in 
leprosy (>90%) in a study with 358 patients. In an study performed by our group in 
2009; 80 leprosy patients, who had completed MDT within 18 months in Ethiopia, were 
assessed using DN4 and LANSS (Haroun et al., 2012). In this study we asked patients 
to evaluate the screening questionnaires. The study found that the DN4 was easier to 
administer than other tools in assessing NP. This finding was proved by patients’ 
choices. Although the sensitivity of DN4 was found to be excellent (100%), its 
specificity was far lower than in the validation studies (45%). This could be because of 
the high numbers of patients with inflammatory pain that were recruited. This should 
not have affected the results concerning DN4 diagnostic accuracy; rather, it indicates 
that patients studied were similar to those usually encountered in regular clinical 
practice. Another study performed by our group in India, has come to a similar 
conclusion; DN4 is easier to apply in identifying NP among leprosy patients (Lasry-Levy 
et al., 2011).  
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5.2.2 The role of Quantitative Sensory Testing 
5.2.2.1 Background  
Quantitative Sensory Testing (QST) is a diagnostic method for accurately assessing 
somatosensory changes in human skin caused by nerve damage (Maier et al., 2010). It 
has been also recommended by NeuPSIG as a useful diagnostic instrument in the 
assessment of NP (Haanpaa et al., 2011a). It is a non-invasive procedure which is a 
sophisticated clinical examination of the sensory nervous system, whereby the 
perception thresholds to various mechanical and thermal sensory stimuli are accurately 
measured. Although it’s utility in routine clinical NP assessment may have limitations 
such as difficulty in standardising and being time consuming (Cruccu et al., 2004), there 
is increasing interest in using QST to give insights into the underlying patho-
physiological mechanisms of chronic pain. 
5.2.2.2 Available instruments 
DFNS-QST protocol 
The German Research Network on Neuropathic pain (DFNS) has developed the 
DFNS-QST protocol in 2006 (Rolke et al., 2006a). It is a comprehensive and validated 
tests including all somatosensory modalities mediated by different nerve fibres (Aβ, Aδ 
and C), that measures: cold and warm detection thresholds, number of paradoxical heat 
sensations during the thermal sensory limen procedure, cold and pain thresholds, 
mechanical detection threshold and mechanical pain sensitivity, dynamic mechanical 
allodynia, temporal pain summation and pressure pain threshold (Rolke et al., 2006b). 
This offers a high degree of detailed and precise information in the clinical diagnosis of 
leprosy related NP. The protocol is a well-established instrument for the assessment of 
NP and data has been collected internationally in over 3,000 neuropathic pain patients. 
In a study of 43 German patients who had neuropathy and dysesthesia in 2008, the QST 
parameters showed a high specificity (80%) but low sensitivity (37%) in the prediction 
of a reduced intraepidermal nerve fibre density as correlate for neuropathy (Scherens et 
al., 2009). 
Quantitative sensory testing and leprosy 
Although QST is widely used as an assessment tool for small fibre function and sensory 
profiles in neuropathies associated with pain (Maier et al., 2010, Rolke et al., 2006b), it 
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has not been used much leprosy patients and certain individual components have been 
measured (e.g. thermal and vibration thresholds) as opposed to the full battery of tests 
required to give the complete sensory assessment, Table 5.2. 
Villarrole et al. in 2007 measured the different responses to the panel of stimuli used in 
a thermal testing analyser and monofilaments in 108 leprosy patients with skin lesions. 
They found that all patients had impaired warm and cold perception (Villarroel et al., 
2007b). This study found that the cut-off points for warm and cold perception 
threshold determined from thermal sensory analysis were 35.1oC and 28.95oC, 
respectively (Villarroel et al., 2007a). Facer et al. 1998, who measured the responses to 
the thermal sensory analyser applied in the skin lesions in 28 leprosy patients, has also 
concluded that thermal threshold for cold and warm were significantly different (Facer 
et al., 1998). However, these studies have assessed the skin lesions in leprosy patients 
with no evidence of nerve function involvement and measured only thermal testing. A 
similar result, showing that warm and cold detection threshold were commonly affected, 
was obtained by van Brakel et al. 2008, who measured the different responses to the 
panel of QST thermal stimuli in a cohort of 303 Indian leprosy patients (van Brakel et 
al., 2008b). 
Lund et al. 2007 measured the different responses to the panel of stimuli used in the 
QST in 17 leprosy patients with chronic pain in India and found 65% of the patients 
had sensory loss for all tested modalities (Lund et al., 2007). The study found that 
patients with chronic pain had lower IENF density and QST parameters (Lund et al., 
2007), however this study has contained relatively small numbers of subjects. 
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Table 5.2. Quantitative Sensory Testing studies in leprosy neuropathy 
Author, 
year, 
country  
Main purpose of 
the study  
Study 
population, 
N 
Intervention / 
test 
Main findings 
Villarroel et 
al. 
(Villarroel et 
al., 2007b)  
Brazil 
To assess leprosy 
skin lesion sensory 
impairment 
Leprosy 
patients: 108 
Thermal Sensory 
Analyser and 
Monofilaments 
All patients  had 
impaired warm and 
cold perception  
Villarroel et 
al. 
(Villarroel et 
al., 2007a) 
Brazil 
To determine the 
frequency of 
thermal sensation 
Leprosy 
patients: 108 
Thermal Sensory 
Analyser (TSA-
2001) 
Warm perception 
threshold: 35.1 o C 
and CPT: 28.95 o 
C 
Abbot et al.  
(Abbot et 
al., 1996) 
Iran 
To assess un-
myelinated fibre 
impairment  
Leprosy 
patients: 39 
Laser Doppler 
flowmetry, electo-
pysiology and 
QST   
Significant 
relationship 
between fibres and 
sensory impairment  
Facer et al. 
(Facer et al., 
2000) 
India 
To explain early 
loss of cutaneous  
pain sensation  
Leprosy 
patients: 28 
Thermal test, light 
touch, Laser 
Dopler and skin 
biopsy 
Sensory loss in 
affected skin 
Brakel et al. 
(van Brakel 
et al., 2008a) 
India 
To compare 
diagnostic test for 
neuropathy 
Leprosy 
patients: 303 
INFIR study 
NCS, Quantitative 
thermal sensory 
test, MFs and 
VMT 
WDT more 
frequently affected 
(29%), CDT (13%) 
Lund et al. 
(Lund et al., 
2007) 
India  
To demonstrate 
the possible 
factors for NP 
Leprosy pts 
completed 
treatment 17 
QST and skin 
biopsy 
65% had total 
sensory loss for all 
modalities  
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5.2.2.3 Justification for using DFNS-QST protocol in leprosy 
This is the first study to document pain sensation using DFNS-QST in leprosy patients. 
These reasons for using the DFNS protocol include the standardisation, the highly 
precise detection of the sensory loss and gain, the validity of the DFNS-QST protocol, 
and its ability to assess the individual’s sensory profile. This protocol is commonly used 
in other conditions such as peripheral nerve injury, postherpatic neuralgia and trigeminal 
neuralgia related neuropathic pain (Maier et al., 2010). The assessment of the exact 
sensory phenotype by QST is also a crucial part of this research project and this 
comprehensive technique is not yet used in leprosy. 
The DFNS-QST protocol is a reliable and well-validated protocol. In recent years, 
several studies indicate a high diagnostic value of its results in both healthy subjects and 
in patients with NP. Maier (Maier et al., 2010) explored the spectrum of sensory 
abnormalities in 1236 patients with neuropathic pain due to different underlying 
diseases. In this large cohort of patients, DFNS-QST was found to be reliable; 92% of 
all patients with proved neuropathy had at least one sensory abnormality compared with 
the contralateral unaffected body area or with the reference data obtained from healthy 
controls. This indicates a good validity of the QST-DFNS protocol as a tool for 
quantifying somatosensory changes and even pain-related phenomena. 
The DFNS-QST protocol is sufficiently sensitive to document the results related to the 
loss of function, i.e. sensory deficit and to abnormal pain-related phenomena, which 
clinically present as various manifestations of pain. This may help to assess the patient’s 
sensory profile and subgrouping of the patients, and thus can be valuable to evaluate the 
underlying NP mechanisms in leprosy.  
This protocol has been recommended by the IASP for the assessment of patients with 
NP, and leprosy patients will benefit from such tool (Haanpaa et al., 2011a, Backonja et 
al., 2013). 
5.2.3 The role of skin biopsy and IENFD 
5.2.3.1 Background 
Skin biopsy provides insight into disease pathophysiology, which may lead to improve 
diagnosis and treatment of chronic pain condition. Its diagnostic yield has already been 
established in many peripheral neuropathies and especially useful when small fibre 
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neuropathy is being considered (Lauria et al., 2009). For instance, skin biopsy is used to 
aid in the diagnosis of Parkinson’s disease specifically to evaluate the potential role of 
alpha-synuclein as a biomarker for this disease (Nolano et al., 2008). Moreover, skin 
biopsies have demonstrated involvement of epidermal small sensory fibres in patients 
with Amyotrophic Lateral Sclerosis (ALS) (Weis et al., 2011). Furthermore, skin biopsies 
have demonstrated involvement of cutaneous innervation in patients with Spinobulbar 
Muscular Atrophy (Kennedy’s disease) (Manganelli et al., 2007). These utilities help to 
evaluate and better understand of somatosensory dysfunction. 
The principal role of skin biopsy in the diagnosis of NP is to determine intra-epidermal 
nerve fibre density (Lauria et al., 2010). Unmylinated C-fibre, which is the only fibre that 
penetrates into the epidermis, is frequently involved in patients with NP. This can be 
assessed by quantifying IENF density in the affected area (Lauria et al., 2010).  
Several studies in clinical settings have examined the correlation between IENF density 
and pain (Devigili et al., 2008, Sorensen et al., 2006, Vlckova-Moravcova et al., 2008b, 
Quattrini et al., 2007, Polydefkis et al., 2002, Zhou et al., 2007).  Sorensen (Sorensen et 
al., 2006) investigated 25 diabetic patients with NP and 13 patients without pain using 
skin biopsy obtained from distal leg. The authors found IENF density was lower in 
patients with NP compared to those without. In HIV-related sensory neuropathy, 101 
patients underwent standardised NP assessment, IENF density was found inversely 
correlated with pain severity assessed with both VAS and the Gracely Pain Score (Zhou 
et al., 2007). Devigili and colleagues (Devigili et al., 2008) investigated 67 patients with 
pure small fibre neuropathy (diagnosed by the presence of at least two abnormal results 
on clinical examinations, QST, and skin biopsy) selected from a cohort of 124 patients 
with sensory neuropathy. The authors noted that Lower IENF density may be 
associated with the presence of NP, but it does not correlate with the intensity of pain. 
5.2.3.2 Available instruments  
Two main methods; punch biopsy and blister techniques are often used to obtain skin 
biopsy samples for assessing small fibre neuropathy. The former one is the most 
commonly performed using 3-mm disposable punch. It is standardised procedure that 
provides information on epidermal nerve fibres, sweat gland, hair follicles, and artero-
venous anastomosis. The technique is validated, safe and minimally invasive (Lauria et 
al., 2010). Whereas, the latter is less invasive and has not been systematically used to 
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investigate patients with small fibre neuropathy. In addition, it does not provide 
information on dermal and sweat gland. In this study I use the 3mm disposable punch 
biopsy technique.   
5.2.3.3 Intra-epidermal nerve fibre density (IENFD) and leprosy 
In leprosy, skin biopsy is often used to define disease classification, but there have been 
only two studies on IENF density measurement and its correlation. The first study is 
performed by Facer in India, investigated 28 leprosy patients and found an inverse 
correlation between nerve fibres in the sub epidermis and thermal threshold (Facer et 
al., 1998). The second one is performed by Lund examined 17 leprosy patients with 
chronic pain (Lund et al., 2007). The authors found IENF density was significantly 
lower compared to the control skin biopsies.  
Studies have revealed a significant correlation between IENFD, pain and QST 
parameters in post herpetic neuralgia, diabetics and HIV neuropathy (Zhou et al., 2007, 
Sorensen et al., 2006, Devigili et al., 2008, Loseth et al., 2008, Vlckova-Moravcova et al., 
2008a). It is uncertain whether intra-epidermal nerve fibre density is correlated with pain 
and quantitative sensory testing parameters in leprosy, although studies confirm leprosy-
related peripheral sensory neuropathy is a small fibre neuropathy. Previous study in 
leprosy has also suggest that a significant correlation between IENFD and QST 
parameters in patients with chronic pain (Lund et al., 2007), however this study has 
contained relatively small numbers of subjects. 
5.2.3.4 Justification for using skin biopsy and IENF density in leprosy 
In this current study, leprosy patients and controls have been assessed for NP using 
standardised clinical assessments and a skin biopsy taken from a pain affected area. A 
crucial part of the pain evaluation is the determination of the density of intra-epidermal 
nerve fibres in the affected areas. 
The 3-mm punch biopsy with linear quantification of IENF density is a reliable and 
efficient technique to confirm the clinical diagnosis of small fibre neuropathy. The 
technique is ethically approved and widely used in other conditions. No side effects 
have been reported in published studies. Recently, it has been recommended by the 
European Federation of Neurological Societies/Peripheral Nerve Societies 
(EFNS/PNS). 
Chapter 5 – The Clinical Problem and Aims of the Thesis 
 
114 
 
5.2.4 The role of Psychological co-morbidity and HRQoL instruments 
5.2.4.1 Background  
NP is often associated with psychological conditions such as depression and anxiety, 
which may affects daily activities and overall quality of life (Meyer-Rosberg et al., 2001). 
This section describes the role of psychological co-morbidity and HRQoL 
questionnaires in the assessment of the impact of leprosy NP.   
According to the World Health Organization health is defined as “a state of complete 
physical, mental, and social well-being, and not merely the absence of disease or 
infirmity” (WHO, 1948). Quality of life questionnaires are important measures of the 
general aspects of an individual’s life, whereas HRQoL questionnaires more specifically 
measure the impact of disease on the patient’s physical, psychological and social 
functioning.  
NP is often associated with a reduced quality of life (Meyer-Rosberg et al., 2001, 
Haanpaa et al., 2011a). A systematic review of the association between NP and health 
related quality of life (Jensen et al., 2007) revealed strong evidence that the presence and 
severity of NP are associated with greater impairments in a number of important 
HRQoL domains. For example, pain intensity and pain interference with function can 
have a marked impact on daily functioning activities, affective and motivational states, 
social relationships, sleep hygiene and economic factors. This impact varies as a function 
of the HLQoL domain being considered and that different measures of HRQoL are 
differentially sensitive to the effect of NP. The principle role of HRQoL questionnaires 
in patients with NP is to provide information about the impact on quality of life, 
particularly when associated with chronic severe pain and suffering (Guyatt et al., 1993, 
Nelson and Berwick, 1989).  
5.2.4.2 Available instruments 
Depending on the outcome measures, the HRQoL instruments can be grouped into 
generic, condition-specific and preference-based measures (Vetter, 2007). The generic 
HRQoL instruments, such as SF-36 and WHOQOL questionnaires, are more general 
and comprehensive. These are often used for evaluating the impact of pain on the 
common elements of health, well-being and functionality. Whereas, the condition-
specific instruments are more suitable for detecting changes due to disease progression 
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or remission. They are also used to detect treatment response (Patrick and Deyo, 1989). 
For instance, NePiQoL and Neuroqol are specifically designed for neuropathy and pain. 
Another important condition-specific instrument is the Brief Pain Inventory (BPI), 
which assesses the impact of NP on the patient (Coplan et al., 2004). BPI has been 
validated in patients with non-cancer pain (Keller et al., 2004). On the other hand, the 
preference-based instruments such as SF-6D and EQ-5D are designed to incorporate 
patients’ opinions of the utility value of a particular health state rather than simply 
describe the condition. They are suitable for cost-effectiveness analysis and can be used 
for a comparison across diseases (Vetter, 2007).     
5.2.4.3 Justification for using GHQ-12 and BPI questionnaires in leprosy  
For this current study, I have looked at the HRQoL questionnaires and found that it is 
more general and not relevant to our patient group, category of measurement, primary 
purpose or setting. For instance, the WHOQOL social relationship questions are not 
relevant to our ultimate objective. Moreover, while WHOQOL includes overall pain as 
one domain, a condition-specific measure can evaluate in depth the impact of NP on 
quality of life. For example, the WHOQOL’s specific pain focused questions, such as 
“Do you worry about your pain or discomfort?” may not detect a clinically significant 
change in leprosy related sensory abnormalities. Furthermore, even if pain is assessed as 
a separate dimension on WHOQOL, the effects of pain severity on health-related 
quality of life is not considered. Hence, I decided to use condition-specific tools for NP 
such as BPI, which are designed to assess specific diagnostic groups particularly with the 
aim of determination of the impact of NP. 
Another important reason is the validity and availability of BPI. Although, no 
recommendations exist on the use of specific HRQoL questionnaires for the assessment 
of quality of life (Haanpaa et al., 2011a), BPI is preferred to be used in cases of severe 
neurological conditions or in short-lived NP conditions (Coplan et al., 2004, Zelman et 
al., 2005). In painful diabetes neuropathy and herpes zoster studies, the usefulness of 
BPI measures of functionality and quality of live have been demonstrated.  In an early 
study performed by our group in 2009; 80 leprosy patients, who had completed MDT 
within the previous 18 months in Ethiopia, were assessed using BPI (Haroun et al., 
2012). In this study the intensity of patient’s pain on health related quality of life, such as 
physical functioning, sleep and mood were assessed. The short version of BPI and 
validated tools are freely available. 
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5.3 Aims and objectives of the thesis 
5.3.1 Aims of study 
The overall aim of the study is to characterise the somatosensory phenotype of leprosy 
patients with chronic neuropathic pain. 
5.3.2 Statement of the hypothesis 
I hypothesised that; 
 The thermal and mechanical detection threshold, pain threshold (CPT and 
WPT), pressure pain threshold (PPT), and vibration detection threshold (VDT) 
are lower in leprosy patients with painful neuropathy than patients with non-
painful neuropathy 
 There is significant impact of neuropathic pain on quality of life and 
psychological well-being in leprosy patients with painful neuropathy compared 
to patients with non-painful neuropathy. 
Specific objectives 
i. To measure the somatosensory responses of leprosy patients including thermal 
detection and pain thresholds, paradoxical heat sensations, mechanical detection 
thresholds to von Frey filaments, vibration detection threshold, mechanical pain 
thresholds to pinprick stimuli and blunt pressure, stimulus/response-functions 
for pinprick and dynamic mechanical allodynia, and pain summation (wind-up 
ratio)  and to compare these measures between leprosy patients with painful 
neuropathy; non-painful neuropathy, leprosy patients without pain and age and 
sex matched healthy controls. 
ii. To elucidate the impact of leprosy NP on quality of life and psychological well-
being in patients with painful neuropathy compared with patients with non-
painful neuropathy. 
iii. To stratify leprosy patients by symptoms, sensory profile and psychological state 
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Chapter 6 Materials and Methods 
6.1 Overview 
This chapter presents the search strategy and definitions of terms used in the study, and 
an overview of the study design including the description of a case-control study as a 
research design and its applicability to this study. The methods of clinical and laboratory 
assessments, including the DFNS-QST protocol are then defined. Finally, an account of 
the data recording and management approaches are provided, including strategies of 
analysis that were used in this study.  
6.2 The search strategy and search criteria 
Literature published up to August 2014 related to leprosy and NP was searched. The 
literature review of leprosy and neuropathic pain was performed using search terms 
listed in Table 6.1. The search was limited to articles published in English. Various 
combinations of the terms were employed (leprosy and neuropathic pain). The main 
research resources used were search engines and bibliographic data-bases. These 
included: PubMed (chosen as it provides a wide coverage of health topics), EMBASE 
(chosen as it provides access to articles with a focus on general medicine), MEDLINE 
(chosen to complement the EMBASE search), and the Cochrane library (chosen to 
ensure capture of articles with clinical interventions). Reference lists in the articles found 
were also searched for relevant articles and the function “related articles” in PubMed 
was used. WHO documents on leprosy were checked on the WHO website. DFNS 
publications on QST were also checked on the DFNS website. Additional references 
were gathered from conference lists and Google internet searches. PhD theses available 
on EThoS (UK theses) and through the LSHTM, and ICL libraries were also checked 
for relevant information. 
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Table 6.1 Search terms used in the study 
Leprosy  Reactions  Neuropathy Pain QST 
Hansen’s disease type 1 reaction 
“T1R” 
subclinical 
neuropathy 
Pain  DFNS-QST 
reversal reaction Nerve damage Neuropathic 
pain 
Quantitative 
sensory testing 
erythema 
nodosum 
leprosum 
“ENL” 
peripheral nerve 
damage “PN” 
non-neuropathic 
pain 
DFNS 
nerve function 
impairment 
“NFI” 
nociceptive pain 
 
6.3 Definitions of terms used in this thesis  
6.3.1 Definitions 
Motor test: test of the function of motor fibres of the nerves, normally performed by 
checking muscle power using voluntary muscle testing (Appendix 24). 
Voluntary muscle test (VMT): test of the function of (voluntary) muscles innervated by 
a particular nerve trunk, normally performed by checking the ability of the patient to put 
a limb into a given position and to hold that position against resistance applied by the 
tester. For standardisation where possible a comparison is made to the unaffected side. 
Motor impairment: motor neuropathy resulting in obvious weakness of the muscles 
innervated by a given nerve. 
Sensory test: test of the function of sensory fibres of the nerves, normally performed by 
checking light touch sensation using application of monofilaments (Appendix 25). 
Semmes-Weinstein monofilament test (MFs): a graded test of touch sensibility based on 
indenting the skin surface with a series of increasing thickness of standard nylon 
filaments. For each thickness it is recorded whether or not the patient feels the touch. 
Three or four sites per nerve may be tested, the severity of the sensation impairment 
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being measured by the thickness of filament just felt by the patient. A normal level of 
0.2g for the hand and 2g for the foot (excluding the heel) is appropriate.  
Sensory impairment: neuropathy of the sensory fibres resulting in obvious reduction in 
the sensory ability of the patient using Semmes-Weinstein monofilaments. 
Clinical neuropathy: sensory, motor or autonomic neuropathy evidenced by clinically 
detectable obvious reduction in function in sensory and/or motor using Semmes-
Weinstein monofilaments and/or VMT. 
6.3.2 Case definitions 
1. Leprosy neuropathy  
A leprosy neuropathy case was defined as a patient with a clinical 
evidence of sensory and/or motor impairment in an area innervated by 
one or more nerve using Semmes-Weinstein Monofilaments (MFs) and 
MRC scale. 
Sensory impairment was defined by a decrease in sensation as measured 
by Semmes Weinstein monofilament testing. In the hands, this was 
defined as not being able to perceive the 0.2gm monofilament at 2 
points out of 3 in each nerve of the hand. In the feet, this was defined as 
not being able to perceive the 2gm monofilament at 3 out of 4 sites of 
the foot.  
Motor impairment was defined by a decrease in voluntary muscle testing 
(VMT) score, by 1 point or more from the normal score of 5, using the 
modified MRC scale. 
2. Sub-clinical neuropathy 
Patients with no clinical evidence of neuropathy based on Semmes-
Weinstein Monofilaments (MFs) and/ or MRC scale, but who showed 
abnormal NCS or thermal testing were allotted to “Subclinical 
neuropathy”. 
3. No clinical evidence of neuropathy 
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For the purpose of this study, no clinical evidence of neuropathy was 
clinically defined by the normal sensory and motor impairment result 
using Semmes-Weinstein Monofilaments (MFs) and MRC scale, 
respectively. Sensory neuropathy detectable by Semmes-Weinstein 
monofilaments, but not meeting the criteria of sensory impairment is 
clinically defined as no clinical evidence of neuropathy. 
4. Neuropathic pain 
A case of NP was clinically defined by the presence of negative or 
positive neurological signs concordant with the distribution of pain at 
the affected peripheral nerves based on a score of ≥ 4/10 using the 
DN4 questionnaire and clinical neurological examination. Duration of 
this pain for three months or more is defined as chronic NP.  
5. Non-neuropathic pain (nociceptive pain) 
For the purpose of the curent study, a case of non-neuropathic pain was 
clinically defined by the occurrence of sharp, dull, or aching pain score 
of < 4/10 using the DN4 questionnaire (Costigan et al., 2009).  Pain 
associated with neuritis reaction, which defined by the development of 
inflammation of nerve sheath without abnormal findings in sensory 
testing, is clinically defined as nociceptive pain (being originated from 
nervi nervorum) (Bove and Light, 1997, Sauer et al., 1999). Also, pain 
associated with type 1 and type 2 reactions is clinically defined as non-
neuropathic pain. 
6. Type 1 reaction  
A type 1 reaction was diagnosed when the patients had erythema and 
oedema of skin lesions. There may be accompanying neuritis and 
oedema of the hands, feet and face. The skin signs were obligatory; the 
nerve and general signs optional (Van Brakel et al., 2005a).  
7. Type 2 reaction  
A type 2 reaction was diagnosed when the patients had crops of tender 
subcutaneous skin lesions. There may be accompanying neuritis, iritis, 
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arthritis, orchitis, dactylitis, lymphadenopathy, oedema and fever. The 
skin signs were obligatory; the nerve and general signs optional (Van 
Brakel et al., 2005a).  
8. Neuritis  
A case of neuritis is clinically defined if the patient has any of the 
following: Spontaneous nerve pain, paraesthesia or tenderness; new 
sensory, motor or autonomic impairment of recent onset; or mixed 
signed. 
6.3.3 Pain terminology 
The pain terminology, which was based on the updated IASP taxonomy (IASP, 1994), is 
given in (Appendix 50).  
6.4 Study design 
6.4.1 An overview of the study design and research procedures 
A range of study designs could be used for this type of analysis. In cross-sectional 
studies, which is a “snapshot” of the population at a single point in time, the exposure 
and disease status are assessed simultaneously in each individual. It is good for 
measuring the scale of a problem e.g. prevalence of disease, but it cannot assess the 
sequence of events, so cannot show that exposure came before the outcome. In case 
control studies, people who have the disease in question (cases) and those who do not 
(controls) are compared with respect to the past exposure of potential causative factors. 
Sometimes case control studies referred to as retrospective studies, because they look 
backwards from the disease to potential causes. In cohort studies, a group of people 
with a particular risk factor is followed to determine whether they develop the disease of 
interest.   
I adopted a case control study to assess the somatosensory parameters related to NP in 
leprosy patients using the QST in 90 leprosy patients. A defining feature of a case-
control study is that the starting point is identification of people with the outcome in 
question. In relation to this study, I chose to identify NP cases among leprosy patients. 
The case definition of NP was clinically defined, and I included all prevalent cases of 
NP (i.e. all NP cases within leprosy population in the BLP catchment area at a specific 
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point in time). Our controls were drawn from the same population and were classified 
into different groups by their neuropathy status and the presence of pain (Table 6.2). 
Three control groups were randomly selected from the leprosy population presenting at 
the BLP and FMR clinics. One group of controls was selected from patients with no 
pain and no clinical evidence of neuropathy. The other two groups were patients with 
pain-free neuropathy and patients with pain and no clinical evidence of neuropathy. In 
addition, a group of healthy volunteers was recruited from the local Indian population. 
Although, this group was not part of the case control series, their data were used for 
comparison with patients along with the DFNS database reference. The reason I 
selected more than one group was due to the heterogeneity of leprosy neuropathy and 
pain. The aim of the study was to investigate the clinical aspect of NP in leprosy. If the 
study had used only healthy controls, the comparison would have been between patients 
who had developed NP and healthy, which might may have introduced inaccuracies in 
the profiling if the patients with leprosy who had pain reported similar profiles to 
healthy controls. In addition, we felt that profiling leprosy without pain might detect 
new neurological abnormalities that could be tested by comparing cases with the control 
group who had neuropathy and pain. Individual matching methods were applied in this 
study. For each individual case, a control was selected who was similar to that case with 
respect to the age and gender. Cases and controls were individually matched by age 
(within approximately 10 years) and sex. For example, if our case was a 34-year-old 
female, I selected a control who was a female aged 30 – 39. 
Table 6.2. Design of study groups selection 
 Neuropathy 
Yes No 
Pain Yes ? NP ? Non-NP 
No Pain free neuropathy No evidence of neuropathy 
 
In relation to this study, the selection of controls was appropriate. The use of these 
methods helped the study as follows: firstly, the population-based controls minimised 
the systematic selection bias. Secondly, having three controls per case improved the 
statistical precision of the profiling estimate. However, increasing the number of 
controls was logistically difficult because of additional resources and time required to 
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interview a greater number of controls. Finally, the advantages of the age and gender-
matched control techniques used for each patient in this study reduced potiential 
sources of confounding and increased the efficiency of the study. Matching our controls 
to cases by age ensured that the age distribution of cases and controls was the same. 
This meant that the effect of the matched age was removed from analysis (i.e. I 
controlled for any confounding effect of age). Another advantage of matching was 
examining fewer patients per group, because the cases and controls were more similar to 
each other than they would be if they were not matched. I tried to match the 
recruitment across the leprosy spectrum (TT, BT, BB, BL and LL), but it became 
difficult to find appropriately matched controls for each case, because the R.J 
classification was poorly documented. However, the matching method is prone to bias 
by making cases and controls more similar than they would otherwise be. Therefore, it is 
not possible to examine the effect of an exposure that has been matched.  
In this study, I chose to characterise the somatosensory profile of leprosy patients with 
NP, and compared the profile among those with leprosy neuropathy and those without. 
However, the study did not consider the association between the leprosy neuropathy 
and NP, or the effect of leprosy or exposure to other variables, for these would fall 
outside the timeframe and objectives of the study. The study would only look at 
profiling characteristic of leprosy patients with NP at one point in time.  
The benefit of a case-control study design is that it can be carried out rapidly and 
relatively cheaply compared to cohort studies. It is also useful for studying rare diseases 
such as leprosy that may take a long time to manifest. However, case-control studies are 
prone to selection bias, particularly in the selection of controls. The design is also prone 
to information bias, because exposure status is determined after the outcome has 
occurred. In addition, case-control studies may not provide information about the 
sequence of events leading up to an exposure or outcome. These studies are also not 
suitable for estimating disease incidence or prevalence. Therefore, in this this study, I 
was unable to estimate the occurrence of NP among leprosy patients. I was also unable 
to establish the causality of NP, and whether leprosy is a consequence or a cause. 
Information on cause-and-effect relationships can be collected by applying a 
longitudinal study design.  
A cohort study, similar to a case-control study, is observational. Two types of cohort 
study are known: descriptive and analytic. In descriptive cohort studies, a group of 
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participants who have experienced an exposure of interest are selected and followed 
over a period of time to determine the incidence of one or more outcomes. In analytical 
cohort studies, the association between an exposure and an outcome are tested. Study 
participants are classified as exposed or unexposed to the risk factor of interest. 
Cohort studies are particularly useful for rare exposures and in situations where more 
than one outcome is of interest. In cohort studies, the exposure is measured at the start 
of the study before the outcome occurs, and so measurement of the exposure is not 
biased by the presence or absence of the outcome. These studies can provide data on 
the time course of the development of the outcome(s), including late effects. Rare 
exposures can be investigated using appropriately selected populations. 
Our study requires the description of the distribution of leprosy NP related to time, 
place, and person. Since the onset of leprosy is usually gradual, if we want to describe 
the onset and characteristics of NP, a cohort study would be the best study design. 
Leprosy is a rare disease, so such a study would require a large study population. In 
nested case-control studies, both cases and controls are derived from the same 
population, with controls being representative of a sample of non-cases. The benefit of 
such study over a case-control study one is that the risk of selection bias is reduced. It 
would thus seem that a cohort study would be the design of choice as it provides a 
wider scope, but due to its nature, some disadvantages are unavoidable. Prospective 
cohort studies are slow and potentially expensive if there is a long period between the 
exposure and the outcome. They are inefficient for rare diseases. Retrospective cohort 
studies depend on pre-existing records of exposure being available and being reliable. 
The exposure status may change during the study in which case exposure status may 
need to be determined again at intervals throughout the study. Furthermore, differential 
loss to follow-up may introduce bias, which is a particular problem when follow-up is of 
a long duration. In long-term cohort studies, it may be hard to ensure that diagnostic 
criteria remain consistent throughout the study, particularly if outcomes are ascertained 
from routine data sources. In nested case-control studies, a cohort study needs to be 
done first. The rarity of disease and long latency are not contra-indications for cohort 
studies, although their disadvantages need to be balanced against the superior quality of 
evidence cohort studies deliver compared with other study designs, such as case-control 
studies. 
Chapter 6 – Materials and Methods 
 
125 
 
For this study, a single time case-control study was feasible in the time frame available. 
This design is quick by nature and it also solves some of the problems associated with 
the cohort study designs, and most importantly, it can provide information of interest as 
discussed above.  
6.4.2 Study setting 
6.4.2.1 Study sites 
India    
Each year India registers about 130 000 new leprosy patents so doing this study in India 
is important and will increase the impact of the study (Figure 6.1). For the current study, 
we collaborated with two Indian centres, The Foundation for Medical Research Indi 
(FMR) and the Bombay Leprosy Project (BLP), where our leprosy group have 
successfully recruited to other leprosy studies, 101 patients were recruited for a study on 
NP. In addition, an ongoing study (TENLEP) associated with Professor Lockwood is 
also based on these two sites. FMR was chosen for the laboratory work (QST testing), 
while BLP was acted as sources of patients into our study. 
 
Figure 6.1. Study site – Mumbai 
 
 
Chapter 6 – Materials and Methods 
 
126 
 
Foundation for Medical Research (FMR) 
The Foundation for Medical Research was established in 1975 as a Public Trust and is 
recognised as a Scientific and Industrial Research by the Government of India. It is a 
continuation of the founder H. Antia interest in leprosy. Dr Antia is a pioneer plastic 
and reconstructive surgeon for leprosy and this continuation of his initial interest of 
leprosy is maintained and extended to involve research on drug-resistant TB and 
medical plants. The foundation has a well-established laboratory facilities (Figure 2.1). 
The leprosy research at the Foundation for Medical Research focuses on neuropathy 
and leprosy treatment. Dr Shetty, who leading the leprosy group, has a pioneering and 
sustained research work on mechanisms of nerve damage which has implications for 
treatment and regeneration. The leprosy group has also been actively involved in 
assessment of drug regimens for treatment of leprosy and prevention of nerve damage. 
FMR is also a recognised centre for epidemiological study and its estimate of the current 
load of leprosy in rural and urban areas challenged the claim of elimination and 
provided the basis for further course of action by the national control programme. 
 
Figure 6.2. Foundation for Medical Research – Mumbai 
Bombay Leprosy Project (BLP) 
The Bombay Leprosy Project, founded in 1976, is the largest referral centre for people 
affected with leprosy and other skin disease in Mumbai. It was established by Dr 
Ganapati with the objective of improving the quality of life of leprosy patients. The 
project covers 23 health posts in Mumbai covering a population of approximately 2 
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million. All consultations at BLP outpatient services and rehabilitation activities are 
provided free of charge for people affected with leprosy. The services are divided into 
satellite leprosy daily outpatient’s clinic, general clinics for people affected with leprosy 
and their families, inpatient services in collaboration with Somayia Hospital and clinics 
for people with other skin diseases. The BLP in particular serves a wide population and 
receives referrals from all over the city as well as the Maharasha region and the whole 
country. Also, it has an intensive data on slum record in the city.  
An average of 2 to 3 new leprosy cases were diagnosed weekly at BLP over the period 
from January to June 2013. In addition, an average of 30 to 35 patients were seen daily 
at the referral centre during the same period and these were mainly leprosy cases with 
complications, many of whom were referred from regions.  
Over the last three decades of leprosy work BLP has reached 1.95 million people of 
which 60% are from slums of Dharavi and other similar slums in G and H wards of 
Mumbai (BLP annual report, 2013). 30,000 patients have been cured with MDT. 
Disabilities have been prevented in 2500 patients. 300 leprosy patients and general 
handicapped persons have been rehabilitated. In addition to the activity related to 
diagnosis and treatment of patients, the BLP has been carrying out operational and 
technical research in the field of leprosy and has published over 300 scientific papers in 
India and International journals. The efforts of BLP have been highly recognised for its 
excellence in leprosy research. 
 
Figure 6.3. Bombay Leprosy Project – Mumbai  
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6.4.2.2 Study team 
The study teams from the BLP and FMR clinics received regular training and updates 
throughout the study. The clinical psychologist had to undergo piloting study 
questionnaire exercises, and the research assistant had onsite training on diagnosing 
leprosy and NP. This step aimed to familiarise teams with the study materials and to 
ensure that they understood the procedures. This was done at the beginning of the 
study. A joint meeting with the director of the BLP (Dr Pai) and Dr Shetty, senior 
researcher at FMR (Figure 6.3), was held on a regular basis (every two weeks for the first 
three months, then monthly till the end of the study). This helped to recruit enough 
patients and to harmonise the work between the two centres. 
6.4.2.3 Study population 
Participants and recruitment 
The following group of participants were recruited for this thesis: 
i. Leprosy patients without pain and no clinical evidence of neuropathy 
ii. Leprosy patients without pain and sub-clinical neuropathy 
iii. Leprosy patients without pain and established clinical evidence of neuropathy 
iv. Leprosy patients with established pain and clinical evidence of neuropathy 
v. Healthy control participants, aged matched to the patients group in India 
vi. Healthy control participants for QST investigator validation in UK 
vii. Healthy control participants for monofilament comparison study in Germany. 
Recruitment  
Patient recruitment 
Patient cohort were recruited from leprosy affected people attending two main centres: 
the BLP and FMR clinics in Mumbai during the period October 12th 2012 to June 30th 
2013 (Appendix 11 and Appendix 12). I attempted to recruit patients across the leprosy 
spectrum (TT, BT, BB, BL and LL) in each cohort where applicable, but as most of 
participants were treated patients at the time of the recruitment it was very difficult to 
retrospectively identify the type of leprosy. All patients had to fulfil the diagnostic 
criteria for leprosy, which includes hypo-pigmented lesions with definite loss of 
sensation, thickened peripheral nerves, and acid fast-bacilli on skin smears (Britton and 
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Lockwood, 2004). All potential participants underwent an initial screening (Appendix 
23). Prior to inclusion in the study, patients underwent a comprehensive assessment in 
order to further determine if they met the eligibility criteria for recruitment. A study 
team member interviewed each participant using a pre-tested questionnaire. The 
assessment of each patient took one hour on average. The clinical assessment was 
comprised of patient’s history and pain drawings including the location, description, and 
intensity of pain. In addition, documentation of clinical evidence of neuropathy were 
collected and related neurological bedside examinations of sensory and motor function 
were conducted. Information from medical records and data relevant to peripheral 
neuropathy and results from any other medical investigations that were available were 
reviewed. All participants were asked to provide a urine sample for sugar testing and a 
blood sample for complete blood counts, blood glucose, thyroid function, vitamin B12 
level, syphilis, HIV and pregnancy (for women).  
The patient’s records, including the findings of the clinical examination and the available 
investigations, were reviewed by the investigator. Individuals who were anaemic, 
diabetic, had hyperthyroidism or hypothyroidism, were B12 deficient, had positive 
serological test for syphilis and/or HIV or women who were pregnant were not eligible 
to enter the study. These patients were able to access routine services and were also 
referred to the nearest facility for special service according to their condition. Those 
who had satisfied the eligibility criteria were invited to take part in the study. 
In particular, patients with symptoms and signs suggestive of NP were recruited through 
a two stage process (Figure 6.4). All patients were screened for neuropathy using MFs 
and the MRC scale after they signed the informed written consent sheet. Those who had 
neuropathy were further screened for pain. Of them, patients with pain were assessed 
for NP using the DN4 questionnaire. Patients who proved to have the two criteria for 
the case definition were considered as leprosy NP. 
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Figure 6.4. Assessment of neuropathy and NP case-definition 
PN: Peripheral Neuropathy  
Subclinical Neuropathy: Patients with no clinical evidence of neuropathy based 
on Semmes-Weinstein Monofilaments (MFs) and/ or MRC scale, but who 
showed abnormal NCS or thermal testing were allotted to “Subclinical 
neuropathy”. 
 
All participants had the following assessments:   
 Demographic description and medical and drug history  
 Completion of pain questionnaires 
 Clinical assessment  
 Quantitative sensory testing 
Healthy volunteer recruitment  
Healthy volunteer participants were recruited from the general population by personal 
invitation and word of mouth. For the study in India, participants were selected from 
the patient’s relatives attending the leprosy clinic based at BLP and staffs from BLP and 
FMR. Potential participants were approached and invited to participate in the study 
(Appendix 5 and Appendix 6). Those who volunteered in response to the invitation 
were given brief feedback asking them to contact the research team should they wish to 
discuss the study or be sent further information. Potential participants were given a 
participant information sheet and then asked to sign a consent form. Eligible 
participants received a questionnaire about their general health status, the “Participant’s 
State of Health Questionnaire” used in the DFNS guidelines. All participants were asked 
to provide a urine sample for sugar testing and a blood sample for complete blood 
counts, blood glucose, thyroid function, vitamin B12 level, syphilis, HIV and pregnancy 
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(for women). Then they underwent a comprehensive clinical examination using DFNS 
QST measurement parameters. 
More details on the recruitment of healthy volunteers in Germany and UK are 
presented in Chapter 7. 
Participants 
Patients with leprosy 
Eligibility 
The study participant had to be a confirmed leprosy case irrespective of whether they 
were receiving, or had received multi-drug therapy or have symptoms of a peripheral 
neuropathy. Study specific entry criteria are described below: 
Inclusion Criteria 
 Able to give informed consent 
 Age 18 to 65 years 
 Able to comply with the protocol  
Exclusion criteria  
 A history of concomitant severe infection such as TB or any other serious 
underlying disease (cardiac, renal, or hepatic) that potentially might affect the 
evaluation of the patient’s pain response.  
 A history of other conditions associated with peripheral neuropathy such as 
Diabetes Mellitus (DM), HIV/AIDS, or nutritional deficiency (Thiamine, B12 
deficiency) 
 Other neurological or psychiatric disease 
 A history of regular, excessive intake of alcohol (alcoholism) 
 Evidence of Thalidomide treatment 
 Evidence of pregnancy or lactating mother 
 Insufficient level of communication (i.e., lack of fluency in any of the three 
languages of the study: English, Hindi, or Marathi).  
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Healthy controls 
Inclusion Criteria 
 Signed the written consent form themselves 
 Age 18 to 65 years 
Exclusion Criteria 
 A history of pain and/or paraesthesia and/or nerve lesion in the extremities  
 Evidence of pain treatment scheduled for the time of the study and intake of 
medication during the time of the study (antidepressant, analgesics, or 
hypnotics) 
 A history of surgery that potentially might affect the sensations in the tested site 
 Evidence of medical disease  
 Other neurological or psychiatric disease 
 Insufficient level of communication as described above 
6.4.3 Sample sizes 
A sample size of 15 participants in each patient group was estimated to be sufficient to 
adequately assess the sensory changes in leprosy patients with NP. The study was 
powered against sensory modalities data required to detect the prevalence of sensory 
changes associated with the risk of developing HIV neuropathy from the pain in the 
HIV-related neuropathy study (Phillips et al., 2014). The HIV study is one of a few 
studies using quantitative sensory testing to assess sensory parameters in NP caused by 
infectious diseases. I had to choose one of the 13 parameters of the DFNS profile on 
which to conduct our power calculation; since loss of mechanical sensation is one of the 
primary manifestations of leprosy we determined that this was the most useful 
parameter. In the previous HIV study, the mechanical detection threshold (MDT) 
showed a significant difference between the z-scores for QST parameters in multi-
ethnic population (MDT mean Z-score difference was 1.4 with a standard deviation of 
1.0). The sample size was calculated based on this result, using a standard deviation of 
1.0, power of β=90% and significance of α=0.05%. 
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6.4.4 Ethics and consent practice 
The study protocols and recruitment procedures were approved by the following ethics 
committees in London and Mumbai: 
1. London School of Hygiene and Tropical Medicine Research Ethics Committee, 
ethical approval reference number: 6181 (Appendix 1). 
2. Imperial College Research Ethics Committee (ICREC), ethical approval 
reference number: ICREC_11_2_3 (Appendix 2). 
3. Foundation for Medical Research Ethics Committee, IEC No _ FMR/ IEC/ 
LEP/ 04/ 2012 (Appendix 3). 
I undertook two courses in good clinical practice (GCP), one at the LSHTM prior to 
starting the study, followed by a refresher course (online) organised by Imperial College 
London. All studies were conducted in adherence to the recommendations for 
physicians involved in research on human subjects adopted by the 18th World Medical 
Assembly, Helsinki 1964 and later revisions. 
Subjects participated in the study after giving written informed consent. The process 
was conducted by a native Hindi/Marathi speaker after he had fully explained the study 
and answered any questions. The study information leaflets (Appendix 13, Appendix 14, 
and Appendix 15) and consent forms (Appendix 20, Appendix 21, and Appendix 22) 
were available in Hindi, Marathi and in English. Participants were informed that they 
had the right to refuse to participate without given reasons. They were also assured that 
they could withdraw at any time from the protocol without giving reasons and without 
prejudicing further treatment. The consent forms were signed by all participants prior to 
inclusion in each study (if they were unable to sign, a thumb print was used instead and 
witnessed by the person obtaining the consent). 
6.5 Clinical and laboratory assessment 
6.5.1 Patient interviews and examinations 
6.5.1.1 Clinical history  
The patient’s demographic information was collected for age, sex, time since leprosy 
symptoms first developed, the clinical R-J classification of their disease, treatment with 
MDT, previous reactions, and past medical history (Appendix 23). A detailed history of 
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their skin and nerve symptoms was taken. The number and morphology of skin lesions, 
the presence of peripheral oedema, nerve tenderness, and paraesthesia or nerve pain was 
recorded. The location of pain was recorded by using a template body map (Appendix 
26); the patient marked the distribution of any type of pain he had. Patients were asked 
about their type of pain, its duration, and the treatment used for it.  
6.5.1.2 Measures 
Translation  
Using standard translation and back translation methods, the English version of all 
questionnaires including the DFNS-QST protocol were translated into local languages 
(Hindi/Marathi) by an independent translation centre in Mumbai (Appendix 52). The 
translated questionnaires were then reviewed by a panel of experts, using the repeated 
‘forward-backward’ procedure. The experts were from BLP, FMR, and the Neurology 
department at JJ Hospital in Mumbai. They are fluent in both English and 
Hindi/Marathi as well as the terminology used in the leprosy and pain field. The 
translation procedure review was conducted several times until an agreement was 
reached for the final version. The translation procedure is further detailed in Chapter 7. 
Patient groups 
Patients who were positive on the screening test for pain then completed the DN4, PD-
Q, and BPI questionnaires. 
Pain intensity 
A supervised assessment of patient pain intensity was adopted due to variable barriers of 
using a pain diary. The patient’s weekly average pain intensity was determined using an 
intensity numeric rating scale which consists of an 11- point numerical scale ranging 
from “0” (no pain) to “10” (worst possible pain) (Farrar et al., 2001). Patients were 
requested to describe the weekly average intensity of pain by choosing the appropriate 
number between 0 and 10 in response to the question, “tell me what number best 
represents the greatest pain you have had in the last week” (Appendix 23).  
The intensity of the various pain components was documented on verbal rating scale 
(mild, moderate, and severe) as part of PRF.  
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The worst and average pain intensity over the week preceding the testing session and 
pain intensity at the time of questionnaire completion were documented on a numeric 
rating scale as part of PD-Q (0 = no pain, 10 = maximum pain). 
Screening questionnaire for NP 
Two NP screening tools were used in this thesis to identify the likely presence of 
suggestive symptoms and signs of NP: the DN4 and the PD-Q. The former 
questionnaire was used for the case definition in this study. The local version of the 
DN4 questionnaire (Appendix 29 and Appendix 30) was obtained from our leprosy 
group study in Mumbai (Lasry-Levy et al., 2011). The PD-Q that was validated in Hindi 
and Marathi was obtained with permission from Pfizer Medical information, India 
(Appendix 32 and Appendix 33). 
DN4 Questionnaire 
The DN4 was applied in an interview format and contained seven sensory descriptor 
items and three clinical examination items. The latter test for allodynia using cotton 
gauze and altered sensation (hypoaesthesia) to touch or a pinprick in the painful area. 
The Hindi/Marathi version of DN4 questionnaire was applied by the local team 
member in the presence of the principle investigator. The first seven items were 
answered and the clinical assessment was done by the principle investigator. The scoring 
of the items ranged from 0 to 1. A score of 1 is given to each positive item and a score 
of 0 to each negative item. The total score was calculated as the sum of all 10 items, and 
the cut-off value for the diagnosis of NP was a total score of 4/10 (Bouhassira et al., 
2005). 
Pain detect questionnaire (PD-Q) 
The PD-Q is comprised of nine questions regarding the severity, course, quality and 
nature of the patient’s pain and the specific NP symptoms (Appendix 32 and Appendix 
33). The scoring of the sensory descriptors ranged from “0” (indicating that the person 
does not experience the relevant sensation) to “5” (indicating that the person feels the 
sensation very strongly). Based on PD-Q results, patients were grouped as follows: 
unlikely NP (a score of 0-12, which indicates a negative result and a NP component is 
unlikely); probably NP (a score of 13-18, which indicates an unclear or ambiguous result 
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that does not preclude a NP component); and definitely NP (a score of ≥ 19, which 
indicates a positive result and NP is likely) (Freynhagen et al., 2006b). 
Brief pain inventory (BPI) 
Patients were asked to respond to the Hindi/Marathi version of the BPI (Appendix 35 
and Appendix 36), rating their current pain intensity and also pain in the last 24 hours at 
its worst, least, and average by using a numeric 11-point scale ranging from 0 “no pain” 
to 10 “pain as bad as you can imagine”.    
Pain-related interference of activities of daily living was assessed using the pain 
interference scale of the BPI (Cleeland and Ryan, 1994). The scale assesses pain 
interference within seven domains: general activity, walking, work, relationships, mood, 
life enjoyment, and sleep. Patients were asked to rate the extent to which their pain 
interfered with these seven quality of life domains on an 11-point scale ranging from 0 
“does not interfere” to 10 “completely interferes”. 
All patients 
Psychological co-morbidity measures 
Psychological factors were assessed with the GHQ-12 (Appendix 37), which is an 
established instrument used to screen for the presence of mental distress (Goldberg, 
1972). In particular, the GHQ-12 asks questions about anxiety and depressive 
symptoms over the past four weeks (Goldberg and Williams, 1988). The GHQ-12 
version, which was validated in Hindi (Gautam et al., 1987), was obtained with 
permission from Professor Shiv Gautam, former president of the Indian Psychiatric 
Society (Appendix 38 and Appendix 39). Before asking the GHQ-12 questions, patients 
were asked to refer to how they had felt during the past four weeks. If they had any 
unhappy feelings, they were asked what causes contributed to them and how much was 
due to their pain, leprosy itself, or general life. These responses were all recorded in the 
PRF. The GHQ-12 questions were administered by a native Hindi/Marathi speaker. 
The interview lasted 5 – 10 minutes. The patients’ responses were scored on a four 
point scale “not at all”, “same as usual”, “more than usual” and “much more than 
usual” giving a score from 0 “no problem” to 12 “severe problem”. Higher scores 
indicated greater psychological distress. For the coding and interpretation of the answers 
see data analysis section below. 
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6.5.1.3 Structured clinical examination 
A comprehensive structured clinical examination was developed to detect clinical signs 
of peripheral neuropathy. The clinical examination was performed on each patient and 
included assessment of neurological examination with special attention to loss of 
sensation over skin lesions and nerves and disability (Appendix 23).   
Neurological clinical assessment  
The neurological examination was performed on each patient and included assessment 
of light touch using cotton gauze and a pinprick sensation using a disposable safety 
needle. Thermal and vibration perception were assessed as part of QST testing. Joint 
position sense of the index finger and big toe were assessed and graded as normal or 
absent. Deep-tendon reflexes (knee, ankle) were also assessed and graded as normal, 
decreased (if present with reinforcement), or absent. Muscle wasting and motor power 
were assessed using a modified MRC scale (described below). An abnormal result was 
taken as two or more symmetrical signs in the hands or feet consistent with peripheral 
neuropathy. 
Skin assessment  
The location and appearance of skin lesions and whether they were overlying the course 
of a peripheral nerve trunk or pain site was recorded on a body map (Appendix 26). 
Nerve assessment 
Nerve function impairment present for more than six months was recorded. The nerve 
involved and the functional modality affected (sensory or motor) was also documented. 
Nerve thickening and tenderness 
The main peripheral nerves, namely the greater auricular, ulnar, median, radial 
cutaneous, lateral popliteal, and posterior tibial nerve were assessed for enlargement and 
tenderness. A palpable nerve was assessed clinically by pressing the nerve against bone. 
The results of nerve palpation, along with the presence of a skin lesion and/or a positive 
skin smear were used to confirm the diagnosis of leprosy, but it was not considered in 
the diagnostic criteria for neuropathy in this study. 
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Nerve function assessments  
Sensory nerve function was assessed using a standard set of coloured Semmes–
Weinstein monofilaments. The monofilaments were designed to apply a graded test of 
touch sensibility based on indenting the skin surface with a series of increasing thickness 
of standard nylon filaments (0.2g, 2g, 4g, 10g and 300g). For each thickness it was 
recorded whether or not the patient felt the touch. Three sites per nerve in the upper 
limb and four in the lower limb were tested. The test sites in the upper and lower limbs 
are shown in Appendix 25. The severity of the sensation impairment was measured by 
the thickness of the filament felt by the patient. A result of monofilament of 0.2gm for 
the hand and 2gm for the foot was taken as a normal reference (van Brakel et al., 
2005b). A patient was diagnosed as having sensory impairment when the monofilament 
threshold was increased from the normal reference. In the hands, this was defined as 
not being able to perceive the 0.2gm monofilament at two points out of three in each 
nerve of the hand. In the feet, this was defined as not being able to perceive the 2gm 
monofilament at three out of four sites of the foot. 
Motor nerve functions were assessed by voluntary muscle testing (VMT) using the 0-5 
modified Medical Research Council (MRC) scale (Appendix 24). An abnormal result in 
the hands or feet was taken as a decrease in VMT score by one or more points from the 
normal score of five using the modified MRC scale. 
Disability assessment 
Leprosy-related disability was assessed using the WHO disability criteria, which defines 
grade 0 as no loss of sensation or visible deformity, grade 1 as loss of sensation without 
visible deformity, and grade 2 as presence of visible deformity (WHO, 2006). 
The patients’ record forms, including the clinical examination, pain symptomatology, 
quality of life, and psychological co-morbidity measures were administered before the 
DFNS-QST testing was performed. Of these questionnaires, the sensory testing 
assessment of the DN4 questionnaire was performed at the area of maximum pain of 
the ulnar nerve territory (Dermatome C8) just prior to administration of the DFNS-
QST testing protocol.  
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6.6 Quantitative Sensory Testing 
6.6.1 Testing sites 
Quantitative sensory testing (QST) was performed for all subjects in the ulnar side of 
the dorsum of the hand bilaterally (supply area of the ulnar nerve dermatome C8) or S1 
dermatomes of the foot bilaterally. These sites were defined and documented on each 
patient’s body map during the screening assessment based on the maximum pain in the 
most affected area as determined by the patients. In patients with bilateral pain, the 
most painful area was chosen as the test site, and the contralateral mirror site as a 
control. However, during the course of patient recruitment it became apparent that 
many patients experienced their maximum pain along the ulnar nerve territories 
proximal to the dermatome C8 or in other body regions. The pressure pain threshold 
(PPT) for dermatome C8 of the hand was assessed over the hypothenar eminence 
muscle. The PPT for the S1 of the foot was assessed over the medial aspect of the 
plantar. Vibration detection threshold (VDT) of the hand and foot was recorded over 
the bony prominence of the ulnar (ulnar styloid process) and medial malleolus, 
respectively (Rolke et al., 2006a, Rolke et al., 2006b). The dorsum of the hand 
(dermatome C8) was the main site for the QST measurements in this study (Figure 6.5). 
This site was selected because the ulnar nerve is the most common nerve affected in 
leprosy, and also to obtain a consistent QST measurement. The lower limb site was 
selected for patients with foot pain. The reason for recruiting four patients with foot 
pain was to assess the IENFD. 
 
Figure 6.5. QST Testing sites 
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6.6.2 Testing protocol  
QST measures were taken according to the standardised DFNS-QST protocol of the 
German Network on Neuropathic Pain, using the same equipment and standardised 
instructions. Applications of the procedure can be seen in the published guidelines by 
Rolke (Rolke et al., 2006a, Rolke et al., 2006b), and an updated version of the protocol 
in Hindi and Marathi can be seen in Appendix 41 and Appendix 42. The test was 
conducted at the FMR laboratory which was quiet, spacious and had a constant room 
temperature. All measures were performed on each subject by the same investigator, 
who was trained and qualified in using the DFNS-QST assessments and instructing 
subjects. Standardised verbal instructions were given to all subject by a native 
Hindi/Marathi speaker. The subject’s positioning remained unchanged for each body 
site to be tested. All tests were first performed over a demonstration site that was not 
later tested during the session. This step aimed to familiarise subjects with the tests and 
to ensure that they understood the procedures. For all patients, testing was performed in 
a standardised order (i.e. control side was tested prior to affected side) (Rolke et al., 
2006a, Rolke et al., 2006b), and for those who were bilaterally affected, the maximum 
pain site was selected as the test site. For healthy subjects, the control and test sites were 
determined randomly from the list. The time needed to complete testing of the full 
protocol per test site was approximately 30 minutes, with the total examination time 
taking 2–2.5 hours. All QST measures were recorded on a specific data collection sheet 
provided by the DFNS. 
The DFNS-QST protocol comprises a set of psychophysical tests that assess the 
functional status of specific somatic sensory modalities in the following standardised 
order: 
 Thermal detection and pain thresholds  
o Detection threshold for cold (CDT) 
o Detection threshold for warm (WDT) 
o Difference threshold for cold and heat (TSL) 
o Cold pain threshold (CPT) 
o Heat pain threshold (HPT) 
o Paradoxical heat sensations (PHS)  
 Mechanical detection threshold (MDT) 
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 Mechanical pain threshold (MPT)   
o Detection threshold for pressure 
o Pressure pain threshold  
 Stimulus-response functions 
o Mechanical pain sensitivity (MPS) 
o Dynamic Mechanical Allodynia (DMA) 
 Wind-up ratio (WUR) 
 Vibration detection threshold (VDT) 
 Pressure pain threshold (PPT) 
A description of the QST procedures and the needed equipment for each test follows:   
Determination of thermal detection and thermal pain thresholds 
Methods and background: The thermal QST tests were the first modality assessed 
and consisted of six different parameters. First, thermal detection thresholds for the 
perception of cold (CDT) and warm (WDT) were measured using the thermal machine, 
followed by thermal sensory limen (TSL: the different threshold for alternating cool and 
warm stimuli), to PHS. Then, the thermal testing battery was conducted by measuring 
cold and heat pain thresholds (CPT; HPT). The method of limits was used (Chong and 
Cros, 2004). For each threshold test, three repetitions were performed at each site. All 
thresholds were determined by continuous ramping of temperature by 10C/s, which 
were immediately stopped when the subject pressed a button. The subject was 
instructed to press the stop-button as soon as the slightest change of temperature (for 
detection threshold) or the first painful sensation (for pain threshold) was perceived 
(Appendix 40). The base line temperature to which the thermode returned before each 
test was 320C, and the cut-off temperatures were 100C and 500C. The contact surface 
area for the thermode was 2.5 cm x 5 cm. An average threshold was calculated from 
three measurements in each area. 
Equipment: The MSA Thermal Sensory Analyzer (Somedic AB, Farsta, Sweden) was 
used to determined thermal detection and pain thresholds (Figure 6.6). It is widely used 
in routine clinical diagnosis to functionally diagnose pain and temperature-conducting 
nerve fibres (C and A-delta fibres). 
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Figure 6.6. MSA Thermal Sensory Analyzer – Somedic  
 
Mechanical detection threshold (MDT) 
Methods and background: The MDT was determined with a standardised set of 
modified von Frey hairs that exert forces between 0.25 and 512mN. The threshold was 
defined as the smallest force necessary for patient perception in response to one von 
Frey filament bending on the skin. This was determined by performing a modified 
“method of limits” manner using series of alternative ascending and descending 
stimulus intensity in five series. Subjects were asked to indicate when they felt the 
slightest touch of the filament (Appendix 40). The von Frey hairs eliciting 16mN force 
were applied first, followed by hairs of consecutively lower intensity until the patient 
could not detect the stimulus being applied. This respective force represents the first 
threshold value. The order in which the stimuli were applied was then reversed and 
stimuli of consecutively greater intensity were applied until sensation was detected (this 
intensity became the second value). Again, hairs with decreasing intensity were applied 
until in total five upper and lower values of detections were fulfilled from which the 
mechanical detection threshold was determined. If the first von Frey filament with an 
intensity of 16mN was not detected, the next highest intensity filament to be detected 
was used as a starting intensity, and the above procedure were applied. This procedure 
were repeated five times. The final threshold was the geometric mean of the five series 
of ascending and descending stimulus intensities (i.e. 10 determinations) (Rolke et al., 
2006b).  
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Equipment: A set of standardised von Frey hairs (0.25 mN, 0.5 mN, 1 mN, 2 mN, 4 
mN, 8 mN, 16 mN, 32 mN, 64 mN, 128 mN and 256 mN) (Optihair2-Set, Marstock 
Nervtest, Schreisheim, Germany). The contact area of the hairs with the skin is of 
uniform size (about 1 mm2) and texture (rounded contact area to avoid sharp edges, 
which could facilitate nociceptor stimulation).   
Mechanical pain threshold (MPT)   
Methods and background: The MPT was measured using a standardised set of 
pinprick punctuate probes that exert fixed stimulus intensities between 8 mN and 512 
mN. The patient’s skin response was sensed to the needle probe itself and not to the 
guided tube. The introduction and removal of the pinprick probes were carried out in 
smooth movements, allowing the probe to be in contact with the skin for two seconds. 
The threshold was defined as a geometric average of the MPT in the tested skin area, 
which was determined by performing a modified “method of limits” using a series of 
alternative ascending and descending pinprick stimulus intensities in five series. A 
pinprick probe with 8 mN was used as starting force. The tip of the needle was gently 
placed perpendicular to the skin’s surface, then a weight was applied. Subjects were 
asked to indicate if the sensation was felt “sharp” or “blunt”. Beginning with an applied 
force of 8 mN stimuli, intensity increased until the sensation induced was described as 
“sharp”. The corresponding force used represented the first threshold value. To follow, 
the order in which the stimuli were applied was reversed by applying stimuli of 
consecutive lower intensities until the quality of the sensation was detected as not sharp 
(i.e. blunt). This force became the second value. The procedures were continued in this 
fashion until, in total, five first and second values of detection were completed from 
which the MPT was determined. The final threshold was the geometric mean of five 
series of ascending and descending stimulus intensities (Appendix 40). 
Equipment: A set of seven metal probes with standardised stimulus intensities (8 mN, 
16 mN, 32 mN, 64 mN, 128 mN, 256 mN and 512 mN) (MRC Systems GmbH, 
Germany) with uniform skin contact area (0.2 mm diameter). Penetration of the skin 
with these stimuli is not possible. 
Stimulus-response functions: mechanical pain sensitivity (MPS) for pinprick 
stimuli and dynamic mechanical allodynia (DMA) for light touch  
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Methods and background: The MPS was assessed using the same weighted pinprick 
probe stimuli of different stimulus intensities as for MPT. These seven pinprick stimuli 
were applied in a balanced order; each stimulus was applied five times. Subjects were 
asked to give a pain rating for each stimulus on an NRS (range 0–100) where 0 means 
“no pain” but is not synonymous with “not felt/ detected” (Appendix 40). An 
undetected stimulus should be noted as Ø. The most intense pain imaginable is 
represented by 100. Pain in response to light touch (i.e. DMA) was tested using 
innocuous stimuli (Q-tip, cotton wisp, and soft brush) applied in between the pinprick 
stimuli in balance and standardised order, and subjects were asked to give a rating on 
the same scale as for pinprick stimuli. The tests for MPS and DMA were applied given 
in runs of 10 (five runs per test sites) and each run consisted of a different randomised 
sequence of seven pinprick stimuli and three tactile stimulus. MPS was calculated as the 
geometric mean of all numerical rating for pinprick stimuli and DMA as the geometric 
mean of all numerical rating across all three different types of light touch stimulators. 
Thus, a stimulus-response function aimed to explore whether a hyper- or hypoalgesia or 
mechanical allodynia was present.  
Equipment: A set of seven metal probes with standardised stimulus intensities (8 mN, 
16 mN, 32 mN, 64 mN, 128 mN, 256 mN and 512 mN) (MRC Systems GmbH, 
Germany) with uniform skin contact area (0.2 mm diameter). In addition, a set of three 
light intensity stimuli: a cotton wisp (3 mN), a cotton wool tip (Q-tip) fixed to an elastic 
strip (100 mN), and a paint brush with an applied force of between 200 mN and 400 
mN was used. 
Wind-up phenomenon (WUR) 
Methods and background: WUR is the perceptual correlate of temporal pain 
summation for repetitive pinprick stimuli. In this test the perceived magnitude of a 
single pinprick stimulus (256 mN) was compared with that of a series of 10 pinprick 
stimuli of the same force repeated at a 1/s rate within an area of 1 cm2. The time 
interval was standardised using a metronome timer (Korg MA-30, Japan). In general, 
immediately following the single stimulus and series of stimuli, an evaluation of the 
sensation was provided according to a verbal numerical scale (0–100: 0, “no pain”; 100, 
“most intense pain imaginable”). First, a single stimulus was applied and the subject was 
asked to give a pain rating for this stimulus. Then the repeated stimuli were applied and 
the subject was requested to give a pain rating representing the pain over that whole 
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series of the 10 stimuli. This procedure of single pinprick stimuli was alternated with the 
series of 10 stimuli until both were performed five times at five different skin sites 
within an area of 1 cm2 of the same testing site. A geometric average of the “wind-up” 
was calculated from the five ratios (Appendix 40). 
Equipment: A single pinprick stimulus with standardised intensity (256 mN) of the 
pinprick set applied in a flat contact area of 0.25 mm diameter. 
Vibration detection threshold (VDT) 
Methods and background: A standardized tuning fork (64 Hz) was used for the 
measurement of vibration detection threshold. The tuning fork had two arms, both of 
them with calibrated weights at their ends. A shape of an elongated triangle and a nine-
point arbitrary scale from 0–8 beside the triangle were imprinted on each weight. Once 
the turning fork start to vibrate, the triangle on each arm appears as two virtual, 
intersecting triangles. The triangles moves exceptionally up the scale, as the arms’ 
vibration decreased. Once the subject indicated that the vibration was no longer felt, the 
nearest value (to the closest half-point) to the point of intersection of the triangles was 
then recorded as the vibration threshold. The threshold was determined by performing 
three series of descending stimulus intensities decided from the “wandering” tip of a 
triangle moved by means of the vibration and indicated on the tuning fork that was 
placed over a bony prominence of the ulnar (ulnar styloid process) for upper extremities 
or medial malleolus for lower extremities (Rolke et al., 2006b). It was measured three 
times as the amplitude at which the vibration was no longer detected, which was 
indicated verbally (Appendix 40).  
Equipment: A Rydel-Seiffer tuning fork (64 Hz, 8/8 scale) (Martin, Tuttlingen, 
Germany) as used routinely in the clinic (Figure 6.7).  
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Figure 6.7. Tuning fork 
 
Pressure pain threshold (PPT) 
Methods and background: The deep PPT was measured above the hypothenar 
eminence muscle of the test and control sites. Pressure was increased continually using a 
pressure stimulus (with an application rate of approximately, 0.5 kg/s corresponding to 
50 kPa/s) until pain was indicated verbally by the subject. The subjects were asked to 
say “now” as soon as the sensation changed from pressure alone to pressure and pain. 
An average of three measurements per site were taken and the mean value of these was 
used for analysis (Appendix 40). 
Equipment: A blunt mechanical stimulus (contact area of the probe is 1 cm2, applied 
force up to 20 Kg/2000 kPa/200 N), with an in-built pressure gauge (Pressure 
algesiometer Wagner Instrument – Somedic AB, Farsta, Sweden). 
6.7 Data recording and management 
6.7.1 Overview  
All data were recorded during the interview assessment on standardised patient record 
forms (PRF) (Appendix 23). The study forms were kept in a separate set of case notes 
from the usual clinical records. All study records were kept in a locked area accessed 
only by two nominated study team members. 
The EpiData 3.1 software, which has an adequate electronic data capture module 
especially for data validation, was chosen as a database for the study. The design and 
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development of the database was done by me. The EQUISTA database system 
(described below), which was developed and provided by the DFNS, was used for the 
QST data.  
6.7.2 Data preparation 
Various steps were taken to prepare the data for statistical analysis. The completed 
questionnaires from healthy participants and patients were checked for missed and/or 
unclear answers. Data from the PRF and questionnaires (GHQ-12, BPI) were coded to 
represent the category they belonged to, for example, female subjects were assigned the 
code 0, and males were assigned 1. The coding sheets were designed before starting data 
collection. The coding system was standardised to maintain consistency through all data 
sets. The data were then verified and entered from the PRF into the data base by myself. 
As there were validation checks in the EpiInfo, the single entry was considered viable to 
ensure that the recorded data on the PRF was transcribed into the database. In addition, 
double entry was done for five patients who were randomly selected for validating the 
quality of data entry process.  
6.8 Statistical analysis 
6.8.1 Strategy of analysis  
Data analysis was conducted using Stata/IC version 13.1 (Stata Corp LP, College 
Station, Texas, USA). Further, QST data analysis was conducted using GraphPad Prism 
version 6.0 for Windows (GraphPad Software, San Diego California, USA). Patients 
with NP or who had a GHQ-12 of three or above (i.e. symptoms and signs suggestive 
of depression) were considered as cases and the outcome was coded as 0 or 1 for the 
purposes of logistic regression. The controls were selected from group 1, 2, and 3, and 
from healthy volunteers.  
The statistical analysis was conducted in two steps: descriptive and analytical. The 
descriptive analysis was carried out for all patients and in groups; the participants were 
described in terms of demographic data and their responses to study questionnaires. 
The second step was the test for the association between exposures and outcome 
variables. Data is presented throughout as mean ± standard error mean unless stated 
otherwise. The QST measures were plotted as dot plots with overlaid box plots for 
mean/median, variance (box), and range (bars). 
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The statistical tests used were: paired and unpaired Student’s t-tests; the Mann-Whitney 
U test (also called Wilcoxon rank-sum test); the Kruskal-Wallis test; Pearson’s Chi-
squared test; and Spearman’s correlation coefficient. A statistical advisor supervised the 
statistical analysis of the data and verified the appropriateness of the tests. The flow 
chart of the appropriate statistical tests is shown in Figure 6.8.  
 
Figure 6.8. Flow charts indicating appropiate statistical test 
The flow chart shows the appropriate techniques in different circumstances. 
Modified from basic statistics road map by Petrie (Petrie and Sabin, 2009)  
 
The normality of the distribution of the continuous data was assessed by generating 
normal histograms for the variables of interest. Two steps were performed to check for 
the skewed or non-normal results: first the bell-shape was checked based on the eyeball 
test, then a confirmatory test was performed using the Shapiro-Wilk test. The null-
hypothesis for this test is that the variable has a normal distribution - a non-significant 
result indicates normality. In case the assumption of normality could not be rejected 
then a parametric test was applied. If the assumption of normality was not reasonable 
and had to be rejected then the non-parametric Mann-Whitney U test was applied. The 
unpaired Student’s t-tests were performed to assess for significant differences between 
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two independent samples testing one variable. One-way ANOVAs were used to assess 
for significant differences between two or more independent samples with one variable 
tested. The two-way ANOVAs were calculated to assess for significant differences 
between two or more independent samples with two variables tested. Non-parametric 
tests were used to assess statistical significance. The Mann-Whitney U test was used to 
assess non-parametric result. The Mann-Whitney U test was used for all statistical tests 
of continuous variables and Fisher’s exact test was used to compare dichotomous 
variables. A significance level of at least p-value ≤0.05 was used to state whether a result 
was significant or not, unless stated otherwise. The number of data values that were 
included in the calculation was represented by “n”.  
6.8.1.1 Descriptive analysis 
In this study the distributions of each of the variables were created to see the 
characteristics of the study population and the validity of the data. For quantitative data, 
the frequency of distribution, cumulative relative frequency, and percentage were 
calculated. For each grouping variable, such as age, the minimum and maximum values 
were obtained and the row data were checked for the accuracy of the limits. The 
variable age was divided into five age-group (18–19/20–29/30–39/40–49/50–59). 
However, the scarcity of events led to a new grouping for analysis purposes. Therefore, 
during multivariate analysis, age was categorized into two groups ≤30 years and >30 
years. This cut off (30 years) was used as the median age skewed to the right on the age 
histogram. Similarly, the period of symptoms prior to diagnosis was grouped into the 
delay in presentation and divided into <six months, from six months to one year, and 
>one year. Other variables that were grouped were: thickened nerves, tender nerves, 
sensory impairment, motor impairment, and depression. These were grouped into 
present or absent. Mean, median, and mode were calculated as measures for data 
location. Range, percentile, and standard deviation (SD) were calculated as measures of 
data spread. The mean and its confidence interval (CI) were reported for continuous 
normally distributed variables, whereas the median and inter-quartile range (the 
difference between the 25th and 75th quartiles) were reported for non-normally 
distributed variables. 
Data were also displayed in graphs. Bar and/or pie charts were used for graphing 
frequency distribution of categorical data, while for the quantitative continuous data the 
histogram was used. Bar charts were also used to represent qualitative data. 
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Brief pain inventory (BPI) 
The descriptive statistics including mean, SD, median, and interquartile range were 
calculate for each patient. To further explore BPI, the worst pain score was taken as a 
reference point, and all patients with a baseline pain score of 0–3 were labelled as having 
mild pain, all patients with a baseline pain score of 4–7 were labelled as having moderate 
pain, and all patients with a baseline pain score of 8–10 were labelled as having severe 
pain. Pearson correlations were then performed to assess associations between all of the 
BPI pain scores in relations to the GHQ-12 scores within each group. 
General health questionnaire (GHQ-12) 
The scoring procedure and calculation methods were applied according to 
recommendations by the author of the GHQ (Goldberg and Williams, 1988). The 
binary scoring using the 0 0 1 1 method for questions on the GHQ, with 0 signifying 
absence of illness was used. The threshold value of three was made to maximise 
sensitivity. Previous studies on leprosy mental disorder used a threshold values range 
from two-to-four (Bhatia M.S et al., 2006, Senturk et al., 2007, Haroun et al., 2012, 
Jindal et al., 2013). The cut-off point of three was considered appropriate, as the 
utilisation of the GHQ-12 in my study was to identify the probable cases and not 
definite ones. In addition, the mean GHQ-12 score of three for the previous study on 
psychological disorders among treated leprosy patients with NP in Mumbai (Lasry-Levy 
et al., 2011), also provided a guide to the best cut-off points as suggested by Goldberg 
and colleagues (Goldberg and Williams, 1988).   
Descriptive statistics including mean, standard deviation, median, and interquartile range 
were calculated for GHQ-12 items. I first graphically compared the distributions of the 
male and female scores for leprosy patients. I then compared the scores between 
patients with no neuropathy, neuropathy, and NP.  
6.8.1.2 Analysis  
Logistic regression was used for the analysis to produce odds ratios and 95% confidence 
intervals for the associations and p-values for any differences in proportions seen using 
the Pearson’s Chi Squared Test, and Mantel Haenzel Odds Test. P-values ≤0.05 
indicated significance. Analysis was done at two levels: first univariate analyses followed 
by multivariate analyses. 
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Univariate analysis 
Initially univariate analysis was applied to assess any possible univariate association 
between all the potential variables and outcomes. It was used to look at the strength of 
associations of the NP (Appendix 46), depression outcomes (Appendix 48), and the 
differences between two groups. 
Multivariate analysis 
To investigate the association between these variables more closely, a logistic regression 
model was developed adjusting each variable for the other one. First multiple logistic 
regression was carried out to look at groups of variables together, followed by stepwise 
logistic regression, which identified an overall simplified model including only the 
important variables. Using this model, variables were added using step-wise methods. 
They were added in the order of effect estimated from the univariate analysis (Appendix 
47 and Appendix 49).  
6.8.2 QST data analysis 
QST data were first entered into an Excel-based spreadsheet (Excel 2007, Microsoft 
USA) data analysis system provided by the DFNS (EQUISTA, Casquar GmbH 
Germany). EQUISTA was designed for data entry of patient demographic and QST raw 
data. The programme automatically performed z-score transformations of raw QST data 
values by comparing them against normative reference data published by the DFNS 
(Magerl et al., 2010); generated thresholds, average ratings, and numbers of observed 
paradoxical heat sensations. The obtained data were entered into Prism 6 (GraphPad 
Prism 6.02) to generate specific QST graphs.  
QST data transformation 
The mathematical transformation of QST data to z-scores has been described by Rolke 
and colleagues (Rolke et al., 2006b). QST data were log-transformed (log10 units) prior 
to statistical analysis except HPT and VDT which were normally distributed as raw data 
(Rolke et al., 2006a, Rolke et al., 2006b). To compare a patient’s QST data profile with 
control data independent of the different units of measurement across QST parameters, 
the patient’s data were z-transformed for each single parameter by using the following 
expression:  
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Z-score = (X [single patient] - Mean [healthy controls])/SD [healthy controls] 
Z-score values were calculated based on the included healthy control group data. This 
approach allowed site-specific normalisation of QST data, where each individual 
parameter was related to its age, gender, and anatomical test site-specific reference 
range. This procedure resulted in a QST profile where all parameters were displayed as 
the number of standard deviations above or below the healthy controls. The algebraic 
sign of z-score values was adjusted for clarity of presentation for each parameter so that 
it reflects the patient’s sensitivity for this parameter. Z-scores above 0 indicate a gain of 
function, where the patient is more sensitive to the tested stimuli compared with healthy 
controls (hyperalgesis, allodynia, hyperpathia), while z-scores below 0 indicate a loss of 
function, referring to lower sensitivity (hypoaesthesia, hypoalgesia) of the patient. Thus, 
elevations of threshold for any of the 13 parameters measured resulted in negative z-
scores.  
After this z-transformation it was straightforward to compare a single patient with the 
group mean of healthy controls, since the reference range of a standard normal 
distribution is defined as follows: 
95% reference range = Mean [healthy controls] ± 1.96 SD [healthy controls] 
The QST scores for individual patients and groups were summarised and presented 
graphically. Significance was accepted at p-values <0.05 for all analyses. The correlation 
between leprosy pain symptomatology and physiological and psychological morbidity 
were assessed by fitting an analysis of rank correlation using Spearman’s test.  
The DFNS coding system published by Maier and colleagues (Maier et al., 2010) was 
used to examine combinations of somatosensory function in leprosy patients with 
neuropathy and pain. A value of 0 was designated for a QST parameter that was found 
within the normal DFNS reference range; the presence of loss of thermal modalities (i.e. 
a loss of WDT or CDT) was designated as L1, and the presence of loss of mechanical 
modalities (i.e. the loss of MDT or VDT) was designated L2. Gain of sensory function 
to thermal modalities was designated G1 and gain of sensory function to mechanical 
modalities as G2. When both thermal and mechanical abnormalities were present they 
were designated as L3 and G3 respectively. 
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Chapter 7 Validation studies 
This chapter describes the pre-implementation work which was conducted prior to the 
introduction of the main QST profiling study. This stage aimed to validate the 
investigator, local centre, and population in India in using the DFNS-QST protocol. 
Further, the training courses on clinical assessment of NP are also discussed. Finally, the 
chapter presents reflective approaches to simplify the DFNS-QST protocol.  
7.1 Background   
Normally for the validation of a new investigator or centre for a certification protocol of 
QST laboratories, the DFNS requires 18 healthy controls in order to validate 
compatibility (Geber et al., 2009). This is for quality internal assay control purposes to 
ensure that the values obtained for this population are within the normative ranges held 
in the large German Research Network on Neuropathic Pain database (DFNS) and 
giving the guarantee to deliver highest possible objectivity within the range of 
psychophysical testing. 
Two validation studies were conducted among healthy volunteers in London (18 
participants) and Mumbai (52 participants). The first study was done in London with 18 
healthy volunteer participants. However, in term of validating the site in India, I decided 
to increase this number to 30 in case there were environmental site differences and 
ethnic differences in the population studied, since the DFNS normative data were 
almost entirely collected in European centres with predominately Caucasian population. 
Should the normative data from this site have differed from those held in DFNS 
database, we would have been able to use this local population of 30 healthy controls 
for data analysis. An additional reason for selecting more local Indian healthy volunteers 
was the targeted number for skin biopsy. As obtaining a biopsy from this population 
was challenging, the recruitment was continued till I reached 30 participants with both 
QST and biopsy. The validation studies were important preliminary work in order to 
conduct a comprehensive somatosensory profile of leprosy patients with NP in a 
resource-limited setting. 
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7.2 Overview of my preparation in this PhD research  
During my PhD research in Professor Lockwood and Professor Rice’s laboratories, I 
sought to understand the clinical aspects of NP in leprosy. Throughout this time I was 
continually developing my experience by attending lectures, seminars, meetings, 
international conferences and training days, all of which employed various teaching and 
learning techniques. In particular, the training in clinical assessment of NP that I had 
was as follows: 
 Professor Lockwood’s clinic (Leprosy clinic at HTD) 
 Professor Rice’s clinic (Pain clinic at CWH) 
 Professor Hadi Manji’s clinic (Neurology clinic Queens Square) 
 Neuropathic pain training course in Finland (Professor Aki Hietaharju) 
 DFNS-QST Training course in Germany (Professors Maier and R-D Treede) 
 Dr Bennett’s lab (Skin biopsy techniques at KCL) 
I developed a broad knowledge of leprosy and NP, and gained the technical skills 
necessary to clinically assess patients with NP. The knowledge and technical skills 
obtained have been critical during my PhD research.  
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7.3 Healthy volunteers study to validate investigator  
7.3.1 Introduction  
In order to obtain accurate data, high quality training and validation of QST 
investigators is essential. This training occurs in two phases: firstly the investigator visits 
a training centre in Germany to be trained in the technique (Geber et al., 2009). The 
QST-training includes information on the equipment, the investigation technique, 
recommended procedures for quality control and analysis and interpretation of results. 
Secondly, the investigator is validated by performing QST on a number of healthy 
volunteers; these data are then submitted to the central DFNS database in order to 
check their validity against a large normal dataset. I qualified in the use of DFNS-QST 
protocol after attending QST-training in Bochum, Germany, and completed the healthy 
volunteers study in London.  
7.3.2 Participants and methods 
I examined the QST sensory parameters in 18 healthy participants aged between 18 to 
55 years (mean ages 32.2 years, SD 9.8). There was more female (n= 11; 61%) than male 
(n= 7; 39%) included in the study. Participants were recruited from the general 
population and/or staffs and students from the LSHTM and ICL by personal invitation 
and word of mouth (Appendix 4). Participants were screened for relevant medical 
history and were specifically questioned about migraine headaches and low back pain. 
Participants suffering from any acute or chronic pain condition were excluded. All 
participants were without any pain medication for at least 24 hours before the 
investigation (Appendix 43). The study was approved by the Imperial College Research 
Ethics Committee (ICREC_11_2_3) (Appendix 2). All subjects participated after giving 
written informed consent.  
I assessed the sensory parameters in the dorsum of the hands: the ulnar side of the 
dorsum of the hand (supply area of the ulnar nerve territory, dermatome C8) and the 
radial side (supply area of the radial nerve, territory C6), using DFNS-QST protocol. 
Testing took 30 minutes per site. The study was conducted at Chelsea and Westminster 
Hospital. The detailed testing procedures of the DFNS-QST protocol are described in 
Chapter 6, in summary the following parameters (Figure 7.1) were assessed: 
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Thermal detection and pain thresholds and the number of paradoxical 
heat sensations: The thermal tests were performed using a MSA (SOMEDIC, 
Sweden, available in three centres). Cold and warm detection thresholds were 
measured first (CDT, WDT). In addition, subjects were asked about PHS during 
the thermal sensory limen (TSL) procedure of alternating warm and cold stimuli. 
Then cold pain and heat pain thresholds were determined (CPT, HPT). The 
mean threshold temperature of three consecutive measurements was calculated.  
Mechanical detection threshold: MDT was measured with a standardised set 
of von Frey hairs that exerts forces upon bending between 0.25 mN and 512 
mN. Using the methods of limits, five thresholds determination were made, 
each with a series of ascending and descending intensities. The final threshold 
was the geometric mean of these five series.     
Mechanical pain threshold: MPT was measured using pinprick stimuli as a set 
of seven pinprick mechanical stimulators with fixed stimulus intensities that 
exerted forces of 8 mN, 16 mN, 32 mN, 64 mN, 128 mN, 256 mN, and 512 
mN. The stimulators were applied at a rate of 2 second on, 2 second off in an 
ascending order until the first percept of sharpness was reached. The final 
threshold was the geometric mean of five series of ascending and descending 
stimuli.  
Mechanical pain sensitivity: MPS was assessed using the same set of seven 
weighted pinprick stimuli to obtain a stimulus–response function for pinprick-
evoked pain. Subjects were asked to give a pain rating for each stimulus on a ‘0–
100’ numerical rating scale (‘0’ indicating ‘‘no pain’’, and ‘100’ indicating ‘‘most 
intense pain imaginable’’). 
Dynamic mechanical allodynia: ALL was assessed as part of the test above, 
using a set of three light tactile stimulators as moving innocuous stimuli: Cotton 
wisp exerting a force of 3 mN, a cotton wool tip fixed to an elastic strip exerting 
a force of 100 mN, and a standardized brush exerting a force of 200–400 mN. 
The tactile stimuli were applied with a single stroke of approximately 2 cm in 
length over the skin.  
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Wind-up ratio: Participants were asked to give a pain rating intensity of a single 
pinprick stimulus (256 mN pinprick) this was compared with the estimated 
mean over the whole series of 10 repetitive pinprick stimuli of the same physical 
intensity (1/s applied within an area of 1 cm2) using a ‘0–100’ numerical rating 
scale. The whole procedure was repeated five times. WUR was calculated as the 
ratio: mean rating of the five series divided by the mean rating of the five single 
stimuli. 
Vibration detection threshold: VDT was performed with tuning fork (64 Hz, 
8/8 scale) that was placed over ulna styloid process and a head of the radius, and 
left there until the subject could not feel vibration any more. VDT was 
determined as a disappearance threshold with three stimulus repetitions.  
Pressure pain threshold: PPT was performed over the thenar and hypothenar 
muscle with a pressure gage device with a probe area of 1 cm2 that exerts forces 
up to 20 kg/cm2 corresponding to 2000 kPa. The pressure pain threshold was 
determined with three series of ascending stimulus intensities, each applied as a 
slowly increasing ramp of 50 kPa/s (0.5 kg /cm2 s). 
 
Figure 7.1. Complete set of QST devices 
Picture taken from Professor Rice’s lab, 2012 
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7.3.3 Data evaluation and results 
Data entry and transformation was carried out using the Equista database that 
developed by the DFNSp. The following analyses were carried out: 
i. Comparison of the results to the 95% confidence interval of the DFNS 
reference data base.  
ii. Number (percentage) of abnormal values  
iii. Calculation of Z-values: data are presented as mean ± SD and based on the 
DFNS reference database, I calculated the z-score for each participant: 
Z-score = (value [single participant] - Mean [controls])/SD [controls] 
iv. Statistical analysis of the z-values of right vs. left ulnar and right vs. left radial 
using t test for the differences between the parameters within each group.    
The result was compared to the 95% confidence interval of the DFNS reference data 
base, DFNS. Of the total 18 subjects only one had 3 parameters; namely (CPT, HPT 
and VDT) for the test side, Figure 7.2, and (WDT, CPT and HPT) for the control side, 
Figure 7.3; which fell outside of the DFNS reference database. The percentage of 
abnormal values in this group is less than 5% and it is therefore acceptable for DFNS 
investigator validation. 
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Figure 7.2. Abnormal parameters in test area compared to DFNS reference 
 
 
 
Figure 7.3. Abnormal parameters in control area compared to DFNS reference 
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Of the 13 parameters obtained for 2 body regions, dynamic mechanical allodynia did 
not occur among healthy subjects. No significant right-left differences for the ulnar 
nerve side were observed (p-values for each parameters where greater than 0.05 and 
range from 0.1 to 0.9) except for MPS (p-value < 0.05) (Figure 7.4 and Figure 7.5). 
 
Figure 7.4. Z-score of Rt vs. Lt ulnar of the 18 subjects compared to DFNS 
Graph shows the Ulnar nerve mean values and 95% confidence intervals of all 
QST parameters in 50 healthy volunteers. The upper confidence limits of all 
QST parameters were within the limits of the reference data. Rt: Right, Lt: Left 
 
 
Figure 7.5. Z-score of Rt vs. Lt radial of the 18 subjects compared to DFNS 
Graph shows the Radial nerve mean values and 95% confidence intervals of all 
QST parameters in 50 healthy volunteers. The upper confidence limits of all 
QST parameters were within the limits of the reference data. Rt: Right, Lt: Left 
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7.3.4 Discussion  
Despite using crude thermal sensory testing for more than a century in the assessment 
of neuropathy in leprosy patients, its application in clinical and research practice has 
been limited (Backonja and Lauria, 2010). The DFNS-QST test is a standardised 
protocol, including standardised instructions for the investigator and subject. It is a non-
invasive method used comprehensively to assess the function of both un-myelinated 
and thinly myelinated small fibres, as well as of the large fibres. Therefore, it has ability 
to characterise somatosensory functions across the full spectrum of nerve fibres 
(Krumova, 2010), (Table 7.1). In addition, because it tests the entire system from 
transduction to perception, the loss of function which manifested clinically as sensory 
deficit, and the abnormal facilitatory phenomena, which clinically present as various 
manifestations of pain, can be easily assessed (Walk et al., 2009).  It also characterises 
the function of nociceptive system, which is not possible with standard methods of 
clinical electro-neurophysiology (Cruccu et al., 2004). These factors make it an 
appropriate tool for assessing sensory parameters related to pain in leprosy patients. 
Table 7.1. Sensory functions represented by different QST parameters 
Axon type  QST parameters 
Aβ-fibre  Mechanical detection threshold for von Frey hairs and vibration tests 
Aδ-fibre Cold detection threshold and the mechanical pain threshold for pinprick stimuli 
C-fibre  Warm detection threshold and heat pain threshold 
 
Furthermore, recent guidelines on NP assessment recommend the importance of 
exploring QST for prospective therapeutic outcome prediction (Haanpaa et al., 2010). 
In a study by Dyveke and colleagues, the differentiation between the DFNS 
somatosensory profile of sensory loss and gain functions was found useful to predict the 
responses to treatment. This was a randomised, double-blind, placebo-controlled, and 
phenotype-stratified clinical trial in which 97 patients with peripheral NP due to 
polyneuropathy were treated with oxcarbazepine or placebo in two 6-week periods. The 
authors reported that oxcarbazepine is more efficacious for relief of NP in patients with 
a sensory gain profile than with a sensory loss profile (Demant et al., 2014). 
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7.4 Healthy volunteers study to validate local centre and population in India 
7.4.1 Introduction 
The aim of this study was to validate the QST parameters in the Indian population and 
the site centre. This was for the purposes of internal assay quality control to ensure that 
the values obtained for this population were within the normative ranges held in the 
large DFNS database, which is based on data from European centres and mainly 
Caucasian subjects.  
7.4.2 Participants and methods 
7.4.2.1 Study design 
This study was initiated as a prospective study to investigate the DFNS-QST protocol in 
an Indian population. It was done at the FMR clinic, from October 2012 to June 2013. 
The study was conducted according to the principles of research in humans specified in 
the Declaration of Helsinki. Ethical approval was obtained from the local Ethics 
committee of the Foundation for Medical Research, Mumbai, India (IEC No _ FMR/ 
IEC/ LEP/ 04/ 2012) (Appendix 3).   
7.4.2.2 Participants  
Fifty-two healthy Indian participants, 28 women and 24 men, mean age 30.75 years, 
range from 18 to 56 years, were recruited in the study (see section 6.4.2.3). All subjects 
participated voluntarily after giving written informed consent. Participants were 
excluded if they had been diagnosed with, or suspected to potentially have, any 
neurological disease including different forms of neuropathy, cutaneous lesions in the 
tested site, systematic disease, chronic pain, or were taking medication during the time 
of study (see Methods section 6.4.2.3). Of the 58 volunteers screened for the study, six 
subjects were excluded. Of these, four had a low Vitamin B12 level, one was anaemic and 
one was pregnant. Travel expenses were reimbursed for all volunteers including those 
who were excluded.  
7.4.2.3 DFNS-QST protocol translation  
A rigorous method for translating and checking DFNS-QST protocol was adopted. The 
forward-translation and back-translation methods were used. This process was only of 
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rigorous translation, but the protocol was not validated (Maki et al., 2014). The aim of 
the translation was to achieve an Indian version of the English DFNS-QST 
questionnaire that was cross-cultural and conceptually equivalent to the local Indian 
population (Maki et al., 2014, Maneesriwongul and Dixon, 2004). The validation 
process, which is the process of investigating the reliability, conceptual equivalence, and 
content validity of translations of questionnaires measures, is beyond the scope of this 
thesis to explain it in detail. The guidelines provided by WHO were considered during 
the translation process (WHO, 2014).  
Forward translation was conducted first by an independent translation centre in 
Mumbai (Appendix 52). The local language versions were then reviewed by a member 
of our research team, Ms Maitreyi Nigwekar, who is a bilingual clinical psychologist. She 
is familiar with the psychophysical terminology of the DFNS-QST instrument and 
instructions, as well as being equipped with the interviewing skills required for the task. 
Also, she is fluent in written and spoken English and is a native speaker of Marathi 
Indian. 
Using the same approach as that outlined in the forward translation, the protocol was 
then translated back into English by an independent translator (Appendix 52). Final 
consensus versions were conducted via an expert panel. The panel included the original 
translator, a clinical psychologist and Dr S. Khadilkar, a neurologist from the Neurology 
department at JJ Hospital. The panel also included Dr Pai from BLP, Dr Vanaja Shetty, 
Ms. Capadia and Dr Pandya from FMR. They are fluent in both English and 
Hindi/Marathi, and are familiar with the terminology used in the leprosy and pain fields. 
The local language versions were reviewed by the panel and any inadequate 
expressions/concepts in the translation were identified and discussed. In addition, any 
discrepancies between the forward translation and the existing or other comparable 
previous versions of the questions were discussed. Discrepancies were discussed until a 
satisfactory version was agreed. The translation procedure review was conducted several 
times until an agreement was reached for the final Hindi/Marathi version.  
Following completion of the translation work, the final versions of the translated 
protocol were sent to the DFNS for approval. Pre-testing of the protocol on the target 
population was done before the final version was used for the study. The pilot was 
tested on a sample of five participants: two volunteers from FMR staff and three 
patients from the BLP clinic. The goal in this step was to test the DFNS-QST 
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instructions and the time taken to complete an interview. The main methodological 
change and modification as a consequence of the piloting was to test only one site. The 
decision to restrict the site of the test to the hand (dermatome C8 bilaterally) instead of 
the hand and feet was made in order to minimise the duration of the interview.   
7.4.2.4 Recording techniques and testing protocol 
The DFNS-QST protocol was tested bilaterally on a defined area on the dorsum of the 
hand (sensory region of the ulnar nerve, dermatome C8) or dorsum of the foot 
(dermatome S1). Participants were tested under identical conditions in a comfortable 
position. Testing was conducted in a quiet room with the ambient temperature 
controlled at 210C to 230C. All participants underwent a practice session in which the 
different parameters were applied to the forearm until they were familiarised with the 
measurement procedure and the equipment. Participants were unable to watch the 
computer screen at any times during the test procedures. They were also not given 
auditory or visual clues to indicate the start of individual stimuli. Testing of each site 
took ~30 minutes and a complete test at all two sites took ~60 minutes. All tests were 
carried out by the same investigator who was trained in the use of QST according to the 
DFNS protocol. All participants who underwent the protocol began with the 
determination of thermal thresholds followed by mechanical thresholds. The detailed 
testing procedures of the different parameters of the standardised QST battery 
according to DFNS protocol is described in chapter 6. These different parameters can 
be listed chronologically as follows:  
 Thermal detection for cold and warm detection threshold (CDT, WDT); 
 Number of paradoxical heat sensations (PHS) during thermal sensory limen 
procedure (TSL); 
 Thermal pain threshold for cold and heat pain threshold (CPT, HPT); 
 Mechanical detection and pain threshold (MDT, MPT); 
 Mechanical pain sensitivity for pinprick stimuli (MPS); 
 Dynamic mechanical allodynia (DMA) for stroking light touch; 
 Wind-up ratio (WUR); 
 Vibration detection threshold (VDT); 
 Pressure pain threshold (PPT). 
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7.4.3 Data evaluation and results 
Data entry and transformation was conducted according to the DFNS guidelines. Data 
were first entered into an Microsoft Excel-spread sheet (Equista database) provided by 
DFNS, which automatically generated thresholds and average ratings and number of 
observed paradoxical heat sensations. The obtained data were entered into a STATA 
data file and GraphPrism to generate analysis and graphs, respectively. The following 
analyses were carried out: 
 Comparison of the results to the 95% confidence interval of the DFNS 
reference data.  
 Number (percentage) of abnormal values 
 Calculation of Z-values: data are presented as mean ± SD and based on the 
DFNS reference database, I calculated the z-score for each participant: 
Z-score = (value [single participant] - Mean [controls])/SD [controls] 
 Statistical analysis of the Z-values of right ulnar vs. left ulnar and using t test for 
the differences between the parameters within each group.    
Fifty-two volunteers participated in this study. All subjects completed all QST 
measurements and 30 subjects completed both QST and skin biopsy interventions; 
there were no drop-outs. None of the subjects reported any adverse effects. Forty-eight 
subjects completed all QST measures in their hands, two subjects on feet, and two 
subjects on both hands and feet. The data obtained from all QST measurements for the 
two test sites are presented as mean and SDs in Table 7.2, Figure 7.6, and Figure 7.7. 
QST in two different test sites yielded values that were within the published DFNS 
reference values; the number of values outside the 95% confidence interval (5.27%) was 
actually slightly higher than its expected published value (5%) (Rolke et al., 2006a, Maier 
et al., 2010). The result was validated by the German Neuropath Pain Group (DFNS). 
7.4.4 Discussion 
This is the first study to use the DFNS-QST protocol in a resource-limited setting 
outside of Europe and validates the Mumbai Centre for the use of the QST. Normative 
QST data are generated by evaluating somatosensory function in healthy volunteers, a 
process in which one body area is assessed using the QST measures according to the 
DFNS protocol. 
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The findings in our study revealed that one or more somatosensory abnormalities were 
present in healthy controls. The percentage of abnormal findings expected in healthy 
controls is 5%, with the exception of DMA, which is not present in healthy controls. In 
accordance with this exception, our data showed abnormal sensory function for 5.27%. 
Although our healthy volunteer data is in line with data published by the DFNS and 
others, the main abnormality occurred mostly in one parameter. For instance, of those 
volunteers who had abnormal findings at the test site “dorsum of the hand”, the wind-
up ratio represented one-third of these abnormalities. This could be explained by the 
complexity of the test and the interpretation by subjects. 
The normative QST data generated from the dermatome C8 of a non-Caucasian 
population may help to increase the generalizability of the DFNS reference database. In 
addition, validating the Mumbai site for QST protocol in Hindi and Marathi may help to 
establish somatosensory profiles in other diseases such as diabetics and HIV/AIDS in 
India. 
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Table 7.2. QST results performed in hands (n=50) and feet (n=4) 
QST parameter * Test sites 
Hand (n=50) Foot (n=4) 
Mean ± SD Number of subjects 
outside the 95% CI 
Mean ± SD Number of subjects 
outside the 95% CI 
Thermal thresholds     
   Cold detection threshold (CDT) Δ ˚C from baseline 32˚C -0.29 ± 0.87 2 -0.23 ± 0.25 0 
   Warm detection threshold (WDT) Δ ˚C from baseline 32˚C -0.45 ± 0.87 3 -0.77 ± 0.57 0 
   Thermal sensory limen (TSL) Δ ˚C -0.78 ± 0.59 1 -1.04 ± 0.48 0 
   Paradoxical heat sensations (PHS) x/3 0.00 ± 0.00 0 0.00 ± 0.00 0 
   Cold pain threshold (CPT) ˚C 1.20 ± 0.49 3 1.01 ± 0.79 0 
   Heat pain threshold (HPT) ˚C 0.40 ± 0.63 1 0.36 ± 0.29 0 
Mechanical thresholds     
   Mechanical detection threshold (MDT) mN 0.97 ± 0.67 1 0.39 ± 0.38 0 
   Mechanical pain threshold (MPT) mN 0.27 ± 0.41 0 0.42 ± 0.15 0 
   Mechanical pain sensitivity (MPS) NRS 0.14 ± 0.66 4 0.43 ± 0.18 0 
   Dynamic mechanical allodynia (DMA) NRS 0.00 ± 0.00 0 0.00 ± 0.00 0 
   Wind-up ratio (WUR)  1.15 ± 1.44 0 0.23 ± 1.00 0 
   Vibration detection threshold (VDT) x/8 0.41 ± 0.42 0 0.41 ± 0.42 0 
   Pressure pain threshold (PPT) kPa -1.22 ± 0.86 4 -1.22 ± 0.86 0 
  5.27%  0% 
* Data are presented as log data (mean and SDs). In addition, number of values outside the 95% confidence interval of the published DFNS 
reference values for each parameter are given (in %) which are calculated as follows: 11 tests x 50 subjects = 550 divided by the number of 
values outside the 95% confidence interval. 
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Figure 7.6. Thermal and Mechanical QST results in hands (n=50) 
 
 
Figure 7.7. Thermal and Mechanical QST results in feet (n=4) 
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7.5 Comparability of mechanical detection and pain thresholds in QST using 
different devices 
7.5.1 Introduction 
The aim of this study was to investigate comparability between different devices namely: 
the Semmes-Weinstein monofilaments, von Frey filaments and “electronic von Frey” 
using the same psychophysical methods for mechanical detection threshold (MDT), 
mechanical pain threshold (MPT), and mechanical pain sensitivity (MPS) within the 
DFNS criteria. The study was designed jointly with Prof Rolf-Detlef Treede from the 
DFNS group. I conducted this study in Prof Treede’s laboratory in Germany and Dr 
Doreen Pfau from the DFNS group completed the analysis and wrote up the findings.  
7.5.2 Materials and Methods 
7.5.2.1 Subjects and test areas 
Thirteen healthy control subjects (7 female, 6 male; mean age 29 years) were investigated 
between March 1st and 25th 2011, after giving written informed consent for the QST 
procedures. Participants were invited and recruited from Mannheim Medical Centre, 
Mannheim. Ethical approval was obtained from the Ethics committee of University of 
Mannheim, Mannheim, Germany. Procedures were in accordance with the Declaration 
of Helsinki. 
Tests were performed in the innervation territories of the right and left ulnar nerve on 
the hand dorsum and on the palmar fingertip (small finger). In the face, test area was 
within the innervation territory of V2 (maxillary nerve) bilaterally. 
7.5.2.2 Equipment 
Von Frey filaments  
The set of von Frey filaments commonly used within the DFNS protocol for testing the 
mechanical detection threshold (MDT) (Marstock nervetest; Marburg, Germany) 
consists of glass fibre filaments with different length and strength. Those factors 
determine the intensity of the force applied to the skin. The tip of the filaments is 
rounded tip in order to avoid sharp edges and subsequently in order to avoid a possible 
nociceptor activation due to sharp edges (Greenspan and McGillis, 1991). Nominal 
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bending forces are logarithmically increasing forces of 0.25 mN, 0.5 mN, 1 mN, 2 mN, 
4 mN, 8 mN, 16 mN, 32 mN, 64 mN, 128 mN, 256 mN and 512 mN. 
Semmes Weinstein monofilaments  
The Semmes Weinstein monofilament (Brazilian filaments; SORRI-Bauru; Brazil) 
consists of a plastic handle supporting a nylon filament. Applying forces of 0.05 g, 1 g, 2 
g, 20 g, 40 g, and 300g (corresponding to 0.5 mN, 9.8 mN, 19.6 mN, 196.1 mN, 392.3 
mN and 2942.0 mN) on the skin using different filaments with the same length but 
different strength. In contrast to the DFNS von Frey filaments, tips presented an edge 
leading to a sharp sensation in some subjects at higher stimulus intensities. For this 
reason, this set of filaments was also used to test the mechanical pain threshold (MPT). 
They are designed to be cheap robust and suitable for use in low/medium resources 
settings. 
Devices for Mechanical pain threshold and Mechanical Pain Sensitivity 
The set of weighted pinprick stimulators used within the DFNS protocol (The Pinprick, 
MRC systems, Heidelberg, Germany) consists of different steel tubes with a 
standardized diameter of about 1 cm. Inside the tubes, weights rest on a rim at the end 
of the tubes when held perpendicularly without touching the skin and end in blunt steel 
rod with a standardized tip diameter of 0.25mm. As soon as the tips touch the skin and 
the tubes are moved slightly towards the skin, forces delivered by the weights are 
completely carried on the skin by the small steel rods, resulting in healthy subjects in 
“blunt” sensation for lower and “sharp” sensations for higher forces. This set of 
stimulators covers intensities representing logarithmically increasing forces of 8 mN, 16 
mN, 32 mN, 64 mN, 128 mN, 256 mN and 512 mN.   
Electronic von Frey filament  
The electronic von Frey filament (Somedic, Sweden) represents a device eligible for the 
testing of a mechanical pain threshold (MPT). The tip diameter is 0.25 mm and thus 
comparable with the set of DFNS pinprick stimulators. The replaceable and sterilisable 
tip tapers in a cylindric form to avoid skin penetration and is connected with a 
handpiece and a force sensor and was connected via a force transducer and a computer 
with the corresponding software. A visual feedback control of the applied ramp rate is 
possible due to flashing lights on the back of the handpiece.  Subjects could indicate the 
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first sharp sensation (mechanical pain threshold; MPT) by a stop button or the pain 
intensity (mechanical pain sensitivity; MPS) by an electronic visual analogue scale (VAS). 
Optical feedback control indicated by flashing lights on the holder was limited to a 
lowest ramp rate of 10g/s, corresponding to about 100 mN/s. As the lowest mechanical 
pain threshold within the normal range according to the DFNS protocol depending on 
age and gender of tested subjects (Magerl et al., 2010) is expected at about 40mN, 
threshold would be missed by applying a ramp rate of 100 mN/s. For this reason we 
added a testing trial with a ramp rate of 1g/s corresponding to ≈10mN/s. Instead of the 
optical feedback control directly on the handpiece, the control of ramp rates was 
possible by an optical feedback given by functions for pressure vs. time on the 
computer screen. Applied stimulus ramps were thus 10g/s and 1g/s, respectively, to test 
a possible influence of subject’s reaction time or the influence of steeper increasing 
pressure ramps delivered by sharp stimuli per se (List et al., 1991). 
Cut-off value for testing on the hand was 74 g, corresponding to 724mN as presenting 
the calculated cut-off value within the DFNS procedure using “The Pinprick” to avoid 
tissue damage. Those values are calculated when the 512mN pinprick stimulator is 
perceived as non-pricking, and a virtual value of 1024 is then defined as pricking 
stimulus intensity, resulting in a geometrical mean value of 724 mN for the mechanical 
pain threshold. Similarly, the cut-off value for testing in the face was 37g, corresponding 
to 362 mN. As the 512 mN Pinprick stimulus is recommended not to be used in the 
face to avoid any skin damage, 512 mN is defined as virtually pricking value if the 256 
mN device is perceived as blunt sensation, resulting in a geometrical mean value of 
362mN.  
7.5.2.3 Procedures 
Mechanical detection threshold (MDT) 
Mechanical detection threshold was performed according to the DFNS protocol using a 
method of limits (Rolke et al., 2006b), 
1) with the DFNS von Frey filament, starting with a probable suprathreshold 
filament of 16mN  
2) with the Semmes Weinstein monofilaments, starting with a probable 
suprashreshold stimulus intensity of 2g, corresponding to 20mN 
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Five subthreshold and five suprasthreshold values were defined. Geometric mean values 
of sub- and suprashreshold stimuli then represent the mean tactile detection threshold. 
Mechanical pain threshold (MPT) 
Mechanical pain threshold was performed with different procedures as described below: 
1. according to the DFNS protocol using the method of limits and asking the 
subject of differentiate between a sharp or blunt sensation evoked by 
i. a set of seven weighted pinprick stimuli (‚The Pinprick’), starting with a 
probable sub-threshold stimulus intensity of 8mN 
ii. Semmes Weinstein monofilaments with a probable sub-threshold 
stimulus intensity of 2 g, corresponding to ≈20mN; as filaments are 
more flexible, any pain sensation was expected for higher intensities 
compared to the blunt needle stimulator (The pinprick). 
Then five sub-threshold and five supra-threshold values were defined. Geometric mean 
values of sub- and supra-threshold stimuli then represent the mean mechanical pain 
threshold. 
2. using a three-time threshold determination of a continuously increasing ramp 
rate at both, 1g/s or 10g/s using the electronic von Frey Filament with a stop 
button. Subjects were asked to press the stop button as soon as they perceive 
any sharp sensation representing the activation threshold of nociceptors (cite). 
Mechanical pain sensitivity 
Using the weighted pinprick stimulators and the Semmes-Weinstein filaments, the 
procedure for testing the mechanical pain sensitivity (MPS) used within the QST 
protocol according to DFNS protocol was used. Mechanical pain sensitivity was tested 
with the same standardized punctate probes as used for testing of the mechanical pain 
threshold.  Dynamic mechanical allodynia (DMA) was tested using standardized light 
touch stimuli: (1) a cotton wisp applying a force of about 3 mN, (2) a Q-tip, fixed in a 
flexible plastic mount, exerting a force of about 100 mN when slightly bent, and (3) a 
standardized brush applying forces of 200–400 mN (Senselab Brush-05, Somedic, 
Sweden). To evaluate the pain intensity of subjects, a numerical rating scale from 0 (no 
pain) to 100 (most intense pain imaginable) was used for all test stimuli. Subjects were 
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free to use integers as well as fractions ad libitum. They were instructed to distinguish 
pain from the perception of touch or pressure by the presence of a sharp or slightly 
pricking or burning sensation.  
Using the electronic von Frey filament subjects rated the intensity of any pain-related 
sensation on an electronic VAS which was connected via the force transducer 
(SenseBox) with the computer, recording ratings and applied forces. Ramp rates were 
the same as for the testing of the mechanical pain threshold via the evF as are 1g/s and 
10g/s. For data analysis, corresponding ratings to the forces within the DFNS protocol 
applied (8, 16, 32, 64, 128, 256 and over extra-trigeminal areas additionally 512 mN) 
were extracted. A small constant of 0.1 was added to each rating to avoid a loss of zero 
values during data analysis (Magerl et al., 2010).  
Order of test procedures 
Within the test protocol, test procedures were performed in the following order: 
i. Mechanical detection threshold (MDT) 
ii. Mechanical pain threshold (MPT) 
iii. Mechanical pain sensitivity (MPS) 
Order was balanced over test areas (face, fingertip, hand dorsum) and over the 
application order of used test devices. 
7.5.3 Results 
7.5.3.1 Mechanical detection threshold 
Mean values for MDT tested by von Frey vs. Brazilian monofilaments did not differ 
over all test areas (Figure 7.8), (mean values over face: 0.46mN vs. 0.59mN (log-mean ± 
SEM: -0.338±0.098 vs. -0.229 ± 0.067); fingertip: 0.57mN vs. 0.62mN (-0.241 ± 0.103 
vs. -0.208 ± 0.053); hand dorsum: 1.88mN vs. 1.83mN (0.273 ± 0.121 vs. 0.263 ± 
0.129) and were highly correlated (r=0.71-0.81). 
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Figure 7.8. MDT results from the face, fingertip and hand 
von Frey (dark bar column) and Brazilian monofilaments (white bar column) 
 
7.5.3.2 Mechanical pain threshold 
Mean values for MPT differed significantly for pinprick stimuli vs. Brazilian 
monofilaments by 24.9mN vs. 12.7mN over face (log-mean ± SEM: 1.396 ± 0.041 vs. 
1.103 ± 0.094; p-value <0.01) but not for the fingertip: 55.1mN vs. 78.1mN (1.741 ± 
0.074 vs. 1.893 ± 0.206) and the hand dorsum: 55.4mN vs. 69.8mN (1.744 ± 0.064 vs. 
1.844 ± 0.182). Compared to values tested by pinprick stimuli, mean values tested by 
the evF differed significantly for both ramp rates in all test areas; in the face with 
90.3mN (1.956 ± 0.054; 1g/s) and 176.0mN (2.245 ± 0.055; 10g/s), on the fingertip 
with 121.8 mN (2.085 ± 0.060; 1g/s) and 223.4mN (2.349 ± 0.034; 10g/s) and on the 
hand dorsum with 144.6mN (2.160 ± 0.061; 1g/s) and 239.6mN (2.379 ± 0.061; 10g/s) 
(Figure 7.9). 
Chapter 7 – Validation studies 
 
175 
 
 
Figure 7.9. Comparison between Pinprik, MFs and evF 
Comparison of the set of weighted Pinprick stimuli (black bars) with the 
Brazilian monofilaments (white bars) and an electronic von Frey filament with 
the ramp rates of 1 g/s and 10g/s (light/dark grey bars). n.s. = non-significant, 
*p-value <0.05; **p-value <0.01; ***p-value <0.001; paired t-test. 
 
7.5.3.3 Mechanical pain sensitivity 
Mean values for complete MPS-DFNS procedure were 1.09/100 in the face (0.039 ± 
0.082), 0.92 on the fingertip (-0.037 ± 0.117), and 0.84 on the hand dorsum (-0.077 ± 
0.083). The calculation of MPS with the evF was not possible as subjects did not rate 
pain below stimulus intensities of 128mN, and cut-off value for the face was set at 
256mN. For this reason, we used a stimulus response function with only 2 stimulus 
intensities for comparison. Mean pain rating for ‘short’ MPS in the face was 7.75 
(0.889±0.103) for Pinprick stimuli vs. evF 1g/s: 0.56 (-0,254 ± 0.138) and evF 10g/s: 
0.25 (-0.601 ± 0.066). On the fingertip, rating was 3.56 (0.551 ± 0.178) for the Pinprick 
vs. evF 1g/s: 0.71 (-0.149 ± 0.153) and evF 10g/s: 0.24 (-0.621 ± 0.089). On the hand, 
rating was 3.59 (0.555 ± 0.134) vs. evF 1g/s: 0.6 (-0.210 ± 0.148) and evF 10g/s: 0.17 (-
0.758 ± 0.041). 
Chapter 7 – Validation studies 
 
176 
 
7.5.4 Discussion 
The DFNS-QST protocol is a standardised method. It has been used globally to explore 
somatosensory profiles in patients with neuropathic pain. The high standardization of 
this QST protocol requires specific devices to be used within the protocol. This may 
represent one of the most important limitations of further expansions of the use of the 
protocol due to high costs and restricted practicability.  
In this study the Semmes-Weinstein monofilaments yield similar results for the testing 
of MDT and MPT according to the DFNS protocol in healthy subjects. Due to larger 
increments of applied intensities compared to the DFNS von Frey filaments, 
neuropathies may be underestimated in more sensitive test areas (face, fingertip). 
Additional variance may arise from non-standardized tip surfaces of the Semmes-
Weinstein monofilaments. The suitability of the use on the hand should be confirmed 
by testing of subjects with sensory loss and gain, i.e. under pathological condition. 
Semmes-Weinstein monofilaments are more robust than the von Frey filaments used 
within the DFNS and cost effective. Further, they are not usually affected with dust or 
required calibration. For these reasons their use would be favourable in resource-limited 
settings, and may also be used for the testing of MDT and replace a set of von Frey 
filaments stimuli used within the DFNS. 
MPT and MPS tested with the electronic von Frey filament are not comparable with the 
responses measured by pinprick stimuli within the DFNS-QST protocol which may be 
caused by a different mode of application (static stimuli vs. dynamic stimuli). For the 
dynamic application, reaction time may play an important role, which is demonstrated 
by different MPT and MPS values for different ramp rates. This indicates that 
investigating comparability between inter-observer testing and test-retest in same 
subjects are needed. 
7.5.5 Conclusions 
The use of the Brazilian monofilaments yield similar results as the DFNS instruments 
for both, MDT and MPT on the hand dorsum but has a limited range of use in more 
sensitive areas due to a limited grading of intensities at lower forces. The electronic von 
Frey filament was frequently insufficient to reach the threshold for sharp sensation as 
used for the DFNS protocol and is not suitable for the use within that protocol. 
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Chapter 8 Results 
8.1 Introduction  
This chapter presents the results of the data analysis as follows: first, descriptive results 
are shown for all leprosy patients, and study groups; followed by results for pain 
description questionnaires; clinical examinations; and Quantitative Sensory Testing. The 
last result section describes the impact of neuropathic pain on quality of life. 
8.2 Descriptive analysis  
8.2.1 Baseline characteristics of study population 
8.2.1.1 Participants  
Ninety-nine leprosy patients with and without pain; and 52 healthy volunteers were 
enrolled into Leprosy Pain India study (LePaIn) between 10th October 2012 and 30th 
April 2013. Patients were allocated into four groups based on clinical evidence of 
neuropathy and presence of pain (Figure 8.1). Thirty-six patients had pain at interview. 
Of these, twenty-four participants were clinically identified as having neuropathic pain 
in the affected ulnar nerve based on a score of ≥ 4/10 of the DN4 questionnaire and 
clinical neurological examination. 
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Figure 8.1. Flow diagram for LePaIn study 
G1: Group 1; G2: Group 2; G3: Group 3; G4: Group 4; UL: Upper limbs; LL: 
Lower limbs 
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Demographic and clinical characteristics 
Age and sex distribution  
The mean age of included patients was 32.8 years (range 18-60 years). More than two 
third of patients were in the age groups 20-29 and 30-39 years. Approximately one fifth 
of the patients were female. The proportion of male and female patients was not evenly 
distributed across age groups. There were relatively few patients aged below 20s and 
above 50s age group (Table 8.1). 
Table 8.1. Age distribution of the sample by sex 
Age group 
(Years) 
Male 
N = 69 (77%)  
Female  
N = 21 (23%) 
Total 
N = 90 (100%) 
<20 5 (7.3%) 1 (4.8%) 6 (6.7%) 
20-29 31 (44.9%) 6 (28.6%) 37 (41.1%) 
30-39 21 (30.4%) 4 (19.1%) 25 (27.8%) 
40-49 6 (8.7%) 6 (28.6%) 12 (13.3%) 
50-60 6 (8.7%) 4 (19.1%) 10 (11.1%) 
 
Geographical distribution 
Ninety patients were seen during the period under study, of which 74 patients (82.2%) 
were recruited from the BLP clinic in Mumbai. Patients came from a wide range of 
leprosy endemic areas in India. Approximately 50% had migrated from outside BLP 
catch-up area of services; the remainder were within the state of Maharashtra. The 
largest single group of patients (42 patients (46.7%)) came from Maharashtra state, with 
33.3% from Mumbai; followed by Uttar Pradesh (31 patients (34.4%); and Bihar (10 
patients (11.1%)). One patient was from Nepal, and had acquired his leprosy in India, 
where he had been living since 1990. The majority of the study population (64 patients) 
had primary education (50 patients) or no formal education (14 patients). Figure 8.2 
shows the geographic origin of 90 patients presenting with leprosy to the BLP and 
FMR. 
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Figure 8.2. Geographical origin of 90 patients presenting with leprosy 
This map is developed by the WHO office in Delhi for the purpose of the 
current study; with kind permission from GIS / SEARO. 
 
Patients’ clinical characteristics  
The demographic and clinical details of the study population are shown in Table 8.2. In 
65 (72.2%) patients, the diagnosis of leprosy was made after six months from the 
patients’ first symptoms. There was a long lag time between the appearance of first 
symptoms and disease diagnosis, mean 2.1 years (range 0.3 – 22 years). In 14 (7BL, 7LL) 
patients, the latent time to diagnosis was 2.1 years (range 0.4 – 10 years). This subgroup 
were potentially infectious to others before diagnosis and treatment. The main reason 
for delay was misdiagnosis or an unusual presentation mimicking other common 
conditions, such as skin diseases. In 33 patients a misdiagnosis was made, all were 
dermatological related conditions such as psoriasis. Two patients had an unusual 
presentation described as neurological condition with no skin involvement. Patient 
factors can cause delay: 31 patient were unaware or neglected their symptoms. 
Patients reported a variety of symptoms at the start of their problems, although none of 
them thought of the possibility of leprosy. In the vast majority (62 patients), these were 
the descriptions of typical leprosy skin lesions. 29 patients mentioned symptoms related 
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to nerve damage: eighteen had anaesthesia; two had loss of warm sensation; four had 
burning and tingling sensations; and five had loss of muscle strength, at their first 
consultation at the BLP clinic. Patients with leprosy frequently presented with 
complications such as reactions. Seven patients were in reaction at the time of 
presentation: three of these were Type I (reversal) reactions requiring treatment with 
oral prednisolone. Four had ENL. In these patients the signs and symptoms of the 
reaction were the stated reason to seek medical assistance. Over three quarters of the 
patients (69 (76.6%)) presented their problem to a private doctor. Only 11 (12.2%) of 
the patients presented directly to leprosy hospital or clinic. Traditional healers, 
alternative medical practitioners and pharmacists were first consulted in 5.7%, 3.3% and 
2.2% of the patients, respectively.  
Of the total sample, 18 (20.0%) patients were newly diagnosed and not started MDT at 
the time of interview; 26 (28.9%) patients had been diagnosed and received MDT within 
the first six month; 11 (12.2%) between six month and one year; and 35 (38.9%) more 
than one year after developing their first symptoms of leprosy (Table 8.2).  
Patients were classified according to WHO field classification as follows: 57 (63.3%) 
patients had MB, and 33 (36.7%) had PB. Only 68 (75.6%) patients had been classified 
clinically using the RJ clinical classification, the remaining 22 (24.4%) was not classified. 
Of the 68 patients, four patients (5.9%) had TT leprosy, thirty (44.1%) had BT, two 
(2.9%) had BB, thirteen (19.1%) had BL, nine (13.2%) had LL, six (8.8%) had pure 
neuritic leprosy, and three (4.4%) had indeterminate leprosy. Of the 90 patients, 18 
(20.0%) patients had not yet received leprosy MDT, 26 (28.9%) patients were already 
taking MDT, and 46 (51.1%) had been released from leprosy treatment (RFT). Of these 
RFT, the mean time since completed treatment was 3.5 years (range 0.04 – 30.9 years). 
Twenty five (27.9) patients had received at least two courses of leprosy treatment. 
Table 8.3 documents the severity of nerve involvement at diagnosis, 36 (40.0%) patients 
had evidence of Grade 1 disability from nerve damage involving their hands or feet, 
with 10% having Grade 2 disability of hands or feet. Two (2.2%) patients had ocular 
disability due to leprosy, one of which had a Grade 2 disability.  
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Table 8.2. Demographic and characteristics of the study population (n=90) 
Variable  Frequency Percentage Variable Frequency Percentage 
Centre 
BLP 74 82.2% Dominant hand Right  86 95.6% 
FMR 16 17.8% Left 4 4.4% 
Language 
Hindi  56 62.2% 
Education 
Illiterate  14 15.6% 
Marathi  32 35.6% Primary  50 55.6% 
English  2 2.2% Secondary  11 12.2% 
Religion 
Hindu 63 70.0% High school  3 3.3% 
Muslim 25 27.8% Higher secondary  4 4.4% 
Christian  1 1.1% College and above 8 8.9% 
Others 1 1.1% 
Alcohol status 
No  64 71.1% 
Smoking 
status 
Current smoker 9 10.0% Yes  26 28.9% 
Former smoker 8 8.9% 
Frequency of 
alcohol use 
Daily  3 3.3% 
Occasionally 9 10.0% Weekly  6 6.6% 
Never smoked 64 71.1% Occasionally  17 18.9% 
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Variable  Frequency Percentage Variable Frequency Percentage 
Occupation 
None 3 3.3% 
RJ classification 
TT 4 4.4% 
Housewife 14 15.6% BT 31 34.4% 
Labour 41 45.6% BB 2 2.2% 
Farmer / skilled labour 9 10.0% BL 13 14.4% 
Office worker / Business 3 3.3% LL 9 10.0% 
Student 7 7.8 PN 6 6.7% 
Delay in 
diagnosis 
No 25 27.8% Indeterminate  3 3.3% 
Yes 65 72.2% Not known  22 24.4% 
Delay in 
diagnosis 
<6month 26 36.1% 
WHO 
classification 
PB 33 34.4% 
6months-12month 11 15.3% MB 57 65.6% 
>12months 35 48.6% 
Duration of 
disease 
Newly diagnosed  18 20.0% 
Main 
reasons for 
delay 
Misdiagnosis 33 50.7% <6months 26 28.9% 
Patients factors  31 47.7 6months up to 1yr 11 12.2% 
Admin factors 1 1.54 Longer than 1year 35 38.9% 
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Table 8.3. Disability grades present in patients at diagnosis (n=90) 
 Grade 0  Grade 1  Grade 2  
Hands and feet 54 (60.0%) 36 (40.0%) 9 (10%) 
Eyes 89 (98.9%) - 1 (1.1%) 
 
8.2.1.2 Study Groups 
Number of participants by group  
Patients were divided into the following groups: leprosy patients with no clinical 
evidence of neuropathy and no pain (Group 1); leprosy patients with subclinical 
neuropathy and no pain (Group 2); leprosy patients with clinical evidence of neuropathy 
and no pain (Group 3); leprosy patients with clinical evidence of neuropathy and pain 
(Group 4). Healthy volunteers group (H.V) (Table 8.4). Group 4 is further divided to 
neuropathic pain subgroup (NP) and non-neuropathic pain subgroup (Non NP).  
Patients with No pain (Group 1, 2 and 3) 
Fifty four patients were recruited in three groups of patients with no pain. Of these, 29 
patients had a diagnosis of leprosy and no clinical evidence of neuropathy: one group of 
14 newly diagnosed leprosy patients had no evidence of neuropathy prior to the study 
(G1); and the other group consisted of 15 patients with leprosy and had subclinical 
neuropathy (G2). Another group consisted of 25 patients had leprosy and had clinical 
evidence of neuropathy (G3).  
Patients with pain (Group 4) 
In total, 36 patients were recruited with pain. There was poor recruitment in the leprosy 
patients with pain and no clinical evidence of neuropathy group mainly because patients 
having completed leprosy treatment with no neuropathic complication may not come to 
the leprosy clinic for their pain condition. Out of 36 patients with pain, 32 (88.9%) 
reported pain in their hand and 4 (11.1%) had lower limb pain. 
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Demographic and clinical characteristics of participants by group 
The five groups were not significantly different with respect to age, weight, height, or 
metabolic factors: Thyroid hormone profiles, glucose, BMI and vitamin B12 level. 
Patient demographics and characteristics by groups are shown in Table 8.5. 
Table 8.4. Number of participants and study groups (n=142) 
Group  Number Gender Age (mean, 
range) 
Healthy volunteers 52 24 male, 28 female 30.75 (18-55) 
No evidence of neuropathy and no 
pain 
14 13 male, 1 female 31.74 (20-51) 
Subclinical neuropathy and no pain 15 10 male, 5 female 30.96 (18-56) 
Clinical evidence of neuropathy / no 
pain 
25 18 male, 7 female 30.39 (18-53) 
Clinical evidence of neuropathy and 
pain 
36 24 male, 12 female 35 (18-60) 
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Table 8.5. Demographic and clinical characteristics of participants by 
group (n=142) 
Variable© Groups 
Healthy  Patients 
Group 1 Group 2 Group 3 Group 4 
Participant’s § 52 (63.6) 14 (9.9) 15 (10.6) 25 (17.6) 36 (25.4) 
 Male  24 (25.8) 13 (12.9) 10 (10.8) 18 (19.4) 28 (30.1) 
Female  28 (57.1) 1 (2.0) 5 (10.2) 7 (14.3) 8 (16.3) 
Age (years) * 30.8±10.1 31.1±9.6 30.9±10.5 30.4±9.2 35.8±13.1 
 Male  30.8±11.2 31.6±9.9 28.2±10.4 30.8±9.6 32.4±12.3 
 Female  30.7±9.3 25.1 36.6±9.1 29.3±8.7 47.9±7.9 
Weight * 59.9±13.6 60.1±9.8 54.6±11.3 58.4±12.8 62.3±10.1 
 Male  65.1±14.0 61.9±7.5 56.6±9.7 61.7±13.5 62.7±10.9 
 Female  55.0±11.4 37.0 50.6±14.3 49.9±5.4 61.3±7.3 
Height † 159.4±8.4 163.4±9.5 157.7±11.0 159.2±7.8 161.0±8.4 
 Male  163.0±8.1 164.8 ±8.2 163.9±6.7 162.7±5.5 164.4±6.7 
 Female  156.1±7.4 145.0 145.2±5.9 150.3±5.3 150.5±5.2 
BMI (kg/m2) 23.6±4.9 22.5±2.8 22.0±4.2 22.9±4.0 24.1±3.8 
 Male  24.5±5.2 22.8±2.5 21.0±3.0 23.2±4.5 23.1±3.3 
 Female 22.7±4.6 17.6 23.8±5.9 22.1±2.2 27.2±4.0 
HbA1C * 5.7 (0.5) 4.9 (1.3) 4.9 (1.0) 4.8 (1.1) 6.9 (8.9) 
 Male 5.8 (0.5) 4.9 (1.3) 5.0 (1.0) 4.7 (1.1) 7.5 (10.4) 
 Female 5.4 (0.4) 1.0 (5.0) 4.6 (1.2) 4.9 (1.2) 5.3 (1.5) 
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T3 * 133 (27) 94 (52) 125 (17) 112 (22) 94 (20) 
 Male 145 (29) 93 (59) 122 (24) 112 (22) 98 (19) 
 Female 115 (8) 100 130 121 (34) 85 (26) 
T4 * 8.6 (2.6) 6.6 (2.1) 8.4 (0.6) 9.0 (2.1) 17.8 (53.3) 
 Male 10.0 (2.4) 7.0 (2.2) 8.0 7.5 (1.3) 6.5 (1.5) 
 Female 15 (24.9) 5.0 9.0 11.0 50 (103) 
TSH * 1.9 (0.9) 1.8 (0.4) 1.3 (0.6) 1.9 (1.3) 2.0 (2.0) 
 Male 1.9 (1.0) 1.8 (0.5) 1.0 (0.0) 2.5 (1.3) 1.8 (1.5) 
 Female  2.0 (0.5) 2.0 2.0 1.0 (1.0) 3.0 (3.1) 
Vitamin B12 * 387 (168) 267 (173) 303 (106) 348 (167) 523 (410) 
 Male 360 (118) 234 (180) 333 (131) 281 (114) 436 (207) 
 Female 427 (248) 400 243.0 436 (207) 927 (595) 
©Data are means (SD) (mean ± standard deviation) or numbers (%); HbA1C – 
Glycated Haemoglobin results are displayed as percentage, reference range (4 to 6%); 
T3 total are displayed as ng/dl, reference range (70 to 204ng/dl); T4 total are displayed 
as µg/dl, reference range (4.87 to 11.72 µg/dl); TSH are displayed as µIU/ml, reference 
range (0.45 to 4.5 µIU/ml); Vitamin B12 results are displayed as pg/ml, reference range 
(187 to 883). *Continuous data if normally distributed were analysed with one way 
anova test (ANOVA). Mean values and SDs shown; † Continuous data not normally 
distributed were analysed using Kruskal Wallis test. Mean values and SDs shown. § 
Categorical data were analysed using Chi squared test of association. Values and 
percentages shown. BMI Body Mass Index. 
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8.3 Clinical symptoms findings 
8.3.1 Pain and sensory symptoms in leprosy patients with pain 
8.3.1.1 Patient details 
Twenty-six patients (72%) had symptoms and signs suggestive of NP identified by the 
DN4 questionnaire and 10 patients (28%) with predominately musculoskeletal/ 
nociceptive pain (non-NP) conditions. 
8.3.1.2 Patient characteristics for pain group 
General characteristics  
The sample of 36 leprosy patients with pain represented a range of neuropathic and 
non-NPs. There were no significant differences between the two pain subgroups with 
respect to age, sex, average pain intensity and frequency in the last four weeks and pain 
intensity during interview. Table 8.6 shows the characteristics of patients with pain 
classified according to the case definition as having Non-NP or NP in both upper and 
lower limbs.  
Site of pain  
Although the most frequent sites of pain for all patients were upper extremities (88.9%), 
which reflects the study methodology, pain frequently occurred in skin lesions, 
peripheral nerves or generalized pain (Table 8.7). Of the 36 patients, 13 had skin lesion 
pain: in 5 patients pain was located in the active untreated skin lesions, and 8 in the 
treated skin lesions. A wide spectrum of pain site presentation was reported in 
peripheral nerves: 9 patients had hand and feet pain; 17 patients reported pain at the site 
of the nerve; and 18 patients had pain in the area of sensory loss over nerve distribution, 
the nerve most often affected by pain was the ulnar nerve in the upper limbs followed 
by the lateral common peroneal nerve in the lower limbs. 14 patients had joint pain, and 
2 patients had foot neuropathic ulcer pain. 
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Table 8.6. Characteristics of patients (n=36) with pain 
Variable Non-NP 
pain group 
(n=10) 
NP pain 
group 
(n=26) 
P- 
value 
Age (years) a 31.9 ± 11.8 37.3 ± 13.8 0.28 * 
Sex (female/male)  3/7 5/21 0.49 § 
Pain duration (weeks) b 4.5 (1; 10)  36 (4; 72)  <0.001† 
NRS at interview (NRS 0-10) b 5.5 (5; 8) 6.5 (5; 9) 0.87 *  
Maximum pain intensity during last 4 weeks b 9.5 (7; 10) 7.5 (6; 9) 0.10 † 
Average pain intensity during last 4 weeks b 5 (4; 6) 5 (4; 7) 0.17 * 
Current pain treatment c 8 (80.00%) 21 (80.77%) 0.96 § 
Number on antidepressant/anticonvulsants c  0 5 (19.23%) 0.13 § 
Number on analgesics (NSAIDs) c 4 (40.00%) 14 (53.84%) 0.71 § 
Number on analgesics (steroid) c 4 (40.00%)  6 (23.08%) 0.41 § 
Pain relief by medication c   7 (70.00%) 13 (50.00%) 0.28 § 
NRS pain relief (NRS 0-10) b 1 (0; 7) 1 (0; 5) 0.09 † 
a mean ± standard deviation; b median (25th percentile; 75th percentile); c number (%); 
*Continuous data if normally distributed were analysed with Student t test. Mean values 
and SDs shown; † Continuous data not normally distributed were analysed using Mann-
Whitney Rank Sum test. Median and quintile (25th percentile; 75th percentile) shown in 
brackets. § Categorical data were analysed using Chi squared test of association. Values 
and percentages shown. 
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Table 8.7. Pain localisation in 36 patients with leprosy 
Site Frequency (%) 
Skin lesions Active untreated skin lesions 5 (13.9%) 
Treated skin lesions 8 (22.2%) 
Peripheral 
nerves 
Hands and feet 9 (25.0%) 
Nerve pain 17 (47.2%) 
Area of sensory loss over nerve distribution 18 (50.0%) 
Others  Joint pain 14 (38.9%) 
Ulcer pain 2 (5.5%) 
 
Duration and severity of pain 
Patients with NP had longer pain duration than those with non-NP and less likely to 
have current pain due to reactions, Table 8.6. Pain had been present for one month or 
less in non-NP patients; whereas neuropathic patients reported pain for longer than 
nine months. The timing of the pain was reported as all the time by 27 (75.0%) patients, 
as less than two hours every day by 6 (16.7%) patients, as occasionally by 3 (8.3%) 
patients, and no patients reported as at least once a week (Figure 8.3).  
 
Figure 8.3. Pain frequency in 36 patients with leprosy 
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Patients with NP rated their present pain as more intense than those with non-NP 
(Table 8.6 and Figure 8.4). This finding was not significant and influenced by taking into 
account gender, or interview setting. Patients with NP were more likely to be taking 
analgesic treatments during the 24 hours prior to the interview than those with non-NP. 
A larger proportion of patients with NP subgroup were on pain medication compared 
to the subgroup with non-NP. Pain intensity at interview (interview NRS) was 
significantly correlated to pain intensity and frequency over the previous week 
(Spearman’s correlation, P value<0.001). Patients more likely to have non-NP had 
higher maximal pain scores during the preceding weeks. 
 
Figure 8.4. Pain grade in 36 patients with leprosy 
 
Reaction and pain groups 
Of the total sample, 26 patients had reactions at the time of interview; and 45 patients 
had never experienced reaction. Of these 26 patients, 9 (34.6%) had a T1Rs, 5 (19.2%) 
had ENL and 12 (46.1%) had neuritis (Table 8.8). 40 (56.3%) patients had a previous 
history of reaction either at diagnosis, during or after MDT treatment. Of these, neuritis 
was commonest (64.4%). 
Non-NP (nociceptive/inflammatory pain) was found in 10 (11.1%) patients of the total 
sample. Of these 10 patients, 7 (70.0%) had a current reaction, 2 (20%) had ulcer in 
their hands or feet, and the remaining 1 (10.0%) had neither reaction nor ulcer. 
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Table 8.8. Association of pain with reactions at the time of examination 
(n=26) 
Leprosy 
reaction 
No pain  
 
Pain Total 
Non-neuropathic  Neuropathic  
T1R n (%) 2 (22.2%) 5 (55.6%) 2 (22.2%) 9 (100%) 
ENL n (%) 1 (20.0%) 2 (40.0%) 2 (40.0%) 5 (100%) 
Neuritis n (%) 2 (16.7%) 2 (16.7%) 8 (66.7%) 12 (100%) 
Total  5 (19.2%) 8 (34.6%) 12 (46.2%) 26 (100%) 
 
Disability assessment 
Disability assessment results reflected high disability for patients with NP and mild 
disability for patients with non-NP, see clinical examination findings below. 
8.3.1.3 Pain description questionnaires 
Pain symptoms using DN4 and PD-Q 
The Hind/Mahrati version of the DN4 was administered to 36 patients with leprosy 
and pain presenting at the clinic. Of the 36 patients who had pain, the description of 
numbness occurred mainly in NP subgroup. Itching, aching and dull type pain was most 
frequently reported in the non-NP subgroup (44.4% – 61.1%). Burning; tingling; sharp; 
pins and needles sensation; and the descriptor electric-shock like were reported in more 
than two thirds of NP patients compared to less than one fifth of non-neuropathic. 
Spontaneous pain was reported in 28 patients during the clinical examination and on 
PD-Q with increased frequency and increased likelihood of neuropathic pain (non-
neuropathic, n=2; neuropathic pain, n=26). Figure 8.5 shows the frequency of reported 
pain descriptors from patients classified as having neuropathic pain, or non-neuropathic 
pain using the DN4 questionnaire. 
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Figure 8.5. Frequency of pain descriptors 
Frequency of pain symptoms (seven symptoms from DN4 questionnaires; 
others: constant and aching or dull are from patients history) reported by 36 
patients with pain, classified as non-neuropathic pain and neuropathic pain. 
 
DN4 questionnaire analysis 
Of the 32 patients with pain concordant with the distribution of sensory loss at the 
affected ulnar nerve in the upper limb, the DN4 identified 24 patients with symptoms 
and signs suggestive of NP (of the 32 patients with upper limb pain, 24 patients had a 
score of 4 or more indicating the presence of NP), (median score 6, interquartile range 
(IQR) 2.0; mean score 5.6, standard deviation (SD) ± 1.4) and 8 patients without NP 
(median score 2.5, interquartile range (IQR) 1.0; mean score 2.5, standard deviation 
(SD) ± 0.5). Figure 8.6 shows the DN4 scores in patients with pain. 
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Figure 8.6. DN4 scores in 32 leprosy patients with upper limb pain 
Frequency of the DN4 scores from 32 patients with upper limb pain, classified 
as non-neuropathic pain (8 patients) and neuropathic pain (24 patients). 
 
Pain symptoms data obtained from patients, who were classified as having non-NP and 
NP using the DN4 and clinical examination of upper limbs, were analysed. A non-
parametric analysis (Mann-Whitney two-sample statistic) between these two subgroups 
was performed. The result showed that questions 1 (burning sensations); question 5 
(pins and needles); question 6 (numbness); question 8 (hypoesthesia to touch); and 
question 9 (hypoesthesia to pin-prick) were associated symptoms between non-NP and 
NP subgroup (p-value ≤0.05; more present in NP patients). When the DN4 score was 
considered in total points, there was also a difference between the two pain subgroups 
(p-value ≤0.001). When the analysis was repeated using binary coding for the DN4 
questionnaire responses in the upper limbs instead of categorical coding, the findings 
were unchanged. Subsequent analyses were performed using binary codes for pain 
symptoms. Significantly, different symptoms were found for five pain symptoms 
between the two pain groups (Table 8.9). 
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Table 8.9. A comparison of symptoms detected by DN4 in pain groups 
(n=32) 
Q1-10: Clinical relevant complaint 
§ 
Frequency of patient’s descriptor present 
Non-NP (n=10) (%)  NP (n=22) (%) P- value 
Q1, burning sensation  3 (30.0%) 16 (72.7%) 0.02* 
Q2, painful cold 0 5 (22.7%) 0.10 
Q3, electric shocks 6 (60.0%) 17 (77.3%) 0.31 
Q4, tingling sensation 8 (80.0%) 20 (90.9%) 0.34 
Q5, pins and needles  2 (20.0%) 14 (63.6%) 0.02* 
Q6, numbness  1 (10.0%) 19 (86.4%) 0.001* 
Q7, itching  4 (40.0%) 5 (22.7%) 0.31 
Q8, hypoesthesia to touch 1 (10.0%) 17 (77.3%) 0.001* 
Q9, hypoesthesia to pin-prick 2 (20.0%) 15 (68.2%) 0.01* 
Q10, painful brush 3 (30%) 5 (22.7%) 0.66 
Ϯ  DN4 questions significant levels Cochran’s nonparametric analysis (McNemar chi-
squared test) for the upper limb pain (n=32). § Q1-10: Question 1 to 10 of DN4 
questionnaire. *P-value ≤0.05 
PD-Q questionnaire analysis  
Of the 32 patients with pain concordant with the distribution of sensory loss at the 
affected ulnar nerve in the upper limb (Figure 8.7), the PD-Q identified 13 patients with 
a likely neuropathic pain component (median score 6, IQR 2.0; mean score 5.6, SD ± 
1.4) and 19 patients with an unlikely NP component (median score 6, IQR 2.0; mean 
score 5.6, SD ± 1.4). The PD-Q’s final results classify patients into no NP, unclear and 
NP. In 28.1% of patients (9/32), results were unclear (median score 6, IQR 2.0; mean 
score 5.6, SD ± 1.4); however a NP component might be present. 
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Figure 8.7. PD-Q scores in 32 leprosy patients with upper limb pain 
Frequency of the PD-Q scores from 32 patients with upper limb pain, classified 
as non-neuropathic pain (8 patients) and neuropathic pain (24 patients). 
 
A non-parametric analysis (Mann-Whitney two-sample statistic) between reported pain 
descriptors from patients classified as having non-NP and NP in upper limb using the 
PD-Q questionnaire was performed. The result showed that responses to questions 1 
(burning sensations); question 2 (pins and needles); and question 6 (numbness) were 
significantly different between these two subgroups (p-value ≤0.05; more present in NP 
patients). When overall PD-Q questionnaire responses were considered in total points, 
there were also a difference between the two pain subgroups (p-value ≤0.001). When 
the analysis was repeated using binary coding for the PD-Q questionnaire responses in 
the upper limb instead of categorical coding, the findings were unchanged (Table 8.10). 
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Table 8.10. A comparison of symptoms detected by PD-Q in pain groups 
(n=32) 
Q1-7: Clinical relevant complaint § Frequency of patients descriptor present 
Non-NP (n=10) (%)  NP (n=22) (%) P- value 
Q1, burning sensation  3 (30.0%) 17 (77.3%) 0.02*  
Q2, prickling 7 (70.0%) 20 (90.9%) 0.01* 
Q3, allodynia 2 (20.0%) 4 (18.2%) 0.90  
Q4, electric shocks 6 (60.0%) 17 (77.3%) 0.31 
Q5, thermal 0 (00.0%) 5 (22.7%) 0.10 
Q6, numbness  1 (10.0%) 19 (86.4%) 0.001* 
Q7, pressure 6 (60.0%) 9 (40.9%) 0.31 
ϮA comparison of pain symptoms detected by PD-Q questionnaire for the two pain 
subgroups, using chi-squared test. § Q1-7: Question 1 to 7 of PD-Q questionnaire. *P-
value ≤0.05 
The responses to DN4 questionnaire had agreement with PD-Q responses when 
identifying neuropathic pain in 21 of the 32 patients with upper limb pain (NP: n = 13; 
Non-NP: n = 8), yielding a 65.6% agreement between questionnaire final results (Table 
8.11). In all discordant (11 patients), a neuropathic pain component was detected by 
DN4 questionnaire, but not with the PD-Q. 
By using the PD-Q final classification as having no neuropathic pain, unclear or 
neuropathic pain; the responses to DN4 questionnaire had agreement with PD-Q 
responses in 13 patients (Non-NP: n = 8, NP: n = 5), which yielded a 40.6% agreement.  
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Table 8.11. A comparison of NP detected by DN4 and PD-Q (n=32) Ϯ 
 DN4 Total 
NP No NP 
PD-Q 
NP 13 0 13 
No NP 11 8 19 
Total 24 8 32 
 
PD-Q 
NP 5 0 5 
Unclear  8 0 8 
No NP 11 8 19 
Total 24 8 32 
ϮA comparison of NP in 32 patients with hands pain detected by DN4 and PD-Q 
questionnaires. Two classifications for PD-Q were used: non-NP and NP; and non-NP, 
unclear and NP  
Patient’s responses to DN4 and PD-Q 
In the 36 patients with pain present at the time of interview, DN4 had been evaluated as 
very easy by 2 (6.5%) patients, easy 21 (67.7%), and fair 8 (25.8%). Similarly, PD-Q was 
evaluated as very easy by 3 (9.7%) patients, easy 16 (51.6%), and fair 12 (38.7%) (Figure 
8.8). No statistical difference between the two groups. 
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Figure 8.8. Patients’ responses for the DN4 and PD-Q questionnaires (n=36) 
 
8.4 Clinical examination findings 
Clinical examination included the following: assessment of skin; evaluation of 
enlargement and tenderness of main peripheral nerves affected by leprosy (greater 
auricular (GA), median, ulnar, radial cutaneous, ulnar branch, lateral popliteal, posterior 
tibial, and sural nerves); nerve function assessment; and disability assessment.  
8.4.1 Skin assessment  
Seventy patients (77.78%) had skin lesions at the time of interview, Table 8.12. Of these 
70 patients, 38 (54.29%) had old skin lesions: fully treated in 32 patients, and partially 
treated in 6. 
Table 8.12. Distribution of skin lesions in leprosy patients (n=90) 
Skin lesion Number (%) 
No skin lesion 20 (22.22%) 
Single skin lesion (SSL) 12 (13.33%) 
2-5 skin lesions 28 (31.11%) 
6-10 skin lesions 16 (17.78% 
More than 10 14 (15.56%) 
V e r y  e a sy E a sy F a ir D if f ic u lt
0
5
1 0
1 5
2 0
2 5
F
r
e
q
u
e
n
c
y
D N 4
P D -Q
Chapter 8: Results 
 
200 
 
8.4.2 Evaluation of enlargement and tenderness of main peripheral nerves 
For the 90 studied patients, 1620 peripheral nerves were assessed for enlargement and 
tenderness in both right and left body side. Nerve enlargement was common (90% of 
the patients had one or more enlarged nerves), and 21% had tenderness of nerves on 
palpation. The ulnar nerves were found to be both the most frequently enlarged and 
tender nerves, followed by the posterior tibial, lateral popliteal, and superficial peroneal 
nerves. The prevalence of palpable nerve enlargement and tenderness on palpation in 
each nerve is shown in Table 8.13. 
8.4.3 Nerve functions assessment   
Nerve function assessments: sensory and muscle strength examination were completed 
for the 90 patients. Nerve function impairment of less than 6 months duration (new 
NFI) was reported for 10 patients (11.11%). A further 36% of patients reported that 
their impairment had been present for longer than 6 months (old NFI). In both old and 
new NFI, sensory loss was more frequent than motor loss or mixed loss. Sensory 
impairment was found in 62 (78%) patients, and motor impairment in 47 patients 
(59%); the ulnar nerve was the most commonly affected nerve.  
The frequency of abnormal tendon reflexes or absent joint position sense in each nerve 
in this cohort was very few. The percentage of absent reflexes in each nerve as follow: 
right biceps (1.11%), right triceps (1.11%), left supinator (1.11%), right knee jerk 
(1.11%), and left ankle (2.22%). Two patients (2.22%) had absent JPS in their right 
index finger, and other two (2.22%) in their right big toe. Impaired JPS or reflexes were 
not associated with the presence of neuropathic pain or depression. 4 – 6  
The frequency of ulnar neuropathy (sensory and motor impairment) detected by the 
different tests is shown in Table 8.14. Of 29 patients with no clinical evidence of 
neuropathy, 15 patients had subclinical neuropathy. Of these 15 patients, 14 patients 
(93.33%) had impairment of two or more QST parameters and classified as having 
subclinical neuropathy (Figure 8.13 – A and B, page – 214). Pooling results for right and 
left dermatomes C8 of the ulnar nerves, where a response was recorded, the QST 
parameters were abnormal in 112/176 (63.63%) of participants (Figure 8.10 – A and B, 
page – 208). The most frequently affected were CDTs and WDTs (thermal QST 
parameters). CDTs were affected as least twice as often as WDTs in the ulnar nerves in 
the subclinical group. This difference was less pronounced on the neuropathy and pain 
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groups. A discrepancy was found between the frequencies of ulnar nerve impairment 
detected by MF and QST thermal tests. This was particularly pronounced in the 
subclinical neuropathy group. For neuropathy and pain groups, WDTs and CDTs were 
significantly more often abnormal than MF and VMT (e.g. 31% versus 89% for the 
neuropathy and pain group, p-value<0.001). Interestingly, vibration sense in leprosy 
ulnar neuropathy were less frequently affected (15%) than other modalities. Overall, on 
the ulnar nerve tests, the sensation conducted by small fibres were the most frequently 
impaired. This confirms that small fibre neuropathy usually precedes large fibre damage. 
Table 8.15 shows the concordance between ulnar neuropathy diagnosed with 
monofilament testing and results of quantitative sensory testing (thermal, vibration and 
combined QST parameters (two or more abnormal parameters)) in 88 patients. 
Combining results for right and left ulnar nerves, monofilaments and QST testing are 
both detected abnormality in 94 of the 176 nerves (ulnar nerve impaired: n= 30; no 
ulnar nerve impairment: n= 64); yielding 83.9% agreement. Concordance between 
monofilament results and QST parameters was best for CDTs and WDT. Unlike 
thermal tests, the VDT results were not concordant with the monofilament results. The 
highest positive concordance was seen between monofilament results and combined 
QST. Combining impairment of any of the QST parameters in one variable improved 
agreement with the monofilament test, over that of individual QST parameters, but 
negative concordance was substantially higher. Up to 50% of nerves with a normal MF 
result had one or more abnormalities in quantitative sensory testing. Similar results were 
observed for the motor assessments. 
8.4.4 Disability assessment 
Disability was assessed using the WHO disability criteria, which define grade 0 as no 
loss of sensation or visible deformity, grade 1 as loss of sensation without visible 
deformity, and grade 2 as presence of visible deformity. 55.56% of participants had 
physical impairment (28.9% grade 1 and 26.7% grade 2). Impairment was associated 
with the hand (46%), followed by 37% associated with the feet and 1% associated with 
eyes (grade 2). 
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Table 8.13. Prevalence of palpable nerve enlargement and tenderness (n=90) 
 Greater A Ulnar  Median  Radial Uln. branch LPN Superficial Post Tibial Sural  
Rt. Lt. Rt. Lt. Rt. Lt. Rt. Lt. Rt. Lt. Rt. Lt. Rt. Lt. Rt. Lt. Rt. Lt. 
Enlarged 9% 12% 64% 73% 26% 22% 40% 37% 11% 10% 37% 56% 44% 51% 56% 48% 24% 24% 
Tender* 0 0 17% 12% 4% 5% 8% 6% 0 0 6% 8% 15% 17% 14% 19% 23% 18% 
*As the tender nerves were always enlarged, the denominator is the enlarged nerves  
Table 8.14. Number and percentage of impaired ulnar nerves (n=90) 
Test  No neuropathy Subclinical neuropathy Neuropathy Neuropathy and pain 
Ulnar nerve Ulnar nerve (n=15) Ulnar nerve (n=24) Ulnar nerve (n=21)* 
Right  Left Right  Left Right  Left Right  Left 
MF 0 0 0 0 10 (41.67%) 6 (25.00%) 6 (31.58%) 6 (31.58%) 
VMT 0 0 0 0 14 (58.33%) 13 (54.17%) 13 (68.42%) 11 (57.89%) 
WDT 0 0 5 (33.33%) 5 (33.33%) 17 (70.83%) 18 (75.00%)  17 (89.47%) 15 (78.95%) 
CDT 0 0 10 (66.67%) 7 (46.67%) 15 (62.50%) 15 (62.50%)  15 (78.95%) 14 (73.68%) 
VDT 0 0 0 0 3 (12.5%) 1 (4.17%) 3 (15.79%) 3 (15.79%) 
*of the 24 patient’s classified as neuropathy and pain over ulnar nerve territory, 3 patients had neuropathy and pain over skin lesion.   
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Table 8.15. Comparability of impairment by MF test and QST (n=88) 
Test* Right Ulnar nerve (n = 88) Left Ulnar nerve (n = 88) 
MF impaired   (n=18)   MF not impaired (n=70) MF impaired   (n=12) MF not impaired (n=76) 
WDT impaired 94% (17)** 50% (35) 83% (10)  43% (33)  
CDT impaired 89% (16) 40% (28) 92% (11)  41% (31)  
Thermal impaired combined 100% (18) 63% (44) 92% (11)  68% (52) 
VDT impaired 11% (2) 6% (4) 17% (2) 3% (2)  
≥2 impaired QST parameters  100% (18)  56% (39)  100% (12)   57% (43) 
*MF = monofilament test, WDT = warm detection threshold, CDT = cold detection threshold, VDT = vibration perception threshold                
**Column % (number of nerves) 
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8.5 Quantitative Sensory Testing (QST) findings in leprosy patients 
DFNS-QST database was used to transform QST raw scores into z-scores, and healthy 
controls data was used for statistical comparisons. The healthy controls, consisting of 52 
age-matched participants, were recruited from the local community. The normative data 
from local population showed similar distribution to those held in DFNS database. 
The results of the QST data analysis are presented as follows: the first part is the 
descriptive results, and comparison of the QST findings between all leprosy patients and 
healthy controls. The second part contains the somatosensory profiling, and the number 
of abnormal QST parameters in leprosy patients with no pain; followed by results for 
patients with pain. The last part describes the QST findings and comparisons of the 
leprosy patients with neuropathic pain. 
8.5.1 QST observations in healthy control participants 
From the 52 healthy volunteers investigated in this study, 102 locations in the upper 
limb (dermatome C8) and 8 locations in the lower limb (dermatome S1) were assessed. 
The measurements were analysed by z-score profiling (Chapter 6), and data was used for 
statistical comparisons. 
8.5.2 QST observations in patients 
For the 90 study patients, 27 990 QST data measurements were obtained from the 
affected and contralateral side and analysed by z-score sensory profiling.   
8.5.3 Distribution of QST measures 
Figure 8.9 illustrates distributions of QST data from the 52 healthy control subjects and 
88 leprosy patients tested in the ulnar nerve territory (dermatome C8). DFNS-QST 
database was used to transform QST raw scores into z-scores, which adjusts for test 
site, gender and age. The horizontal axis (x-axis) demonstrates the QST parameters after 
z-transformation, and the vertical axis (y-axis) indicates the percentage of cases (patients 
or healthy controls). As paradoxical heat sensations and dynamic dynamic mechanical 
allodynia normally do not occur in healthy participants, z-transformation could not be 
calculated. Thus, data are shown as percentage of participants showing PHS and DMA. 
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For healthy control subjects, QST measures fell within the normal range of the DFNS-
QST references (Chapter 7). QST measures for leprosy patients demonstrated similar 
distribution shapes compared to healthy control subjects, but with larger standard 
deviations indicating diverse sensory findings. For thermal and mechanical detection 
thresholds (non-nociceptive parameters: CDT, WDT, TSL, MDT, VDT), there were 
significant leftward shifts, suggesting the presence of hypoesthesia. For pain thresholds 
(nociceptive parameters: CPT, HPT, PPT, MPT, MPS, WUR), there were slight leftward 
shifts, suggesting the presence of hypoalgesia. The high prevalence of hypoethesia and 
hypoalgesia led to difficulties in performing WUR, which was the most frequently 
missing QST parameter in the cohort (21%). Overall, abnormal findings for loss of 
function (30.5%) across all QST parameters in patients with leprosy were more 
frequently observed than gain of function phenomenon (1.7%).  
For thermal detection threshold (CDT, WDT, TSL), only sensory loss signs (thermal 
hypoethesia) were detectable in the affected area. For pain thresholds, negative sensory 
signs (thermal hypoalgesia) also dominated in 7.9% of the patients for CPT and in 
31.8% for HPT. Sensory gain signs (thermal hyperalgesia) were absent in affected area 
for both CPT and HPT. Patient’s measures of MDT demonstrated a broader 
distribution and showed a leftward shift compared to the healthy controls (Figure 8.9 - 
J). Thus indicating that the negative sensory sings (mechanical hypoesthesia) were 
frequent in the affected area. VDT, WUR and PPT patient’s data exhibited similar 
distribution to the control’s data. 
For dynamic mechanical allodynia (DMA) and paroxysmal heat sensation (PHS), which 
are pathological phenomena and normally do not occur in healthy subjects, the 
occurrence in leprosy patients was rare (range between 2.3% for DMA and 13.6% for 
PHS). DMA was present in 2.3% of patients, but mostly of very mild intensity. 
PHS in the affected area was reported in twelve patients, but it is not clear whether this 
phenomenon is part of sensory gain. In these twelve patients, PHS was reported once in 
three patients, twice in one patient, and three times in eight patients. 
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A) CDT B) WDT C) TSL D) CPT 
    
E) HPT F) PPT G) MPT H) MPS 
    
I) WUR J) MDT K) VDT L) DMA and PHS 
    
Figure 8.9. Distribution of the QST parameters after z-transformation 
Distribution of the QST data using DFNS reference data. Affected ulnar nerve territory of all leprosy patients (n=88) (red circles/ solid 
line) in comparison with the controls (n=50) (green square/solid line). The y-axis indicates the percentage of cases (patients or controls). 
For PHS and DMA % are plotted versus original data: occurrences of PHS (0–3), log numerical ratings scale for DMA (0–100) 
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8.5.3.1 Frequencies of abnormal QST values 
Of the 90 patients with leprosy, 86 patients had completed a full DFNS QST measures 
in the upper limbs, 4 patients in the lower limbs and 2 patients in both upper and lower 
limbs. The frequencies of abnormal QST values for each parameter was identified by 
absolute (outside 95% CI of DFNS reference data) and relative (side-to-side differences) 
sensory abnormalities (Figure 8.10). In these 88 patients tested in the ulnar nerve 
territories (dermatome C8), the abnormal sensory loss was highly prevalent, and 
significant rates were found primarily for non-nociceptive thresholds in approximately 
two third of the patients (60%) for thermal detection; and in about half of the patients 
for mechanical detection thresholds (46%), but rarely for vibration thresholds (8%). 
Almost no one had sensory gains for the non-nociceptive parameters. 
For nociceptive parameters (pain), sensory loss (hypoalgesia) was frequent (range 7.9% - 
42%), but sensory gain was rare (18%). Of these detected abnormalities, about one third 
of the patients with relative sensory loss were identified by side-to-side comparison (for 
different parameters between 2.3% – 15.9% additional patients), but again almost none 
with relative sensory gain for the nociceptive parameters. Remarkably, cold pain 
hypoalgesia was only detectable by side-to side comparison. Hypoalgesia was most 
frequently detected for pinprick, followed by heat, blunt pressure, and cold. Paroxysmal 
heat sensation was about as frequent as Wind up ratio. Dynamic mechanical allodynia 
was rare.  
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Figure 8.10. Frequencies of abnormal QST measures 
Frequencies of abnormal QST measures (values outside the 95% CI of the 
reference data base) in the affected ulnar nerve site. Shaded areas of the bars 
illustrate percentage of abnormal findings according to absolute reference data, 
open areas of bars according to abnormal side-to-side difference. The y-axis 
shows percentage of patients (n = 88), with positive sensory signs plotted 
upwards and negative sensory signs plotted downwards. (A) QST parameters 
that display loss or gain of function (B) Parameters, which are absent in normal 
subjects and can only present as sensory gain as defined by DFNS. 
8.5.3.2  Differences between patients with leprosy and healthy controls 
There were significant differences between the patients with leprosy and healthy 
controls in all QST thermal measures (mean and standard deviation of the DFNS z-
score); CDT, WDT, TSL, CPT and HPT (p-value <0.0001). Patients had increased cold 
and warm thresholds; and were less sensitive to heat, and cold pain stimuli. For QST 
mechanical measures, there were significant differences in MDT, MPT, and MPS (p-
value <0.0001). No significant differences in VDT, WUR, or PPT were found between 
the two groups (p-value >0.5, p-value >0.6, and p-value >0.5, respectively) (Table 8.16, 
Figure 8.11 and Figure 8.12).  
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Table 8.16. A comparison of QST measures between patients and controls 
QST 
Parameter 
Controls (n=50) Leprosy patients (n=88) 
P value 
Mean SD Mean SD 
CDT (°C) -0.12 1.8 -2.94 0.89 <0.0001 
WDT (°C) -0.43 0.74 -2.84 1.52 <0.0001 
TSL (°C) -0.75 0.57 -2.82 1.39 <0.0001 
CPT (°C) 1.24 0.48 0.30 0.65 <0.0001 
HPT (°C) 0.55 0.53 -0.87 1.03 <0.0001 
MDT 1.08 0.66 -1.69 2.86 <0.0001 
MPT 0.27 0.38 -0.72 1.06 <0.0001 
MPS 0.17 0.55 -0.43 1.21 <0.0001 
WUR 0.62 1.02 0.59 1.44 0.45 
VDT 0.48 0.28 0.17 0.98 0.49 
PPT -1.07 0.68 -1.05 0.90 0.62 
Ϯ  Means and standard deviation (SD) of QST parameters of leprosy patients tested on 
the ulnar area (C8) compared to controls tested on the same site (n=50). QST data are 
shown as mean for untransformed data (HPT, VDT) and transformed mean for log-
normally distributed data. 
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Figure 8.11. Thermal QST measures for patients (n=88) and controls (n=50) 
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Figure 8.12. Mechanical QST measures for patients (n=88) and controls (n=50) 
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8.5.4 Somatosensory profiles of leprosy patients 
8.5.4.1 Sensory profile and number of abnormal findings 
Z-score sensory profiles of all leprosy patients compared to control 
The QST sensory profiles for ulnar nerve territory (maximum pain area on dermatome 
C8) and by group (HC, patients with no pain, and patients with pain) shown as z-scores 
are presented in Figure 8.13 and Table 8.17. For the current study, the QST parameters 
are grouped into thermal and mechanical parameters; and to allow for easy visual 
comparison, the z-scores sensory profile are also shown for all patients by each group 
independently.  
8.5.4.2 Distribution of QST measures in patients without pain 
The z-score DFNS-QST sensory profiles for all thermal and mechanical parameters in 
patients with leprosy and no pain in the ulnar nerve territories (dermatome C8) are 
illustrated in Figure 8.13 and Table 8.17. For patients with no clinical evidence of 
neuropathy (Group 1), the mean values of all QST parameters were within the 95% 
confidence interval of the DFNS and local Indian healthy controls references (Figure 
8.13 - A). Patients with no clinical evidence of neuropathy based on MFs and/ or MRC 
scale, but who showed abnormal nerve conduction study (NCS) or thermal testing were 
classified as “Subclinical neuropathy”.  
Of the 29 patients with no clinical evidence of neuropathy, 14 patients were identified as 
having subclinical neuropathy using the thermal testing compared to 15 patients using 
NCS (data for NCS were not presented), indicating that QST measures can differentiate 
neuropathy from no neuropathy (Figure 8.13 - A and B). 
Patients with subclinical neuropathy (Group 2) and clinical evidence of neuropathy 
(Group 3) had z-scores beyond the 95% confidence interval of the DFNS and local 
Indian healthy controls references. Their sensory profiles were characterised 
predominately by a loss of function, indicated by increased thermal and mechanical 
thresholds (Table 8.17). In these two groups, a thermal loss of function was 
demonstrated for non-nociceptive CDT, WDT, TSL; and nociceptive parameters CPT, 
and HPT in the ulnar side compared to healthy controls (Figure 8.13 - B and C). For 
mechanical QST parameters, a loss of function was demonstrated for the non-
nociceptive parameter MDT; and for the nociceptive parameters MPT, and MPS. 
Chapter 8: Results 
 
213 
 
Although MPT, MPS, VDT, WUR, and PPT in the subclinical group; and VDT, WUR, 
and PPT in the neuropathy group, were abnormal in the affected side (Table 8.17) they 
did not reach statistical significance compared to healthy controls data (p-values >0.05). 
In both groups, there was no evidence of sensory gain.  
The thermal and mechanical frequencies of z-score values outside the 95% confidence 
interval of the DFNS and HC group which indicating a loss of function (<- 1.96), for 
patients with subclinical neuropathy, were as follows: CDT (53.3%), WDT (40.0%), TSL 
(56.6%), CPT (6.7%), HPT (13.3%), MDT (26.7%), MPT (10.0%), MPS (30.0%), and 
PPT (30.0%) (Table 8.22). For the clinical evidence of neuropathy group, the 
frequencies of the abnormal values were as follows:  CDT (53.3%), WDT (40.0%), TSL 
(56.6%), CPT (6.7%), HPT (13.3%), MDT (26.7%), MPT (10.0%), MPS (30.0%), and 
PPT (30.0%) (Table 8.22). WUR was not consistently present in any of the affected 
and/ or contralateral ulnar side. No patients had DMA in any of the affected and/ or 
contralateral ulnar side. PHS in the affected area was frequently reported in nine 
patients. In these nine patients, PHS was reported once in five patients, twice in two 
patients and three times in two patients (Table 8.22). 
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Figure 8.13. Leprosy sensory profiling 
The z-score sensory profiles are shown of (A) patients with no clinical evidence 
of neuropathy (n=15), (B) patients with sub-clinical neuropathy (n=14), (C) 
patients with clinical evidence of neuropathy (n=25), and (D) patients with pain 
(n=32) 
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Table 8.17. Descriptive statistics for QST parameters Ϯ 
QST Parameter Ϯ   Groups 
Healthy 
control 
(n=50) 
Patient (n=88) 
Group 1 Group 2 Group 3 Group 4 
T
h
e
rm
a
l 
Q
S
T
 p
a
ra
m
et
e
rs
 
CDT (°C) -0.12 (0.89) -0.54 (0.88) -2.13 (1.01)* -3.13 (2.06)* -3.24 (1.99)* 
WDT (°C) -0.43 (0.74) -0.51 (0.75) -1.80 (1.20)* -3.07 (1.59)* -3.23 (1.41)* 
TSL (°C) -0.75 (0.58) -0.77 (0.67) -2.08 (0.77)* -2.78 (1.55)* -3.27 (1.34)* 
CPT (°C) 1.24 (0.48) 0.81 (0.77) 0.58 (0.56)* 0.13 (0.69)* 0.30 (0.62)* 
HPT (°C) 0.55 (0.53) 0.13 (0.84) -0.33 (1.11)* -0.99 (0.97)* -1.08 (0.93)* 
M
e
c
h
a
n
ic
a
l 
Q
S
T
 p
a
ra
m
e
te
rs
 
MDT(mN) 1.08 (0.66) 0.80 (0.85) 0.10 (1.73)* -2.44 (3.34)* -2.83 (3.10)* 
MPT (mN) 0.27 (0.38) 0.41 (0.60) -0.11  (0.80) -1.00 (1.07)* -0.80 (1.05)* 
MPS (0-100) 0.17 (0.56) 0.34 (0.68) 0.33    (1.12) -0.68 (1.16)* -0.63 (1.14)* 
VDT (x/8) 0.48 (0.28) 0.34 (0.59) 0.41    (0.47) 0.20    (0.89) -0.24 (2.04)* 
WUR (ratio) 0.62 (1.02) 0.73 (1.07) 0.78    (1.29) 0.84    (1.75) 0.25    (1.19) 
PPT (kPa) -1.07 (0.68) -1.19 (0.68) -1.31  (0.78) -1.25  (0.90) -0.71   (0.90) 
Ϯ  Means and standard deviation (SD) of QST parameters of healthy controls (HC), and 
leprosy groups (Group 1, 2, 3, and 4) in the maximum pain area (C8). QST data are 
shown as mean for untransformed data (HPT, VDT) and transformed mean for log-
normally distributed data. *p-value <0.05. 
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Figure 8.14. Thermal QST measures for leprosy patients with no pain (n=54) 
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Figure 8.15. Mechanical QST measures for leprosy patients with no pain (n=54) 
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8.5.4.3 Distribution of QST measures in patients with pain 
The z-score DFNS-QST sensory profiles for thermal and mechanical parameters in 
patients with leprosy and pain (Group 4) are illustrated in Figure 8.13 - D (above), 
Figure 8.16 and Figure 8.22 (below); and Table 8.18. Patients with leprosy and pain were 
further sub-grouped according to the DN4 score and neuropathy which was classified 
clinically by using MFs and/ or MRC scale (but no NCS), as follows: no neuropathy and 
DN4 <4 (2 patients); no neuropathy and DN4 ≥4 (2 patients); neuropathy and DN4 <4 
(6 patients); and neuropathy and DN4 ≥4 (22 patients) (Table 8.18). In all these sub-
groups patients had z-scores beyond the 95% confidence interval of the normal 
reference values for CDT, WDT, and TSL. The dominant sensory characteristics was a 
loss of function in the C8 area of the ulnar nerve territory. For mechanical QST 
parameters, a loss of function was demonstrated for the MDT and WUR in the no 
neuropathy subgroup (p-value <0.05) (Table 8.18); MDT, and MPS in patients with 
neuropathy and DN4<4; and MDT, and MPT in patients with neuropathy and DN4 
≥4.  
In addition, few leprosy patients with any type of pain demonstrated signs of a gain of 
sensory function indicated by the presence of WUR and DMA. The former was present 
in eight (12.5%) patients. Two (3.1%) patient demonstrated DMA in the QST tested site 
(dermatome C8), but it was present nine (41.1%) patients along the ulnar nerve territory. 
PHS in the affected area was frequently reported in eleven (17.2%) patients. In these 
four patients, PHS was reported once in three patients, and three times in eight patients 
(Table 8.22).   
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Figure 8.16. Sensory profiling for pain patients (n=32) Ϯ 
The z-score sensory profiles of the ulnar tested sites are shown of patients with 
no clinical evidence of neuropathy and DN4 <4 (Green), or DN4 ≥4 (Blue); 
clinical evidence of neuropathy and DN4 <4 (Pink), or DN4 ≥4 (Red); and 
controls (Black) 
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Table 8.18. QST parameters for leprosy patients with pain Ϯ 
QST 
parameter 
Healthy 
controls 
(n=50) 
Patients with pain in upper limbs (n=32) 
No neuropathy Neuropathy 
DN4<4 
(n=2) 
DN4≥ (n=2) DN4<4 
(n=6) 
DN4≥ 
(n=22) 
CDT (°C) -0.12 (0.89) -2.26 (1.38)* -2.22 (2.59)* -2.84 (2.11)* -3.13 (2.08)* 
WDT (°C) -0.43 (0.74) -2.97 (1.29)* -2.62 (1.57)* -2.31 (1.97)* -3.15 (1.39)* 
TSL (°C) -0.75 (0.58) -2.61 (0.80)* -2.29 (1.50)* -2.36 (2.05)* -3.24 (1.27)* 
CPT (°C) 1.24 (0.48) 0.43 (0.70) 0.94 (0.66) 0.28 (0.71)* 0.35 (0.64)* 
HPT (°C) 0.55 (0.53) -1.27 (0.87)* -0.73 (1.10) -0.69 (1.12)* -0.92 (1.03)* 
MDT(mN) 1.08 (0.66) -0.80 (1.06)* -1.34 (0.04) -2.38 (3.47)* -3.13 (2.08)* 
MPS 0.17 (0.56) -0.13 (0.78) -0.26 (0.79) -0.82 (0.57)* -0.57 (1.27)* 
MPT (mN) 0.27 (0.38) -0.18 (0.47) 0.33 (0.22) -0.45 (0.72) -2.94 (3.17)* 
VDT (x/8) 0.48 (0.28) 0.33 (0.57) 0.64 (0.00) -0.41 (1.64) -0.28 (2.18) 
WUR  0.62 (1.02) -1.22 (0.10)* 0.27 (1.28) 1.00 (1.05) 0.27 (1.15) 
PPT (kPa) -1.07 (0.68) -0.65 (0.11) -0.98 (0.15) -0.51 (0.74) -0.76 (0.97) 
Ϯ  Means and standard deviation (SD) of QST parameters of leprosy patients with pain 
in the ulnar area (C8). QST data are shown as mean for untransformed data (HPT, 
VDT) and transformed mean for log-normally distributed data. *p value <0.05 
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8.5.4.4 Distribution of QST measures in patients with and without pain 
Z-scores of sensory profiles of the patients with pain and without pain in the upper 
limbs are illustrated for each group (Table 8.19 and Figure 8.17). Healthy control 
participants are represented by a z-score of “zero”. In both subgroups all QST 
parameters fell outside the 95% confidence interval of our healthy controls data (i.e. z-
score >-1.96 or <1.96 standard deviation). QST measures cannot be used to 
differentiate leprosy patients with and without pain. 
In patients with or without pain, thermal and mechanical detection thresholds; pain 
thresholds were significantly reduced on the affected side compared to the healthy 
control subjects (CDT: p <0.0001, WDT: p <0.0001, TSL: p <0.0001, CPT: p <0.001, 
HPT: p <0.001, and MDT: p <0.0001) (Figure 8.17). Other QST parameters (VDT, 
WUR and PPT) were not statistically significant compared to healthy control subjects in 
affected side. Although patients with and without pain both had QST parameters 
beyond 95% confidence interval of the references, these measures cannot be used to 
differentiate leprosy patients with and without pain (Table 8.19). In this study, QST 
results revealed that the number of sensory abnormalities did not differ between 
patients with and without pain.  
 
 
 
 
 
 
 
 
 
Chapter 8: Results 
 
222 
 
 
 
 
  
Table 8.19. QST parameters in leprosy patients with and without pain Ϯ 
QST 
parameter 
Patients without Pain (n=54) Patients with pain (n=32) P-value 
Mean  SD Mean  SD 
CDT (°C) -3.74 2.13 -3.29 2.10 0.35 
WDT (°C) -3.62 1.36 -3.31 1.44 0.59 
TSL(°C) -3.10 1.66 -3.23 1.44 0.91 
CPT (°C) -0.10 0.49 0.34 0.66 0.35 
HPT (°C) -1.22 0.94 -1.02 1.06 0.81 
MDT(mN) -3.27 3.21 -2.76 3.36 0.37 
MPT (mN) -1.43 1.06 -0.92 1.13 0.34 
MPS (0-100) -1.08 1.16 -0.81 1.01 0.74 
VDT (x/8) 0.08 1.03 -0.19 1.38 0.74 
WUR (ratio) 1.10 1.72 0.17 1.26 0.08 
PPT (kPa) -1.34 0.10 -0.74 0.95 0.27 
Ϯ  Means and standard deviation (SD) of QST parameters are shown of leprosy patients 
with and without pain in the ulnar area (C8). QST data are shown as mean for 
untransformed data (HPT, VDT) and transformed mean for log-normally distributed 
data 
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Figure 8.17. QST findings for leprosy patients (n=88)and controls (n=50) 
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8.5.4.5 QST findings in leprosy patients with neuropathic pain 
Sensory phenotypes 
Patients with leprosy NP demonstrated z-scores beyond the 95% confidence interval of 
the normal reference values in almost all QST parameters, except for VDT, PPT and 
WUR, in the maximum pain area over the ulnar nerve territory (dermatome C8) (Figure 
8.18). Data analysis on the individual level for frequencies of abnormal values gave a 
similar findings (Figure 8.19 and Table 8.20). Two thirds of these findings were 
identified by direct comparison to reference data, which is defined as an absolute 
abnormality; and about one third by side-to-side difference i.e. relative abnormality (if a 
patient’s values were abnormal in both tests, only abnormality with respect to absolute 
reference data was counted). Figure 8.19 shows the percentage of abnormal values in 
the leprosy patients presented with NP.  
Of the twenty four patients with NP components in the ulnar nerve territory, three 
patients had NP in their skin lesions which were not tested as part of the QST protocol. 
In the remaining 21 patients, 84-94% had abnormal sensory loss and significant rates 
were found primarily for non-noxious detection for thermal detection transmitted by 
small nerve fibres (CDT (84.2%), WDT (89.5%), TSL (94.7%): p-value <0.0001); and in 
about one quarter of the patients for mechanical detection conducted by large nerve 
fibres (MDT (73.7%): p-value <0.0001). Remarkably, sensory loss was also frequent for 
pain parameters, in particular for pinprick (MPT (85.7%), MPS (78.9%): p-value 
<0.0001); and heat pain (HPT (52.6%): p-value <0.0001) (Table 8.18). Although 
patients had abnormal PPT, WUR and VDT in the affected side (VDT (26.3%), PPT 
(15.8%), and WUR (15.8%)) (Table 8.19 and Figure 8.17 - B), they were not significantly 
different from healthy controls data (PPT, WUR and VDT: p-values >0.05). 
The sensory gain in patients with leprosy NP was not consistently present in the tested 
site (dermatome C8). The most prevalent findings of sensory gain was the presence of 
WUR in three (15.8%) patients, and in nine (47.4%) patients the thresholds was not 
detected as the patients did not feel the stimulus. Only one (5.3%) patient had pain to 
light touch (DMA) demonstrated in the QST tested site (dermatome C8). In addition, 
DMA was present in six (31.6%) patients along the ulnar nerve distribution, but not at 
the QST tested site. No abnormal hypersensitivity were found in all other pain 
Chapter 8: Results 
 
225 
 
parameters. PHS in the affected area was frequently reported three times in 3 (15.8%) 
patients, but it is not clear whether this phenomenon is part of sensory gain. 
 
 
Figure 8.18. Leprosy neuropathic pain sensory profiling 
QST profiles QST profile of 24 patients with clinical evidence of neuropathy 
and DN4≥4 in ulnar nerve territory (dermatome C8) (red symbols), using a QST 
test protocol according to the German Research Network on Neuropathic Pain 
(DFNS). Data are presented as z-scores, using the following expression: Z-value 
= (Value patients – Mean control) / SD control. Data of healthy control 
patients are represented by a z-score of “0”; patients’ data are presented as 
positive or negative z-values. The grey area represents the confidence interval of 
healthy control patients. Values are defined as pathological when deviating more 
than two SD from the respective control sample (age- and sex-matched). This 
profile shows signs of sensory loss detected by increased thermal detection 
thresholds (CDT, WDT) and increased mechanical detection thresholds (MDT). 
No signs of sensory gain are found by pinprick hyperalgesia (MPT, MPS). QST 
quantitative sensory testing; SD standard deviation; CDT cold detection 
threshold; WDT warm detection threshold; TSL thermal sensory limen; CPT 
cold pain threshold; HPT heat pain threshold; PPT pressure pain threshold; 
MPT mechanical pain threshold; MPS mechanical pain sensitivity; WUR wind-
up ratio; MDT mechanical detection threshold; VDT vibration detection 
threshold; NRS numerical rating scale; DMA dynamic mechanical allodynia; 
PHS paradoxical heat sensation. 
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The abnormal values from the QST testing were categorised with respect to loss (L) and 
gain (G) of sensation from reference data taking age and sex into account (Magerl et al., 
2010). Loss of sensation was further categorised to L0: no loss, L1: thermal 
hypoaesthesia, L2: mechanical hypoaesthesia, L3: thermal and mechanical hypoaesthesia; 
and gain of sensations was G0: no hyperalgesia, G1: thermal hyperalgesia, G2: 
mechanical hyperalgesia, G3 thermal and mechanical hyperalgesia (Table 8.20 and Table 
8.22). This defines the abnormal sensitization of unmyelinated cutaneous nociceptors 
(irritable nociceptors) phenotype as L0G1, L0G2, L0G3, L2G1, L2G2, and L2G3; and 
the abnormal sensation of complete deafferentation of both large and small diameter 
fibres “non-irritable nociceptor” phenotype as any combination including L1 or L3, and 
L0G0 and L2G (Fields et al., 1998). The sensory phenotypes of patients with leprosy 
neuropathic pain was characterised predominately by a loss of function, indicated by 
increased thermal and mechanical threshold in the affected areas. The most prevalent 
combinations characterising most of the patients were sensory loss for both thermal and 
mechanical stimuli, combined with no sensory gain (Table 8.20). Only 4/21 patients had 
some form of abnormal mechanical pain (19%). Thus mechanical hyperalgesia was very 
rare and no thermal hyperalgesia. Mechanical hyperalgesia, if present, was usually 
accompanied by thermal and mechanical sensory loss.  
Based on the QST findings patients were grouped as follows: patients with pain without 
hyperalgesia or allpdynia “non-irritable nociceptor phenotype”. In this group, which 
including most of the patients, profound loss of small and large diameter fibre functions 
was documented. The second group had pain associated with small fibre deafferenation. 
In these patients, which represent the minority of the study cohort, pain and 
temperature sensation were profoundly impaired but allodynia was present “irritable 
nociceptor phenotype”. 
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Figure 8.19. Percentages of abnormal QST values in NP patients 
Percentages of abnormal QST values in 21 patients with NP in C8. Shaded areas 
of the bars illustrate percentage of abnormal findings according to absolute 
reference, open areas of bars according to abnormal side-to-side difference. (A) 
Parameters that display loss or gain of function (B) Parameters, which are absent 
in normal subjects and can only present as sensory gain as defined by DFNS. 
 
Table 8.20. Frequency of abnormal values in NP (n=21) Ϯ 
Loss 
(detection) 
Gain (pain) 
No gain (G0) Thermal (G1) Mechanical (G2) Both (G3) All  
No loss (L0) - (0%) - (0%) - (0%) - (0%) - (0%) 
Thermal (L1) - (0%) - (0%) - (0%) - (0%) - (0%) 
Mechanical (L2) - (0%) - (0%) - (0%) - (0%) - (0%) 
Both (L3) 15 (86%) - (0%) 4 (19%) - (0%) 21 (100%) 
All   15 (86%) - (0%) 4 (19%) - (0%) 21 (100%) 
Ϯ  Frequency of different combinations of abnormal values in 21 patients with NP in 
dermatome C8. L0: no loss, L1: thermal hypoaesthesia, L2: mechanical hypoaesthesia, 
L3: thermal and mechanical hypoaesthesia; G0: no hyperalgesia, G1: thermal 
hyperalgesia, G2: mechanical hyperalgesia, G3 thermal and mechanical hyperalgesia. 
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8.5.4.6 Comparison of sensory profiles between groups  
Side-to-side comparison of QST sensory profiles (pain group) 
Sensory profiles of the symptomatic and asymptomatic upper arms are illustrated for 
each pain subgroup (non-NP subgroup Figure 8.20 and NP subgroup Figure 8.21) in 
the maximum pain area. Healthy control subjects are represented by a z-score of “zero”. 
In both subgroups QST parameters fell outside the 95% confidence interval of our 
healthy controls data. Compared to asymptomatic side, patients with painful neuropathy 
have lower thermal detection threshold and pain threshold (CPT, HPT). Remarkably, in 
these patients, the responses to QST stimuli can identify abnormalities in somatosensory 
system, but it cannot be used to differentiate leprosy patients with and without pain. 
Patients with leprosy non-neuropathic pain 
In patients with non-NP in upper limbs, all thermal detection thresholds; and pain 
parameters, in particular for heat, cold and pinprick pain thresholds were significantly 
reduced on the symptomatic side compared to the asymptomatic side in the tested area 
(p-value <0.05) (Figure 8.20). 
Patients with leprosy neuropathic pain 
Of the 24 patients with NP in upper limbs, 4 patients had NP in the skin lesions, one of 
them located in the tested site (dermatome C8). So, 21 patients with maximum pain in 
the dermatome C8 were included in this comparison. Of these 21 patients, six had 
bilateral pain and the remaining 15 had unilateral pain. In these 21 patients, all thermal 
detection thresholds; and pain parameters, in particular for heat, cold and pinprick pain 
thresholds were significantly reduced on the symptomatic side compared to the 
asymptomatic side in the tested area (p-value <0.05) (Fig). Side-to-side comparison of 
all other QST parameters (MDT, WUR, VDT and PPT) were not significant.  
Figure 8.21 -B demonstrates the percentages of the occurrence of PHS (0-3) and DMA 
(log numerical rating scale 0-100). The reports of both were infrequent. One patient 
with NP demonstrated DMA, but none in the asymptomatic side. PHS was reported by 
one patient once; and by four patients three times on the symptomatic side. Two 
patients reported PHS three times on the asymptomatic side. 
Chapter 8: Results 
 
229 
 
 
Figure 8.20. Somatosensory profiles in Non-NP patients 
Somatosensory profiles (A), and occurrence of DMA and PHS (B) of the 
symptomatic (empty circle symbol “red”) and asymptomatic (empty square 
symbol “black”) side in 8 patients with leprosy non-neuropathic pain in ulnar 
nerve territory. Error bars indicate the standard error of measurement. Healthy 
control subject are represented by a z-score of “zero” 
 
Figure 8.21. Somatosensory profiles in NP patients 
Somatosensory profiles (A), and occurrence of DMA and PHS (B) of the 
symptomatic (empty circle symbol “red”) and asymptomatic (empty square 
symbol “black”) side in 21 patients with leprosy NP in ulnar nerve territory. 
Error bars indicate the standard error of measurement. Healthy control subject 
are represented by a z-score of “zero” 
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Figure 8.22. QST findings for patients with pain (n=32) and controls (n=50) 
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Table 8.21. Comparison between symptomatic and asymptomatic sides (n=21) Ϯ 
QST parameter Maximum pain area over ulnar nerve territory (C8) 
Neuropathic pain Non-neuropathic pain 
Asymptomatic Symptomatic P-value Asymptomatic Symptomatic P-value 
CDT (°C) -2.05 (1.89) -3.70 (2.07) 0.018 -1.31 (0.98) -3.23 (1.93) 0.088 
WDT (°C) -2.29 (1.23) -3.57 (1.28) 0.001 -0.88 (0.77) -3.15 (1.66) 0.024 
TSL (°C) -2.44 (1.24) -3.58 (1.24) 0.009 -0.95 (0.80) -3.02 (1.69) 0.039 
CPT (°C) 0.54 (0.63) 0.15 (0.54) 0.052 0.83 (0.67) 0.12 (0.60) 0.075 
HPT (°C) -0.38 (1.01) -1.30 (0.85) 0.005 0.28 (0.84) -1.31 (0.76) 0.005 
MDT (mN) -2.04 (2.61) -3.78 (3.21) 0.092 0.57 (0.34) -2.35 (2.97) 0.079 
MPT (mN) -0.17 (1.02) -1.18 (1.13) 0.009 0.08 (0.59) -.55 (0.61) 0.102 
MPS (NRS 0-10) 0.23 (1.34) -0.96 (1.09) 0.006 -0.34 (0.85) -0.74 (0.62) 0.350 
WUR (ratio) 0.28 (1.14) 0.15 (1.28) 0.780 1.44 (1.74) -0.06 (0.97) 0.058 
VDT (x/8) 0.46 (0.43) -0.70 (2.67) 0.117 -0.65 (1.47) -0.01 (1.46) 0.470 
PPT (kPa) -0.48 -0.83 0.331 -0.69 (0.30) -0.50 (0.74) 0.612 
 Ϯ  Comparison between symptomatic and asymptomatic sides of 21 leprosy patients with neuropathic pain in the upper limbs using the QST 
parameters. Data are shown as mean for untransformed data (HPT, VDT) and retransformed mean for log-normally distributed data 
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Table 8.22. Distribution of abnormal findings in study population (n=142) Ϯ 
 Patients without pain Patients with pain 
QST 
Parameter 
HC 
n=52 
Group 1 
n=14 
Group 2 
n=30 (two sites) 
Group3 
n=48 (two sites) 
Non-NP 
n=10 (test site) 
NP 
n=22 (test site) 
 Gain Loss Gain Loss Gain Loss Gain Loss Gain Loss Gain Loss 
CDT 0 0 0 0 0 16 0 33 0 5 0 16 
WDT 0 0 0 0 0 12 0 38 0 6 0 17 
TSL 0 0 0 0 0 17 0 34 0 6 0 18 
CPT 0 0 0 0 0 2 0 4 0 1 0 2 
HPT 0 0 0 0 0 4 0 17 0 3 0 10 
MDT 0 0 0 1 0 8 0 23 0 2 0 15 
MPT 0 0 0 0 0 3 0 22 0 2 0 12 
MPS 0 0 0 0 0 9 0 19 0 1 0 14 
WUR 0 0 4 0 8 0 13 0 0 1 0 3 
VDT 0 0 0 0 0 0 0 3 0 1 0 5 
PPT 0 0 0 0 0 0 0 13 0 1 0 3 
DMA 0 0 0 0 0 0 0 0 1 0 1  0 
PHS 0 0 1 9 1 3 
Ϯ  Number of individuals within each group with z-score values outside the 95% confidence interval of healthy control participants (± 1.96 SD). 
HC: Healthy control participants; Group 1: No evidence of neuropathy and no pain; Group 2: Subclinical neuropathy and no pain; Group 3: 
Clinical evidence of neuropathy and no pain; Non-NP: Inflammotory/ nociceptive pain; NP: Clinical evidence of neuropathy and pain 
(DN4≥4). Gain: Number of patients with positive individual z-score values, indicating an increased sensitivity compared to normative data (>+ 
1.96 standard deviation). Loss: Number of patients with negative individual z-score values, indicating a decreased sensitivity compared to 
normative data (>+ 1.96 standard deviation). As no DMA occurred in healthy subjects, z-score values could not be calculated. Data are shown 
as absolute number of participants showing DMA.  
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8.6 Pain intensity and quality assessment 
Patients with pain were asked to rate their current pain and estimate a level for their 
worst and average pain in the previous week using the NRS and BPI. All patients with 
pain (36) completed pain questionnaire. The individual scores in total and scores within 
each pain subgroup are shown in Figure 8.23, Table 8.23, and Table 8.24. 
Figure 8.23 shows the distribution of pain scores (worst, average and current pain). The 
worst pain scores were not normally distributed, and the Shapiro-Wilk test was 
significant (W = 0.94, p-value = 0.03). Kurtosis was 1.81 and skewness was 0.74, which 
confirms that worst pain score is not a form of normal distribution, as in a normal 
distribution, both values should be zero (Kim, 2013).  
The mean of current pain scores was slightly worse at 5.9 than average pain, and the 
median was six (interquartile range from 3 – 10). The mean of the worst pain intensity 
experienced by patients in the last week was high at 7.5 out of 10 (maximum score), and 
the median was eight (interquartile range from 4 – 1). The mean of the average pain 
intensity reported by patients in the previous week was relatively high at 5.3. Descriptive 
statistics for pain intensity measures are presented in Table 8.23.  
Table 8.24 and Figure 8.24 display the scores for the BPI severity measure. Mean and 
median scores are displayed as well as how the scores were distributed between the 
neuropathic and non-NP groups. The two groups were compared according to pain 
intensity. The Mann-Whitney U test (for worst pain) and mean comparison test (for 
average and current pain) were conducted. None of the test results showed a significant 
difference (p-values: 0.09, 0.85, and 0.5 respectively). 
The proportions of men and women who reported pain were quite similar (40% of men, 
38% of women) (p-value =0.8). Women were slightly more likely than men to report a 
pain score of 4 or more, indicative of pain severity. The mean pain value for women was 
7.4 and for men was 7.6 (p-value=0.06). No differences in mean score for men and 
women who reported pain interference problems. The mean interference value for men 
was 37 and for women was 36.7 (p-value=0.9). 
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Figure 8.23. Distribution of pain scores (n=36) 
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Table 8.23. Descriptive statistics for pain intensity measures (n=36) 
Pain measures Mean SD 95% CI Median Interquartile range  
NRS current pain 5.97 2.47 5–7  6 3–10 
NRS worst pain 7.50 2.35 7–8  8 4–10 
NRS average pain 5.31 1.94 5–6    5 3-8  
 
Table 8.24. Pain intensity between pain groups (n=36) 
Variable Non-NP group NP group  
Mean (SD) Median (IQ) Mean (SD) Median (IQ) 
NRS current pain 5.5 (2.42) 5.5 (5–7)  6.15 (2.51) 6 (5–8)  
NRS worst pain 8.5 (2.01) 9.5 (7–10)  7.12 (2.01) 8 (5–9)  
NRS average pain 2.49 (2.01) 5 (3–7)  5.35 (2.01) 5 (4–6)  
 
 
Figure 8.24. Pain intensity in NP and non-NP sub-groups (n=36) 
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8.7 Evaluation of psychological co-morbidity and HRQoL 
8.7.1 Health related quality of life 
8.7.1.1 Pain interference with daily life 
The BPI is designated to evaluate pain interference over a variety of domains over the 
last 24 hours using a standard 0 – 10 Likert scale (0 = Does not interfere versus 10 = 
completely interferes). Patients were asked to rate how much their pain was interfering 
with aspects of daily life in the last 24 hours. Of the 36 patients with leprosy and pain, 
35 (97%) patients completed the BPI related questions (Table 8.25). 
Pain interference levels were moderate-to-severe, with the mean ranging from 4.1 to 6.0 
across the selected daily life aspects. The collective patient group had a total interference 
score of more than four, which may be considered to be a high level of interference 
(Cleeland, 2009). Pain substantially interfered (≥4 on 0 – 10 scales) with normal work 
(mean 6.06, SD 3.11), sleep (mean 5.94, SD 3.30), and mood (mean 5.71, SD 3.22).  
Overall, patients reported variable levels of interference per domain; however, the 
highest levels of interference were observed in sleep, work, and mood. The lowest levels 
of interference were observed in walking ability (Figure 8.25). The former three vital 
aspects of daily life have been found to be affected due to leprosy patients feeling pain. 
Table 8.25. Descriptive statistics for pain interference using BPI (n=35) 
Pain interference Mean SD* 95% CI** Median IQ range  
General activity 5.23 2.81 4–6 5 4–7  
Mood 5.71 3.22 7–8 5 5–7 
Walking ability  4.11 3.12 3–5 5 0–7 
Normal work 6.06 3.11 5–7 7 3–9 
Relations 4.26 3.51 3–5 4 0–7 
Sleep 5.94 3.30 5–7 7 4–8 
Enjoyment of life 5.69 2.98 5–7 6 4–8 
*SD = standard deviation **CI = confidence interval   
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Figure 8.25. BPI Pain interference 
Pain interference in various activities of daily life in 35 leprosy patients with pain 
 
8.7.1.2 Comparing pain interference scores between pain groups 
The NP and non-NP sub-groups were compared with pain interference on BPI. As 
expected, the BPI interference mean total score was significantly higher in the NP group 
(mean 41.5, SD 11.9) compared to the non-NP sub-group (mean 25.7, SD 17.8) (p-value 
<0.004). The high scores present in the NP group indicate that a patient’s pain has an 
impact on their day-to-day living and quality of life.  
The scores for each interference domain were normally distributed (the Shapiro-Wilk 
test W: 0.96 – 0.980, P-values: 0.19 – 0.90). The Mann-Whitney U test as well as mean 
comparison tests were conducted for each domain between the two pain sub-groups, 
and both showed consistent results. All of the test results were significantly different (p-
value <0.05) except for mood (p-value = 0.07), walking ability (p-value = 0.47), and 
normal work (p-value = 0.17) when analysed by type of pain. These results indicate that 
NP in patients with leprosy has a greater negative impact on sleep (p-value <0.001), 
relations with other people (p-value <0.03), enjoyment of life (p-value <0.04), and 
compromised ability to perform general activities (p-value <0.05) compared to patients 
with non-NP (Figure 8.26). A further sub-analysis for the patients with upper limb pain 
showed that normal work–Including both work outside of the home and housework–
was significantly different between pain sub-groups (p-value = 0.04), (Table 8.26). 
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Compared to the mild and moderate pain groups, patients in the severe pain group had 
higher ratings on the BPI interference items (mood, relations with others, sleep, and 
enjoyment of life), and the mean interference scores increased with increasing pain 
intensity. However, results of analysis of variance showed no statistical difference (p-
value >0.05).  
Overall, NP frequency was found to be high among leprosy patients. In addition, the 
patients’ worst pain scores on average were high and severe. Furthermore, NP affected 
patients’ life activities. Thus, the impact of NP on quality of life seems to be prevalent 
among leprosy patients. Its psychological effect on leprosy patients will be discussed in 
the following section. 
 
Figure 8.26. Mean BPI interference scores in patients with pain 
Mean scores in BPI interference in patients with non-neuropathic pain (n=10, 
white bar) vs. neuropathic pain (n=25, black bar). *P-value < 0.05 
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Table 8.26. BPI interference in pain groups 
BPI interference Non-NP (n=10) NP (n=25) P- value 
BPI general 
activity 
No interference 3 0 0.02 
Mild  1 0 
Moderate  5 15 
severe 1 6 
BPI mood No interference 3 0 <0.01 
Mild  4 3 
Moderate  0 9 
severe 3 9 
BPI walking 
ability  
No interference 3 5 0.80 
Mild  2 2 
Moderate  4 11 
severe 1 3 
BPI normal 
work 
No interference 1 0 0.04 
Mild  3 2 
Moderate  4 9 
severe 2 10 
BPI relations 
with other 
people 
No interference 6 2 0.03 
Mild  1 5 
Moderate  2 8 
severe 1 6 
BPI sleep No interference 5 0 <0.01 
Mild  0 2 
Moderate  4 10 
severe 1 9 
BPI enjoyment 
of life 
No interference 2 0 0.1 
Mild  3 3 
Moderate  3 11 
severe 2 7 
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8.7.2 Psychological well-being 
8.7.2.1 Evaluation of the psychological well-being with the GHQ-12 
Descriptive analysis 
A total of 89 patients (98.9%) completed the GHQ-12 questions in the study. Sixty six 
point three percent of the respondents had a GHQ-12 score of three or more. The 
overall mean score for the GHQ-12 of the patients was 3.52 (SD 2.11) (Table 8.27) and 
the median score was four (inter-quartile range 2–5). The distribution of scores obtained 
from men and women are shown in Figure 8.27. The median value for men was three 
and for women was 4.5. No significant differences were observed.  
Over 57% of patients had a feeling of “under strain” and suffered from stress. The 
other most common symptoms were “feeling unhappy and depressed” (51.7%), sleep 
problems almost every night (43.8%), could not overcome difficulties (38.2%), and lost 
confidence (37.1%). In addition, 29 patients (32.6%) felt worthless, 24 patients (27%) 
were not feeling happy, and 20 patients (22.5%) could not face problems. Other 
symptoms of mental disorders were much less common, and included not enjoying 
activities (15.7%), could not make a decision (11.2%), could not concentrate (8.99%), 
and a feeling of “not playing a useful part” (6.7%). Thus, more than two-thirds of the 
patients were considered to have possible psychological distress (anxiety and 
depression).  
In patients with no clinical evidence of neuropathy, the proportion of patients scoring 
three or higher using the GHQ-12 was 35.7% (mean 2.29, SD 1.94), compared to 66.7% 
(mean 3.07, SD 1.83) in the sub-clinical neuropathy group, 58% (mean 3.08, SD 1.97) in 
the neuropathy group, and 83.3% (mean 4.5, SD 2.01) in the pain group (Table 8.27). 
Patients with neuropathy and pain had a poorer mental health compared to other 
groups (p-value <0.001) (Figure 8.28).  
Among patients with pain, 30 individuals (83.33%) had a GHQ score of three or more, 
compared to 29 (54.72%) among non-pain patients. 24 patients (92.31%) with NP had a 
GHQ score of three or more, compared to six patients (60%) in the non-neuropathic 
group. Figure 8.29 shows the distribution of GHQ-12 scores of three or more in leprosy 
patients with and without pain. 
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Figure 8.27. Distribution of GHQ-12 scores (n=89) 
Distribution of GHQ-12 scores in men (median 3, above thresholds: 64%) and 
women (median 4.5, above thresholds: 75%) 
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Table 8.27. GHQ-12 scores Ϯ 
GHQ-12 item Groups Total 
scores 
(n=89) Group1 
(n=14) 
Group2 
(n=15) 
Group3 
(n=24) 
Group4 
(n=36) 
Could not concentrate  1.9 (0.5) 1.8 (0.7) 1.5 (0.7) 1.5 (0.7) 1.6 (0.7) 
Lost sleep  2 (0.7) 2.5 (1.0) 2.3 (0.7) 2.6 (1.0) 2.4 (0.9) 
Not playing a useful part 1.7 (0.5) 1.9 (0.5) 1.7 (0.7) 1.5 (0.6) 1.6 (0.6) 
Could not make a decision 1.8 (0.6) 1.6 (0.6) 1.8 (0.7) 1.9 (0.7) 1.7 (0.7) 
Felt under strain 1.9 (1.1) 2.1 (1.0) 2.5 (1.1) 2.7 (0.9) 2.4 (1.0) 
Could not face difficulties 2.1 (0.7) 1.9 (0.9) 1.9 (1.0) 2.4 (0.9)  2.1 (0.9) 
Not enjoying activities 1.9 (0.7) 2 (0.7) 1.8 (0.9) 1.5 (0.7) 1.7 (0.8) 
Could not face problems 2.1 (0.7) 1.9 (0.6) 1.9 (0.9) 1.7 (0.7) 1.9 (0.8) 
Unhappy and depressed 1.6 (0.9) 2.2 (1.2) 2.1 (1.1) 2.7 (1.0) 2.3 (1.1) 
Lost confidence  1.9 (0.7) 2.1 (0.8) 1.8 (0.8) 2.4 (0.9) 2.1 (0.9) 
Felt worthless  1.5 (0.8) 1.4 (0.8) 2 (0.9) 2.2 (0.9) 1.9 (0.9) 
Not feeling happy 2.1 (0.8) 1.9 (0.8) 1.8 (0.8) 2.1 (1.0) 1.9 (0.9) 
All GHQ-12 items 2.3 (1.9) 3.1 (1.8) 3.1 (1.9) 4.5 (2.0) 3.5 (2.1) 
Ϯ  A table displaying the scores for the GHQ-12 and how these scores were distributed 
between the groups (No neuropathy, sub-clinical neuropathy, neuropathy, and 
neuropathy and pain), as well as total scores. Mean values and SDs shown  
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Figure 8.28. Overall score of GHQ-12 in 89 leprosy patients 
The relation between the presence of neuropathy, pain and overall score of 
depression in 89 leprosy patients. 
 
 
Figure 8.29. GHQ-12 score of 3 or more in 89 leprosy patients  
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Analysis  
Univariate analysis 
Univariate analysis was carried out for the association between the variables and mental 
health (depression) as an outcome. The following factors were strongly associated with 
the outcome: patients’ motor nerve impairment, delay in presentation, WHO-disability 
classification, disease duration, and the presence of pain particularly neuropathic pain 
(p-value <0.001). There was, however, some evidence of an association between mental 
health status and educational qualifications (p-value = 0.04), disease duration (p-value = 
0.05), presence of skin lesions on examination (p-value = 0.06), number of skin lesions 
on examination (p-value = 0.07), sensory nerve impairment (p-value = 0.08), and the 
presence of a reaction on examination (p-value = 0.1). Other variables showed no 
evidence of an association (p-value >0.2). Appendix 48 shows the distribution of GHQ-
12 (above a threshold) cases by patients’ characteristics and the odds ratios for each 
variable. 
GHQ scores and social, clinical features and pain variables 
In the following section the association between psychiatric morbidity and social and 
clinical findings are described.     
Association between socio-demographic variables and GHQ scores 
The prevalence of significant psychiatric morbidity between those in different age 
groups and sexes were not statistically different (Appendix 48). This may be due to age 
and gender match of the study population. However, at all ages and for both sexes, 
those who have some formal educational qualifications had better mental health than 
those who had no such qualifications. The difference between these two categories was 
more pronounced in the 20–29-year old age group. For men there was a statistically 
significant difference between those with and without qualifications in relation to their 
mental health. While those with no qualifications reported a higher prevalence of 
psychiatric morbidity in the youngest age groups, the differences were small and there 
was no difference at ages 30–39, 40–49 and >50. There was no difference for women 
across the five age bands. The odds ratios for educational level were found to be 
marginally significant (p-value <0.04). Married participants had approximately the same 
prevalence of psychological morbidity as single or separated, widowed, or divorced 
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participants. Of currently married participants, 67.8% had a higher GHQ-12 score, 
while 63.3% of the non-married group had a higher GHQ-12 score. 
Association between clinical findings and GHQ scores 
Patients who had clinical evidence of motor impairment were significantly more likely to 
have scored above the GHQ-12 threshold score (crude OR 3.13, 95% CI 1.20–8.18). Of 
patients with motor impairment, 78.26% obtained higher GHQ-12 scores, compared to 
53.49% of patients who did not have motor impairment. In comparison with motor 
impairment, neither sensory impairment nor neuropathy (both sensory and motor) 
showed a statistical association with a GHQ-12 score, p-values 0.08 and 0.07 
respectively. There was, however, a clear relationship between ulnar neuropathy and 
GHQ-12 score (crude OR 4.46, 95% CI 1.55–12.82). 
There was a clear relationship between the presence of disability and GHQ-12 score. 
Patients who reported having a disability at diagnosis or at the time of interview were 
more likely than those who did not to have a GHQ-12 score of three or more. For 
respondents who had a disability at diagnosis, the figures were 82.9% and 17.1% 
respectively, and for those who had a current disability they were 75.5% and 55.0% 
(Appendix 48). Of those who had a previous reaction, 90% had a higher GHQ-12 score 
compared to 80% of patients who did not experience a reaction.  
There was also a clear relationship between the reaction and GHQ-12 score. Patients 
who reported having a previous reaction were more likely than those who did not to 
have a GHQ-12 score of over three (crude OR 2.25, 95% CI 1.13–8.21).   
Association between pain and GHQ scores  
Large differences were evident when comparing those respondents who reported having 
pain symptoms and those who did not. Of the former, 83.3% had a GHQ-12 score of 
three or more, while the equivalent figures for the latter were 54.7%. Among those who 
had pain, respondents with symptoms and signs suggestive of neuropathic pain were 
more than nine times more likely to have an above-threshold GHQ-12 score than those 
with non-neuropathic pain (crude OR for neuropathic pain 9.93, 95% CI 2.13–46.35; 
crude OR for non-neuropathic pain 1.24, 95% CI 0.31–4.91). Twenty-four out of 26 
patients (92.3%) with a presentation suggestive of NP using the DN4 questionnaire had 
a higher GHQ-12 scores compared to 60% of those patients presenting with complaints 
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of non-neuropathic pain, and 54.72% of the no pain group. The greatest difference was 
for men at age 20–29 and 30–39 where those with neuropathic pain were more likely to 
have a high GHQ-12 score than those in the non-neuropathic pain group. At the oldest 
female age group, smaller numbers obscure the pattern. Overall, there were clear 
relationships between the presence of neuropathic pain and GHQ-12 scores. Those 
who were diagnosed with neuropathic pain had the worst mental health. 
Multivariate analysis 
 Logistic regression 
Adjusted odds ratios for experiencing mental health disturbances were estimated using 
logistic regression. Stepwise logistic regression modelling was done (Appendix 49). The 
main social and clinical findings were included in the model for GHQ-12. This 
modelling allowed us to assess the association for each variable, adjusting for others, 
and to examine which factors affected the odds of having a high score on the GHQ-12. 
All variables and not only those significantly associated variables (above a certain p-
value in the univariate analysis), were considered for the multivariate regression model. 
For instance, gender and age group did not have a significant effect on the association, 
but were included in the multivariate regression model, as both are known universal 
confounders. Variables were retained in the final multivariate regression model when 
the model found significant evidence (p-value <0.05) with that variable included than 
without it, using a likelihood ratio test. In the model, the variable most significant in the 
univariate analysis was included first (forward regression). The next variable selected in 
the model for inclusion was then the one that best improved the model based on the 
LRT test until no additional variables improved the model significantly. In addition, all 
potential variables were included in the model first and then removed one-by-one 
starting with those least associated with the outcome (backward regression).   
After adjusting for all other factors in the model, the odds of having significant 
psychiatric morbidity fell by more than one third  (from 9.60 to 6.25). This result 
showed that the magnitude of the association decreased, but strong evidence of an 
association between psychiatric morbidity (anxiety and depression) and presence of 
neuropathic pain (p-value = 0.03) remained. There was strong evidence of reduced odds 
for the presence of neuropathic pain compared to patients with no neuropathic pain. 
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While there was a tendency for the presence of disability, particularly motor nerve 
impairments, to have higher psychiatric morbidity, there was no statistical significance 
(p-value 0.09). Neither socio-demographic factors nor disease duration were associated 
with mental health in either men or women.     
The major determinant of mental health of the cohort was the presence or absence of 
chronic pain, “neuropathic pain”, or presence of disability, “motor nerve impairment”. 
The likelihood of psychiatric morbidity increased if neuropathic pain was present. The 
odds of psychiatric morbidity in those with neuropathic pain was 6.25 the odds of 
disorder in those without pain. At this stage in the study, we would suspect that those 
with chronic neuropathic pain were at a higher risk of developing worse mental health. 
This result would make sense, as patients with neuropathic pain are more likely to suffer 
from its impact on all quality of life modalities. 
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Chapter 9 Discussion 
9.1 Introduction 
The aim of this doctoral thesis was to investigate the clinical characteristics of patients 
with leprosy-associated NP and to establish the somatosensory profiles of such patients. 
Recent advancement of NP assessment has included two aspects. First, the 
identification and baseline profiling of patients with NP, including different dimensions 
of chronic pain problems, and second, the adaptation and development of a 
comprehensive clinical trial design for NP treatment. I hypothesised that: 
i. Patients with painful neuropathy have a different sensory profile compared to 
patients with non-painful neuropathy 
ii. Patients with NP endure a greater quality of life and psychological well-being 
burden than those with leprosy and neuropathy, but without NP.  
These baseline comprehensive hypotheses were tested in a case-control study of a 
leprosy cohort consisting of patients with established pain and neuropathy, patients with 
pain-free and established clinical evidence of neuropathy, patients with no pain and no 
clinical evidence of neuropathy, and local healthy volunteers recruited in Mumbai, India. 
9.2 Summary and discussion of the findings  
Somatosensory profiles were compared to those from the DFNS-QST reference data 
and local Indian healthy control subjects. The pattern in all leprosy patients revealed a 
novel profile not previously seen in other NP conditions whereby cool and warm 
detection thresholds and also mechanical detection were lowered but vibration 
perception was preserved. This is somewhat different to profiles seen in other NP 
conditions. Patients with leprosy NP had a high rate of abnormal findings in almost all 
QST parameters when measured in the maximum pain area in the ulnar nerve territory. 
Their sensory profiles were categorised into two subgroups. The majority of patients 
have spontaneous pain with evidence of sensory loss, but no sign of sensory gain, these 
findings are consistent with peripheral neuronal damage. The second subgroup showed 
pain and temperature sensation to be profoundly impaired, but light mechanical stimuli 
produced pain (dynamic mechanical allodynia). Surprisingly, the obtained QST profiles 
in leprosy patients with pain were not significantly different from those patients without 
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pain. Patients with NP had poor quality of life and psychological well-being compared 
to those with pain-free neuropathy. Hence, the characterisation of patients with respect 
to the NP is of therapeutic significance. 
9.2.1 Sociodemographic, clinical and epidemiological characteristics of study 
participants 
The sociodemographic profile found in this study is comparable with those in other 
studies conducted in different parts of India, which point out gender bias, illiteracy, and 
a move to a city as constant characteristics of leprosy populations (Thakkar and Patel, 
2014, Van Brakel et al., 2005a). The age profile of the patients was younger than the 
general population. In India more than 65% of the population are below the age of 35 
years (WHO, 2014). Approximately one third of the population sample were in their 
third decade. The relatively few patients in either the under 20s age group or the above 
50s age group probably reflect the sampling method and the nature of the disease.  
In leprosy, the proportion of male to female is identical (1:1) up to puberty, then 
changes to 2:1 which reflects the natural history of the disease (Guinto and Rodriguez, 
1936). In our cohort, the proportion of male and female patients was not evenly 
distributed across age groups and the ratio of 3:1 was also slightly different from that in 
the general leprosy population. This could be explained by the sampling method of the 
study. In many developing countries leprosy clinics are accessed by more men than 
women. In addition, bias in favour of men is also found in India (Hausmann, 2013). The 
high illiteracy and low educational level in our cohort reflects the strong association in 
most leprosy populations with complex variables of poverty such as income, housing 
quality hygiene and education. The geographical distribution of our cohort sample was 
also typical of the general leprosy population in India. In this study, half of the patients 
recruited at the BLP had moved from rural areas to Mumbai. This could be explained by 
the strong association between leprosy and poverty (Murto et al., 2013), as leprosy may 
be characterised by rural incidence and urban prevalence, i.e. cases move to cities. 
Regarding clinical characteristics, it is worth noting that the high prevalence of MB cases 
associated with the high percentage of disability grade 2 at diagnosis is indicative of late 
diagnosis and lack of early detection of cases. Grade 2 disability at diagnosis, which is 
defined as the presence of visible deformity, is an indicator of the late diagnosis and 
severity of the disease. In our cohort, 10% of patients had disability grade 2 at diagnosis. 
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Our finding is similar to results from the INFIR cohort study (9.6%). The proportion of 
grade two disability in newly diagnosed leprosy cases in India reported by WHO at 3% 
(WHO, 2013b) this could be explained by the fact that the WHO figure included PB 
cases who usually have lower rates of disability. The high percentage of grade 2 disability 
at diagnosis in our cohort suggests that the risk of leprosy transmission is still ongoing 
in the study area. Delayed presentation is a known risk factor for disability in leprosy 
(Schreuder, 1998, Meima et al., 1999). A study from Thailand (Schreuder, 1998) has 
shown a highly significant correlation between the proportion of new cases with 
disability and delay in diagnosis. An Ethiopian study found an odds ratio of 2.1 for 
grade 2 disability when registration was delayed by more than 2 years (Meima et al., 
1999). In this study, we found that more than 70% of the patients had had symptoms 
for more than 6 months before starting their MDT treatment. Data on the main reasons 
for this delay were related to misdiagnosis and patient’s unawareness of the disease; 
other studies have found similar level of delay, explained by stigma and difficulties 
accessing services (Lockwood and Reid, 2001, Nicholls et al., 2003). These findings 
indicate that there is still more work to be done to prevent and manage disability in 
leprosy. A recent publication on the use of the WHO disability grading system by Cross 
and colleagues (Cross, 2014), used Delphi methods to reach a consensus among fifteen 
experts on the prevention of disability due to leprosy. The authors defined the terms 
more precisely and provided guidelines for use in the clinic, which can be immediately 
applied. There is limited time for the current global strategy, which proposed the target 
of reducing the rate of new cases with grade 2 disabilities per 100 000 population by at 
least 35% by the end of 2015, compared to the baseline at the end of 2010 (WHO, 
2009a). However, the new guidelines may help to improve disability assessment, 
monitoring and successful leprosy burden reduction.  
Twenty six patients (28.9%) had leprosy reactions at the time of examination, and 
previous history of reaction was reported by 40 patients (56%). Nociceptive joint pain is 
likely to be reaction associated. Pain associated with neuritis reaction, which is defined 
by the development of inflammation of a nerve sheath without abnormal findings in 
sensory testing, is considered to be of inflammatory origin and clinically defined as 
nociceptive pain (originating from nervi nervorum) (Bove and Light, 1997). However, if 
an inflammatory neuritis causes nerve damage then the pain, is by definition, 
neuropathic. Inflammatory pain is usually considered to be of nociceptive character, 
because it partly results from hyperexcitability of intact nociceptive dorsal root ganglion 
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neurons innervating inflamed tissue. However, chronic inflammatory pain is often 
characterized by positive signs such as allodynia, suggesting a possible neuropathic 
component. Recent studies have shown that inflammation-induced nociceptor 
hyperexcitability is sustained by C-nociceptors, which may contribute to inflammatory 
hyperalgesia (Flynn et al., 2014). This may also explain why in some inflammatory 
conditions nociceptive and NP may overlap. In our study, patients with reactions could 
have been over-represented, but this group is still attending leprosy services and 
therefore accessible to our recruitment tactics. The high prevalence of reactions in our 
cohort supports the growing evidence that the development of NP is probably 
immunologically mediated (Lund et al., 2007). The immune response in the peripheral 
nerves may recur and if it repeatedly affects the peripheral nerves, chronic-post 
inflammatory pain may result. Lockwood and colleagues (Lockwood et al., 2002) have 
shown that M. leprae protein and lipid antigens are present in skin and nerves at the time 
of acute reversal reactions. These data show the importance of reactions in pain among 
leprosy patients; they can be significant risk factors for the development of chronic NP. 
The epidemiological profile in this cohort had a prevalence of leprosy neuropathy of 
68%, with 60% of those reporting pain. NP was found in 28.8% of the patients. This 
finding is similar to the large epidemiological studies: In the INFIR cohort study, the 
neuropathy is consistently reported at around 40% (van Brakel et al., 2005b). New 
peripheral nerve damage is present in about 65% of cases. In our previous study in 
Ethiopia, pain was experienced in 60% of the patients who had completed their MDT 
within 18 months (Haroun et al., 2012). The prevalence of NP in this study is lower 
than other NP due to infectious disease, such as HIV-SN, which stand at 40%. Previous 
epidemiological studies on leprosy neuropathy and pain showed that NP occurs in up to 
30% of patients in the long term (Hietaharju et al., 2000, Stump et al., 2004, Saunderson 
et al., 2008, Lasry-Levy et al., 2011, Haroun et al., 2012, Ramos et al., 2014). This 
supports the validity of the NP criteria used, and it is likely that these findings would be 
applicable to larger leprosy populations and in different settings. However, this study 
did not find some of the well-established risk factors for leprosy neuropathy and pain, 
such as reaction (Appendix 47). This could be because the case control study was 
powered against the sensory changes associated with risk of developing HIV neuropathy 
from the pain in HIV related neuropathy study (Phillips et al., 2014), and was not 
designed to elucidate these risk factors in the same way as larger epidemiological studies. 
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The HIV study is one of few studies to use quantitative sensory testing to assess sensory 
parameters in NP caused by infectious diseases.  
9.2.2 Diagnostic tools  
9.2.2.1 Case definition  
The ability of health personnel in remote leprosy clinics to identify NP in patients with 
chronic pain is unclear. In this study, leprosy patients with NP were defined in a 
stepwise manner. First monofilaments and VMT, which are widely used in leprosy 
clinics, were used to confirm that some damage to the somatosensory sensory system 
along ulnar nerve territory had occurred. A sensory deficit in the innervation territory of 
a lesioned nerve is a diagnostic criterion of NP (Treede et al., 2008, Haanpaa et al., 
2011a). Secondly, as the presence of nerve damage per se does not necessarily indicate 
that pain is neuropathic in origin, patients were further classified based on a score of ≥ 
4/10 using the DN4 symptom descriptors questionnaire. Using this definition, would 
provide simplicity, validity, utility and affordability for use in most routine clinical 
practice in leprosy population. This indicates that our case definition may help to 
develop a new tool for the assessment of NP in leprosy that might be useful in 
resource-limited settings. 
9.2.2.2 Pain symptoms 
Screening tools are used to alert clinicians to the possibility of NP (Haanpaa et al., 
2011a). In previous studies done in collaboration with the Bombay Leprosy Project in 
India, ALERT hospital in Ethiopia, and LSHTM we demonstrated that the DN4 
questionnaire is valid in its application in the leprosy NP in different languages and 
settings (Lasry-Levy et al., 2011, Haroun et al., 2012). In this study, I used the DN4 
questionnaire for the case definition of NP; a score of 4 or higher in patients with 
evidence of neuropathy. In addition, I used PD-Q to verify the DN4 result.  
NP, based on the identification of common pain symptoms and sensory tests over the 
ulnar nerve territory (C8) obtained with the DN4 questionnaire, was identified in the 
pain group with mean scores of 5.6 out of 10, specifically with the presence of 
“numbness” in the NP and “aching or dull pain type” in non-NP patients. The presence 
of NP in patients with upper limb pain was identified in 24 patients out of 32. The 
number of DN4 sensory pain descriptor items described by those patients was higher 
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than that identified by examination of sensory function. Similar findings were also 
observed in a study by Bouhassira, who compared the clinical features of NP and non-
NP in 160 patients in France (Bouhassira et al., 2005). In our study “tingling”, 
“burning”, and “numbness” were the sensory descriptors most widely used by NP 
patients. Hypoesthesia to touch and pin-prick were much more frequent in NP than in 
non-NP patients. These findings are consistent with previous studies on NP in 
Fibromyalgia (Petzke et al., 2003, Staud et al., 2003). The presence of “painful brush” 
sensation was also more frequent in NP compared to the non-NP group, although it 
was not statistically significant.      
In this study clinical examination, and the DN4 questionnaire, were used for the case 
definition of leprosy NP. The PD-Q identified fewer patients (13 subjects) with NP 
components compared to DN4. Of 32 patients with upper limb pain, 24 patients were 
clinically classified by DN4 as definite NP, while PD-Q identified only 5 of these 
patients. There were inconsistent responses to the common questions between DN4 
and PD-Q in 60% of cases. It is unclear if the lowered sensitivity of PD-Q in our cohort 
might be related to the validity of the questionnaire in this population and setting, as 
there are no previous studies documenting the clinical diagnostic accuracy and reliability 
of PD-Q in leprosy. Similar findings were also observed in patients with neck/upper 
limb pain by Tampin and colleagues (Tampin et al., 2013). In this study, the author 
investigated the application of LANSS and PD-Q in 152 patients with neck/upper limb 
pain. Both questionnaires failed to identify a large number of patients with clinically 
classified definite NP. These findings suggest that the application of PD-Q in patients 
with leprosy NP is limited. 
Another potential observation regarding the differences between the DN4 and PD-Q is 
questionnaire design. For instance, the number and type of questions are different: the 
DN4 consists of 10 symptom and clinically-related questions; while PD-Q contains only 
seven symptom-related questions. The phrasing of the questions and the scoring 
method are also different. Whilst DN4 uses yes or no fixed scores for each question, 
sensory descriptor questions are score-weighted in PD-Q. The latter scoring may 
introduce bias, as responses could be vulnerable to subjective psychological factors, 
which potentially contribute to an overall higher score. These observations in 
questionnaire design and low sensitivity between the two instruments, support the use 
of DN4 as screening tools for leprosy NP.  
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Patients were asked to evaluate the administration of NP screening tools; no difference 
was found between DN4 and PD-Q. In a previous study, we documented that DN4 
was easier to administer than the LANSS in patients with leprosy and NP (Haroun et al., 
2012). 
9.2.2.3 Clinical examination 
The nine nerves commonly affected in leprosy, namely: greater auricular, median, ulnar, 
radial cutaneous, ulnar branch, lateral popliteal, superficial peroneal, posterior tibial, and 
sural nerves were assessed in a cohort of 90 patients with and without neuropathy and 
pain. Of these nine nerves, I compared the sensory and motor findings from ulnar nerve 
examinations between groups. I also compared the results of the QST tests against 
monofilament testing.  
In this study, abnormal tendon reflex or JPS was present in very few patients (only 
around 2%). This is typical for leprosy, and accords with previous observations. 
Jennekens and colleagues, who examined 28 male leprosy patients, found abnormal JPS 
of one or more digits in 33% of the participants (Jennekens and Jennekens-Schinkel, 
1992). In the INFIR cohort study around 2% of the 303 subjects had abnormal reflexes 
or JPS (van Brakel et al., 2005b). Ramadan and colleagues found ‘diminished’ reflexes in 
45% of their patients and ‘diminished joint and vibration sensation’ in 33%. However, 
the patient group in the latter study was older and had longer histories of leprosy. In our 
study, the presence of abnormal reflexes or JPS could be explained by neuropathy of 
long duration (van Brakel et al., 1994b).  
In the subclinical neuropathy group, the QST findings showed ulnar impairment in up 
to two third of the patients. This indicates that QST testing is a more efficient method 
of clinical detection than those currently used in leprosy neuropathy. A similar 
conclusion, that monofilament and VMT are not very sensitive methods in detecting 
neuropathy, was also observed by McKnight, who further analysed the data from the 
INFIR cohort study (McKnight, 2010). However, the use of monofilament and VMT in 
resource-limited setting is reliable (Brandsma et al., 2014). In Chapter 7, I showed that 
the use of monofilament in detecting touch sensation in healthy volunteers is 
comparable to electronic von Frey, but may be different in pathological conditions. The 
low sensitivity of clinical evidence of neuropathy in detecting ulnar impairment 
compared to QST in the subclinical neuropathy group can be explained by the fact that 
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thermal (warm and cold) sensation occurs early in leprosy, which cannot be detected by 
monofilament. Another explanation could be related to the scale used for the VMT 
grading range; 4 scores instead of 3 for abnormal limits (Van Brakel et al., 2007). The 
new grades of weakness are more difficult to assesses in comparison to no weakness 
(Brandsma, 2000). 
In the current study, I found that all nerves classed as impaired on the monofilament 
test also had two or more QST based abnormal parameters. In the ulnar nerve the 
combined thermal tests were impaired in all right ulnar nerves, and in more than 90% of 
left ulnar nerve impaired according to the monofilament test. In addition, a substantial 
proportion (>60%) of the nerves had impaired thermal sensation, but normal touch 
sensation. These findings indicate that, if touch sensation is affected, one of the QST 
parameters will also be abnormal. Unlike the INFIR cohort study findings (Van Brakel 
et al., 2005a), our study showed that impaired thermal sensation may be detectable 
before touch sensation. Our findings could be explained by the fact that small, 
unmyelinated fibres are the first to be affected in leprosy (Shetty et al., 1988, Shetty et 
al., 1977). 
In our cohort, the pattern assessing large afferent fibre using monofilament and 
vibration tests revealed a loss of touch sensation, but vibration perception was 
preserved. These findings were fully compatible with what might be expected from 
leprosy neuropathy, i.e., not all ulnar nerves with impaired touch had impaired vibration 
sense. This is similar to the findings for neuropathy assessment in the INFIR cohort 
study by Brakel and colleagues (Van Brakel et al., 2005a). The authors found high 
negative concordance between monofilament and vibration perception; if the 
monofilament test was normal, the vibration test was also normal in the great majority 
of nerves. This indicates that the vibration perception test is less sensitive for detecting 
sensory neuropathy in leprosy than monofilament testing. 
9.2.2.4 Metabolic factors  
In this cohort, the mean values of plasma level of vitamin B12 across the study group 
were high, unlike the healthy cohort where three volunteers with very low levels of B12 
were identified. Vitamin B12 deficiency is an important factor in the development of 
peripheral neuropathies (Reynolds, 2014). The low vitamin B12 observed in our healthy 
volunteers could be explained by Indian dietary habits, as the majority of volunteers 
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were vegetarian. Higher plasma levels in our patients, particularly the neuropathy and 
pain group, could be explained by the fact that 60% of them were on vitamin 
supplementation. Vitamins are givens to all patients as a routine treatment at the BLP 
clinic. 
9.2.3 Quantitative sensory testing  
This is the first study to use the DFNS-QST protocol in a resource-limited setting and 
validates the Mumbai centre for the use of the QST. The QST machine (MSA 
Thermotest, Somedic) used in this study was easy to operate. The protocol is highly 
relevant in leprosy, because both small and large fibres are damaged. 
QST results are interpreted on the basis of a DFNS reference data set that is stratified 
for age and gender (Rolke et al., 2006a, Magerl et al., 2010). It contains a description of 
somatosensory profile and, subsequently, refers to possible underlying mechanisms.   
9.2.3.1 Differences between healthy controls and patients 
Consistent differences in quantitative sensory testing results were observed between our 
local Indian samples of healthy control participants and patients with leprosy. The most 
frequent differences was sensory loss indicated by increased thermal detection 
thresholds (CDT, WDT) and increased mechanical and vibration detection thresholds 
(MDT, VDT) in leprosy patients compared to healthy controls. This highlights the fact 
that nerve damage is a characteristic of leprosy, even if there is no clinical evidence of 
neuropathy using monofilaments and/or voluntary muscle testing. 
QST measurements in the current study revealed that patients with leprosy had a 
widespread loss of function in the tested site (dermatome C8) in most DFNS-QST 
thermal and mechanical sensory parameters, but also that vibration sense tend to be 
preserved. About two thirds of participants showed a loss of function of at least one 
sensory modality. The same was found for leprosy patients in the INFIR study by Van 
Brakel et al; loss of temperature sensation, but retained vibration perception (Van Brakel 
et al., 2005a). Vibration “sense” is mediated by large afferent Aαβ fibres (Light and Perl, 
1993). VDT and monofilaments tests both assess large afferent fibre function, it was 
therefore expected that vibration test would also be affected. One explanation would be 
that the preserved vibration sense reflects the type of nerve fibres that are damaged in 
leprosy (i.e. there is a preservation of the large myelinated sensory fibres that transmit 
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vibration sense in leprosy). Another explanation for the preserved vibration in this 
cohort could be because vibration is transmitted by bone not skin which may not reflect 
abnormality in the cutaneous nervous system. Further explanation again would be the 
preserved spinal dorsal columns in leprosy. The supporting explanation for this may be 
that since the spinal dorsal columns are preserved in leprosy, one needs less intense 
afferent input to perceive vibration and the remaining sensory input is sufficient for 
vibration and yet not of other thermal and mechanical parameters.      
In concordance with our hypothesis, patients with leprosy had localised sensory 
abnormalities in the tested ulnar site (negative sensory signs: reduced thermal and 
mechanical modalities), indicating a loss of small and large sensory fibre function. The 
main sensory finding was loss of function of the C and Aδ mediated sensory modalities 
of thermal non-nociceptive parameters (60%) and functions mediated by large fibres 
(Aβ) (46%), except for vibration sense (8%). This is similar to previous findings for 
leprosy patients in the INFIR study; loss of thermal sensation, but retained vibration 
sense (Van Brakel et al., 2005a, van Brakel et al., 2008a). In contrast, abnormal negative 
nociceptor QST parameters ranged from 7.9% (CPT) to 42% (MPS). The presence of 
these negative sensory findings is indicative of peripheral nerve damage (Hansson, 
2002). Loss of function occurred in all sensory fibres tested (C, Aδ and Aβ), which is 
consistent with previous findings in patients with peripheral nerve damage and in 
patients with HIV sensory neuropathy (Kleggetveit and Jorum, 2010, Phillips et al., 
2014). 
9.2.3.2 Somatosensory profiles in patients with and without pain 
Patients with and without pain had a similar sensory abnormalities for nociceptive and 
non-nociceptive QST parameters. Abnormality of thermal, and mechanical detection 
thresholds; and pain thresholds to the nociceptive parameters were common and similar 
in both patients groups compared to healthy controls. Although the cumulative 
frequency of abnormalities in any of the thermal and mechanical measures were higher 
in patients with painful neuropathy, it was not statistically significant. The QST findings 
showed a pattern of profound sensory loss in both groups. A similar distribution of 
QST profile in patients with and without pain has previously been reported in other 
conditions. In a recent study of HIV painful neuropathy, the results resemble those of 
the present study. In a QST profile study of 66 HIV infected participants, Phillips and 
colleagues (Phillips et al., 2014), reported no differences in regard to thermal and 
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mechanical perception thresholds between painful and non-painful sides of denervated 
skin. In addition, the authors found that patients with painful neuropathy had profound 
loss to vibration sense. The implications of our findings that leprosy patients with pain 
do not have significantly different QST profile from leprosy patient without pain is 
discussed in detail in section 9.3.6, page 276. 
In this study, the differences in QST parameters between symptomatic and 
asymptomatic sides in 21 leprosy patients with symptoms and signs suggestive of NP 
and 10 patients with non-NP, was investigated. The QST findings demonstrated a 
significant loss of function mediated by nociceptive and non-nociceptive sensory fibres 
in both sides of the NP groups; these findings are consistent with the characteristics of 
NP (Haanpaa et al., 2011a). However, in patients with non-NP, the QST findings 
demonstrated a significant loss of function on the symptomatic side compared to the 
asymptomatic side. These findings indicate that unlike non-NP, in patients with NP 
there was no significant side-to-side difference in any QST parameters in the maximum 
pain area. Our findings could be explained by the fact that in NP patients, loss of 
thermal and mechanical detection may occur bilaterally. Contralateral loss of thermal 
detection has been observed in patients with nerve damage (Leffler and Hansson, 
2008b, Jaaskelainen et al., 2005). In patients with trigeminal neuropathy, contralateral 
loss of thermal detection was associated with the presence of ipsilateral NP. This was 
explained by peripheral nerve damage induced inhibition or disturbed excitatory 
connections within the central pathways mediating non-noxious thermal information 
from the contralateral side (Jaaskelainen et al., 2005, Davis et al., 2011).   
Our results indicate that the QST measures allow us to differentiate between patients 
with and without neuropathy, but cannot be used to differentiate between leprosy 
patients with and without pain, which is similar to the study by Phillips and colleagues 
(Phillips et al., 2014).  
9.2.3.3 Somatosensory profiles in patients with NP  
The description of the somatosensory profiles in patients with leprosy NP is the central 
focus of this doctoral thesis. As mentioned in the introduction, baseline profiling is an 
important step towards better understanding of pathophysiological mechanisms as well 
informed mechanism based prescribing, which in turn influences clinical trial design and 
drug responder defining NP treatment (Reimer et al., 2014). 
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To our knowledge, this is the first study to comprehensivly investigate the clinical 
presentation of NP in leprosy. A detailed description of the leprosy NP phenotype is 
given. As expected, the majority (90%) of leprosy NP patients showed sensory 
abnormalities at their ulnar affected side. This is similar to the findings for NP patients 
by Maier and colleagues (Maier et al., 2010): In this study, 1236 patients with NP of 
different aetilogies were investigated and somatosensory profiles of all patients were 
assessed, the authors reported a high percentage (92%) of patients with at least one QST 
abnormality. The most prevelant profiles were thermosensory and mechanical 
hypoesthesiac (in up to 41%). 
In our study, across different thermal and mechanical modalities, the predominant 
profile in leprosy NP was loss of sensory function; 90% of leprosy NP patients showed 
a loss of function of at least one sensory modality. In concordance with our hypothesis, 
sensory loss of functions was predominately found in non-nociceptive parameters, with 
higher incidence for thermal function mediated by small nerve fibres (CDT 84.2%, 
WDT 89.5%, TSL 94.7%) and mechanical function mediated by large nerve fibres 
(MDT 73.7%), whereas loss of vibration sense mediated by dorsal column tract 
occurred in 26.3%. Similarly, sensory loss of function in nociceptive parameters 
occurred in most patients (MPT 85.7%, MPS 78.9%, and HPT 52.6%), except for 
pressure pain (15.8%), which reflects the innervation of deep muscles rather than 
cutaneous sensory receptors. On the other hand, sensory gain of functions for both 
non-nociceptive and nociceptive parameters was rare. 5.3% of the patients had DMA 
and 15.8% had abnormal WUR. 15.8% of the patients had PHS. 
In patients with pain and neuropathy group, I found that 26.5% of them had increased 
vibration detection threshold (i.e. loss), while our finding of generalized retained 
vibration sense in non-NP patients is consistent with previous studies (Van Brakel et al., 
2005a). Our demonstration of increased vibration detection threshold in patients with 
NP has not been reported in leprosy, but corresponds with other NP conditions (Maier 
et al., 2010, Konopka et al., 2012).  
In studies conducted by Hammond and colleagues in India, the vibration thresholds, 
which were assessed using a biosthesiometer technique, were found useful for predicting 
the risk of plantar ulcer (Hammond and Klenerman, 1988), risk of tarsal disintegration 
(Klenerman et al., 1990), and for diagnosing sensory impairment in skin lesions 
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(Klenerman and Hammond, 1988). The authors showed that vibration sense was 
affected in 90% of feet at risk of ulceration. 
This important findings, as it reflects that a considerable percentage of patients (26.5%) 
had impaired vibration sense, wich could be a potiential predictor for the development 
of NP in leprosy. This observation is again indicative of peripheral nerve damage. 
Previous studies of patients with NP have shown that loss of sensory function is 
associated with central or peripheral nerve damage which may be complicated by 
ongoing pain via increased ectopic activity (Liu et al., 2000, Orstavik et al., 2006, Zhao 
et al., 2006, Vaso et al., 2014). This is usually associated with high incidence of thermal 
and mechanical loss of function. The frequent sensory loss found in leprosy NP patients 
may indicate peripheral nerve damage. 
Although PHS in the affected area was frequently reported (15.8%), its consideration in 
regards to sensory function is still controversial: some believe it to be a sensory gain 
phenomena and others a sensory loss.  
Interestingly, in this group of leprosy patients with NP I found an appreciable 
percentage of patients (5.3% and 19%) who had pain due to light moving mechanical 
stimuli (allodynia) in the tested site C8 and along the ulnar nerve territory, respectively. 
This finding is consistent with peripheral nerve damage. Sandkuhler had similar findings 
assessed behavioural hypersensitivity to stimuli after inducing a mechanical peripheral 
damage in animal models of NP; high rates of positive sensory signs, such as, blunt 
pressure pain, dynamic mechanical allodynia, and pinprick hyperalgesia were also found  
in patients with peripheral nerve damage (Sandkuhler, 2009). 
The pathophysiological mechanisms of NP associated with leprosy are not well 
established. They may involve the development of peripheral nerve damage or central 
mechanisms, or both. In this study, the QST findings have shown that the majority of 
patients have spontaneous pain with evidence of sensory loss, but no signs of sensory 
gain (hyperalgesia or allodynia). Such patients characteristically have lost both small and 
large diameter fibres. In this group, the pain is possibly due to increased spontaneous 
activity in deafferented central neurons and/or reorganization of central connections 
(Wallace and Rice, 2008). A few other leprosy patients have abnormal sensitization of 
unmyelinated cutaneous nociceptors (irritable nociceptors). In these patients, the QST 
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results have shown that pain and temperature sensation are profoundly impaired but 
light mechanical stimuli often produce pain (allodynia). In these patients, allodynia may 
be due to the formation of new connections between non-nociceptive large-diameter 
primary afferents and central pain transmission neurons (Fields et al., 1998).  
In summary, the profile of NP associated with leprosy shows signs of sensory loss by 
increased thermal detection thresholds (CDT, WDT) and increased mechanical and 
vibration detection thresholds (MDT, VDT). No signs of sensory gain are found by 
pinprick hyperalgesia (MPT, MPS), except for DMA and WUR. This sensory phenotype 
of sensory loss in patients with leprosy is likely to reflect the underlying pathology 
peripheral nerve damage. 
9.2.4 Pain intensity and quality assessment  
Self-reported pain intensity in leprosy patients was assessed using the BPI. Despite 
different pain distribution in NP and non-NP, the two groups reported similar pain 
intensity. Similar findings were also reported in PHN and LBP (Daniel et al., 2008). 
These finding support the evidence that patients with NP suffer to a similar extent to 
those with nociceptive pain (Haythornthwaite and Benrud-Larson, 2000). The average 
pain intensity among patients with NP was 5.4. Previous pain studies on NP describe 
“worst pain (rated as five or above)” as significant pain, and report it as contributing 
disproportionately to more functional impairment. In this study, around 40% of patients 
with NP rated their worst pain as five or more, which is lower than in the Ethiopian and 
Brazilian study of leprosy patients with NP (Haroun et al., 2012, Stump et al., 2004). 
The genders different in responses to pain severity or pain-related functioning in 
patients with leprosy are not known. In this study I found that no significant sex 
differences in measures of pain and functioning (depression symptoms, pain severity or 
interference). A similar finding, no differences between men and women in their 
responses to pain, were reported by Racine in study from UK, USA and Canada. The 
authors used a cross-sectional design with a cohort of 747 women and 48 men with 
fibromyalgia syndrome referred to The Fibromyalgia Day Program (Racine et al., 2014) . 
These findings oppose the fact that women typically report more frequent and/or 
severe pain than men (Unruh, 1996). Our findings suggest that no important differences 
exist between men and women in the study. However, there might be a gender bias, as 
we know that more men than women develop leprosy. The inclusion of the differences 
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between men and women in how they view and cope with leprosy-related pain would 
add further knowledge to the overall concept of pain in leprosy. 
9.2.5 Psychological co-morbidity and HRQoL 
This study is the first to use validated structured instruments to evaluate the impact of 
pain on health-related quality of life and psychological state among leprosy patients with 
and without pain in India. The BPI interference subscale mean total score (5.29) was 
significantly higher in the patients with NP sub-group than the non-NP. This indicates 
that NP may cause substantial interference with the activities of daily living among 
leprosy patients. The domain of “Sleep” was identified as a major independent variable 
affected by pain in leprosy. The prevalence of psychological co-morbidity in this cohort 
was 66.3%. Our study has shown that anxiety and depression were highly prevalent in 
NP patients. 
Overall, NP is associated with poor general health. In a French nationwide survey on 
the impact of NP on quality of life among 4,554 members of the general population, 
respondents who reported pain with neuropathic characteristics had a higher 
anxiety/depression score and higher degree of impairment in all dimensions relating to 
quality of life compared to those reporting pain without NP characteristics and those 
without pain (Attal et al., 2011a). Similarly, in a study from the UK population using SF-
36 General Health Questionnaire, found that the quality of life was worse in the 
presence of NP than non-NP of the same severity (Smith et al., 2007). The same 
findings were also confirmed in a recent systematic review of health utilities on NP 
(Doth et al., 2010). The authors also found that the intensity of NP was more important 
in determining the extent of its health impact. Cognitive behavioural implications are 
important in the management of patients with chronic neuropathic pain (Daniel et al., 
2008). 
9.2.5.1 Health-related quality of life (HRQoL) 
For the BPI interference scores, a measure of how the patients’ pain interferes with 
every day activities, the greatest impact of pain on leprosy patients was in terms of 
“normal work”, “sleep”, and “mood”. Between patients groups, there were significant 
differences of pain on the domain of “general activity”, “relations with other people”, 
“sleep” and “enjoyment of life”. Patients in the NP group with upper limb pain had 
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significantly poor scores for all pain interference domains of the BPI except “mood” 
and “walking ability” compared to non-NP. 
BPI interference has been previously measured in patients with leprosy NP in Ethiopia 
(Haroun et al., 2012). In our previous study, Ethiopian patients who had completed 
MDT within the past 18 months were selected. Results were compared with non-NP, 
and found that NP interfered in the domains of “general activity”, “normal work”, and 
“enjoyment of life”.   
Patients with leprosy NP show interference from pain and reduced quality of life 
compared to patients without NP across most domains of the BPI. Findings were 
comparable to the impact of NP on quality of life in other infectious painful 
neuropathies, but NP in leprosy appears to be associated with greater disability and poor 
overall perception of general health (van Brakel et al., 2012). In a study by Serpell, who 
investigated the burden of PHN in 152 patients from Britain aged 50 years or older 
using BPI, the interference score revealed a substantial impact of pain on the domains 
of “enjoyment of life”, “mood”, and “sleep” (Serpell et al., 2014). Phillips and colleagues 
(Phillips et al., 2014), who studied 66 HIV-infected patients, also reported that patients 
with painful neuropathy had higher BPI interference scores compared to pain-free 
neuropathy. The high BPI interference scores found in our study indicate that patients’ 
pain is associated with a negative impact on their day to day living and their quality of 
life. These findings support the growing evidence that patients with NP have a strong 
association with the domains of HRQoL (Jensen et al., 2007). This indicates that leprosy 
NP has produced an additional quality of life burden over that of leprosy itself or 
leprosy with painless nerve damage. Therefore, there is a pressing need to further 
investigate specific consequences in patients with leprosy and to assess these HRQoL 
domains in NP clinical trials.  
9.2.5.2 Psychological co-morbidity  
NP was found to be the most important factor independently associated with 
psychological co-morbidity using logistic regression analysis. This finding supports 
previous observations of leprosy patients from Ethiopia, India and Brazil, in whom the 
prevalence of psychiatric illness is high and the presence of pain was significantly 
associated with psychological co-morbidity (Haroun et al., 2012, Lasry-Levy et al., 2011, 
Reis et al., 2013). This indicates that the concomitant chronic NP pain may exacerbate 
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existing psychological morbidity and challenges patients’ adjustment and coping with 
their life.  
Our findings of increased depressive symptoms in patients with and without neuropathy 
appear to extend those of our previous study (Haroun et al., 2012), in which we found a 
linear relationship between pain and psychological distress. Our study controls for the 
presence of clinical evidence of neuropathy differentiated patients with and without 
pain. Our study found that even patients with subclinical neuropathy and pain had 
greater psychological co-morbidity. NP and psychological co-morbidity association was 
also found in HIV painful neuropathy (Wright et al., 2008, Phillips et al., 2014). These 
findings support the importance of NP, not only as a physical symptom, but as a 
possible cause of psychological co-morbidity. A study on HIV-associated neuropathy in 
South East Asia found that 20% of patients had sensory neuropathy and 36% had 
depression (Wright et al., 2008). It is possible that association with psychiatric co-
morbidity could be due to reverse causality, which cannot be fully discarded, since 
patients with psychological disturbance have been shown to have a decreased threshold 
for pain (Steer et al., 1993). The consistent and strong association found in this study 
between NP patients and psychological co-morbidity, suggests the need to find another 
way of understanding and treating NP. The utility of the biopsychosocial model 
developed by Novy and colleagues (Novy et al., 1995), which showed growing empirical 
support and acceptance, would be useful for understanding and treating leprosy NP. In 
this model, both physical and psychological factors are believed to contribute to the 
experience of pain. These findings also highlight the importance of an in-depth profiling 
of NP that includes psychological factors, particularly if tricyclic antidepressants were to 
be tested for efficacy in treating NP. 
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9.3 General discussion 
Pain is a common problem among leprosy patients in clinical practice particularly in 
endemic countries. Leprosy-associated NP, which occurs as a result of persistent nerve 
damage in patients successfully treated with MTD, is now being recognised as an 
important long-term complication. Our leprosy group at LSHTM has recently shown in 
India and Ethiopia that 17-20% of treated leprosy patients cured of their infection but 
left with peripheral nerve damage, have significant NP (Lasry-Levy et al., 2011, Haroun 
et al., 2012). NP in leprosy leads to impaired quality of life, and increased use of health 
care, and is associated with more co-morbidity such as anxiety, depression, and sleep 
disturbances compared to non-NP (Schmidt et al., 2009). For individuals, life with such 
pain can be disabling even after their disease has been “cured”. 
The treatment of patients with NP remains a challenge (Finnerup et al., 2010). There are 
no disease-modifying therapies for NP yet. The current treatments are symptom control 
based, notably associated with variability of treatment response among patients with 
pain. For instance, patients with HIV-SN do not respond to pregabalin or amitriptyline 
treatment whereas many of those with other neuropathies do respond to these drugs. 
This may be explained by the heterogeneity of pain at clinical presentation, different 
underlying pain type or patterns and different aetiologies. In leprosy, pain is also 
heterogeneous with different clinical presentations, and associated with varying pain 
types and mechanisms. Different types of patients can be distinguished: those with pain 
associated with reactions “nociceptive pain” and those with NP; overlap of the two 
categories may occur. Improvement of treatment outcomes requires identification of 
such differences and the appropriate classification of patients with leprosy pain 
conditions. Recent developments in the treatment of NP have proposed that the 
somatosensory characterisations of these patients, with respect to distinguishing the type 
of pains, is of therapeutic relevance as NP requires a different treatment approach to 
non-NP (Baron et al., 2010a, Baron et al., 2012, Freeman et al., 2014). Recent 
developments have also shown that even within one underlying cause, the 
somatosensory profiles have different subgroups of patients with NP (Baron et al., 
2009, Maier et al., 2010). In patients with radiculopathy, Baron and colleagues (Baron et 
al., 2010b) found that the individual differences in response to NP treatment were due 
to differences of somatosensory profiling, which may be associated with different 
underlying pain.     
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A recent guideline on the assessment of NP by IASP recommends the use of clinical 
tools such as NP screening questionnaires and QST testing (Haanpaa et al., 2011a). 
Unlike for NP caused by infectious diseases such as PHN (Pfau et al., 2014) and HIV 
(Phillips et al., 2014), there has been little work on the assessment of leprosy NP. The 
impact of NP in leprosy is also not well represented in the literature. The overall aim of 
this thesis was to accurately characterise patients with and without neuropathy; and 
patients with and without pain, with particular emphasis on pain and neuropathy. Pain 
subgroups were chosen as they have commonalities in their clinical pain characteristics. 
In this section, the classification of pain in leprosy, the application and utility of the 
quantitative sensory testing used in this thesis for the somatosensory characterisation of 
leprosy patients with NP and interpretation of somatosensory profiling, is the focus for 
general discussion. The strengths and limitations of the study; reflective thoughts of 
how I would do the work if starting now, implications of the current work, and 
suggestions for future work, will also be presented. 
9.3.1 Classification of pain in leprosy 
This study used a recent NP definition and guidelines published by the IASP. However, 
there is currently no proper systematic classification of NP in leprosy, which led to 
inconsistency in the thesis. The definitions of the IASP were simple to use at the start of 
the study, but became difficult when I applied them. For the practical difficulties see the 
LePaIn flow chart (Figure 8.1). In particular, the definition and classification of neuritis 
in leprosy was practically difficult. According to the IASP definition, neuritis is 
inflammation of a nerve, but if this causes nerve damage then the pain, is by definition, 
neuropathic. In the field of leprosy, neuritis is defined as an acute loss of function 
(Wagenaar et al., 2012). This loss of function could be without pain, and that is why we 
regularly use the monofilaments and MRC grading system to identify patients who have 
got silent neuritis. It is not clear whether this neuritis is an acute neuropathic pain or 
neuropathic pain of different type. This indicates that a review of the classification of 
pain in leprosy is needed. 
9.3.2 Somatosensory profiling 
Quantitative sensory testing is a sophisticated measurement which assesses 
psychophysical responses to systematic and quantifiable sensory stimuli for the purpose 
of characterising somatosensory profiling. It can be simply described as follows: an 
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increasing and quantified sensory stimulus is applied to an individual, they are asked 
with specific questions to report either a perception or pain threshold. Therefore, 
participants’ responses are potentially influenced by psychological components 
(Backonja et al., 2013, Backonja et al., 2009, Shy et al., 2003). In addition, there are 
different methods for both the stimulus application (such as mechanical stimuli, 
electrical stimuli, or contact heat stimuli) and for the response measures, which can be 
simple measures like pain threshold and intolerance or more complex processes, like 
temporal summation and conditional pain modulation. Furthermore, demographic 
factors (age and gender), site of test, environment, training of the instructor and 
instructions given to participants have an impact on QST measures (Magerl et al., 2010). 
Hence, standardisation of testing protocol is required to facilitate validity and 
comparison of QST data between studies. The German Network on NP has developed 
such a standardised DFNS-QST protocol (Rolke et al., 2006a, Rolke et al., 2006b). It 
has proved to be a useful tool in identifying the underlying sensory abnormalities in 
each patient groups and in identifying the differences between the groups in regard to 
their underlying pain type. The use of QST profiling was important to distinguish 
groups because the occurrence of nerve damage does not necessarily mean that any pain 
is neuropathic in origin (Landerholm et al., 2010). The DFNS-QST protocol was 
employed in this thesis. 
In our study, I found that obtaining full DFNS-QST profiles in leprosy patients 
provided new insights beyond studies that only used thermal testing. Initially I 
considered whether leprosy patients or group of patients differ in their QST profiles 
from people who are not experiencing pain, and I found that a variety of differences 
occurred. The QST findings revealed profound signs of sensory loss through increased 
thermal detection thresholds (CDT, WDT) and increased mechanical and vibration 
detection thresholds (MDT, VDT). Also the findings showed a variety of thermal 
(HPT/CPT) pain stimuli and pricking mechanical pain (MPT, MPS). The QST findings 
of the differences between leprosy patients and healthy controls were statistically 
significant, except VDT, WUR and VDT; with patients showing higher sensory loss 
than pain-free controls. These patterns are the same for patients with and without pain. 
Thus, it can be seen that I have several QST parameters that distinguish leprosy patients 
with clinical evidence of neuropathy from patients with no evidence of neuropathy and 
controls. 
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Another issue that I considered is the possibility to subgroup leprosy patients with pain 
based on their responses to QST testing. I referred to a development by the DFNS 
group, who studied 1236 patients with NP due to different diseases and categorised 
their findings according to sensory loss and/or gain. They found that a minority of 
patients showed no sensory changes in their profile, but most showed some evidence of 
sensory perturbation: some showed only loss or negative signs, while some patients 
showed only gain or the positive signs. The remaining patients showed a combination of 
loss and gain sensory profile. The authors found that all subtypes are presented within 
each diagnosis. They concluded that if this reflects different pain mechanisms, a single 
pain treatment within the diagnosis is not helpful. Fortunately, they found 
commonalities across pain diagnosis. For instance, some patients with trigeminal 
neuralgia showed only sensory gain profile, while patients with polyneuropathy showed 
only sensory loss. Therefore, the authors concluded that these profiles might be better 
targets for treatment than the diagnosis of the condition. In the present study, I found 
that the somatosensory profile of leprosy NP could be categorised into two main 
subgroups. The first one is a patient who shows signs of predominant sensory loss only, 
where the profile shows signs of sensory loss through increased thermal detection 
thresholds (CDT, WDT and TSL) and increased mechanical and vibration thresholds 
(MDT and VDT), but no signs of sensory gain (hyperalgesia and/ or allodynia). The 
second group is patients with a combination of symptoms and signs. In this subgroup, 
the profile shows both sensory loss and gain. The pain and temperature are profoundly 
impaired, but the condition is associated with light mechanical touch pain (dynamic 
mechanical allodynia) occurred in 5.3% and WUR 15.8%. 
Finally, I would like to discuss the implication of these findings along with a recent 
clinical case report published by Baron and colleagues (Westermann et al., 2012), which 
I think points towards future work. They report on a patient with bilateral burning and 
prickling pain in the T9-11 (at-level pain) following spinal cord injury. Pain on both 
sides was described the same way by the patient; burning, pricking, and severe in nature. 
On the right side, the QST findings showed a normal sensory profile and cold 
hyperalgesia, suggesting central NP mechanism. On the left side, there was a loss of 
thermal and mechanical sensation, suggesting peripheral nerve damage mechanism 
(deafferenation). There was also more loss of IENFD on the left side compared to the 
right. The patient was treated with pregabalin, and the result was unilateral pain relief 
only in the area with remaining sensory function, but not the pain on the left. In spite of 
Chapter 9 – Discussion 
 
269 
 
the fact that this a single case report, I think the scenario could also be relevant in 
leprosy patients with NP. This somatosensory profile for leprosy NP may assist 
researchers in designing clinical trials for targeting more specific management for these 
patients. I recommend that leprosy patients with dominant sensory loss profile be 
treated differently from patients who have combined sensory loss and gain. 
9.3.3 Strengths and limitations 
The principle strength of the current study is the comprehensiveness of the profiling 
measures employed to investigate NP in patients with leprosy. In contrast to studies 
using QST as a stand-alone test for characterisation, this study explored the multiple 
facets of NP including symptoms and sensory signs, metabolic dysfunction and 
psychological state. This facilitated the differentiation of subgroups of NP in leprosy 
pain and provided valuable new insights for treatment. 
Limitations to this study related to the recruitment of participants; choice of assessment 
instruments; communication using patient’s pain terminology; and QST-related 
methodological considerations. 
A relatively small number of participants with NP were enrolled, particularly patients 
with sensory gain. As the ulnar nerve is the most commonly affected by leprosy, this site 
was deliberately chosen for the QST test of the C8 dermatome. However, this limited 
the recruitment of patients with NP. Patients with leprosy experience pain in multiple 
locations. During testing it was found that some patients had painful areas that were not 
precisely confined to the QST test site (multiple pain areas). For instance, patients with 
NP over treated skin lesion or skin lesion over the dermatome C8 proved extremely 
difficult to recruit. Out of 36 clinically examined patients with leprosy and pain, four 
patients had skin lesion pain over ulnar territory. Of these four patients, only one 
fulfilled the criteria of our QST site, which may have been insufficient for analysis. QST 
testing over the affected area in these patients may have been useful. Similarly, it was 
found that pain associated with light mechanical touch (allodynia) was confined to the 
ulnar nerve territory, but not QST tested site. In retrospect, including assessment of the 
entire ulnar nerve territory in our study would have been useful. As the sample size for 
patients with combined sensory gain and loss was small, any subgroup in the statistical 
analysis was not necessarily significant, due to loss of power. This meant that the logistic 
regression model had a very wide CI (95%). The small sample size also limits the 
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conclusions that can be drawn from the impact of NP on health related-quality of life. A 
larger subgroup of patients with combined sensory gain and loss was necessary for 
statistical analysis.  
A potential limitation also relates to the sampling process used in the study. Since more 
than 80% of the study cohort were selected from one centre this may have introduced 
bias and may reduce the generalisability of our results to the larger population of 
patients with leprosy. Similarly, patients with leprosy reactions were over-represented in 
our study. Those patients were attending leprosy service at BLP clinic and therefore 
accessible to our recruitment. This could be a source of recruitment bias. In addition, it 
was less likely to recruit cured patients who have no ongoing symptoms of nerve 
damage and will not be attending a clinic. It would have been ideal to recruit patients 
from different study sites.  
In this study the diagnosis of leprosy neuropathy was based on clinical evidence; no 
additional techniques were used to investigate neuropathy. This study used Semmes-
Weinstein monofilaments to evaluate abnormal sensory nerve function. Semmes-
Weinstein monofilaments have limited sensitivity and specificity; to reach the definitive 
diagnosis of neuropathy, an additional measure of abnormal nerve function such as 
NCS would have contributed to the accurate identification of neuropathy and increased 
the accuracy of the diagnosis of NP. Measures of abnormal finding by NCS were used 
only for patients in the subclinical group as part of the TENLEP study (Wagenaar et al., 
2012); to carry out more detailed NCSs in such a setting is challenging. In addition, 
autonomic nervous testing of nerve function was not performed in this study; this might 
have increased the number of patients with neuropathy.    
Another potential limitation related to the health-related quality of life instruments. 
Recent recommendations in the IASP guidelines concerning NP assessment (Haanpaa 
et al., 2011a), suggests using a generic HRQoL measure such as medical outcome short 
survey (SF-36). This study used the BPI measure which while also recommended by the 
IASP, is a condition-specific instrument appropriate for detection of treatment 
response, whereas the SF-36 measure is suitable for evaluating the impact of pain on the 
common elements of health (Brazier et al., 1992).  
In this study the diagnosis of psychological disorder was based on assessment by GHQ-
12 questionnaire; no additional techniques were used to assess anxiety and depression. 
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In addition, the influence of pain catastrophising on impact of NP is not considered 
(Phillips et al., 2014). It influences chronic perceptions of one’s pain (Lame et al., 2005). 
Such data may have further supported the interpretation of the impact of leprosy NP on 
quality of life and allowed for comparison with the quality of life changes in other pain 
conditions; any specific consequences; and whether or not the findings really 
contributed to overall health. This study used GHQ-12 to assess symptoms and signs 
suggestive of depression (i.e. a score of three or more); for more objective diagnosis of 
anxiety syndromes and depression an additional measure of clinical criteria would have 
contributed to the accurate identification of psychological status.  
Communicating with patients regarding their pain complaints was difficult in this study. 
The use and interpretation of the word “pain” is dependent on local cultural context 
and language, which changes from one setting to another. For example, many people in 
South Africa and India interpret the word “numbness” to mean “nothing” (Haroun, 
2014). Additionally, communicating through a third person increases the risk of 
misunderstanding. To overcome this, communication was limited to a few sentences at 
a time and detailed examples were used to illustrate meaning. This strategy was 
developed from prior experience in communicating with leprosy patients through a 
third person in a study from Ethiopia, which helped to convey the desired message 
during the current study.  
Another potential limitation also related to the fact that patients were using medication 
for their pain relief, which may contribute to variability in responses obtained and may 
decrease levels of pain. This may be considered as a confounding factor in the data 
analysis. 
The main limitations of the QST were the onerous technical requirements. The time 
needed to complete the full DFNS-QST protocol during our study was extensive; it 
took 30 minutes to complete a single QST test on one ulnar site and one hour for both. 
In addition, the questionnaires and clinical examination assessment completed prior to 
QST, required an additional 45-60 minutes. 
Other methodological design limitations were related to the QST procedure: the high 
number of tests, and methods of limits. While QST is used to assess somatosensory 
function thresholds using 13 parameters, perhaps not all these parameters provide 
additional information compared with standard assessment of pain patients. If the QST 
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protocol were abbreviated, the duration of the procedure would shorten. Specifically, 
excluding mechanical pain sensitivity would have made testing easier and faster. The 
methods of limits algorithm used in this study provided highly reliable threshold results, 
but took a long time to complete, particularly in patients with long standing disease of 
the hand. In such situations, the test could take more than an hour per site to complete.  
Another limitation of the QST method is that the repeated testing in one area could lead 
to sensitisation that would confound the QST-Data results. In study from Germany by 
Grone and colleges (Grone et al., 2012), who investigated the effect of testing order on 
the results of QST. Twenty healthy subjects were tested twice, 1 week apart with 2 
different QST testing orders: the standardized testing order according to the German 
Research Network on Neuropathic Pain and a modified testing order in which 
mechanical stimuli were applied before thermal stimuli. The authors found that 
preceding mild thermal stimulation might lead to a sensitization to mechanical stimuli 
and thus to mechanical hyperalgesia. Alternative habituation mechanisms in the 
modified testing order resulting from repeated pinprick stimulation at the beginning 
should also be debated. I personally, believe that in theory we should do thermal testing 
second, but since the DFNS-QST protocol has always done in the other order it is best 
to keep to that. 
Another potential limitation also relates to the fact that QST uses psycho-physical 
methods which require the attention and cooperation of the subject. For instance, the 
subject’s concentration, motivation, reaction time and ability to respond quickly using 
the hand clicker can influence the results. Hence, the subjective character of the data 
collected through this method reduces acceptance. In addition, our cohort expectation 
was high in terms of demonstrating their problem. Participants may exaggerate the 
response and bias towards a bad outcome in order to get more attention and treatment. 
However, there is no algorithm of psychophysical testing that can reliably overcome the 
bias toward showing abnormality found in patients who wish to demonstrate more 
disability than they have, for whatever reason (Dyck et al., 1998). These observations 
emphasise the limitation of QST which cannot be considered as a single test to provide 
full somatosensory profile in patients with NP (Pfau et al., 2012), but it should be 
thought of as an additional tool to map the area of interest in terms of standard bedside 
sensory testing (Hansson et al., 2007). 
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Despite these limitations, our study used stringent criteria for NP, which in turn proved 
that the diagnosis of NP may be considered optimal. The study still provided an in-
depth characterisation of somatosensory profile of patients with leprosy NP and view of 
the impact of pain upon quality of life.   
9.3.4 Practical considerations in doing research in resource-limited settings 
9.3.4.1 QST battery high technical requirements 
Nerve damage is a frequent complication in leprosy patients with and without pain. The 
DFNS-QST battery provides a comprehensive assessment of this impairment; however, 
the practicality of using such techniques in resource-limited settings were, prior to this 
study, unknown. The DFNS-QST protocol and skin biopsy were used to characterise 
somatosensory profiles in 90 leprosy patients and 52 healthy volunteers in India. The 
ulnar nerve territory (dermatome C8) was tested. The QST findings were comparable 
with a study on HIV painful neuropathy done in London (Phillips et al., 2014). This 
study suggests that the use of DFNS-QST protocol in resource-limited settings is 
technically feasible. While I was not sure of the DFNS-QST protocol feasibility in 
resource-limited settings, it appears to be valid because the findings from our study were 
consistent with the DFNS database and other studies (Rolke et al., 2006a). However, 
there were some practical considerations with environment, local idiom, and logistics. 
The testing environment caused the greatest challenge. For instance, ambient room 
temperature (around 31.2 0C in Mumbai during August 2012) is critical for the MSA 
thermal stimulator machine, as well as maintaining temperature distribution across the 
thermode surface over the tested skin site. In addition, some of devices, such as, 
pinprick are highly sensitive to dust. Furthermore, the DFNS-QST protocol required 
patients’ concentration, which in turn depends on the size and quietness of the room. 
Given the high number of patients and associated co-patients in the leprosy clinic, 
problems with noise were unavoidable.    
Although our study was carried out in a well-established centre, the Foundation for 
Medical Research, the erratic electricity supply still remains a potential limitation to the 
feasibility of using QST.  We encountered frequent loss of electricity supply and power 
cuts due to overburden of the system and the thermal electrode of the QST device is 
sensitive to fluctuating electric current. To re-calibrate the device after sudden power 
cut was time consuming. 
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Another potential challenge to the feasibility was the lack of knowledge of the local 
idiom. Although the full DFNS-QST protocol was translated and back translated into 
the local languages (Hindi and Marathi), the need for knowledge of local social 
conditions is considerable. Training on social conditions (local idiom) may encourage 
the introduction of novel technology into a new setting.    
Finally, logistics and costs must be considered when implementing QST in resource-
limited settings. The rules and regulations for the importing of machinery and the 
bureaucracy of taxation are logistically extensive. The initial set up cost of approximately 
£15 000 is considerable. In addition, the QST kit requires maintenance after being 
established, adding to the expenses. 
This study is the first to present a detailed assessment of the challenges facing the use of 
the DFNS-QST protocol in a developing setting, and validates the Mumbai centre for 
the use of QST. The lessons learned with this particular setting of patients emphasise 
the importance of understanding the local language and customs.  
The way forward in minimizing the QST high technology requirements is better 
knowledge of local-society, and development of resources and tools. Without human 
resources, willingness to learn and understanding of the benefit, it will be difficult in 
practice. The identified challenges may be overcome through improved capacity and 
increased motivation. Potentially the development of battery operated QST, would 
overcome other challenges. 
9.3.4.2 Tissue biopsy and IENFD challenges 
Intra-epidermal nerve fibre density (IENFD) is a technique for measuring the endings 
of small peripheral nerve fibres in the epidermis. It provides anatomical data regarding 
the sensory nervous system, whereas QST provides functional/physiological data. Both 
are useful and complementary tools. IENFD has been used for identifying the presence 
of nerve damage in other peripheral neuropathies (Haanpaa et al., 2011a). IENFD in 
affected skin is measured by a skin biopsy taken from patients with suspected small fibre 
neuropathy (Sommer and Lauria, 2007, Holland et al., 1998). Skin biopsy (3mm punch 
biopsy) is a safe and reliable technique and has therefore become a widely used tool to 
investigate IENF (Lauria et al., 2005). 
Chapter 9 – Discussion 
 
275 
 
This study was designed to assess the IENFD in leprosy patients in line with the recent 
NeuPSIG guidelines on the assessment of NP (Haanpaa et al., 2011a). I hypothesised 
that skin biopsy examination of patients with NP would show significant loss of intra-
epidermal fibres in affected sites compared to asymptomatic sites.  
A total of 200 biopsy samples were collected: 170 samples from 85 patients and 30 
samples from 30 healthy participants. Each sample was divided into 2 pieces. These 
samples were processed and stored frozen at -80 0c in FMR. While it was planned to 
transfer the samples to Oxford, UK, the administrative practicality of this process 
proved difficult within the timeframe of the study. Tissue transfer permission is not 
granted, and the decision on how to process the biopsy is under review. 
9.3.5 If I had to start now, this is what I would do differently 
I qualified in using the DFNS-QST protocol application and now I have data from my 
leprosy study. I had a lot to learn in the beginning, but I quickly learned what I needed, 
in particular to apply this advanced technology in a resource-limited settings. However, I 
always felt that if I worked in leprosy neuropathy and pain, I would have started off 
with an in-depth foundation. I am happy with what I obtained, but if I could start over 
again, I would probably chose to have a shorter protocol with more patients. It would 
have been useful to develop a simpler version of the DFNS-QST protocol that could be 
applied in routine clinical examinations to diagnose small-fibre neuropathies, requiring 
less psychophysical patient collaboration, having lower cost, maintaining features of 
high accuracy and rapidity, and with applicability to poor psychomotor performance. 
Such a tool would be more practical, particularly in resource-limited settings. 
In hindsight, the use of the QST protocol according to the DFNS represents a 
comprehensive protocol of somatosensory profiling and was very useful in leprosy; 
however, identification of new neurological abnormalities to differentiate patients with 
and without pain is not yet possible. It would have been useful if to examine other 
possibilities such as skin biopsy and IENF density. 
In hindsight, the use of the BPI measure is appropriate for detection of treatment 
response in patients with NP. It would have been useful if to use the SF-36 measure for 
evaluating the impact of pain on HRQoL. 
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The recruitment of leprosy patients with NP to the study was not representative of all 
types of pain in those patients (i.e. pain in nerve affected territory and pain in skin 
lesions). It would have been useful if I had powered the study to the NP patients in each 
subgroup. This would have given a sample size of 15 patients with NP in each. 
I wish I had tested the entire ulnar nerve territory and/or other pain location. This 
would have given further positive sensory gain findings. Similarly testing the QST 
parameters in the skin lesions would have been of great value. 
9.3.6 What contributions has this study made to our knowledge?  
In the literature I reviewed, I found that while the concept of sensory profiling using 
tools such as QST was well established in NP field, it was not evident in leprosy NP, 
hence there has been a contribution to knowledge in the later practice through this 
study. 
This is the first study using the DFNS-QST protocol in a resource-limited setting and 
validates the Mumbai Centre’s for the use of the QST. Normative QST data are 
generated by evaluating somatosensory function in healthy volunteers, a process in 
which one body area is assessed using the QST measures according to the DFNS 
protocol. This study contributed to the DFNS reference database with normative data 
from the dermatome C8 of non-Caucasian population. 
To facilitate the identification of leprosy patients with NP, a simple case definition was 
introduced in this thesis using the DN4 questionnaire and clinical examination, by 
which the patient’s pain could be categorised as NP or non-NP pain. This case 
definition aimed to identify a leprosy patients with NP in a resource-limited setting. Our 
findings showed the utility of this simple case definition, and it could be introduced in 
other leprosy populations. 
Furthermore, the QST investigative tool methodology for sensory profiling, is still 
emerging as a field of research; therefore, new questions investigating practice have 
come from this research. Firstly, why do leprosy patients with pain not have significantly 
different QST profiles than leprosy patients without pain? This observation is 
interesting given recently increased use of QST worldwide. One could argue that the 
way this study was designed and implemented actually caused this results, but because 
this study was three-way case controlled with age and gender matched control (i.e. 
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controls were selected correctly from the study population), this is not likely. All 
methods were carefully planned to improve the study design. In addition, the QST 
testing was carried out by a trained and qualified candidate according to the DFNS 
criteria (Geber et al., 2009), ensuring that protocol of QST laboratories was properly 
used. The second concern of the investigating practice being proposed by thesis, is: how 
specific are QST measures in identifying phenotypical abnormalities of leprosy patients 
with neuropathy that is associated with pain? In this context, if investigating 
somatosensory changes contribute to the presence or absence of pain could also be 
valuable. 
In the current study the QST measures did not identify new abnormalities for patients 
with and without pain. Similar findings were also obtained by Phillips in HIV-related 
painful neuropathy (Phillips et al., 2014), unlike other studies in patients with pain, 
where the QST tool has identified abnormalities. Maier and colleagues studied sensory 
abnormalities in 1236 patients with NP due to different underlying diseases (Maier et al., 
2010). In this large cohort of patients, DFNS-QST measures showed that 92% of all 
patients with proven neuropathy had at least one sensory abnormality compared with 
the contralateral unaffected body area or with the reference data obtained from healthy 
controls. Pfau and colleagues also showed the applicability of the DFNS-QST protocol 
in identifying abnormalities in PHN (Pfau et al., 2014). In all these studies, age and 
gender match healthy controls were designed. These studies were therefore similar to 
ours in study design. It is suggested that a shorter protocol in more leprosy patients may 
be the best options for leprosy NP. In this context, the current study has shown that 
investigating leprosy patients using the DFNS-QST protocol was time-consuming and 
demanding for both-investigators and patients. The protocol needs to be simplified to 
become a regular screening tool in resource-limited settings. Therefore, there is a 
pressing need to identify the most sensitive QST measures to determine somatosensory 
abnormalities for each NP entity in leprosy. 
The findings from the current study will contribute to clinical practice in leprosy NP. I 
demonstrated that, by using the DFNS-QST measures from the healthy controls, the 
interpretation of sensory findings for patients with NP may be different compared to an 
un-affected contralateral side, which is usually used as a reference in clinical practice. I 
have shown that in leprosy patients with unilateral NP, bilateral sensory changes occur 
too. This observation of bilateral sensory abnormalities in leprosy patients with 
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unilateral NP is of great importance clinically, because it indicates that the mirror 
unaffected side should be used carefully as a reference side in sensory examinations in 
clinical practice (Konopka et al., 2012). In addition, this work validate thermal 
abnormalities and preserved JPS and vibration in leprosy patients. This may help 
clinicians to differentiate leprosy from other peripheral neuropathies; if vibration and/or 
JPS are preserved in patients with peripheral neuropathy, think of leprosy.  
Through my doctoral investigation, although I have not found differences between 
patients with and without pain in terms of their detailed sensory profiles, this tells us 
that another tool is needed to identify neurological abnormalities in those patients. It 
could be said that my thesis made a contribution to knowledge about the implications of 
the current work (i.e. the investigation approach of leprosy NP). Thus, tools such as 
skin biopsy and its IENF density are now being proposed by this piece of work since it 
is vital to explore other possible differences. IENF density provides anatomical data 
regarding the sensory nervous system, whereas QST provides functional and 
physiological data. Therefore, doing the biopsies is very important, as it might indicate 
what other tools need to be used in future. 
Another contribution from this work that still needs further research is the identification 
of patients who are at risk of developing pain. This work highlights the question, as 
temperature abnormalities are a marker of neurological abnormality in pain, why do all 
leprosy patients not have pain? Furthermore, the thermal abnormality found in this 
study indicates the need for a field friendly temperature testing, for example apps 
applications. This will help early detection and treatment of neuropathy in leprosy.  
The findings of our profiling measures in leprosy neuropathy are also of relevance for 
routine clinical use and clinical trials in resource-limited settings. For instance, the 
selection of sub-groups based on specific QST parameters for the clinical evaluation of 
drugs will improve trial sensitivity. Moreover, including simplifying sensory and 
symptom profiles of patient responses to various sensory stimuli such as heat and 
pressure will empower post-hoc analysis of responders/non-responders, which will then 
be used to enable efficient prescribing to patients likely to respond to the drug when the 
intervention is introduced into clinical practice. In addition, knowledge gained in 
profiling this patient population could also help to determine a mechanism-based 
therapy for NP. 
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Finally, the study contributions included development of skills of the health facility staff 
at collaborating centres. They improved their skills in identifying leprosy patients with 
NP using clinical examinations and highly specialised techniques. These are generic skills 
that can be transferred to other settings in India, including non-leprosy NP diseases 
such as diabetic and HIV-painful neuropathy. In addition, this study may have an 
impact on policy makers, as there are many governmental and non-governmental 
leprosy experts in India who can contribute to policy guidelines. I think even 
highlighting the issues around NP in leprosy would move quickly into priority in 
treatment. Hence, this work contributed to the academic work in India and policy 
benefits will follow. 
9.3.7 Future perspectives 
The DFNS-QST protocol enables a standardised approach to be used when assessing 
patients with NP. A simple and robust diagnostic tool in identifying neurological 
abnormalities in leprosy patients with NP can be developed. This would help to answer 
the question, “why do leprosy patients with pain not have significantly different profiles 
than leprosy patients without pain?” or “who is at risk of developing leprosy NP?” The 
tool would help to accurately identify patients for both large epidemiological studies in 
resource-limited settings and for future clinical trials. 
The identification of stratified sub-groups of leprosy patients with NP through this 
doctoral thesis has established important steps for the future therapeutic efficacy 
approach. However, findings are not yet sufficient. New therapeutic concepts based on 
sub-group characteristics of NP leprosy patients with a dominant sensory loss profile 
and patients who have combined sensory loss and gain need to be developed. Possibly, 
this sub-grouping approach needs further modification to better assign patients to 
interventions, but indeed, the two sub-groups should receive different treatments. 
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Chapter 10 Conclusions and Recommendations 
10.1 Conclusions 
This study aimed to establish the somatosensory characteristics of leprosy patients with 
persistent neuropathy, both with and without neuropathic pain. The QST parameters 
were effective in detecting neuropathy, but were not able to distinguish between patients 
with and without neuropathic pain. A major finding of this thesis demonstrates that 
leprosy patients with persistent neuropathy have a unique somatosensory profile 
compared to other conditions. 
10.2 Recommendations 
Based on the research findings presented in this thesis and the acknowledged 
limitations, the following steps are recommended: 
1. A clear classification of leprosy related neuropathic pain should be developed. 
Neuropathic pain can present in a number of ways in leprosy. For instance, 
acute pain may be the presenting symptom in a patient with leprosy who is 
seeking treatment. In this setting, the pain may be nociceptive in nature, usually 
due to reactions. However, the type of acute pain from neuritis or other leprosy 
nerve involvement is not well classified. Acute pain in leprosy can be classified 
into acute pain with reactions and neuropathic pain. The classification should 
also involve the newly developed grading system for the assessment of 
neuropathic pain (Treede et al., 2008). The grading system of neuropathic pain 
proved to be useful for the identification of neuropathic pain in patients with 
neck-arm pain (Tampin et al., 2013). Leprosy patients with pain can be 
classified as having probable, possible, or definitive neuropathic pain. This 
would add further help to the identification of leprosy related neuropathic pain.  
2. Understanding of the pathophysiology of leprosy neuropathy and in particular, 
the unique feature of loss of one Aβ fibre mediated sensory modality 
(mechanical detection threshold) accompanied by preservation of another 
(vibration detection threshold) requires further elucidation which will have 
physiological implications for understanding other conditions as well as the 
opportunity to develop specific diagnostic tools. 
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3. Future research should investigate the methods of self-reporting pain in 
determining the prevalence and impact of neuropathic pain in leprosy patients 
using pain questionnaires. Self-reported pain relies on two factors: the 
description questionnaire used and cultural barriers to reporting or not 
reporting pain. Leprosy is global disease, but the same terms cannot be used in 
different settings. 
4. Psychological distress was found significantly higher in leprosy patients with 
neuropathic pain than those with painless neuropathy, as well as the additional 
quality of life burden that leprosy neuropathic pain has produced over that of 
leprosy itself or leprosy with painless nerve damage. Future studies should 
consider these observations for the identification and treatment of neuropathic 
pain in leprosy. 
5. Future research should include the development of new tools for identifying 
leprosy neuropathic pain to inform the appropriate treatment. Given that the 
full QST battery is beyond the feasibility of most centres in poorer leprosy-
endemic countries, a simple and robust diagnostic tool is required. The new 
tools should include a specific QST parameters such as thermal and vibration 
testing and requiring less psychophysical patient collaboration, having lower 
cost, maintaining features of high accuracy and rapidity, and with applicability 
to poor psychomotor performance. Such tools need to be validated, tested, and 
deployed in clinical settings. Once established as valid and reproducible, tools 
for neuropathic pain may be used to identify patients for clinical trials that may 
be developed in the future. 
6. A future study should consider a stratified grouping of somatosensory findings: 
patients with a dominant sensory loss profile and patients who have combined 
sensory loss and gain, for a future therapeutic efficacy approach. The 
differentiation between the somatosensory profile of sensory loss and sensory 
gain could help to predict responses to treatment. 
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